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Abstract 
 
 
The preparation of a variety of novel macrocyclic model systems based on 2-(2-
hydroxyethoxy) phenol and both aliphatic and aromatic linkers has been achieved. 
Optimization of the alkylation and ring closure step conditions has given a robust and 
reliable protocol for cyclizing the precursors of dimeric morphine macrocycles.  
Herein we disclose the synthetic methodology, structural characterization and 
biological evaluation of a series of morphine macrocycles and their precursors. These 
macrocyclic chiral species varying in terms of cavity size, were synthesized by a 
concise synthetic route exploiting the two hydroxyl groups in the morphine moiety.  
 
18 model macrocycles varying in ring sizes (23-28 atoms), number of aromatic rings 
(2-4), and number of donor atoms (6-10 including oxygen and nitrogen) were 
characterized by a range of spectroscopic techniques including 1H, 13C NMR, HRMS 
and IR. Both the macrocycles and their precursors were screened for therapeutic 
activity as part of our cancer research program. Binding affinities were also assessed 
by extraction studies against a series of metal picrates. 
 
A small library of analogues of adrenaline was synthesised by a novel 
environmentally benign Friedel-Crafts reaction. In this thesis we have developed 
Friedel-Crafts reactions using this green methodology by reacting a glyoxamide with 
aromatic nucleophiles in the presence of a Lewis acid catalyst in organic solvents. 
Furthermore, the reactions proved to work smoothly using an aqueous environment 
in which novel compounds of interest as pharmaceutical intermediates containing 
heterocyclic rings were synthesised avoiding formation of hydrochloric acid as a 
byproduct.  
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1 Introduction 
 
Molecular recognition lies at the heart of virtually all biological phenomena and 
model studies of molecular recognition in biomimetic settings are necessary to 
provide important insight into the mechanisms of life processes. One of the essential 
processes occurring in living systems is the specific recognition of a particular chiral 
molecule by receptor “host” which specifically recognizes a stereoisomer “guest”. In 
living organisms the chemical or biological activity of a compound often depends 
upon its stereochemistry. For this reason crown ethers have been the subject of 
intensive study for over forty years. The serendipitous discovery of macrocyclic 
polyethers and their selective complexation of alkali metal cations is regarded as the 
beginning of supramolecular chemistry. This discovery is generally also associated 
with the pioneering work of Charles Pedersen on macrocyclic polyethers, published 
in 1967, which opened up the new field of supramolecular chemistry1. For the past 
40 years this branch of chemistry has been considered to be one of the most dynamic 
interdisciplinary sciences, combining elements of chemistry, physics and biology. At 
the heart of supramolecular chemistry are non-covalent bonds, including 
electrostatic, hydrogen bonding, Van der Waals and hydrophobic interactions. The 
great diversity of synthetic possibilities and immense number of molecular 
interactions place supramolecular chemistry at a distinctive position in the history of 
science. The major contributions to the development of supramolecular chemistry 
were made by C. Pedersen, D. J. Cram and J.-M. Lehn who were awarded the Nobel 
Prize in Chemistry in 1987. Impressive numbers of synthetic, as well as many natural 
macrocyclic species have been studied since then, and frequently unexpected ligand 
properties have emerged. Cellular studies have established that macrocyclic ligand 
complexes play a significant role in many fundamental biological systems, such as 
photosynthesis and the transport of oxygen in mammalian and other respiratory 
systems. These discoveries using synthetic macrocycles as models for the biological 
systems occurring macrocyclic ligand complexes has provided an impetus for much 
of this research. Aspects of macrocyclic chemistry are also of relevance to a number 
of other areas such as organic synthesis, metal-ion catalysis, metal-ion 
discrimination, and analytical techniques, as well as a variety of potential medical 
and industrial applications.  
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1.1 Naturally occuring relatives of crown ethers 
 
Nature has found ways to complex cations using substances such as valinomycin, 
nonactin or monesin using not only simple ethers but carbonyl groups, ketones and 
other residues2,3. The compounds that have thus far inspired the greatest interest to 
chemists working in the macrocycle area are those capable of binding cations. 
Compounds that can bind and transport cations are referred to as ionophores and the 
antibacterial nature of those compounds arises from their interference with cellular 
content and membrane function thus interfering with the normal working of the cell. 
Valinomycin 1 is a depsipeptide that exhibits antibiotic activity and is produced by 
microorganisms Streptomyces fulvissimus strains, however, Merrifield and coworkers 
have also prepared this cyclic peptide synthetically4. 
Structurally valinomycin is a cyclic compound composed of alternating α-amino 
acids and α-hydroxy acids and has been found to form especially stable complex 
with potassium resulting in formation of  a lipophilic outer shell  which envelopes 
the metal ion thus facilitating ion transfer through cell membranes. 
 
Fig.  1.1 Valinomycin 1 
 
Nonactin 2 incorporates four ether and four ester groups and while complexing 
potassium the cyclic molecule twists until it resembles the seam of a tennis ball5. An 
important feature of these macrocycles is that on metal coordination the inside of the 
complex is hydrophilic while the outside is hydrophobic. Complexation is 
consequently favoured by non polar conditions.  
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Nonactin is a member of the macrotetrolide antibiotics, isolated from Streptomyces 
cultures6. Nonactin is biologically important because of its ability to bind alkali metal 
cations. Potassium is bound selectively in the presence of sodium making nonactin 
an effective ionophore against Gram positive bacteria, mycobacteria and fungi7. 
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Fig.  1.2 Nonactin 2 
 
From a synthetic point of view the total synthesis of nonactin was a challenging goal, 
completed first by Gerlach8, then by Schmidt9, Bartlett10, Fleming11 and Lee12. 
However, availability of this complex natural product is still limited by a low overall 
yield.  
Monensin 3 is an acyclic carboxylic acid ionophore obtained from the soil bacterium 
Streptomyces cinnamonensis. It is known to be an anticoccidial agent, and a growth-
promoting feed additive in agriculture13. Monensin forms a cyclic complex with 
metal cations using both the carboxyl group at one end of the structure and a 
hydroxyl at the other. 
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 This results in the formation of a pseudo-macrocyclic complex with mono and 
divalent cations and allows them to be transported across cellular membranes.  
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Fig.  1.3 Monensin 3 
 
The most important discovery was that monensin proved to be highly selective for 
Pb2+ compared with other divalent cations, moreover it accelerates the excretion of 
this cation that has previously accumulated, without depleting the organs of zinc or 
copper14. This feature of monensin, used alone or in combination with other agents 
could be useful for the treatment of Pb2+ poisoning. 
 
 
1.2 Preparation of crown ethers 
 
Pedersen’s pioneering work revealed a major new development in the study of the 
metal-ion chemistry of macrocyclic ligands1. It became clear that crowns exhibit a 
number of unusual properties such as the ability to form complexes with alkali metal 
ions which, in certain cases, are stable in aqueous solution. Furthermore, they can 
also form stable complexes of a range of non-transition metal ions but tend to bind 
less strongly. If some of the oxygen atoms in a cyclic polyether are replaced with 
nitrogen or sulfur atoms, it is possible to change the selectivity of such a macrocycle 
towards metal cations. According to Pearson’s HSAB (“hard and soft acid and 
bases”) theory that “hard” acids prefer to bind to “hard” or nonpolarizable bases, and 
“soft” acids favor “soft” polarizable acids15. If one oxygen atom in 18-crown-6 4 is 
replaced with a nitrogen atom, it has been observed that the selectivity of the new 
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aza-analog between potassium and silver is similar. However, if a second nitrogen 
atom is introduced 5 the selectivity between silver and lead cations increases 
significantly. In the case of sulfur derivatives it has been discovered that the 
selectivity between Ag+ and Pb2+ depends strongly on the position of nitrogen in the 
ring, however, thio-crown 6 binds stronger to the transition metal cations over the 
potassium cation (Table 1.1)16. 
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Cation 
(solvent) Equilibrium constans log K 
K+ (methanol) 6.10 2.04 1.15 
Ag+ (water) 1.60 7.80 4.34 
Pb2+ (water) 4.27 7.01 3.30 
Table  1.1 Stability constans for 1:1 18-crown-6 and its aza- and thio- analogs  
 
Crown ethers are relatively easy to prepare from inexpensive commercially available 
precursors and are both easy to modify and chemically stable. It is also possible to 
create macrocyclic species which are tailor-made for complexation. Most crown 
ethers have been built around the ethyleneoxy unit, which is a readily available 
substrate. The first macrocycle dibenzo-18-crown-6 9 was synthesized by Pedersen1. 
He reacted catechol (1,2-dihydroxybenzene) 7 with 2,2’-dichlorodiethyl ether 8 in 
the presence of sodium hydroxide in n-butanol at 117 °C. The final product was 
isolated by recrystallization to give fluffy needles in 40 % yield (Fig. 1.4). 
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7 8 9
 
Fig.  1.4 Synthesis of dibezno-18-crown-6 9 
 
This early preparation of dibenzo-18-crown-6 has been used as a model for many 
subsequent crown preparations. One of the main obstacles in the preparation of 
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macrocyclic rings is the formation of polymeric side products. To minimize this 
problem many preparations of the polyether class of macrocycles have been carried 
out using high dilution techniques17. A typical direct synthetic procedure involves 
combining equimolar concentrations of two reagents incorporating the required 
fragments for the target macrocycle such that a 1:1 condensation occurs. By 
employing high dilution conditions it is more likely to favour ‘head-to-tail’ 
cyclization, rather than an intermolecular condensation leading to oligomeric or 
polymeric products. Another very important factor in the synthesis of macrocyclic 
structures is the effect of metal ions in promoting cyclization reactions. It has been 
recognized and defined by Bush and Thomson18, however, the first real evidence for 
the template effect came from Greene’s work19. Pedersen had previously synthesized 
18-crown-6 by reacting hexaethylene glycol monochloride in the presence of 
potassium tert-butoxide. Obtained yield for the cyclization step was only 1.8 %. 
However, Greene demonstrated the applicability of the template idea to macrocyclic 
polyether synthesis by reaction of triethylene glycol and triethylene ditosylate in the 
presence of potassium cations as matrices. Under those reaction conditions the yields 
increased dramatically and 18-crown-6 was formed in 93 % yields (Fig. 1.5). 
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Fig.  1.5 Synthesis of 18-crown-6 employing potassium cations as a templating agent 
 
Mandolini who investigated the template effect of alkali metal cations on the 
intramolecular cyclization reaction of o-HO-C6H4(OCH2CH2)4Br in the presence of 
Et4NOH as a base20,21. Mandolini further demonstrated that the most suitable 
templates for preparation of benzo-15-crown-5, benzo-18-crown-6 and benzo-21-
crown-7 would be metal cations in the following order: Na+, K+, Cs+ 22.  
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1.3 Chiral crown ethers  
 
The design and synthesis of crown ethers possessing chiral recognition ability has 
been extensively explored over the past 40 years. Optically active crown ethers that 
have great potential for the separation of enantiomers and for analytical purposes 
have become a very important and attractive discipline of host-guest chemistry. One 
of the advantages of crown ethers containing chiral building blocks is that for the 
majority of them it is rather easy to modify the chiral cavity in order to improve 
enantiomer selectivity. Cram and co workers made the first advancement towards the 
preparation of chiral polycyclic ethers by incorporating binaphthyl subunits in the 
macrocyclic ring23,24,25. 
 
O
O O
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CH3
CH3
O
O
O
R R R
10 11
 
Fig.  1.6 Structures of chiral crown ethers with binaphthyl units 
 
Macrocycle 10 shows high chiral discrimination on interaction with racemic amine 
salts. Such subtle behavior mimics the discrimination that is characteristic of 
interactions between a wide range of optically active biological molecules. Chiral 
recognition of this type also provides a molecular basis for the design of new hosts 
for the practical resolution of amino acids and their esters26. For example, crown 
ether 11 which was also investigated by Cram has shown very high chiral recognition 
towards the phenylalanine methyl ester perchlorate salt27. 
Chiral crowns have been employed for optical resolutions via both liquid-liquid and 
solid-liquid chromatography, where crowns were immobilized on solid substrates 
such as silica gel or polystyrene28. Chiral crown ethers with chiral biphenanthryls as 
a part of the macrocyclic cavity have been synthesized and described by Yamamoto 
(Fig. 1.7)29. 
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The synthesis of two reported macrocyclic structures (-)-(S)-12 and (-)-(R,R)-13 
began with the preparation of 10,10’-dihydroxy-9,9’-biphenanthryl, which was 
obtained as a racemic mixture then purified into the constituent (R) and (S) 
enantiomers. The (S) enantiomer underwent a condensation reaction with 
pentaethyleneglycol ditosylate to give crown ether (-)-(S)-12 in 22% overall yield. 
The (R) enantiomer was reacted with diethyleneglycol ditosylate to give the crown 
ether (-)-(R,R)-13 in 12.5% overall yield. These two crown ethers have been tested 
for chiral recognition towards chiral guest molecules. Crown ether (-)-(S)-12 was 
shown to have better enantiomeric selectivity toward 1,2-diphenylethylamine.  
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Fig.  1.7 Structures of chiral crown ethers incorporating biphenanthryl unit  
 
Chirality also has been introduced into crown hosts using optically active functional 
groups other than bis-β-naphthol. For example the crown 14 derived from the 
optically active sugar D-mannitol exhibits varying degrees of chiral recognition 
towards a range of optically active hosts30. 
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Fig.  1.8 Structures of macrocycles derived from D-mannitol and L-tartaric acid 
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Another example is the crown 15 which incorporates an L-tartaric acid moiety and in 
this case the chiral host has shown much less distortion of the periphery of the crown 
than in crowns incorporating binaphthyl or biphenanthryl units31,32. 
Hirose et al reported the synthesis of phenolic chiral crown ethers using (S)-(+)-
mandelic acid derivatives as the source of the chiral unit33. Chiral recognition of 
secondary amines by these compounds has been investigated.  
OH OTHP
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OH OH
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O
O
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22  n=3
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v
16 17
 
Fig.  1.9 Synthesis of chiral macrocycles based on (S)-(+)-mandelic acid derivatives 
Reagents and conditions: (i) a. 5-Bromo-1,3-bis(bromomethyl)-2-methoxybenzene, NaH, b. 
pyridinium p-toluenesulfonate, ethanol, 95%; (ii) NaH, glycol ditosylate (n=1), 44%; (n=3) 36%; 
(n=4), 25%; (iii) n-BuLi, hexane; H2O, (n=1), 62 %; (n=3) 62 %; (n=4), 68 %; (iv) EtSNa, DMF, 
(n=1), 91 %; (n=3) 86 %; (n=4), 30 %; (v) HNO3, NaNO2. 
 
The synthesis started with condensation of 2 equivalents of mandelic acid derivative 
16 with 5-bromo-1,3-bis(bromomethyl)-2-methoxybenzene in the presence of NaH 
then deprotection of THP groups with pyridinium p-toluenesulfonate in ethanol to 
give 17 in 95 % overall yield. Podand 17 was then reacted with different di(p-
toluenesulfonate) ethylene glycols under high dilution conditions  in the presence of 
NaH as a base, to form p-methoxy aryl bromide crown ethers 18-20 in up to 25 % 
yields. The further steps were to remove bromine substituting para-position on the 
aromatic ring by reaction with n-BuLi then selective cleavage of the methyl ether 
with sodium ethanethiolate in DMF. As a final step nitration reaction was performed 
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using a HNO3/NaNO2 mixture to introduce a nitro group in the para position to the 
phenolic hydroxyl group. These macrocycles incorporating a chiral moiety with 
varied cavity sizes 21-23 were capable of binding primary and secondary amines and 
also recognizing their chirality. Since pseudo-18-crown-6 exhibits excellent 
enantioselectivity toward primary ethanolamine derivatives, analogues of 24-crown-
8 were expected to possess a larger binding site and therefore bind selectively to 
secondary amines. Among all the macrocyclic compounds reported p-nitro phenolic 
crown ethers showed the most promising results as chiral hosts for secondary amines. 
Crown ether 22 showed the best selectivity, with crown ether 21 being too small to 
accommodate a secondary amine and crown ether 23 being too large to efficiently 
inhibit binding of the unwanted enantiomer.  
Pedersen synthesized the first series of chiral crown ethers containing cyclohexyl 
units by hydrogenation of dibenzo-18-crown-61. This method afforded a mixture of 
the cis,syn,cis- and cis,anti,cis-isomers, however, since then various synthetic 
approaches have been used to selectively prepare the cis,anti- isomer34,35. One 
approach employed (+)-(1S,2S)-trans-cyclohexane-1,2-diol which was alkylated 
with allyl bromide, then the product was submitted to ozonolysis followed by a 
reductive work-up36. The resulting diol was then transformed into a ditosylate 
derivative and reacted with a series of different diols to yield the corresponding 
chiral macrocyclic structures 24-26. It is worth mentioning that 26 has also been 
synthesized via an enzymatic reaction37. 
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Fig.  1.10 Chiral crown ethers containing cyclohexyl units 
 
Another group of optically active macrocycles based on either cis-1-
phenylcyclohexane-1,2-diol, trans-1-phenylcyclohexane-1,2-diol38 or trans-1-
diphenylcyclohexane-1,2-diol, as chiral subunits, have been reported by Naemura 
and co-workers39. Naemura’s preparation of optically active 18-crown-6 macrocycles 
of this type involved performing enantioselective hydrolysis on ester precursors of 
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the required diols using pig liver esterase. The reason for this was that the enzymatic 
method of obtaining chiral cyclohexane-1,2-diol derivatives gave higher optical 
purity and was more straightforward than chemical methods.  
 
O
O
O
O
H
Ph
O
O
O
O
O
O
Ph
O
O
Ph
O
O
O
O
O
O
H
Ph
(R,R)-(-)-27 (R,S)-(-)-29(S,R)-(-)-28
 
Fig.  1.11 Optically active 18-crown-6 macrocycles with chiral cyclohexane unit 
 
Further synthesis of macrocycles containing one cyclohexane-1,2-diol unit was 
attempted by refluxing the corresponding chiral diol in THF with 
pentaethyleneglycol bis(toluene-p-sulphonate) in the presence of NaH and KBF4. 
Isolated yields for the corresponding macrocyclic products varied from 15 to 62%. 
These chiral crown ethers have been tested for transport of enantiomeric molecules 
through bulk liquid membranes, using two guest species, (±)-1,2-diphenylethylamine 
hydrochloride and methyl (±)-phenylglycinate hydrochloride. In particular crown 
ether (R,S)-(-)-29 exhibited high enantiomer selectivity for (±)-1,2-
diphenylethylamine, suggesting that at least two phenyl units are required on these 
macrocycles to act as a significant steric barrier for the guest species tested. 
Attachment of additional benzyl, ester and amide groups to 14-crown-4 has been 
performed by the condensation reaction of (S)-1,4-benzyloxymethylbutane-2,3-diol 
and 1,10-dichloro-4,7-dioxadecane in the presence of tBuOLi in tBuOH40.  
 
O O
O O
R
R'
O O
O O
R 30 R, R'= OCH2Ph
31 R, R'= OH
32 R, R'= OTs
33 R, R'= CN
34 R, R'= CO2Me
35 R, R'= CONBu2
36 R, R'= CONMe2
 
Fig.  1.12 Chiral 14-crown-4 ether 
 
Mono- and di-substituted macrocycles 30 have been modified by first removing the 
benzyl groups via hydrogenation then bonding the alcohol groups of the products by 
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tosylation 32. The tosylates were then substituted by treatment with sodium cyanide 
to give nitriles 33, then methanolysed in the presence of HCl to yield methyl esters 
34. Hydrolysis with Me4NOH/MeOH-H2O gave carboxylic acids which were 
converted to acid chloride with PCl5. In the final step acid chlorides of the mono- and 
disubstituted 14-crown-4 ether were reacted with N,N-dibutylamine or N,N-
dimethylamine  to form the corresponding amide products 35, 36. 
Macrocycles 35, 36 were then tested for Li+ selectivity in a solution mimicking blood 
serum and the disubstituted bis-N,N-dibutylamide crown ether proved to be the best 
and was superior to previously reported systems41,42. 
α-Amino acids such as L-valine, L-leucine, L-isoleucine and L-phenylalanine have 
been used to create crown ethers incorporating chiral units in the structure43,44. First 
the α-amino acids 37 were converted into the corresponding chiral glycols 38 then 
reacted with pentaethylene glycol ditosylate 39 in the presence of a template sodium 
ion. All macrocycles 40-43 were synthesized in yields varying between 28-45 % for 
the final macrocyclization step. 
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40 R = CH(CH3)2, 37 % yield
41 R = CH2CH(CH3)2, 30 % yield
42 R = CH(CH3)CH2CH3, 28 % yield
43 R = CH2Ph, 45 % yield
37 38
39
 
Fig.  1.13 Synthesis of chiral 18-crown-6 from α-amino acids 
Reaction conditions: i) NaNO2, CH3COOH; ii) LiAlH4, THF; iii) NaOH, dioxane/water 
 
1.4 Chiral macrocycles based on sugar moiety 
 
The disaccharide sucrose presents a useful source of chirality for chemical synthesis, 
however, the eight hydroxyl groups in its structure pose a considerable synthetic 
challenge in terms of selectivity. Differentiation between individual hydroxyl groups 
is difficult and the glycosidic bond is highly sensitive in acidic media. In spite of 
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these difficulties sucrose had been applied to the synthesis of bio-degradable 
polymers and surfactants, using a biocatalytic approach to ensure regioselectivity45. 
O
ORO
O
RO
OH
RO
OR OR
OH
OH
44 R = Bn 
 
Fig.  1.14 Sucrose unit 
 
Sucrose has also been used to prepare sucroses modified at the terminal positions, so 
connection of the C-6 and C-6’ positions opened a route to the crown ether type 
analogs with sugar incorporated into the macrocyclic backbone46. Jarosz et al 
selected 2,3,3’,4,4’-penta-O-benzylsucrose 44 for the preparation of macrocyclic 
derivatives containing the sucrose unit (Fig 1.15)47 48.  
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Fig.  1.15 Chiral macrocycles with sucrose unit 
 
Crown ether analogues of varying macrocyclic ring size with sucrose units 
incorporated were prepared by reaction of 44 with the corresponding polyethylene 
ditosylates. Reactions were carried out in DMF at RT in the presence of NaH giving 
the corresponding macrocycles in up to 52 % yield. Subsequently, simple 
hydrogenolysis with hydrogen gas and 10 % Pd/C in an ethanol/ethyl acetate mixture 
removed the benzyl protecting groups and allowed isolation of the free macrocycles. 
However, for chromatographic purposes these were further acetylated and isolated as 
peracetates. 
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A series of crown ether derivatives containing D-glucose and polyethylene glycol 
units where the sugar moiety is introduced into the crown ether periphery via 1,4-
hydroxy groups has been synthesized from allyl-α-D-glucopyranoside and the 
corresponding polyether ditosylates49. Macrocycles 51, 52 and 55 were prepared by 
reaction of 2-hydroxy ethyl 2,3,6-tri-O-benzyl-4-O-(2-hydroxyethyl)-α-D-
glucopyranoside 50 with the appropriate polyethylene glycol ditosyl esters under 
anhydrous conditions in THF, at 70 °C in the presence of  NaH in yields of 30-34 %.  
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51 n = 1, R = Bn ;
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53 n = 1, R = H ;
54 n = 2, R = H ;
55 R = Bn ;
56 R = H ;
BnO
50
 
Fig.  1.16 Chiral crown ethers with D-glucose unit 
 
Further hydrogenolysis to remove the benzyl groups in compounds 51, 52, 55 was 
carried out in methanol/ethyl acetate (9:1) solution in the presence of 10 % Pd/C to 
give unprotected chiral mono-gluco-crowns 53, 54, 56.  
Faltin et al reported a synthesis of chiral crown ethers based on gluco- and 
galactopyranoside moieties 1,4- and 1,6-bridged with ethylene glycol units50,51. The 
synthesis of chiral galacto-crown ethers based on galactopyranosides is presented in 
Fig. 1.17. Polyethylene glycol side chains in the 4- and 6-positions of the 1-thio-D-
galactopyranoside derivatives 57 and 61 were incorporated under phase transfer 
conditions to give phenyl 2,3,6-tri-O-benzyl-4-[2-(2-chloroethoxy)ethyl]-1-thio-β-D-
galactopyranoside 58 in 90 % yield and phenyl 2,3,6-tri-O-benzyl-6-[2-(2-
chloroethoxy)ethyl]-1-thio-β-D-galactopyranoside 62 in 80 % isolated yields, 
respectively. Subsequent side chain elongations were realized by alkoxylation with 
tetraethylene glycol in the presence of potassium hydroxide and the final 
intramolecular transglycosidation steps of compounds 59 and 63, were carried out 
using N-iodosuccinimide (NIS) and catalytic amounts of triflic acid (TfOH) in 
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anhydrous acetonitrile or dichloromethane in the presence of a template salt, 
potassium borofluoride. 
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i = (ClC2H4)2O/ THF/ KOH/ H2O/ TBAHSO4; R.T./ 3-5 d;
ii = HO(C2H4O)3C2H4OH/ KOH/ 70 oC/ 30 h;
iii = NIS / TfOH / KBF4 / MeCN / 3 h;
i' = (ClC2H4)2O/ THF/ KOH/ H2O/ TBAHSO4/ R.T./ 20 h;
ii' = HO(C2H4O)3C2H4OH/ KOH/ 5 h/ 60-70 oC; 
iii' = NIS/ TfOH/ KBF4/ MeCN/ R.T./ 20 h;
 
Fig.  1.17 Synthesis of galacto-crown ethers 
 
According to Scheme 1 product 60 was prepared in 61 % yield and turned out to be 
exclusively the β-linked galacto-crown ether although the reagent NIS/TfOH does 
not normally lead to formation of a specific anomer53. Moreover, the high                
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β-selectivity seems to be independent of both the solvent and addition of a template 
salt. The last step of the synthesis of galacto-crown ether 64 proceeds in 38 % yield 
and only the α-configured macrocyclic product was identified. The high α-
stereoselectivity of the intramolecular transglycosidation which generated a 23-
membered 1,6-ansa-galactoside was unexpected because the polyethylene glycol 
chain seems to be flexible enough to allow an intramolecular nucleophilic attack on 
the glycosidic centre from either the β- or the α-face. Complexes containing chiral 
ligands based on carbohydrates are of interest in asymmetric catalysis51. A rhodium 
(I)-chelate of a D-pyranoside 2,3-O-bisphosphinite was even used in an industrial 
process for L-DOPA 53. 
 
1.5 Chiral aza-macrocycles 
 
L-Valine has been used as a precursor to prepare two chiral monoaza-15-crown-5 
ethers54,55. The synthesis began with the reduction of L-valine to L-valinol which was 
then benzylated to form the N-benzyl amino alcohol. Subsequent reaction with 
ethylene oxide to form a diol was followed by nucleophilic substitution of triethylene 
glycol ditosylate to form aza-crown 65 or 1,2-bis(2-tosylethoxy)benzene to yield 
product 66 respectively.  
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Fig.  1.18 Chiral monoaza-15-crown-5 ethers 
 
65 and 66 were tested for molecular recognition towards (R,S)-α-phenylethylamine 
and (R,S)-α-(1-naphthyl)ethylamine and their protonated perchlorate salts.  
Another example of a chiral macrocycle derived from an amino acid is the chiral aza 
crown ether 67 synthesized from L-threonine56. 
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Fig.  1.19 Chiral aza crown ether 67 synthesized from L-threonine 
 
The first step of the synthesis was benzylation of the amino and carboxyl groups, 
followed by reduction of the carbonyl group with LiAlH4 to give an alcohol. O-
alkylation of the primary alcohol with diethylene glycol dichloride has been 
accomplished in 50 % aq. NaOH and NBu4HSO4. The two final steps were to 
deprotect the N-benzyl groups by hydrogenation using Pearlman’s catalyst, then the 
two molecules of unprotected amine underwent a cyclization reaction to yield crown 
ether 67 in 42 % yield.  
Zhao and Hua synthesized new chiral macrocyclic compounds containing pyridine 
moieties and chiral L-amino acids as a part of the macrocyclic ring57. The procedure 
was initiated by condensation of 2,6-bis(hydroxymethyl)pyridine 68 and the 
corresponding L-amino acid 69 in the presence of DMAP and DCC. Final acylation 
of the chiral diamine 70 was performed by employing high dilution techniques. This 
step yielded two macrocyclic products 71 and 72 in 15 % and 13 % yield, 
respectively. 
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Fig.  1.20 Synthesis of chiral macrocycles containing pyridine moieties and chiral L-amino acids 
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These new macrocyclic receptors have been tested towards different D- and L-amino 
acid methyl ester hydrochlorides to measure whether they exhibit enantiomeric 
recognition.  
A chiral diaza 18-crown-6 derived from (R)-(+)-1-phenylethylamine has been 
synthesized by Demirel and Bulut58. The synthesis of podand 73 started with one pot 
reaction of catechol and ethylene oxide in the presence of piperidine hydrochloride in 
methanol. Conversion of the hydroxy groups into tosylates was achieved by treating 
the diol with para-toluenesulfonyl chloride in pyridine. Amination was accomplished 
by heating 1,2-bis(2-p-tolylsulphonylethoxy)-benzene with (R)-(+)-1-
phenylethylamine in xylene at 120 °C. Podand 73 was then used for subsequent 
macrocyclization steps with 1,2-bis(2-p-tolylsulphonyl-ethoxy)benzene and 
triethylene glycol ditosylate, respectively in the presence of tripropylamine. Finally 
macrocycles 74, 75 were isolated in 45 % and 54 % yields, respectively. 
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Fig.  1.21 Chiral diaza 18-crown-6 derived from (R)-(+)-1-phenylethylamine 
 
Reaction conditions: i) tripropylamine (10 eq), xylene, 120 °C, 48h; ii) tripropylamine (10 eq); 
xylene, 120 °C, 48h; iii) tripropylamine (10 eq), triethylene glycol ditosylate, xylene, 120 °C, 48h; 
 
Synthetic routes for preparation of macrocycle 77 were based on the same 
procedures as products 74 and 75. The routes started with alkylation of (R)-(+)-1-
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phenylethylamine with triethylene glycol ditosylate then finally macrocyclization 
with another equivalent of triethylene glycol ditosylate yielded product 77 in 48 % 
isolated yield.  
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1.6 Application of crown ethers 
1.6.1 Crown ethers in chromatography 
 
The selective binding properties of crown ethers have allowed them to be applied 
widely in chromatographic techniques. 
Immobilized polyether systems are generally synthesized by either copolymerization 
of suitably functionalized macrocycles in the presence of cross-linking agents or by 
appending functionalized macrocycles to existing polymeric species59. Structures 78-
80 presented below exhibit different polymer types and have been employed in ion-
selective membranes, as chromatographic stationary phases in HPLC and even for 
trace enrichment of radionuclides. Polymer 79 has been found to capture selectively 
K+ and Cs+ from methanol or methanol/water system while immobilized crown ether 
system 80 attached to silica has been employed to separate F¯, Cl¯, Br¯ and I¯ from 
each other as well as SO42¯ from Cl¯ using Na+ as a counter ion. Utilization of 
immobilized benzo-18-crown-6 on a polystyrene matrix as the solid phase for HPLC 
has made a clean resolution of alkali metal halides and also divalent alkaline earth 
metal salts possible 60. 
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Fig.  1.22 Crown ethers incorporated on polystyrene and silica gel 
 
In most cases only one enantiomer of chiral drugs has the desired bioactivity while 
the other may be inactive or even display undesirable side effects like toxicity61. It is 
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therefore crucial that the drug be properly analyzed for enantiomeric purity. One of 
the great problems faced by the pharmaceutical industry is the quantitation of 
undesired enantiomers in drug raw material. In order to determine enantiomeric 
purity, it has become advantageous to create a specific host molecule which would 
act as a molecular sensor, with the capability to differentiate enantiomers. Such 
molecular sensors would afford rapid and effective analysis for enantiomeric 
materials and also play an essential role in developing the techniques of enantiomer 
separation and assays for exact enantiomeric composition. For this purpose the liquid 
chromatography of enantiomers on chiral stationary phases (CSPs) incorporating 
binaphthyl units 81 have been developed to perform separation of such species like 
biologically important chiral primary amines62, chiral cyclic amines63, amino 
alcohols64 and α- and β-amino acids65,66. Chiral drugs such as baclofen (muscle 
relaxant), primaquine (antimalarial) and gemifloxacin mesylate, a new 
fluoroquinolone antibacterial agent have also been efficiently resolved using 1,1’-
binaphthyl units67. 
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Fig.  1.23 Structures of CSPs based on chiral crown ethers incorporating 1, 1’-binaphthyl and tartaric 
acid units 
 
Incorporation of (+)-(18-crown-6) 2,3,11,12-tetracarboxylic acid on the stationary 
phase 82 was used to resolve of α-amino acids, α-amino amides and α-amino esters68 
including afloqualone (muscle relaxant), and also primaquine69. Crown ether-based 
chiral stationary phases have also been used to resolve racemic primary amines70. 
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1.6.2 Crown ethers in organic synthesis 
 
One obstacle to the development of new reagents for organic synthesis is that the 
majority of inorganic salts are insoluble or sparingly soluble in organic solvents. This 
problem can often be eliminated by employing crown ethers which improve the 
solubility of polar species in non-polar environments by forming complexes with 
metal cations. A variety of organic reactions use polyether macrocycles in this way, 
including saponification, esterification, redox reactions, nucleophilic substitution 
(fluorination, alkoxylation, cyanation, nitration), elimination, (carbene and nitrene 
formation, decarboxylation) and condensation reaction (alkylation, arylation). 
 
1. Solid/liquid and liquid/liquid phase transfer catalysis 
 
The presence of 18-crown-6 in a solution of KF and acetonitrile generates ‘naked’ 
fluoride ion. The considerable nucleophilicity of this anion under these conditions is 
demonstrated by the fact that it is capable of displacing leaving groups from both sp2 
and sp3 hybridized carbons in various structural environments71,72,73,74,75,76. 
 
CH3(CH2)7Br CH3CN
CH3(CH2)7F
CH2Cl
CH3CN
CH2CN
CH3(CH2)7Br CH3CN
CH3(CH2)7NO2
CH3(CH2)7Br CH3(CH2)7I
KF, 18-crown-6
KCN, 18-crown-6
KNO2, crown ether
KI, crown ether
 
Fig.  1.24 18-crown-6 in organic synthesis 
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2. Saponification of sterically hindered esters 
 
Pedersen recognized that by using hydrophobic dicyclohexano-18-crown-6 83 it is 
possible to dissolve potassium hydroxide in hydrocarbon media such as toluene and 
benzene1. The resulting “free” OH- anion has been shown to be an excellent reagent 
to hydrolyze sterically hindered esters under such conditions.  
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Fig.  1.25 Dicyclohexano-18-crown-6 in ester hydrolysis 
 
3. Nucleophilic substitution reactions  
 
Simmons also recognized the great potential for crown ethers in synthetic 
applications and realized that nucleophilic substitution reactions might take place in 
systems which had previously proved resistant. When 1,2-dichlorobenzene 84 and 
potassium methoxide were heated at 90 °C in the absence of solvent the reaction 
yielded 2-chloroanisole 85 as the only product. However, formation of the meta-
isomer was not observed, suggesting that nucleophilic aromatic substitution had 
occurred, but not by formation of aryne as an intermediate, the mechanism normally 
invoked for such a reaction77. 
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Fig.  1.26 Dicyclohexano-18-crown-6 in nucleophilic substitution reaction 
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4. Reduction reactions of ketones to secondary alcohols 
 
Use of dibenzo-18-crown-6 9 together with sodium borohydride also improves the 
reducing power of this reagent when reacting with a number of ketones to give the 
corresponding alcohols in quantitive yields78. 
Cyclohexanol 87 has been prepared from cyclohexanone 86 using mild reaction 
conditions in 92 % yield. The increased yield in this reaction probably stems from 
the high reactivity of a “naked” BH4¯ anion. 
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Fig.  1.27 Dibenzo-18-crown-6 in reduction reaction 
   
5. Base-catalyzed elimination reactions 
 
Bartsch investigated the behaviour of potassium tert-butoxide in elimination 
reactions in the presence and in the absence of crown ether.  Addition of 
dicyclohexano-18-crown-6 into the reaction mixture significantly increased reactivity 
and also influenced the geometry of the product 79. 
 
Ph Ph
H
TsO H
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+
tBuOK
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syn-elimination anti-elimination
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30%
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70%
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Fig.  1.28 Dicyclohexano-18-crown-6 in elimination reaction 
 
6. Oxidation reaction with potassium permanganate 
 
Potassium permanganate is a powerful oxidizing agent, however, its general utility is 
limited by its solubility properties. It is a crystalline purple compound that fails to 
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dissolve in anhydrous benzene.  However, when used in the presence of crown ethers 
and a little water ‘purple benzene’ is generated,  enabling oxidations to be performed 
in benzene80. Sam and Simmons showed that ‘purple benzene’ can oxidize a range of 
alkenes, alcohols, aldehydes and alkylbenzenes to the corresponding carboxylic acids 
under mild conditions in near quantitive yields81. An interesting example is the 
reaction of β-pinene 88 in the presence of ‘purple benzene’ where the double bond of 
the terpene system is cleanly cleaved forming cis-pinonic acid 89 in 90 % yield.  
 
CH2COCH3
HOOCKMnO4
18-crown-6
β-pinene 88 cis-pinonic acid 89   90 % yield
 
Fig.  1.29 18-crown-6 in oxidation reaction 
 
 
7. Catalysis of asymmetric aldol condensation 
 
Gao and Martell investigated the catalytic properties of chiral polyaza macrocyclic 
ligand and its zinc(II) complexes 90 in the direct enantioselective aldol reaction of 4-
nitrobenzaldehyde 91 and acetone 92 in DMSO at RT82. Chiral complex 90 catalyzed 
the aldol reaction at a concentration of 5 mol% and 4-hydroxy-4-(4-
nitrophenyl)butan-2-one 93 of configuration (R) was isolated in up to 95 % yield 
with  enantiomeric excess of 57 %. 
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Fig.  1.30 Enantioselective aldol reaction catalysed by a chiral macrocycle 90 complexed to diethyl 
zinc 
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8. Alkyne addition to aldehydes 
 
The 1,1’-binaphthyl macrocycle 94 has been employed as a ligand to form a Lewis 
acidic complex for asymmetric catalysis83. Asymmetric addition of alkynes to linear 
or branched aliphatic aldehydes was investigated in the presence of chiral 
macrocycle 94 (20 mol%), complexed with Me2Zn (2 eq) as the catalyst. The 
reactions were carried out in THF or CH2Cl2 at RT and the results demonstrated that 
chiral 94 and its Me2Zn complex is an excellent catalyst for the synthesis of chiral 
propargyl alcohols and the ee of the products varied from 89-96 %. 
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Fig.  1.31 Synthesis of propargylic alcohols catalysed by a chiral macrocyclic catalyst of 94 with 
Me2Zn 
 
9. Asymmetric epoxidation of alkenes 
 
Optically active metallosalens are widely used catalysts for asymmetric synthesis84. 
This is mainly due to their facile preparation which gives rise to a highly asymmetric 
coordination sphere, and their versatile catalytic activity that depends on the nature 
of the metal chelated by the salen ligands85. Synthesis of chiral macrocycles and their 
manganese(III) salen complexes has been reported by Martinez et al 86. 
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Fig.  1.32 Asymmetric epoxidation of alkenes with macrocyclic catalyst 95 
 
The catalytic properties of 95 were investigated in the asymmetric epoxidation of 
various alkenes with NaOCl or H2O2 as an oxygen atom donor. Depending on the 
features and the stability of the complex enantiomeric excesses up to 96 % have been 
obtained in the asymmetric epoxidation, together with a quantitative conversion of 
the olefin.   
 
10. Enantioselective Michael addition 
 
Cram first reported the use of chiral crown ethers incorporating a 1,1-binaphthyl 
moiety as chiral phase transfer catalysts for the classical Michael addition87. 
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Fig.  1.33 Michael addition catalyzed by a chiral crown complex of 97 with tBuOK 
 
Cram’s new approach afforded Michael addition product (S)- 96 with high yields (up 
to 100 %) and satisfactory ee (up to 65 %) catalysed by a complex formed between 
potassium tert-butoxide and the chiral host 97. 
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More recently Boyle et al developed a new class of chiral cage annulated 
macrocycles and investigated their use as catalysts for enantioselective Michael 
addition88. 
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Fig.  1.34 Michael addition catalyzed by a chiral crown complex of 98 with tBuONa 
 
The catalytic activity of the cage macrocycle 98 in the Michael addition of 2-
nitropropane 99 to chalcone 100 was investigated using stoichiometric tBuONa with 
respect to macrocycle 1:1. Firstly, reaction in the absence of the macrocycle was 
attempted but failed to give the Michael adduct and starting material was recovered. 
18-Crown-6 as a control host catalyzed the reaction with 54 % yield and 0 % ee (as 
expected racemic product was obtained), whereas the cage macrocycle 98 gave 
product 101 in low yield (20 %) but with an impressive enantiomeric excees of 92 %.  
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11. Enantioselective Friedel-Crafts reaction 
 
Zhu et al synthesised a new macrocyclic salen ligand from 2,6-bis-hydroxy-methyl-
4-tert-butyl phenol in a five-step synthesis89. 
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OH OH
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Fig.  1.35 Enantioselective Friedel-Crafts reaction catalyzed by chiral macrocycle complex of 102 with 
Ti(OiPr)4 
 
Macrocycle 102 was then employed as a chiral ligand with Ti(OiPr)4 (1:1) to 
investigate the enantioselective Friedel-Crafts reaction of N,N-dimethylaniline 104 
with ethyl glyoxylate 105. Reactions carried out in the presence of 10 mol% of the Ti 
macrocycle catalyst in Et2O at 0 °C, gave 85 % isolated yield of 106 and an excellent 
enantioselectivity of 98 %. Very similar results were observed using 5 mol% of 
catalyst, whereas further decreasing the amount of catalyst (to 2 mol%) resulted in 
lower chemical yields, although a high enantiomeric excess of 95 % was maintained. 
For comparison Friedel-Crafts reactions were carried out employing titanium 
complexes with chiral ligand 103. Use of these catalysts gave good yields of the 
expected 2-(4-dimethylaminophenyl)-2-hydroxyacetic acid ethyl ester 106, but with 
a significant drop in enantioselectivity.  
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1.7 Catalytic Friedel-Crafts Reactions 
 
Electrophilic substitution of aromatic rings with carbonyl compounds via the Friedel-
Crafts reaction is one of the most fundamental C-C bond-forming reactions in 
organic chemistry90. The Friedel-Crafts reaction, which typically requires a Lewis 
acid catalyst provides access to a range of biologically active compounds with 
applications in the pharmaceutical, agrochemical and material science areas. 
Conventional Friedel-Crafts reactions between acid chlorides and aromatic 
compounds normally require one equivalent of a strong Lewis acid, such as AlCl3, 
and anhydrous reaction conditions. 1 equivalent of HCl is generated as a by product, 
which requires disposal91,92. However, if an aldehyde is used as the electrophile 
instead of an acyl chloride, a clean reaction to give a benzylic alcohol takes place. If 
a substoichiometric Lewis acid can be used to promote the reaction then it may be 
classified as 100 % atom efficient.  
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Fig.  1.36 Friedel-Crafts reaction 
 
This project focuses on the developing synthetic methodology of facile and direct 
preparation of compounds based on the phenylethanolamine core, by reaction of 
activated glyoxamides with electron-rich aromatic nucleophiles in Lewis acid 
catalysed Friedel-Crafts reactions.  
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Fig.  1.37 Direct preparation of phenylethanolamine library 
 
The advantage of the Friedel-Crafts approach is that Friedel-Crafts products can be 
synthesized in high yields often with catalytic Lewis acids like Cu(I), Cu(II), Zn(II), 
Sc(III), Yb(III) in substoichiometric amounts. Furthermore, by introducing chiral 
ligands, chiral Lewis acid catalysts can be formed in order to control the 
enantioselectivity of Friedel-Crafts reactions with activated aldehydes and 
ketones93,94. This aspect is crucial considering the importance of enantiopure 
compounds as pharmaceuticals and cosmetics. An example of a chiral product from 
the enantioselective Friedel-Crafts reaction is provided by substituted mandelic acid 
derivatives including p-aminomandelic acid derivatives and mandelic amide 
compounds which have dual activities as antibacterial and anti-ageing agents95. 
Mandelic acid 107 has bacteriostatic properties and is used as an antiseptic in urinary 
tract infections. Furthermore, mandelic acid and its derivatives are useful as 
intermediates in the synthesis of target molecules for other applications96.  
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Fig.  1.38 Target compounds of interest 
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The target scaffold of phenylethanolamine can also be found in such 
pharmacologically active compounds as adrenaline 108, nitrogen mustards 109 and 
salbutamol 110. Adrenaline is a neurotransmitter and plays a central role in the short-
term stress reaction in the human body97. The nitrogen mustards include cytotoxic 
chemotherapy agents, as well as mustard gas a chemical warfare agent98. Salbutamol 
is a short-acting β2-adrenergic receptor agonist used for the relief of bronchospasm in 
conditions such as asthma and chronic obstructive pulmonary disease (COPD), and is 
usually given by the inhaled route for direct effect on bronchial smooth muscle99  
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1.8 P- glycoprotein efflux pump 
 
P-glycoprotein (P-gp) is a multidrug efflux pump. It is one of the membrane bound 
glycoproteins that allow cancer cells to develop a resistance not only to a single drug 
but towards other structural and mechanistically unrelated drugs, a phenomenon 
called multidrug resistance (MDR)100. P-gp efflux pumps operate by removing the 
anticancer drugs from the cell. They can be activated by environmental stress from 
foreign chemicals or heat, and display a tendency to over express in cancer cells 
decreasing the concentration of chemotherapeutics in these cells, which in turn 
allows the cancer cells to survive101. Because these transporters are the biggest single 
cause for failure of anticancer chemotherapy, considerable effort has been invested in 
the development of compounds that behave as blockers of the transport protein and 
hence can restore the sensitivity of the cell to anticancer drugs.  
 
1.8.1 P- glycoprotein efflux pump inhibitors 
 
P-gp inhibitors are non-cytotoxic agents that, when used in combination with drugs 
pumped by P-gp, restore the sensitivity of cells to these therapeutic agents 
maintaining their intracellular concentration102. This can have implications for the 
treatment of diseases such as cancer and HIV, since P-gp has the facility to confer 
resistance by detecting, binding and removing a wide variety of hydrophobic and 
amphipathic compounds from the cell103. The pharmacological approach to 
circumvention of MDR began with the report by Tsuruo that the calcium channel 
blocker verapamil and the phenothiazine derivative trifluperazine potentiate the 
activity of vincristine104. Since then the identification of lead compounds in this area 
has been based mainly on serendipity. P-gp inhibitors, also known as P-gp 
modulators and chemosensitizers have been classified into several groups 
distinguished by their structural features. Among them are calcium channel blockers, 
calmodulin antagonists, protein kinase C inhibitors, natural products such as steroids, 
cyclic peptides and flavanoids and miscellaneous compounds. They can also be 
broadly separated into three categories based on their interaction with P-gp: high-
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affinity substrates of the P-gp pump, efficient inhibitors of ATP hydrolysis coupled 
P-gp transport, and partial substrates/inhibitors. Most chemosensitizers display their 
MDR reversal activities by competitively binding to the drug binding sites on P-gp or 
non-competitively binding to the modulatory site103. 
The first generation of P-gp inhibitors embraced compounds that were synthesised 
for other therapeutic purposes but showed their resistance modulation effect when 
administered in combination with some anticancer treatments. They showed 
undesirable side effects at the concentrations necessary to inhibit P-gp clinically. 
Among them were the calcium channel blocker, verapamil and cyclosporine A. The 
second group of chemosensitizers includes analogues of the first group, but designed 
in a way to reduce their toxicity. One of them is dexverapamil 111, the (R)-isomer of 
verapamil which lacks the cardiac effects of the (S)-isomer, but retains the ability to 
inhibit P-gp. 
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Fig.  1.39 Dexverapamil 111 
 
Dexverapamil binds reversibly to P-gp and inhibits the binding of many 
chemotherapeutic agents and other inhibitors of P-gp. Dexverapamil is not the most 
potent P-gp inhibitor. In fact its analogue Roll-2933 112, was found to be ten times 
more potent than dexverapamil in reversing resistance to doxorubicin105. 
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Fig.  1.40 Structure of Roll-2933 the analogue of (R)-verapamil 
 
Cyclic peptides and also the immunosuppressants cyclosporine A and tacrolimus  
113 are used in organ transplantation and they can also act as P-gp inhibitors106. 
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Fig.  1.41 Structures of tacrolimus 113 and valspodar (PSC-833) 114 an analogue of cyclosporine A 
 
Correspondingly, valspodar (PSC-833) 114 is a structural analogue of 
cyclosporine A that lacks its immunosuppressive effects, but remains an effective P-
gp inhibitor. It is under phase two clinical studies107. 
Another family of third generation chemosensitizers that have been clinically 
evaluated are biricodar (VX-710) 115108 and dofequidar (MS-209) 116109 which 
inhibit both P-gp and MDR1, whereas zosuquidar (LY-335979) 117 is a selective 
inhibitor of P-gp110. 
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Fig.  1.42 Structures of biricodar (VX-710) 115, dofequidar (MS-209) 116 and zosuquidar  
(LY-335979) 117 
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Calmodulin antagonists are another class of P-gp inhibitors. These include 
flupentixol 118. Both the cis and trans isomers of flupentixol are P-gp inhibitors, 
with the trans isomer being four times more potent than the cis 111. 
N
N
OH
S
F
F
F
118
 
Fig.  1.43 Structure of flupentixol 118 
 
P-gp has been shown to bind reversibly to most steroids. However, the more 
hydrophilic steroids are too easily transported and tend to be less useful as P-gp 
inhibitors. In contrast hydrophobic (lipophilic) steroids are transported less 
efficiently and as such are more useful P-gp inhibitors. Progesterone 119, a hormone 
that occurs naturally in humans, was found to bind to P-gp but appears not to be 
transported by protein112. This result indicated the possibility of using progesterone 
as a P-gp inhibitor, but further testing demonstrated that progesterone was found to 
be less effective than (R) -verapamil. 
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Fig.  1.44 Structures of progesterone 119, megestrol acetate 120 and mifepristone 121 
 
Other steroids such as megestrol acetate 120 and mifepristone RU486 121, have been 
tested, and have proved to be more effective inhibitors of P-gp than progesterone, but 
their activity has not exceeded that of (R)-verapamil. Also P-gp inhibitors such a 
ethacrynic acid 122, irofulven 123 and SN-22995 124 are in advanced clinical trials 
as MDR modulators113.  
 
Introduction 
 
37 
O
Cl
Cl
CH2
CH3
O
CO2H
CH3
O
CH3
OH CH3
OH NH
N
CH3
CH3
O
124122 123
 
Fig.  1.45 Structures of ethacrynic acid 122, irofulven 123 and SN-22995 124 
 
Elacridar (GF120918) 125 was discovered in the search for potent and selective P-gp 
inhibitors and was proven to inhibit activity of both the P-glycoprotein drug pump 
and breast cancer resistance protein (BCRP; A3CG2)114. It proved to be about 100-
fold more potent than the widely used P-gp inhibitor cyclosporin A115. In clinical 
studies with oral dosing of the topotecan, a chemotherapeutic used to treat ovarian 
and lung cancer, elacridar maximized the bioavailability of the anticancer drug116. 
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Fig.  1.46 Structure of elacridar 125 
 
In this short review a few illustrative examples have been included to show the 
diversity of structures which have been shown to act as P-gp inhibitors. To date a 
complete structure activity relationship study of each class of P-gp inhibitors has not 
been carried out. Instead Wang et al117 have compiled a list of requirements that 
potential P-gp inhibitors should have. This list has been compiled from a large group 
of compounds and categorizes them into seven classes according to their structural 
features. Studies have indicated that transmembrane sequences of P-gp involved in 
substrate interaction contain a high number of amino acids with hydrogen bond 
donor sides such as the OH, NH2, NH, SH groups of amino acids. Another important 
feature for maximum binding to P-gp is the presence of ortho-substituted aromatic 
rings and the fragment C-C-X-C-C, where X=O or N and where a tertiary nitrogen is 
preferential. The lipophilicity as measured by the (log P)2 parameter was found to be 
a very important physicochemical property of P-gp inhibitors. Hydrophilic fragments 
like carboxylic acids, phenols, anilines and quaternary ammonium compounds were 
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found to possess deactivating inhibiting properties118. This discovery correlates well 
with an independent study concluding that an effective P-gp modulator candidate 
should have a minimum log P of 2.92, and should have a main chain length of not 
less than 18 atoms, together with a high energy value for the HOMO and at least one 
tertiary, basic nitrogen atom119.  
 
1.9 Conclusion 
 
Macrocyclic compounds have been proven to have therapeutic potential in many 
areas and have been tested as antibacterial and antifungal agents, also as potent 
hepatitis C virus protease inhibitors, and as cancer therapeutics106. In the past years 
several macrocyclic compounds have been found to potentiate the activity of 
anticancer drugs by inhibiting P-gp in cancer treatment120.  
Macrocycles have the capability to provide diverse functionality and stereochemical 
complexity in a conformationally pre-organized ring structure. This ability can result 
in high affinity and selectivity towards a wide range of targets, including metal 
cations, amines, amino acids and proteins. Macrocyclic products have evolved to 
fulfil numerous synthetic and biochemical functions, and their profound properties 
have led to their development as drugs, sensors and catalysts. Numerous examples of 
chiral macrocycles containing naturally occurring compounds e.g. sugars and amino 
acids have been presented. Although macrocycles containing opiates e.g. morphine 
and its derivatives have not been synthesised. The strong analgesic properties shown 
by morphine make it one of the most effective pain killers in the treatment of 
moderate to severe pain. Also its complexed three-dimensional rigid structure is an 
interesting subject to investigate. Therefore, it is an appealing challenge to combine 
the properties of macrocycles with the well known activity of morphine. Such unique 
compounds could play an advantageous role in asymmetric catalysis especially to 
control stereoselectivity in Friedel-Crafts reaction products.  
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2 Friedel-Crafts Chemistry 
2.1 Preparation of L-tartramides 
 
A series of tartramides were prepared according to methods reported in the literature. 
The tartramides 127-129 were synthesised from diethyl-L-tartrate and the 
corresponding acyclic amine by refluxing in methanol121, whereas tartramides 130 
and 131 were prepared by stirring of diethyl-L-tartrate and the corresponding cyclic 
amine in methanol at RT for two days122. Compounds 127-131 were recrystallized 
from toluene or benzene to provide crystalline products in good yields varying from 
36 to 92 %.  
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Fig.  2.1 Synthesis of the symmetrical tartramides from diethyl-L-tartrate 
 
Tartramides 127-131 were oxidatively cleaved to form glyoxamides for subsequent 
Friedel-Crafts chemistry. 
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2.2 Oxidative cleavage of L-tartramides 
 
Glyoxamides were prepared by oxidative cleavage of tartramides with periodic acid 
in organic solvents CH2Cl2 or Et2O123. Oxidation with periodic acid was performed 
by dissolving the tartramide in the anhydrous solvent and then adding the oxidizing 
agent (1.1 eq) in small portions over 1 h, and allowing the reaction to continue at 
0 °C for an additional hour. The crude was finally poured onto molecular sieves (4Å) 
to remove any water, filtered and evaporated.  
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Fig.  2.2 General synthesis of glyoxamides by periodic oxidative cleavage 
 
Attempts to purify the glyoxamides were undertaken by vacuum distillation from 
toluene, Kugelrohr distillation and sublimation. However, none of these attempts 
allowed for satisfactory purification of the glyoxamides. Therefore in most cases the 
crude glyoxamide was used without further purification in subsequent Friedel-Crafts 
reactions.  
 
2.3 Friedel-Crafts reactions 
2.3.1 Catalytic Friedel-Crafts reaction of N,N-dimethyl glyoxamides 
 
A series of catalytic Friedel-Crafts reactions between N,N-dimethyl glyoxamide 132 
and N,N-dimethylaniline 104 were carried out in the presence of various Lewis acids 
under a variety of reaction conditions. First the Lewis acid catalyst was dried under 
high vacuum for 2 h then the organic solvent, N,N-dimethyl glyoxamide 132 and 
N,N-dimethylaniline 104 were added and the reaction stirred at the corresponding 
temperature for the experiment (Table 2.1). After each experiment crude 1H NMR 
analysis was carried out, prior to purification by column chromatography.    
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However, in each experiment none of the desired compound 133 was observed. 
Instead N,N-dimethylaniline was recovered and N,N-dimethyl glyoxamide was found 
as a mixture of unidentified products. 
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Fig.  2.3 Catalytic Friedel-Crafts reaction of N,N-dimethyl glyoxamide 132 with N,N-
dimethylaniline 104 
 
Entry Lewis 
acid 
Catalyst
[mol %] 
Ratio 
1:2 
Solvent Temp. 
[oC] 
Reaction 
time [h] 
Product 
133 
1 Cu(OTf)2 10 1:2 THF 20/65 32/22  0 
2 Cu(OTf)2 10 1:2 Et2O 20/35 34/32  0 
3 Cu(OTf)2 50 1:5 CH2Cl2 0/20 8/72 0 
4 Zn(OTf)2 20 1:4 THF 20 62 0 
5 Sc(OTf)3 30 1:4 THF 20 72  0 
6 Al(OTf)3 10 1:4 THF 0/20 8/72  0 
7 La(OTf)3 20 1:4 THF 20 72  0 
8 Yb(OTf)3 20 1:3 THF 20 72  0 
9 SnCl2 20 1:3 THF 0/20 8/72  0 
10 SnCl4 10 1:3 CH2Cl2 20 72  0 
11 TiCl4 10 1:3 CH2Cl2 0/20 8/72  0 
Table  2.1 Results for the catalytic Friedel-Crafts reaction of N,N-dimethyl glyoxamide 132 with N,N-
dimethyl-aniline 104 under various reaction conditions 
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2.3.2 Catalytic Friedel-Crafts reaction of 2-oxo-2-(pyrrolidin-1-yl)acet-aldehyde 
 
A series of Friedel-Crafts experiments between 2-oxo-2-(pyrrolidin-1-
yl)acetaldehyde 134 and N,N-dimethylaniline 104 were also performed and carried 
out in the presence of catalytic amounts of various Lewis acids (Table 2.2). The 
reaction procedure embraced the drying of the catalyst under high vacuum, then 
subsequent addition of 2-oxo-2-(pyrrolidin-1-yl)acetaldehyde and N,N-
dimethylaniline. The reactions were stirred at the corresponding temperature, and 
then a 1H NMR of the crude and separation by column chromatography was 
performed for each experiment. The desired Friedel-Crafts reaction product 135 was 
not identified, instead N,N-dimethylaniline was recovered and product 136 was 
identified as a side product. 
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Fig.  2.4 Catalytic Friedel-Crafts reaction of 2-oxo-2-(pyrrolidin-1-yl)acetaldehyde 134 with N,N-
dimethylaniline 104 
 
Product 136 was isolated as a white solid after each catalytic Friedel-Crafts 
experiment employing 2-oxo-2-(pyrrolidin-1-yl)acetaldehyde 134. This dimeric 
hemiacetal forms as a result of a reaction between the hydrate and either a second 
molecule of hydrate or glyoxamide. This dimeric form of 2-oxo-2-(pyrrolidin-1-
yl)acetaldehyde was unreactive in catalytic Friedel-Crafts reaction. 
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Fig.  2.5 Side product of catalytic Friedel-Crafts reaction of 2-oxo-2-(pyrrolidin-1-yl)acetaldehyde 134 
with 104 
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Exp. 
no 
Lewis 
acid 
Catalyst
[ mol %] 
Ratio 
2:1 
Solvent Temp.
[°C] 
Reaction 
time [h] 
Product
135 
1 Zn(OTf)2 20 4:1 CH2Cl2 20/35 72 0 
2 Zn(OTf)2 50 4:1 THF 20/65 48/21 0 
3 Zn(OTf)2 20  5:1* toluene 20/35 44/26 0 
4 Zn(OTf)2 40  5:1* toluene 20 72 0 
5 Cu(OTf)2 10 2:1 CH2Cl2 20 84 0 
6 Cu(OTf)2 20 2:1 THF 20 84 0 
7 Sc(OTf)3 10 2:1 CH2Cl2 20 84 0 
8 Al(OTf)3 10 2:1 CH2Cl2 0/20 8/74 0 
9 La(OTf)3 10 2:1 CH2Cl2 20 84 0 
10 Sn(OTf)2 10 2:1 CH2Cl2 20 84 0 
11 Yb(OTf)3 10 2:1 CH2Cl2 20 84 0 
12 SnCl2 20 2:1 CH2Cl2 20 72 0 
13 SnCl4 20 2:1 CH2Cl2 20 72 0 
14 TiCl4 20 2:1 CH2Cl2 0/20 8/72 0 
Table  2.2 Results for the catalytic Friedel-Crafts reaction of 2-oxo-2-(pyrrolidin-1-yl)acetaldehyde 
134 with N,N-dimethylaniline 104 under various reaction conditions 
* glyoxamide was added as a mixture with toluene (3 mL) 
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2.3.3 Catalytic Friedel-Crafts reactions of ethyl glyoxylate 
 
After a series of unsuccessful attempts at performing the Friedel-Crafts with a series 
of glyoxamides, ethyl glyoxylate 105 was used as a known substrate for the Friedel-
Crafts reaction93. Ethyl glyoxylate was prepared from ethyl-L-tartrate 126 by the 
same oxidative cleavage with H5IO6 in CH2Cl2. The Friedel-Crafts reaction were 
carried out in the presence of 10 mol% of Cu(OTf)2 in CH2Cl2 under N2 and 
compound 137 was isolated in 58 % yield, whereas 138 in 42 % yield. 
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Fig.  2.6 Preparation of 137 and 138 from ethyl glyoxylate 105 by catalytic Friedel-Crafts reaction 
 
2.3.4 Catalytic Friedel-Crafts reactions of ethyl 3,3,3-trifluoropyruvate  
 
Further Friedel-Crafts experiments employing ethyl 3,3,3-trifluoropyruvate 139 and 
substoichiometric catalytic amounts of Lewis acid were performed according to the 
reported method94. Commercially available ethyl 3,3,3-trifluoropyruvate 139 was 
reacted with N,N-dimethylaniline 104 in the presence of 5 mol% of Zn(OTf)2 in 
CH2Cl2 at 20 °C under N2 to give 140 in 76 % isolated yield and with 1,3-
dimethoxybenzene to give 141 in 57 % isolated yield. 
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Fig.  2.7 Preparation of 140 and 141 by catalytic Friedel-Crafts reaction 
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After the success of these experiments more reactive heteroaromatic nucleophiles 
like indoles and pyrroles were screened. Catalytic Friedel-Crafts reactions were 
carried out between indole 142 and N,N-dimethyl glyoxamide 132 in the presence of 
a substoichiometric catalytic Lewis acid. The first experiment employed 20 mol% of 
Cu(OTf)2 and was run for 32 h at 20 °C in THF. In keeping with the high 
nucleophilicity of indole the product isolated was found to be that of double addition 
143 (Table 2.3). Further experiments carried out over a shorter period of time, and 
with a ratio of starting materials of 1 to 5 and at 0 °C, still proceeded with formation 
of product 143. Formation of the product of monoaddition was not observed. 
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Fig.  2.8 Catalytic Friedel-Crafts reaction of N,N-dimethyl glyoxamide 132 with indole 142 
 
Entry Catalyst 
[mol%] 
Ratio 
142:132 
Solvent Temp. 
[oC] 
Reaction 
time 
Yield [%] 
143 
1 Cu(OTf)2  (20) 1a:2 THF 20 32 h 12 
2 Cu(OTf)2  (40) 1a:5 CH2Cl2 20 10 min. 17 
3 Cu(OTf)2  (20) 1b:5 THF 0 2 h 14 
4 CuCl   (20) 1b:5 THF 20 52 h 16 
5 Cu(OTf)2  (5) 1a:5 CH2Cl2 20 10 min. 0 
Table  2.3 Results for the catalytic Friedel-Crafts reaction of N,N-dimethyl glyoxamide 132 with 
indole 142 under various reaction conditions 
a
 142 added in one portion;  b 142 added in solution, dropwise 
 
After a series of experiments employing glyoxamide and indole and the unexpected 
formation of the product of double addition, it was decided to screen the catalytic 
Friedel-Crafts reaction between indole and ethyl pyruvate under various reaction 
conditions. 
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2.3.5  Catalytic Friedel-Crafts reactions of ethyl pyruvate  
 
All reactions presented in Table 2.4 were performed with ethyl pyruvate 144 and N-
methylindole 145, however each experiment proceeded with isolation of the product 
of double addition 146. For each experiment 5 mol% of catalyst was used and the 
highest yields were observed when Zn(OTf)2 and Cu(OTf)2 were applied. Use of 
Sc(OTf)3 gave product 146 in 77 % yield, whereas changing the anion in the 
scandium Lewis acid resulted in a decrease in yield for ScCl3 (60 %) and Sc(OiPr)3 
(12 %) with the bulky and electron donating isopropoxy group as a ligand. When 
CuCl was used it took 96 h for the reaction to reach completion and product 146 was 
isolated in 78 % yield. However, when ‘harder’ Cu(II) salts were used as the Lewis 
acid, the reaction was complete after 4 h. Formation of the double addition product 
was observed even when decreased reaction temperature     (-20 °C and 0 °C) and 
when N-methyl indole 145 was added dropwise into the reaction environment. Even 
under these mild conditions, formation of the mono addition product 147 was not 
observed. When the relatively weak Lewis acid Mg(OTf)2 was employed to catalyze 
the Friedel-Crafts reaction (Entry 10) the formation of any product was not observed 
and starting materials were recovered. 
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Fig.  2.9 Friedel-Crafts reaction product of mono addition 147 
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Fig.  2.10 Catalytic Friedel-Crafts reaction of ethyl pyruvate 144 with indoles 
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Entry Ratio 1:2 
[mmol] 
Catalyst          
[5 mol%] 
Solvent Temp.
[°C] 
Reaction 
time [h] 
Yield [%] 
146 
1 1 : 5 CuCl CH2Cl2 20 76 78 
2 1 : 5* Cu(OTf)2 Et2O 20 4 88 
3 1 : 5* CuCl2 THF 20 4 83 
4 1 : 5* Zn(OTf)2 CH2Cl2 0 6 89 
5 1 : 5* Zn(OTf)2 CH2Cl2 -20 7 66 
6 1 : 5* La(OTf)3 CH2Cl2 0 6 63 
7 1 : 5* Sc(OTf)3 CH2Cl2 20 16 77 
8 1 : 5 ScCl3 CH2Cl2 20 14 60 
9 1 : 5 Sc(OiPr)3 CH2Cl2 20 48 12 
10 1 : 5 Mg(OTf)2 THF 20 48 0 
11 1 : 5* Al(OTf)3 Et2O 0 7 74 
Table  2.4 Results for the catalytic Friedel-Crafts reaction of ethyl pyruvate 144 with N-methyl indole 
145 under various reaction conditions 
* N-Methylindole was added dropwise as a solution in the reaction solvent 
 
Products of double addition 148 and 149 were prepared in the presence of 5 mol% of 
Lewis acid and similarly as in the previous experiments mono addition Friedel-Crafts 
products were not observed.  
 
2.3.6 Catalytic Friedel-Crafts reaction of ethyl 3,3,3-trifluoropyruvate with 
indoles 
 
Catalytic Friedel-Crafts reactions between ethyl 3,3,3-trifluoropyruvate 139 and 
indoles resulted in formation of mono addition Friedel-Crafts products in agreement 
with the literature94. As in previous cases the metal catalyst was pre-dried under high 
vacuum then freshly distilled solvent and reactants were added and stirred at RT for 
the duration of the reaction. When CuCl was used to catalyze the reaction, the time 
required to consume the starting materials was 74 h, whereas with employment of 
CuCl2, the reaction was completed after 13 h. In this set of experiments the Friedel-
Crafts mono adduct 150 was isolated and formation of the double addition product 
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was not observed. In two cases (entry 4 and 8) when Al(OTf)3 and SnCl4 were 
employed the formation of neither products occurred. 
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Fig.  2.11 Catalytic Friedel-Crafts reaction of ethyl 3,3,3-trifluoropyruvate 139 with indoles 
 
Entry Catalyst Catalyst 
[mol%]   
Ratio 
1:2 
Solvent Temp. 
[°C] 
Time 
[h] 
Yield [%] 
150 
1 CuCl 10 1:2 CH2Cl2 20 74 94% 
2 CuCl2 10 1:2 CH2Cl2 20 13 91% 
3 Zn(OTf)2 5 1:2 CH2Cl2 20 13 93% 
4 Al(OTf)3 5 1:2 CH2Cl2 20 12 0 
5 La(OTf)3 5 1:1 CH2Cl2 20 13 91% 
6 Sc(OTf)3 5 1:1 CH2Cl2 20 12 64% 
7 SnCl2 10 1:1 CH2Cl2 20 12 93% 
8 SnCl4 10 1:1 CH2Cl2 20 12 0 
Table  2.5 Results for the catalytic Friedel-Crafts reaction of ethyl 3,3,3-triluoropyruvate 139 with N-
methylindole 145 under various reaction conditions 
Compound 151 was synthesised in the presence of 5 mol% of Cu(OTf)2 from indole 
and was isolated in 91 % yield.  
 
2.3.7 Friedel-Crafts reaction of glyoxamides in aqueous solution  
 
Since catalytic Friedel-Crafts reaction between N,N-dimethyl glyoxamide 132 and 
indole 142 proceeded with formation of the Friedel-Crafts double adduct 143 it was 
decided to perform the reaction in the absence of a Lewis acid and in aqueous 
solution124. Reactions between glyoxamide and indole were carried out in both sat. 
NaHCO3 and 1M NaCl solutions (Table 2.6) and an excess of glyoxamide was used. 
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Reactions were stirred for 16 h at RT and in both cases the isolated product 143 was 
that of double addition. 
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Fig.  2.12 Friedel-Crafts reaction of N,N-dimethyl glyoxamide 132 with indole 142 
 
Entry Catalyst       
[mol %] 
Ratio 
1:2 
Solvent Temp. 
[oC] 
Reaction 
time 
Yield [%] 
143 
1 no catalyst 1:4 sat. NaHCO3 RT 16 h 79 
2 no catalyst 1:4 1M NaCl RT 16 h 86 
Table  2.6 Results for the Friedel-Crafts reaction of N,N-dimethyl glyoxamide 132 with indole 142 in 
water solution   
 
The Friedel-Crafts reaction in aqueous solution between N-methyl pyrrole 152 and 
N,N-dimethyl glyoxamide 132 proceeded with the formation of the mono-adduct 153 
in both saturated NaHCO3 and 1M NaCl. These results are surprising especially 
because an excess of glyoxamide was not used. The ratio of aromatic nucleophiles to 
glyoxamide was 1:1 and mono addition product was isolated by column 
chromatography in 81 and 86 % yield respectively.  
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Fig.  2.13 Friedel-Crafts reaction of N,N-dimethyl glyoxamide  132 with N-methyl pyrrole 152 
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Entry Catalyst       
[mol %] 
Ratio 
1:2 
Solvent Temp. 
[oC] 
Reaction 
time 
Yield [%] 
153 
1 no catalyst 1:1 sat. NaHCO3 RT 16 h 81 
2 no catalyst 1:1 1M NaCl RT 16 h 86 
3 Cu(OTf)2  (15) 1:1 CH2Cl2 0 2 h 0 
4 Zn(OTf)2  (50) 1:1 CH2Cl2 RT 36 h 0 
Table  2.7 Results for the Friedel-Crafts reaction of N-methyl pyrrole 152 with N,N-dimethyl 
glyoxamide 132  
 
In contrast catalytic Friedel-Crafts experiments carried between 152 and 132 in the 
presence of Cu(OTf)2 and Zn(OTf)2 in organic solvent did not proceed with 
formation of 153 (Table 2.7). Instead N-methyl pyrrole and N,N-dimethyl 
glyoxamide in a polymeric form were recovered. 
Similar results were observed for Friedel-Crafts experiments carried out in water and 
in organic solvents in the presence of a catalyst for 2-oxo-2-(pyrrolidin-1-
yl)acetaldehyde 134 and N-methyl pyrrole 152. In the first case the Friedel-Crafts 
monoadduct product 154 was isolated in 92 and 94 % yield respectively, whereas the 
catalytic Friedel-Crafts did not take place in CH2Cl2 and only starting material was 
recovered.  
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Fig.  2.14 Friedel-Crafts reaction of 2-oxo-2-(pyrrolidin-1-yl)acetaldehyde 134 with N-methyl pyrrole 
152 
 
Entry Catalyst       
[mol %] 
Ratio 
1:2 
Solvent Temp. 
[oC] 
Reaction 
time [h] 
Yield [%] 
154 
1 no catalyst 1:1 sat. NaHCO3 RT 16  94 
2 no catalyst 1:1 1M NaCl RT 16  92 
3 Zn(OTf)2  (15) 1:1 CH2Cl2 0 2  0 
4 Cu(OTf)2  (50) 1:1 CH2Cl2 RT 36  0 
Table  2.8 Results for the Friedel-Crafts reaction of 2-oxo-2-(pyrrolidin-1-yl)acetaldehyde 134 with N-
methyl pyrrole 152   
Friedel-Crafts Chemistry 
 
51 
2.3.8 Catalytic Friedel-Crafts reaction in ionic liquids 
 
Since ionic liquids have been reported to be good solvents for Friedel-Crafts 
chemistry125, a series of catalytic Friedel-Crafts experiments using 1-butyl-3-
methylimidazolium tetrafluoroborate (BMIMBF4) and 1-butyl-2,3-
dimethylimidazolium tetrafluoroborate (BDMIMBF4) were performed. First, 
reactions between commercially available phenylglyoxal monohydrate 155 and N,N-
dimethylaniline 104 in the presence of 10 mol% of Zn(OTf)2 were carried out at 
40 °C and 60 °C since these two particular ionic liquids required an increased 
temperature to reduce their viscosity. After stirring for 16 h, the double adduct 156 
was isolated by column chromatography in 91 % and 93 % yield, respectively. To 
evaluate the effect of the solvent, an analogous experiment was performed in 
CH2Cl2, however after 3 days at RT the reaction did not reach completion 
(monitoring by TLC) and product 156 was isolated in 74 % yield.  
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Fig.  2.15 Catalytic Friedel-Crafts reaction of phenylglyoxal monohydrate 155 with N,N-
dimethylaniline 104 
 
Exp.
no 
Catalyst Catalyst
[mol%] 
Ratio 
1:2 
Solvent Time 
[h] 
Temp. 
[°C] 
Yield 
[%] 156 
1 Zn(OTf)2 10 1:4 BMIMBF4 16 40 93  
2 Zn(OTf)2 10 1:4 BDMIMBF4 16 60 91  
3 Zn(OTf)2 10 1:4 CH2Cl2 78 RT 74 
Table  2.9 Results for the catalytic Friedel-Crafts reaction of phenylglyoxal monohydrate 155 with 
N,N-dimethylaniline 104 under various reaction conditions 
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Three Friedel-Crafts experiments employing 2-oxo-2-(pyrrolidin-1-yl)acetaldehyde 
134 and aromatic nucleophiles were carried out in the presence of Zn(OTf)2 in 
BMIMBF4 at 40 °C. However, with the glyoxamide none of the Friedel-Crafts 
reactions in ILs gave the desired product.  
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Fig.  2.16 Catalytic Friedel-Crafts reaction of 2-oxo-2-(pyrrolidin-1-yl)acetaldehyde 134 with aromatic 
compounds 
 
Ionic liquids exhibit the ability to dissolve both metal catalysts and organic reagents 
which in some cases may increase the activity of the catalyst. Also with this reaction 
we have demonstrated the feasibility of metal triflates as Lewis acids for Friedel–
Crafts acylations in an imidazolium ionic liquid. It was intended that the use of an IL 
as a solvent for the catalytic Friedel–Crafts reaction might facilitate the reaction 
between glyoxamide and aromatic nucleophiles. These reactions proved to work 
more efficiently when Zn(OTf)2 was used as a catalyst in the IL than when the 
reaction was performed in a conventional organic solvent (74 %). Nevertheless, the 
double addition product was the only one isolated despite the fact that an excess of 
glyoxylate was used.  
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2.4 Conclusion 
 
Friedel-Crafts chemistry between glyoxamides and aromatic nucleophiles in the 
presence of a Lewis acid catalyst proved to be more difficult then with α-keto esters 
and glyoxylate esters. In the case of ethyl 3,3,3-trifluoropyruvate a series of Friedel-
Crafts reactions using either N,N-dimethylaniline or 1,3-dimethoxybenzene 
succeeded, giving Friedel-Crafts products in very good yields. Similarly, catalytic 
Friedel-Crafts reactions with indoles were effective, and gave products of mono or 
double addition, depending on which carbonyl compound was used as the 
electrophile. Ethyl 3,3,3-trifluoropyruvate 144 underwent catalytic Friedel-Crafts 
reaction with indoles to form only the product of mono addition, using a Lewis acid 
catalyst, whereas experiments with ethyl pyruvate afforded only the double adduct. 
The difference in reactivity between ethyl pyruvate and ethyl 3,3,3-trifluoropyruvate 
with indoles is due to the presence of three electronegative fluorine atoms which 
destabilize the cation 157 required for further reaction giving double addition (Fig. 
2.17). The opposite situation takes place for the Friedel-Crafts reaction with ethyl 
pyruvate where cation 158 is further stabilized by an electron-donating methyl group 
and undergoes further electrophilic substitution with indole.   
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Fig.  2.17 Intermediate cations 157 and 158 
 
Friedel-Crafts Chemistry 
 
54 
Catalytic F-C reactions between ethyl glyoxylate and aromatic nucleophiles proved 
to work effectively, despite the fact that ethyl glyoxylate was used as a crude mixture 
after periodic oxidation of ethyl-L-tartrate. In contrast, glyoxamides exhibit lack of 
reactivity in the catalytic Friedel-Crafts reaction with substituted benzene rings. 
However, catalytic Friedel-Crafts reactions between N,N-dimethylglyoxamide with 
an electron rich heteroaromatic indole ring proceeded with formation of the double 
adduct 143 with yields ranging from 12 to 17 %. Friedel-Crafts reactions between 
glyoxamides and both indoles and pyrroles in aqueous solution proceeded with 
preparation of the double adduct 143 with indole in 86 % yield and mono adducts 
153 and 154 for N-methyl pyrrole (81 to 94 % yield). These reactions occurred in 
water which suggests that in this case it was not the aldehyde but the hemiacetal form 
which was the reactive one. Furthermore, catalytic Friedel-Crafts reactions between 
phenyl glyoxylate monohydrate and N,N-dimethylaniline nucleophiles proved to 
work in ILs and in CH2Cl2 to give the double addition product 156 in high yields 
(74-93 %). It may be speculated (concluded) that the success of these experiments 
may depend on the form of the carbonylic compound and suggests the more reactive 
one may be the hydrated form of glyoxyaldehyde. 
For catalytic Friedel-Crafts of glyoxamides considerable effort was expended on 
purifying the glyoxamides. Attempts to purify the glyoxamides were undertaken by 
vacuum distillation from toluene, Kugelrohr distillation and sublimation. However, 
none of these attempts allowed for satisfactory purification of the glyoxamides.  
After each catalytic Friedel-Crafts experiment employing 2-oxo-2-(pyrrolidin-1-
yl)acetaldehyde 134 white solid was collected and identified as a compound 136.  
This dimeric hemiacetal (see experimental, page 198 1H NMR in CDCl3 and D2O) 
formed as a result of a reaction between the hydrate and either a second molecule of 
hydrate or glyoxamide. At this stage it should be emphasized that dimer 136 can 
exists as a cyclic trimer 136a. Analogically to formaldehyde which trimeric form 
136b was found to be more stable and easily handled source of anhydrous 
formaldehyde. Therefore, appearance of 136 requires further investigation. 
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Fig.  2.18 Dimeric 136 and trimeric 136a form of 2-oxo-2-(pyrrolidin-1-yl)acetaldehyde and 1,3,5-
trioxane 136b trimeric form of formaldehyde and reaction schemes between 136 and heterocycles 
 
The dimeric form of 2-oxo-2-(pyrrolidin-1-yl)acetaldehyde, 136 was then reacted in 
a catalytic Friedel-Crafts reaction with indole, however without further success. 
Whereas, when 136 was introduced into the aqueous solution and reacted with N-
methyl pyrrole, the formation of the mono adduct was observed by analysis of the 1H 
NMR of the crude.  
An important achievement was the successful preparation of Friedel-Crafts products 
using more environmentally-friendly, aqueous conditions. It has been demonstrated 
that the Friedel-Crafts reaction of glyoxamides with heteroaromatic compounds in 
water can proceed smoothly without the use of traditional Lewis acid catalysis. The 
reactions proceeded well for indole, however only the double addition adduct was 
obtained. For pyrroles the mono adduct from electrophilic substitution by 
glyoxamides at the 2-position was observed as the only product. The results show 
that the NaHCO3-H2O and NaCl-H2O solutions have unique properties for the 
Friedel-Crafts reaction which results in formation of Friedel-Crafts adducts in high 
yields. However, at the present stage of this investigation we do not have sufficient 
mechanistic details to account for the role of the solvent composition in the 
selectivity of the reaction.  
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3 Model Macrocycles and their Precursors 
 
In our research we investigated two possible routes for the preparation of 
macrocyclic model systems. The first synthetic route was a two pot synthesis in 
which phenoxy-linked open structures undergo ring-closure to the macrocycle via an 
aliphatic linker in the presence of a templating agent and under high dilution 
conditions. The second synthetic route investigated was a one-pot synthesis, which 
provided a rapid and straightforward method to perform the sequence, however 
optimization of reaction conditions may be time consuming.  
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Fig.  3.1 Two different routes for preparation of macrocycles 
 
The macrocyclization process can be promoted either by suppressing the 
intermolecular reaction (resulting in polymerization) or facilitating the 
intramolecular one. We chose to combine these approaches by suppressing 
competing reactions, via the use of moderate to high dilution conditions, while 
promoting cyclization via the template effect.   
The classical method commonly known as macrocyclization was developed during 
Ziegler’s studies in the 1930s126. This method employs an approach based upon the 
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high dilution technique, and under these conditions the probability of intermolecular 
reactions between the reacting partners, leading to formation of oligomers is 
radically decreased. An intramolecular reaction does not require interactions between 
molecules, so consequently high dilution does not affect the efficiency of cyclization. 
This method is essentially universal and for the past 70 years numerous compounds 
with medium to large rings have been synthesised in this way127. The technical 
inconvenience of this method is that even a small amount of product requires large 
volumes of solvent which is also undesirable from an environmental point of view.  
A fairly different approach enhancing the probability of the intramolecular pathway 
emerged with the discovery of crown ethers as a new class of complexing agents. 
Pedersen’s pioneering experiments in this area revealed an unusual phenomenon 
when 18-membered polyether was formed in high yields by the condensation of two 
moles of catechol with two moles of 2-chloroethyl ether (Fig. 3.2).  
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Fig.  3.2 Synthesis of dibenzo-18-crown-6 in the presence of templating agent 
 
The result was truly remarkable as, in this case, the macrocyclization proceeded 
efficiently without high-dilution conditions. In fact, up to one mole of the product 
(360 g) was prepared in a volume of just 5 litre of solvent. The striking efficiency of 
this reaction was correctly ascribed to the forced proximity of the reacting centres 
induced from the template effect of the sodium ion during the cyclization step. It was 
suggested that, owing to the coordination effect of the metal ion, the cyclization 
precursor is formed with a set of donor sites (six ether oxygens) wrapped around a 
central ion. This pseudo cyclic conformation is ideal for the geometry of the 
transition state required for the closure of the 18-membered ring and hence formation 
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of the macrocycle is greatly facilitated. The same reaction performed in the presence 
of lithium or ammonium bases invariably led to the formation of linear oligomers. 
Further studies documented the universal validity of using multisite binding and an 
entry into new areas of organic chemistry was opened.  
 
The two methods for macrocycle formation  
1)  by two step synthesis from phenoxy-linked macrocyclic precursors (160-166);  
2)  by one pot approach from 2-(2-hydroxyethoxy)phenol,  
are now presented. 
 
3.1 Preparation of phenoxy-linked open structures 
 
Phenoxy linked open structures 160-166 were synthesised by reacting 2-(2-
hydroxyethoxy)-phenol 159 with the corresponding alkyl halides, according to 
Fig. 3.3. 
Seven novel model macrocyclic precursors have been synthesised by the alkylation 
of commercially available 2-(2-hydroxyethoxy)-phenol 159 with the corresponding 
alkyl chlorides, bromides or iodides in the presence of K2CO3 in DMF. These 
reactions occurred in moderately to high yields varying from 54 % for 160 to 92 % 
yield for 166. 
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Fig.  3.3 Synthesis of phenoxy-linked open structures 
Reaction conditions: Na2CO3 or K2CO3, DMF, 120 °C, 7h; 
 
For all the experiments where alkyl chlorides were employed for alkylation of the 
diol 159 the isolated yields of the products were higher. Whereas the experiments 
employing alkyl bromides or in the case of 162 an alkyl iodide, open structures have 
been isolated in slightly lower yields (Table 3.1) 
 
Compound 160 161 162 163 164 165 166 
 Isolated yields [%] 
Alkyl 
chloride 54 86 81 88 91 78 92 
Alkyl 
bromide - 68 - 77 71 76 - 
Alkyl 
iodide - - 54 - - - - 
Table  3.1 Isolated yields for phenoxy-linked open structures 160-166 
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All the compounds prepared have been characterized by 1H and 13C NMR and their 
exact masses have been confirmed by HRMS. The macrocyclic precursors have been 
used in the next step, for the preparation of macrocyclic structures. Ring closure 
reactions have been achieved by introduction of alkyl bromides or chlorides into the 
open structures using high dilution techniques.  
 
3.2 Preparation of macrocycles from their phenoxy-linked precursors  
 
The two-pot synthesis was carried out using phenoxy-linked macrocyclic precursors 
that were reacted with the corresponding alkyl dichloride, dibromide or diiodide 
according to the general scheme on Fig. 3.4. Using this approach eighteen novel 
model macrocyclic structures have been successfully synthesized and isolated.  
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Fig.  3.4 Synthesis of macrocycles from phenoxy-linked precursor 
 
Efforts towards the synthesis of model macrocycles commenced with a series of 
unsuccessful ring closure experiments using alkyl chlorides and alkyl bromides 
under mild reaction conditions. Therefore acyl chlorides which are more reactive 
towards alcohol groups under mild reaction conditions were investigated as 
alternative linkers. In each case the reaction was carried out in boiling 
dichloromethane in the presence of K2CO3. The number of equivalents of base used 
in each reaction was not less then 8 for each phenoxy-linked open structure. 
Satisfactory results gave us crucial information about the quantity of base required 
for successful ring closure reactions with the phenoxy-linked macrocyclic precursors. 
Reaction progress was monitored by TLC and when the reaction was complete it was 
quenched with water, followed by a standard basic workup. Macrocycles 167 and 
168 were isolated in 31 % and 26 % yields respectively. 
Model Macrocycles 
 
61 
N
ClCl
OO
N
ClCl
OO
O
O
OO
O
O
N
OOOH
O
OH
O
OO
OH
O
O
OH
O
O
N
O O
OO
O
O
O
O
K2CO3, DCM, reflux
K2CO3, DCM, reflux
31 % isolated yield
26 % isolated yield
167
168
164
163
 
Fig.  3.5 Macrocyclization of macrocyclic precursors 163 and 164 with 2,6-pyridine dicarbonyl 
dichloride 
 
Based on these promising results new macrocyclic model systems containing both 
aromatic and aliphatic ether chains were synthesized from 1,5-bis[2-(2-
hydroxyethoxy)phenoxy]-3-oxapentane 161 on a 1 mmol scale in 100 mL of 1,4-
dioxane. Macrocycle 169 in the Fig. 3.6 was synthesized using 8 mmol of KOH as a 
base in refluxing solvent with the addition of potassium iodide. The presence of the 
iodide salt in the reaction environment improved reaction yields by nucleophilic 
displacement of the Cl with KI to give alkyl iodide, known as a Finkelstein 
reaction128,129. Presence of 10 mol% of KI in the ring closure reaction environment to 
synthesise 169 improved conversion by 15% (a 40 % and b 55 %). Preparation of 
macrocycle 170 with addition of KI into the reaction proceeded with 50% conversion 
(d), whereas reaction carried out without KI gave 40% conversion (c) (Fig. 3.6). 
Similar results were obtained for preparation of 171, without KI the reaction proceed 
with a conversion of 35% (e) while addition of NaI increased conversion to 45% (f), 
Fig. 3.6. All three macrocycles were purified by column chromatography on silica 
gel, using chloroform/ethyl acetate mixtures as the eluent. Surprisingly isolated 
yields were not as high as was expected. However, the moderate yields may be due 
to the presence of ethylene oxide chains in each of the compounds that render them 
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difficult to remove from silica gel. Isolated yields were 32 %, 29 % and 26 %, 
respectively.  
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Fig.  3.6 Synthesis of macrocycles 169-171 with 1,5-bis[2-(2-hydroxyethoxy)phenoxy]-3-oxapentane 
unit 161 
Reaction conditions: a) KOH, 1,4-dioxane, reflux; b) a, KI; c) NaOH, 1,4-dioxane, reflux; d) c, NaI; 
e) KOH, 1,4-dioxane, reflux; f) e, KI; 
 
The results presented in Fig. 3.6 encouraged us to optimise the reaction conditions in 
order to maximize yields. A limited study at optimization reactions was carried out 
on example 169 to determine the most favourable reaction conditions, considering 
such factors as number of moles of base, additives (NaI, KI), choice of solvent and 
solvent volume. Various bases (e.g. NaH, NaOH, KH, KOH, CsOH and Ba(OH)2) in 
different solvents (e.g. DMF, THF, 1,4-dioxane) were screened (Table 3.2).  
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Fig.  3.7 Reaction scheme for preparation of 169 
 
Entry Base Base 
[mmol] 
Additives Solvent Temp 
[°C] 
Time [h] Conv 
[%] 
1 NaOH 10 - THF 66 46 28 
2 NaOH 10 NaI THF 66 46 30 
3 NaOH 10 - 1,4-D a 101 46 35 
4 NaOH 10 NaI 1,4-D a 101 46 38 
5 KOH 10 - THF 66 46 44 
6 KOH 10 KI THF 66 46 50 
7 KOH 10 - 1,4-D a 101 46 50 
8 KOH 10 KI 1,4-D a 101 46 60 
9 KOH 4 KI 1,4-D a 101 46 0 
10 KOH 6 KI 1,4-D a 101 46 35 
11 KOH 8 KI 1,4-D a 101 46 55 
12 KOH 12 KI 1,4-D a 101 46 70 
13 KOH 16 KI 1,4-D a 101 46 60 
14 KOH 20 KI 1,4-D a 101 46 60 
15 LiOH 12 - 1,4-D a 101 46 0 
16 CsOH 12 - 1,4-D a 101 46 40 
17 Ba(OH)2 12 - 1,4-D a 101 46 0 
18 NaH 10 - THF 0-R.T. 6/18 25 
19 KH 10 - THF 0-R.T. 6/18 30 
Table  3.2 Various reaction conditions for preparation of macrocycle 169. a1,4-D; 1,4 Dioxane 
 
This series of experiments proved that the optimal number of moles of base required 
to effect ring closure varies from 8-12 mmoles (8-12 eq), with the preferred base 
being sodium or potassium hydroxide in THF or 1,4-dioxane. Experiments carried 
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out using less then 6 mmol base did not lead to macrocyclization. Also the solvent 
studies focused on THF and 1,4-dioxane rather then DMF in order to facilitate 
purification. These experiments also demonstrated that in general, if THF is replaced 
by a higher-boiling solvent such as 1,4-dioxane conversion of starting materials tends 
to increase. As presented in Table 3.2 synthesis of 169 was performed under various 
reaction conditions, with the most efficient ring closure taking place using not less 
then 10 mmol of KOH and 0.1 mmol of KI in refluxing 1,4-dioxane (entries 8,12). 
The optimal molar ratio of base to substrate was 12 for the highest conversion, in the 
presence of an iodide salt. Sodium hydroxide was also effective in promoting 
alkylation of the primary alcohol, with subsequent macrocyclization. Again 
maximum product formation was observed in experiments carried out in a solvent 
with a higher boiling point and in the presence of an iodide salt. Experiments 
employing hydroxides with small cationic radius e.g. LiOH and relatively big 
cationic radius, such as Ba(OH)2 gave poor results. In the first case a trace amount of 
product was observed, whereas formation of the product in the second case was 
negligible. In addition, the effect of stronger bases e.g. sodium and potassium 
hydrides on the macrocyclization was investigated. Reactions were stirred at 0 °C in 
THF for 6 h then at room temperature overnight. Considering the hazardous 
properties of alkali metal hydrides, as well as the unimpressive reaction yield, the use 
of these bases was not pursued further in our research.  
A limited study to establish the optimum quantity of solvent for the macrocyclization 
reaction was also investigated as a important issue to conclude whether it is the 
template effect or high dilution that benefits the reaction most. Experiments were 
carried out with varying amounts of 1,4-dioxane together with 10 mmol of both 
potassium hydroxide and 0.1 mmol of potassium iodide (Table 3.3). 
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Entry Base Base 
[mmol] 
Additives 
(0.1mmol) 
Solvent Solvent 
[mL] 
Conv 
[%] 
1 KOH 10 KI 1,4-D 8 trace 
2 KOH 10 KI 1,4-D 20 44 
3 KOH 10 KI 1,4-D 40 62 
4 KOH 10 KI 1,4-D 60 70 
5 KOH 10 KI 1,4-D 80 72 
6 KOH 10 KI 1,4-D 100 74 
7 KOH 10 KI 1,4-D 120 77 
8 KOH 10 KI 1,4-D 150 65 
9 KOH 10 KI 1,4-D 200 63 
10 KOH 10 KI 1,4-D 250 68 
Table  3.3 Solvent effect on preparation of macrocycle 169. a1,4-D; 1,4 Dioxane 
 
The experiments in Table 3.3 show that the optimal range for the volume of solvent 
varies between 60 mL and 120 mL (entry 4-7). This suggests the importance of the 
template effect, which appears to play a key role in the macrocyclization step. 
Previous experiments (Table 3.2) show that the use of bases with lithium or sodium 
counter cations proceeded with lower reaction conversions compared with reactions 
carried out in the presence of potassium bases. This is most likely due to the fact that 
the cations with a smaller radius than potassium cannot fit effectively to template the 
macrocycle for efficient ring closure. Instead oligomeric products are formed. In 
Fig. 3.8 the two possibilities of behaviour for the macrocyclic precursor, either in the 
presence or absence of a potassium cation templating agent. The first path depicts the 
open structure encircling the templating agent. This shape is the consequence of 
interactions between the metal cation and oxygen-donor atoms. In the absence of a 
templating agent, the second route is followed in which 161 adopts a linear 
conformation and in that shape oligomeric products are more likely to be formed.  
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Fig.  3.8 Macrocyclic precursor 161 in the presence and absence of the template 
 
A series of macrocyclic compounds starting from the precursor 162, 1,8-bis[2-(2-
hydroxyethoxy)phenoxy]-3,6-dioxaoctane have been synthesised according to 
optimized reaction conditions. As shown in Fig. 3.9, for each reaction, potassium 
hydroxide (12 mmol) and potassium iodide (0.1 mmol) in moderate dilution (80 mL 
per 1 mmol) were used to synthesise the macrocycles in isolated yields between 38-
51 %.  
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Fig.  3.9 Synthesis of macrocycles from 1,8-bis[2-(2-hydroxyethoxy)phenoxy]-3,6-dioxaoctane 162 
 
Synthesis of the macrocycles 176, 177 and 178, starting from 1,3-bis[2-(2-
hydroxyethoxy)phenoxy]-m-xylene precursor 164 were carried out as in previous 
cases on a 1 mmol scale, employing 12 mmol of metal hydroxide under dilute 
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conditions using 80 mL of 1,4-dioxane (Fig. 3.10) First the macrocyclic precursor 
was stirred for 1 hour in the presence of the base at 60 °C before addition of the 
corresponding alkyl dichloride. Macrocycle 178 was first synthesized in the presence 
of sodium hydroxide because the introduced ortho-xylene unit is “shorter” than the 
meta and para isomers and the macrocyclic precursor might better accommodate the 
smaller sodium cation. However, this was not observed as the subsequent reaction 
with potassium hydroxide gave a higher conversion (60 %) compared with sodium 
hydroxide (45 %). 
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Fig.  3.10 Synthesis of macrocycles 176-178  
 
All of the macrocycles were purified by column chromatography on silica gel using 
chloroform as the mobile phase for 177 and 178 and the more polar mobile phase of 
chloroform and ethyl acetate (3:1) for 176. Moreover, macrocycle 176 required 
further recrystallization from CH2Cl2/MeOH (5:1) so the final isolated yield of pure 
compound was 43 % whereas compound 177 was isolated in 44% yield. Macrocycle 
178 was isolated in 29 % and 47 % yield, respectively. 
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Macrocycles prepared from precursor 163 and corresponding α,α’-dichloro-xylenes 
were synthesized efficiently in the presence of potassium hydroxide and its iodide 
salt in refluxing 1,4-dioxane (Fig. 3.11). Compounds 179 and 181 were isolated in 
good yields of 43 % and 48 %, whereas purification of product 182 yielded pure 
macrocycle in a mere 5 % yield.  
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Fig.  3.11 Synthesis of macrocycles 179-182 
 
Macrocycle 180 was synthesized under a variety of reaction conditions in order to 
screen the effect of the metal base in cyclising rings of different sizes (Table 3.4). 
The synthesis of 179 carried out in the presence of potassium hydroxide and its 
iodide salt proceeded most efficiently, giving 70 % conversion and 53 % isolated 
yield (entry 6). Sodium hydroxide gave significantly lower yields than the potassium 
base, whereas lithium hydroxide did not lead to formation of 180. Moreover, with 
LiOH the starting material was recovered quantitatively. Reactions carried out in the 
presence of caesium hydroxide proceeded well and addition of iodide salt improved 
reaction conversions and increased isolated yields still further. Use of barium 
hydroxide did not provide with formation of the macrocycle 180. 
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 Base 
(12mmol) 
Solvent 
(80 mL) 
Additives Reaction 
time [h] 
Temp. 
[°C] 
Conv. 
[%] 
Yield 
[%] 180 
1 LiOH 1,4-Da - 48 101 0 0 
2 NaOH THF NaI 64 66 25 18 
3 NaOH 1,4-Da NaI 62 101 32 20 
4 NaH THF - 6/18 0-R.T. 21 16 
5 KOH THF KI 46 101 55 46 
6 KOH 1,4-Da KI 48 101 70 53 
7 KH THF - 6/18 0-R.T. 44 35 
8 CsOH 1,4-Da - 48 101 45 39 
9 CsOH 1,4-Da KI 48 101 54 43 
10 Ba(OH)2 1,4-Da - 48 101 0 0 
Table  3.4 Various reaction conditions for synthesis of macrocycle 180. a1,4-D; 1,4-dioxane 
 
The series of experiments to prepare 180 under different reaction conditions 
confirmed that the optimal reaction conditions are potassium hydroxide with addition 
of its iodide salt in an aprotic solvent. According to the results, changing the solvent 
from THF (b.p. 66 °C) to 1,4-dioxane (b.p. 101 °C) increased the reaction conversion 
from 55 to 70 % (entries 5,6). Also, the presence of potassium iodide in the reaction 
flask (Finkelstein modification) increased the yields from 45 % to 54 % (entries 8, 
9). Relatively lower conversion was observed for experiments using sodium 
hydroxide, possibly as a result of reduced template effect. It is also possible that the 
deprotonated alcohol might form a tighter ion pair with the smaller sodium cation, 
compared with the larger potassium cation, therefore stabilizing the alkoxide anion 
and making it less reactive. While not as effective as potassium hydroxide, caesium 
hydroxide also improved yields compared with reactions carried out using sodium 
hydroxide.  
Macrocycles 183 and 184 were synthesised according to the usual method on a 
1 mmol scale and in the presence of potassium hydroxide and potassium iodide in 
1,4-dioxane. Macrocycle 183 was purified by column chromatography on silica gel 
with chloroform/ethyl acetate (3:1) as the mobile phase to give 38 % yield. 
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Compound 184 was isolated by recrystallization from chloroform/methanol (4:1) and 
then chloroform to give 184 in 49 % yield. 
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Fig.  3.12 Synthesis of macrocycles 183 and 184 
 
Macrocycles 170, 180, 183 were also synthesized from the corresponding phenoxy-
linked macrocyclic precursors and corresponding alkyl bromides.  
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Fig.  3.13 Macrocycles 170, 180, 183 synthesized with α,α’-dibromo and α,α’-dichloro-xylenes 
 
These experiments were performed to rapidly determine which of the alkyl halides is 
a more effective alkylating agent under the optimized reaction conditions. As shown 
in Table 3.5 reaction conversion and isolated yields were slightly higher for 
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experiments employing alkyl bromides in the ring closure step.  This might be a 
result of the fact that bromide is a better leaving group than chloride and may react 
more readily, increasing formation of the desired product. In both cases of 
purification of 183, isolated yields were noticeably lower than for the other 
macrocycles. This may be due to the presence of the pyridine ring which is more 
likely to interact with silica gel during chromatography separation, therefore it is 
more difficult to purify. 
 
  Alkyl chlorides Alkyl bromides 
entry Macrocycle conversion Isolated yield conversion Isolated yield 
1 170 40 % 32 %  55 % 41 %  
2 180 40 % 28 %  55 % 37 %  
3 183 50 % 22 %  60 % 38 %  
Table  3.5 Results of macrocyclization using alkyl chlorides versus bromides 
  
 
3.3 Preparation of macrocycles by one pot synthesis 
 
Several approaches have been made to synthesize macrocycles by a one-pot 
synthesis. The advantage of this type of synthesis is that it allows for preparation of a 
macrocyclic precursor with concomitant macrocyclization. This method not only 
saves time and reduces the number of synthetic steps but also avoids costly and 
sometimes difficult purifications. Macrocycle 184 was synthesized using a one pot 
synthesis in moderate yield by reacting 1 equivalent of 2-(2-hydroxyethoxy)-phenol 
159 with 0.5 equivalents of 2,6-bis(chloromethyl)pyridine 185 in the presence of a 
base in 6 mL of 1,4-dioxane. A very important factor in this case is the stoichiometry 
and choice of base. Sodium or potassium hydroxides are strong enough bases to 
deprotonate not only the phenol but also the aliphatic alcohol under the reported 
reaction conditions130.  Therefore to avoid the formation of polymeric side products, 
exactly one equivalent of base must be added for each equivalent of 2-(2-
hydroxyethoxy)-phenol 159 in the reaction. Formation of macrocyclic precursor 166 
was monitored by TLC and additional equivalents of base (up to 5 eq.) and 1,4-
dioxane (100 mL) were added to the reaction flask until complete conversion of 
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starting materials had taken place. The reason for introducing additional solvent is to 
maintain high dilution conditions for the ring closure step and minimize formation of 
oligomeric and polymeric side products. Addition of 0.5 eq. of 2,6-bis(chloromethyl) 
pyridine 185 together with small amounts (0.1 eq) of potassium or sodium iodide 
was followed by refluxing the reaction mixture for 2 days. Macrocycle 184 was 
isolated in 6 % yield when sodium hydroxide was used as a base and in 13 % yield 
when potassium hydroxide was employed.  
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Fig.  3.14 Synthesis of macrocycle 184 in one-pot approach 
 
Identical reaction conditions have been applied to the one-pot synthesis of 
macrocycle 180. Isolated yields of product 180 for the reaction with sodium 
hydroxide (7 %) and potassium hydroxide (11 %) were disappointedly moderate 
compared with a two-step synthesis, approach. 
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Fig.  3.15 Synthesis of macrocycle 180 in one-pot approach 
 
Analogous attempts to prepare of 180 were performed employing caesium hydroxide 
or potassium tert-butoxide as a base in 1,4-dioxane. However, only trace amounts of 
the final product 180 were observed and product was not isolated further.  
A number of trials were also undertaken to prepare macrocycle 186. A variety of 
bases and solvents were screened to promote formation of the intended product, 
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including lithium, sodium and potassium hydroxide in THF, 1,4-dioxane or DMF. 
Furthermore, for the second, ring-closing step, even stronger bases such as sodium 
and potassium hydrides in THF at RT did not lead to the cyclization.  
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Fig.  3.16 Attempts to synthesis of macrocycle 186 
 
Every attempt at the preparation of macrocycle 186 was unsuccessful including 
efforts to synthesize this compound by a two step synthesis. Furthermore, even trials 
of various base and conditions failed to lead to a successful synthesis of 186. 
Preparation of macrocycles 180 and 184 by a one-pot approach proved to be 
successful, however, isolated yields were unsatisfactory and varied between 6 to 
13 %. Therefore the one-pot method was decided not to be explored further, in 
favour of the more efficient two-pot approach. 
 
3.4 Spectroscopic discussion on model macrocycles 
 
3.4.1 NMR study of 173 and 182 
 
The 1H NMR spectra of 173 and 182 are depicted in Fig. 3.18 and Fig. 3.19 
respectively. The para substituted aromatic CHs for both macrocycles appear as 
singlets at δ 7.42 for 182 and at δ 7.33 for 173. Hydrogens adjacent to each other in 
the catechol ring were expected to appear as a double doublet, but instead merged 
into a broad multiplet integrating to 8 protons. The benzylic protons of the para-
xylene groups in 182 and 173 can easily be distinguished since both appear as 
singlets at distinctly different chemical shifts. In the case of 182 the benzylic 
methylene group (12,12’) is covalently bonded to a phenoxy group and appears  at δ 
5.05. However, in para-xylene 173, the benzylic methylene (9,9’) is covalently 
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linked to an alkoxy group and so is shifted further upfield and appears as a singlet at 
δ 4.62. This difference is due to the electron-withdrawing effect of oxygen which is 
greater for aromatic ethers than for aliphatic ones. The polyethylene protons 7,7’ and 
8,8’ in 182 appear as doublet of doublets at δ 4.11 and δ 3.83 respectively, with a 
coupling constant of 4.4 Hz. Similarly, the hydrogens at positions 9,9’ and 10,10’ 
have resolved as doublet of doublets at δ 3.68 and δ 3.53 with the J value of  4.6 Hz. 
The singlet at δ 3.51 is due to the chemically equivalent protons of 11,11’. Protons 
12,12’ and 7,7’ in the structure 173 appear as doublet of doublets further downfield 
at δ 4.11 (J=4.4Hz) and δ 4.06 (J=4.8Hz) due to the electron-withdrawing effect of 
the catechol ring. This separates them from the doublet of doublets of 13,13’ and 8,8’ 
at δ 3.79 (J=4.4Hz) and at δ 3.73 (J=4.8Hz) respectively in which methylenes are 
linked only to aliphatic ether oxygens. The equivalent hydrogens (14,14’) resonate as 
a singlet at δ 3.55 in the same way that the protons (11,11’) did in 182. The ethylene 
protons from the ether linkage have been expected merely to couple with each other 
to give a pair of triplets. The pattern produced in this case is, however, clearly more 
complicated. The complexity comes from the fact that the pairs of ethylene nuclei are 
not magnetically equivalent and in consequence produce AA’BB’ system.  
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Fig.  3.17 Macrocycles 173 and 182 
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Fig.  3.18 1H NMR spectrum of 2,3,14,15,21,24-tribenzo-1,4,7,10,13,16,19,26-octaoxacycloocta-
eicosa-2,14,21,22,23-tetraene, 173 
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Fig.  3.19 1H NMR spectrum of 2,3,6,9,12,13-tribenzo-1,4,11,14,17,20,23,26-octaoxacycloocta-eicosa-
2,6,7,8,12-tetraene, 182 
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 s m s dd dd dd dd s 
182 14,14’ 3-6,3’-6’ 12,12’ 7,7’ 8,8’ 9,9’ 10,10’ 11,11’ 
 
7.42 6.92-6.80 5.05 
4.11 
J=4.4Hz 
3.83 
J=4.4Hz 
3.68 
J=4.6Hz 
3.53 
J=4.6Hz 
3.51 
173 11,11’ 3-6,3’-6’ 9,9’ 12,12’ 7,7’ 13,13’ 8,8’ 14,14’ 
 
7.33 6.85-6.77 4.62 
4.11 
J=4.4Hz 
4.06 
J=4.8Hz 
3.79 
J=4.4Hz 
3.73 
J=4.8Hz 
3.55 
Table  3.6  1H NMR spectroscopic details for macrocycles 173 and 182 
 
The 13C NMR spectrum of 173 (Fig. 3.21), shows some variation from the 182 
macrocycle presented in (Fig. 3.20). The most noticeable differences in chemical 
shift occur for nuclei in the catechol ring. The oxygen substituted aromatic carbons 
(1,1’ and 2,2’) in 173 linked to the polyethylene spacer units appear at δ 148.98 as a 
peak of double intensity, whereas in 182 two separate peaks of weaker intensity for 
2,2’ at δ 149.38 and 1,1’ at δ 148.61 were identified. Subsequently the substitution 
pattern was found to have a significant effect on the appearance of adjacent tertiary 
carbons in the catechol unit. In 173 4,4’, 5,5’ have virtually identical chemical shift 
values of δ 121.49 and δ 121.46, while a small variation in the appearance of the 
corresponding signals in the 13C NMR spectrum of 182 was recorded at δ 121.87 
(4,4’) and δ 121.32 (5,5’). Similarly, minor differences in chemical shift between two 
macrocycles were observed for 3,3’ and 6,6’. Consequently in 173 these tertiary 
carbons resonate at near identical chemical shifts of δ 114.31 and δ 114.07 
respectively, whereas the signals for 6,6’ and 3,3’ appear at chemical shifts of δ 
115.48 and δ 113.82 for 182. The four tertiary para-carbons for both macrocycles 
173 and 182 appear as single peaks of double intensity at δ 127.9 for 173 and at δ 
127.7 for 182. In 173 the secondary carbon (9,9’) of the benzylic methylene group is 
shifted downfield to δ 73.15, which is comparable with the value of δ 71.21 for 
12,12’ in macrocycle 182. 
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Fig.  3.20 13C NMR spectrum of 2,3,6,9,12,13-tribenzo-1,4,11,14,17,20,23,26-octaoxacycloocta-
eicosa-2,6,7,8,12-tetraene, 182 
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Fig.  3.21 13C NMR spectrum of 2,3,14,15,21,24-tribenzo-1,4,7,10,13,16,19,26-octaoxacycloocta-
eicosa-2,14,21,22,23-tetraene, 173 
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3.4.2 NMR study of 174 
 
In the 1H NMR of 174 (Fig. 3.23) the major differences in chemical shift compared 
with 173 appear amongst the polyethylene protons. The 13,13’ and 7,7’ protons in 
174 appear as overlapping doublet of doublets, making it difficult to determine the 
coupling constants. Overlapping was also observed for protons 8,8’ and 14,14’ which 
resonate as a multiplet (δ 3.78-3.75), instead of the anticipated two doublet of 
doublets integrating to 8 protons. In contrast the ethylene group (15,15’) appears as a 
singlet, integrating to 4 hydrogens at δ 3.62. In the aromatic region the adjacent 
hydrogens in the ortho-xylene ring appear as double doublets, with the meta-CH 
(12,12’) at δ 7.35 and the ortho-CH (11,11’) at δ 7.19 with coupling constants values 
of 5.6 Hz and 3.2 Hz, respectively. As in previous spectra the aromatic protons of the 
catechol rings appear as a multiplet in the region δ 6.81-6.76, integrating to 8 
hydrogens.  
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Fig.  3.22 Macrocycles 174 
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Fig.  3.23 The 1H NMR spectrum of 2,3,14,15,21,22-tribenzo-1,4,7,10,13,16,19,25-octaoxa- 
cyclohexaeicosa-2,14,21-triene, 174 
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Fig.  3.24 The 13C NMR spectrum of 2,3,14,15,21,22-tribenzo-1,4,7,10,13,16,19,25-octaoxa- 
cyclohexaeicosa-2,14,21-triene, 174 
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In the 13C NMR spectrum of 174 (Fig. 3.24) signals of double intensity due to the 
quaternary aromatic carbons substituted with oxygen (1,1’,2,2’) in the catechol ring 
have been identified at δ 147.9, whereas the aromatic carbons assigned to the ortho-
xylene unit (10,10’) appear at δ 135.58. The ortho- and meta-CH in the xylene ring 
(11,11’ and 12,12’) appear at δ 127.89 and δ 126.7 respectively. The CH signals of 
the catechol ring ortho (3,3’,6,6’) and meta (4,4’,5,5’) appear upfield, compared with 
the signals of the xylene unit at δ 120.38 and δ 113.16. The CH’s in the catechol 
system are both markedly shielded compared with an unsubstituted aromatic ring 
(benzene CH 128). The shielding is greater for the ortho-CH 3,3’ and 6,6’ (δ 113) 
because of efficient mesomeric electron-donation from the non-bonding electron 
pairs on oxygen (Fig. 3.25). The para-CH 4,4’, 5,5’ also benefits from mesomeric 
conjugation, but less efficiently (δ 120).  
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Fig.  3.25 Mesomeric effect, ortho-CH and para-CH 
 
The benzylic CH2 9,9’ (174) situated between an oxygen and the aromatic ring 
appears as a singlet at δ 70.02. This signal appears upfield with respect to the 
corresponding benzylic CH2 of 173 which appears at δ 73.15. Finally, the signals of 
the polyethylene chain appear in same region as in the previous examples (174, 184) 
in the region from δ 6.99-6.78. 
 
3.4.3 NMR study of 181 
 
The proton 1H NMR of the macrocycle 181 containing four aromatic rings is 
presented in Fig. 3.27. The protons associated with para-phenyl aromatic ring appear 
as a singlet at δ 7.41 integrating to four hydrogens. The double doublets 
corresponding to the ortho- and meta-protons at positions 12,12’ and 11,11’ have 
chemical shifts of δ 7.26 and 7.21 respectively. The hydrogens of the ortho 
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substituted catechol appear as a multiplet upfield of the other aromatic hydrogens in 
the range of δ 6.96-6.82, integrating to eight protons. The benzylic methylene 
protons for the ortho- and para-xylene rings, both appear as singlets at different 
chemical shifts. The first singlet at δ 5.00 is due to the para 13,13’ hydrogens, 
whereas the ortho-methylene protons 9,9’ are shifted upfield by approximately 
0.33 ppm to a chemical shift of δ 4.67, with both singlets integrating to four protons. 
The two doublet of doublets at δ 4.12 and 3.77 refer to the protons of the ethylene 
units 7,7’ and 8,8’ as a consequence of a AA’BB’ system.  
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Fig.  3.26 Structure of 181 
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Fig.  3.27 The 1H NMR spectrum of 2,3,6,9,12,13,19,20-tetrabenzo-1,4,11,14,17,22-hexaoxa-
cyclotetraeicosa-2,6,7,8,12,19-hexaene, 181 
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In the 13C NMR spectrum of 181 (Fig. 3.28) the aromatic carbons bonded to the 
oxygen atoms have chemical shifts of δ 149.49 (2,2’) and δ 149.05 (1,1’), 
respectively. The aromatic CH groups para to the oxygens (14,14’) appear at δ 
136.85, while the CHs  ortho to oxygen (10,10’) resonate at δ 136.44. The other 
aromatic carbons from the ortho-xylene unit (11,11’ and 12,12’) resonate at δ 127.79 
and δ 128.95, respectively. Tertiary aromatic carbons of para-xylene ring 
(15,15’,16,16’) have merged into a signal of double intensity at δ 127.43. 
Analogously to 182 the tertiary carbons associated with the catechol rings resonate as 
separate signals, with 4,4’ at δ 121.83 and 5,5’ at δ 121.59. Carbons labelled as 6,6’ 
and 3,3’ have also resolved into separate signals, however with close chemical shifts 
of δ 115.19 and at δ 114.52, respectively. The signals for the secondary aliphatic 
carbons in the methylene group “spacers” appear at δ 71.21 for 13,13’ and at δ 70.99 
for 9,9’.  
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Fig.  3.28 The 13C NMR spectrum of 2,3,6,9,12,13,19,20-tetrabenzo-1,4,11,14,17,22-hexaoxa- 
cyclotetraeicosa-2,6,7,8,12,19-hexene, 181 
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3.4.4 The 1H NMR studies of 171 and 172 
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Fig.  3.29 Macrocycles 171 and 172 
 
The 1H NMR of 171 and 172 are shown in Fig. 3.30 and Fig. 3.31 respectively. The 
aromatic proton 12 of the pyridine ring in 171 appears as a triplet, representing the 
highest chemical shift of δ 7.67 with a coupling constant of 7.6 Hz. The protons 
adjacent to 12 appear as a doublet with identical J values and integrating to two 
hydrogens. As in previous cases protons at positions 3-6 and 3’-6’ appear as a 
multiplet in the chemical shift range δ 6.85-6.80. The methylene groups (9,9’) 
linking the pyridine ring to the ether oxygen appear as a singlet at δ 4.82. In the 
region from δ 3.75 to 4.25 typical of glycol ethers, the four doublet of doublets 
ethylene units appear at δ 4.14 (13,13’) and 3.93 (14,14’) (both J values of 4.4 Hz) 
and at δ 4.03 (7,7’) and  δ 3.83 (8,8’), both with a J value of 4.8 Hz. This complexity 
comes from the fact that the pairs of nuclei 7,7’, 8,8’, 13,13’, 14,14’ are not 
magnetically equivalent. All of them are examples of AA’BB’ system. 
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Fig.  3.30 The 1H NMR spectrum of 2,3,11,12,18,20-tribenzo-19-aza-1,4,7,10,13,16,22-heptaoxa-
cyclotetra-eicosa-2,11,18,19-tetraene, 171 
 
Fig. 3.31 shows the 1H NMR spectrum of 172 containing a meta-xylene unit as part 
of the macrocyclic ring. Proton 13 in the meta-substituted aromatic system appears as 
a singlet at δ 7.28, whereas protons 11,11’ and 12 appear as a multiplet at δ 7.25 to 
7.22. A second multiplet at δ 6.82-6.78 is due to the ortho catechol system and 
integrates to eight protons. The methylene hydrogens 9,9’ resolve as a singlet at δ 
4.60. Ethylene units from the ether linkages have merged into double doublets with 
coupling constants of 4.4 Hz and chemical shifts of δ 4.11 and δ 3.79 for 14,14’ and 
15,15’, respectively, and δ 4.05 and δ 3.71 for 7,7’ and 8,8’, with coupling constants 
of 4.8 Hz. 
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Fig.  3.31 The 1H NMR spectrum of 2,3,14,15,21,23-tribenzo-1,4,7,10,13,16,19,25-octaoxacyclo 
heptaeicosa-2,14,21,22-tetrene, 172 
 
3.5 Conclusion 
 
New phenoxy-linked precursors of macrocyclic compounds have been successfully 
prepared by alkylation of 2-(2-hydroxyethoxy)phenol 159 with a variety of alkyl 
dihalides in DMF in the presence of K2CO3. Synthesised compounds were isolated in 
high yields varying between 54 to 91 %. All seven structures have been identified by 
NMR and HRMS. For six of the macrocyclic precursors, it was possible to confirm 
their structures by X-ray crystallography (Chapter 5).  
All these phenoxy-linked macrocyclic precursors were subjected to ring closure 
reactions employing the template effect and high dilution techniques.   
Two routes of synthesis of model macrocycles were investigated:  
A. from phenoxy-linked open structures,  
B. one pot synthesis from 2-(2-hydroxyethoxy)phenol.  
The one-pot approach proved to be a straightforward method, however isolated 
yields for compounds prepared according to this method were unsatisfactory (6-
13 %) The approach of synthesis of model macrocycles from their phenoxy-linked 
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open structures was more extensively investigated. Various bases and solvents were 
screened which established that the greatest yields for the macrocyclization step were 
accomplished in the presence of KOH and KI in refluxing 1,4-dioxane. It was 
established that the presence of a templating agent plays a crucial role in that step. A 
series of alkali metal bases were screened with the presence of K+ compared to Cs+, 
Na+ or Li+ enabling the reaction to proceed with the highest yield. The advantage of 
this method compared to the one pot synthesis is good overall yields of synthesised 
macrocycles, which varied between 24-47% isolated yields. Eighteen model 
macrocyclic structures based on 2-(2-hydroxyethoxy)phenol unit and both aromatic 
and aliphatic ethereal linkers were successfully synthesised and isolated. A library of 
macrocycles and their phenoxy linked precursors were screened as therapeutics as 
part of our cancer program (Chapter 7). Assay of binding extraction studies of 
synthesized compounds towards a selection of metal picrates was also performed 
(Chapter 6). 
A further reason for synthesising a variety of macrocyclic model systems based on 2-
(2-hydroxyethoxy) phenol and optimizing reaction conditions was to explore the 
reactivity and behaviour of the two hydroxyl groups in diol to established reaction 
procedures on the preparation of morphine macrocycles.  
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Fig.  3.32 Similar features in structures of 2-(2-hydroxyethoxy) phenol 159 and morphine 187 
 
It was expected that both alcohol groups in morphine will react in the same order 
(would exhibit similar reactivity) as per the 2-(2-hydroxyethoxy) phenol system. 
Therefore extensive effort was undertaken for optimization for the alkylation of diol 
and ring closure step conditions, especially that the diol substrate is sterically less 
rigid and more easily available. 
  
87 
 
 
 
 
 
 
 
 
 
“Of all the remedies which a kind Providence has bestowed upon mankind for the 
purpose of lighting its miseries, there is not one which equals opium in its power to 
moderate the violence of so many maladies and even to cure some of them” 
 
Thomas Sydenham 1624-1689 
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4 Morphine compounds 
 
The powerfully euphoric and analgesic opium alkaloids have fascinated mankind 
since the days of antiquity. The active principles of opium have been known for 
years to be highly powerful pain relievers. Morphine and its 3-O-methylated form, 
codeine are principal constituents of opium and can be obtained by isolation from the 
unripe seed pods of the opium poppy, Papaver somniferum131. 
In 1805 the active principle of opium was isolated in pure form as a white crystalline 
powder and named “morphium” after Morpheus, the ancient Greek god of dreams132. 
Since then morphine became one of the most commonly prescribed drugs in medical 
practice and was widely employed to treat ailments as diverse as diabetes, asthma, 
diarrhoea and ulcers as well as being used in the relief of moderate to severe pain. 
However, the dark side of morphine is that it is highly addictive and tolerance, 
physical and psychological dependence develop very rapidly. 
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Fig.  4.1 (-)- Morphine 187 
 
The activity shown by morphine including both analgesic potency and narcotic side 
effects, has been proven to depend on its structural arrangement. The specific set of 
structural features common to the opioid family are: a tertiary nitrogen with a small 
alkyl substituent, a quaternary carbon, a phenyl group or its isosteric equivalent 
directly attached to the quaternary carbon and finally a two carbon spacer between 
the quaternary carbon and the tertiary nitrogen. All of the derivates of morphine 
which possess this basic ring structure can act as either an agonist or antagonist of 
the opioid receptor. Therefore, some of them are used as effective analgesics for the 
treatment of pain while others are useful as opioid antagonists for the treatment of 
narcotic overdosage or opioid addiction. 
Codeine is one of the constituents of opium and is approximately one-sixth as 
effective an analgesic as morphine. It is commonly prescribed as a cough suppressant 
and mild pain reliever. One of the better known examples of a morphine derivative is 
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heroin. Heroin (diamorphine) presents the same structural features as morphine, 
except that both of the hydroxyl groups have been modified by acetylation. 
Diamorphine has physiological effects that are essentially the same as those of 
morphine except that it acts faster and so has a greater potency. The presence of the 
two acetyl units on the hydroxyl groups makes heroin very lipid-soluble and so it 
readily enters the brain where it is rapidly hydrolyzed to morphine, whereas 
morphine itself is less lipid-soluble and thus crosses the blood-brain barrier more 
slowly. 
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Fig.  4.2 Morphine derivatives codeine 188, diamorphine 189 and thebaine 190 
 
Another ingredient of opium, thebaine has been found to be a biochemical precursor 
of morphine and codeine. Thebaine has no therapeutic application, but is used 
industrially for the production of synthetic opiates such as oxymorphone 191, 
naloxone 192 and etorphine 193.  
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Fig.  4.3 Morphine derivatives oxymorphone 191, naloxone 192 and etorphine 193 
 
Opiates induce such an intense biological response because of their binding 
properties to specific receptor sides within the central nervous system and 
gastrointestinal tract133. The opioid receptors (G protein-coupled receptors) have 
been identified as a large protein family of transmembrane receptors which can be 
activated by binding to ligand structures like peptides, proteins, hormones, 
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pheromones or neurotransmitters (including the skeleton of morphine). Three distinct 
classes of mammalian opioid receptor µ, κ and δ have been identified and have been 
the subject of intense studies134,135,136. 
Morphine itself is a selective µ-type receptor agonist, and so the analgesia it elicits is 
also accompanied by euphoria, decreased gastrointestinal motility (leading to 
constipation), physical dependence, and respiratory depression137,138. The latter is 
usually the cause of death upon morphine overdose. The synthetic opiate 
oxymorphone has been found to be a µ-agonist with ten times the potency of 
morphine, whereas the closely related naloxone actually antagonises all types of 
opioid receptors and is a useful antidote to morphine overdosage. Etorphine has a 
thousand times the potency of morphine as a µ-agonist and greatly depresses 
respiration. That is why its use is mainly reserved for the immobilisation of very 
large animals, such as elephants.  
The harrowing addiction to morphine continues to provide impetus to the quest for 
alternative drugs, based on the morphine skeleton, that are powerful analgesics but 
do not have the undesirable side effects. The opium alkaloids and their analogues are 
called opioids and all of these compounds bear a strong structural resemblance one to 
another, which first suggested that there are receptors in animals complementary in 
structure to morphine and its family139. 
Synthesis of the morphine skeleton has been a great challenge for organic chemistry 
for the past decade140. There is continuing interest in developing total synthetic 
routes because of the broad range of pharmacological properties of morphine 
alkaloids and related compounds. Many routes and possibilities for analogues have 
been already reported, however, at an industrial scale none of them can be considered 
an efficient alternative to isolation of morphine from poppies141,142.  
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4.1 Preparation of morphine macrocycle precursors 
 
Vögtle and Frensch have reported a method for preparation of open chain oligomeric 
ethylene glycol ethers 194 and 195 with two terminal morphine groups143. The 
reaction was carried out by refluxing the oligomeric dichloride with morphine in wet 
butanol in the presence of sodium hydroxide as a base. Structure 194 was isolated in 
8% yield and 195 in 10 % yield. Attempts to join two morphines with 2,6-
bis(bromomethyl)pyridine were also undertaken. However, in this case 6-(3-
morphinylmethylene)-2-pyridinyl-methanol 196 was isolated as the major product in 
10 % yield.  
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Fig.  4.4 n=1; 1,8-bis(3-morphinyl)-3,6-dioxaoctan, 194; n=2; 1,11-bis(3-morphinyl) -3,6,9-trioxa-
undecane 195, 6-(3-morphinylmethylene)-2-pyridinylmethanol 196 
 
In our research a series of novel macrocyclic precursors containing two morphine 
units in the structure were successfully synthesized and isolated. Methodology used 
for this purpose was however, different from the one established by Frensch. Also 
reaction conditions developed for preparation of phenoxy-linked model systems 
based on the 2-(2-hydroxyethoxy)-phenol unit 159 did not prove useful.  
Developing a satisfactory method which allows preparation of the desired 
compounds in high yields and purity was achieved by screening of series of reactions 
employing a variety of bases e.g. Na2CO3, K2CO3, Cs2CO3, NaOH, NaOMe, KOH 
and DMAP in different solvents: MeOH, acetone, DMF, THF and 1,4-dioxane. The 
best base/solvent combination for preparation of compounds 194, 198, 199 and 200 
proved to be NaOMe in refluxing MeOH. By employing these conditions the final 
products were synthesized in isolated yields ranging from 64 % to 94 %. However, 
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synthesis of 201 and 202 by this method did not give satisfactory yields, and instead 
for synthesis of 201 and 202 potassium tert-butoxide in refluxing THF was preferred. 
Under these conditions 197, 201 and 202 were isolated in 28 %, 51 % and 37 % 
yields, respectively. Notably, in all cases, the use of bromides or iodides instead of 
chlorides leads to a significant increase in the quantity and purity of the products.  
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Fig.  4.5 Precursors of morphine macrocycles 
 
Compounds 194, 198-200 were prepared by alkylation of morphine with the 
corresponding alkyl halides in absolute methanol in the presence of 3 eq of sodium 
methoxide as a base. First the morphine hydrochloride salt was suspended in solvent 
and then while stirring the suspension of salt, a solution of sodium methoxide in 
methanol was added dropwise over 1 hour. Next, the alkylating agent was added in 
one aliquot and the reaction was stirred at 64 °C for 48 h. In each case the reaction 
mixture was purified by column chromatography, to give the linked morphine in 
yields varying between 36-94%. Several attempts to prepare 194 using 1,2-bis(2-
chloroethoxy)ethane 203 in the presence of sodium methoxide in methanol or sodium 
ethoxide in ethanol were undertaken and in both cases product was isolated in 42 % 
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yield. However, the highest yield (94 %) of 194 was obtained for reaction of 1,2-bis-
(2-iodoethoxy)ethane 204 in methanol in the presence of sodium methoxide. 
Compound 198 was prepared in a one step synthesis by reaction of morphine with 
α,α’-dibromo-p-xylene 206 in the presence of sodium methoxide  in absolute 
methanol. The crude product was purified by column chromatography, to give 198 in 
a 68 % yield, a considerable improvement over the yield of 36 % obtained by 
refluxing of morphine with α,α’-dichloro-p-xylene 205 and sodium carbonate in 
THF. 
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Fig.  4.6 Synthesis of 194, 198, 199, 200 
 
Likewise, compound 199 was synthesised from morphine hydrochloride and α,α’-
dibromo-m-xylene 207 then isolated by column chromatography in 72 % yield. 
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Again the use of alternative bases led to less satisfactory yields, with potassium 
hydroxide in THF giving 17 %, potassium carbonate in 1,4-dioxane 27 % and 
sodium carbonate in DMF no product at all. 
Compound 200 was also synthesized using the optimum conditions of NaOMe/abs. 
MeOH and then purified by column chromatography, to give the crystalline 
macrocyclic precursor in 48 % yield. 200 was again prepared, however, in lower 
yields (18 %) using α,α’-dichloro-o-xylene 208 and sodium carbonate in 1,4-dioxane. 
Attempts to prepare 202 by reaction in NaOMe and abs MeOH did not succeed, 
therefore synthesis of intended 202 was repeated, however in boiling THF in the 
presence of potassium tert-butoxide. 202 was isolated by column chromatography in 
37 % yield. 
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Fig.  4.7 Synthesis of 197, 201 and 202 
 
Isolated yields for the preparation of 201 by reaction of morphine and 2,6-
bis(chloromethyl)pyridine 185 in MeOH and NaOMe were disappointingly low 
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(12 %). However, the synthesis using tBuOK in THF again proved superior and 
under these conditions 201 was prepared in 42 % isolated yield after column 
chromatography. In common with the general pattern, attempts to prepare 211 were 
undertaken using both NaOMe in abs MeOH and tBuOK in THF, reaction 
conditions. Both 2-chloroethyl ether 209 and 2-bromoethyl ether 210 were 
employed, however formation of 211 was not observed.  
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Fig.  4.8 Synthesis of 197 
 
Instead considerable amounts of 197 were isolated with the higher yields observed 
when 2-bromoethyl ether 210 replaced 2-chloroethyl ether 209 as the alkylating 
agent. Furthermore, replacing sodium methoxide with the preferred base tBuOK in 
refluxing THF increased the yield from 16 to 28 %. Perhaps low quality of the 
alkylating agent and simultaneous hydrolysis of one of the halide groups was the 
main reason for the formation of mono-morphineglycol 197.  
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Fig.  4.9 Structures of morphine macrocyclic precursors 194, 198-202 
 
All six morphine macrocyclic precursors 194, 198, 199, 200, 201 and 202, containing 
two morphine units in the structures, were prepared by our developed concise 
synthetic route. The most difficult part was the purification and isolation of the 
products. Attempts at recrystallization, Soxhlet extraction and conversion of selected 
structures into their hydrochloride salts to facilitate purification proved unsuccessful 
and finally every compound was only obtained in a pure form after column 
chromatography on silica gel, using a DCM/MeOH/NH4OH mixture. All compounds 
were identified by 1H, 13C NMR, IR and HRMS. 
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4.2 Modifications on 6-hydroxyl group of morphine 
 
As has been established codeine and morphine derivatives are favourable from a 
pharmacological point of view as targets for SAR studies. Another example is 
morphine 3,6-dinicotinate 213 which shows decreased physical dependence and 
respiratory depression compared with morphine144. The synthetic route to 3,6-
dinicomorphine 213 and 6-nicocodeine 214 commences with conversion of nicotinic 
acid into nicotinic chloride 212 with thionyl chloride. After evaporation of excess 
chlorinating agent, chloroform and pyridine were added to the residue, followed by 
either morphine or codeine. Depending on the reaction conditions either one, or both 
of the hydroxyl groups in morphine can be esterified to form either 3,6-
dinicomorphine or 3-nicomorphine145.  
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Fig.  4.10 Synthesis of 213, 214 
 
Nicotinate of codeine 214 did not show any analgesic activity, however morphine 
3,6- dinicotinate 213 proved to have the same analgesic potency as morphine. 
In our laboratory compound 213 was prepared according to Hosztafi’s procedure in 
74 % isolated yield. This encouraged us to employ the same reaction conditions to 
introduce nicotinyl units onto the secondary alcohol functions of compound 194.  
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Fig.  4.11 Synthesis of 215 
 
In a first step nicotinic chloride 212 was again obtained from nicotinic acid and 
thionyl chloride and then dry chloroform and dry pyridine were added to the residue 
and refluxed. While cooling the mixture down 10 °C 194 was added in small 
portions over 30 min, allowed to warm to RT and then stirred for 16 h. The crude 
was loaded directly onto a silica column and chromatographed to give 215 as a 
crystalline solid in 34 % yield. Furthermore, acetylation of 199 with acetic anhydride 
was also studied and this experiment afforded the product 216 in 29 % isolated yield. 
These successful experiments encouraged us to investigate alkylating linkers as a 
means of accessing the target macrocyclic compounds.  
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Fig.  4.12 Synthesis of 216 
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4.3 Preparation of morphine macrocycles  
 
We succeeded with successful synthesis and isolation of four morphine macrocycles 
(Fig. 4.13). Previously optimized reaction conditions for the ring closure step of the 
model systems were employed. 
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Fig.  4.13 Morphine macrocycles 217-220 
 
After a series of unsuccessful attempts at ring closure reactions on macrocyclic 
precursors, it turned out that the success of this reaction largely depends on the 
choice of the spacer linking the phenol groups. We discovered that macrocyclic 
precursor 194 with the longer and more likely flexible alkyl linker (dioxa-octane) 
would accept the shortest spacers between the secondary alcohol functions (e.g. 
meta-xylene).  
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Fig.  4.14 Synthesis of macrocycles 217, 218, 219 containing morphine units 
 
Even with such favourable systems, the metal template is still a key factor and 
successful macrocyclization reactions generally required potassium or caesium 
hydroxide in refluxing THF. As was already established, morphine open structure 
194 containing the longest ethereal chain reacted with α,α’-dichloro-o-xylene 208 in 
the presence of KOH and KI or CsOH and KI to form the target compound 217 in 
26 % and 17 % isolated yields, respectively. The effectiveness of potassium as a 
template may correspond to the similarity between this molecule and 18-crown-6. 
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Fig.  4.15 Etheral oxygens of 194 templating metal cation 
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Identical reaction conditions were applied to the preparation of macrocycle 218, 
however this time higher yields were obtained with CsOH as the base, instead of 
KOH. Purification was carried out by column chromatography to give 218 in 11 % 
and 18 % yields, respectively. Ring closure of 194 with 2,6-bis-
(chloromethyl)pyridine 185 was carried out using various reaction conditions. As 
shown in Table 4.1 (entries 7-10) formation of the product was not observed using 
sodium or barium hydroxide. However, macrocycle 219 was successfully isolated 
from reactions carried out in the presence of KOH or CsOH in 13 % and 21 % yields, 
respectively. The most difficult macrocycle to synthesise was 220, which is derived 
from macrocyclic precursor 198 which incorporates a para-xylene spacer. As a result 
it is less flexible than the polyetheral chain in 194, which possibly resulted in the 
relatively low isolated yields for 220 (Table  4.1, entries 11,12).  
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Fig.  4.16 Synthesis of morphine macrocycle 220 
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Entry Compound Base Additive Solvent Temp 
[°C] 
Yield 
[%] 
1 217 NaOH NaI THF 64 0 
2 217 KOH KI THF 64 26 
3 217 CsOH KI THF 64 17 
4 218 KOH KI THF 64 11 
5 218 CsOH KI THF 64 18 
6 218 Ba(OH)2 KI THF 64 0 
7 219 NaOH NaI THF 64 0 
8 219 KOH KI THF 64 13 
9 219 CsOH KI THF 64 21 
10 219 Ba(OH)2 KI THF 64 0 
11 220 KOH KI THF 64 17 
12 220 CsOH KI THF 64 9 
Table  4.1 Reaction conditions for preparation of morphine macrocycles 217-220 
 
At the beginning of this chapter it was hypothesised that morphine macrocycles can 
be successfully synthesised under the condition that the linkers connecting the two 
morphine structures should differ in terms of length and flexibility. To support this 
conclusion a series of negative results from ring closure experiments are recorded 
(Table 4.2-4.6). 
 
Open structure Alkyl linker Base/additive Solvent Yield 
[%] 
ClCl
 
KOH/KI THF 0 
Cl Cl
 
CsOH/KI THF 0 
N
ClCl
 
CsOH/KI THF 0 
O
OH
O
N
CH3
O
OH
O
N
CH3
 
ClCl
 
KOH/KI THF 0 
Table  4.2 Attempted preparation of morphine macrocycles from 199 
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Open structure Alkyl 
linker 
Base/additive Solvent Yield 
[%] 
Cl Cl
 
KOH/KI or 
CsOH/KI THF 0 
OH
O
O
N
CH3OH
O
O
N
CH3
 
ClCl
 
KOH/KI or 
CsOH/KI THF 0 
Table  4.3 Attempted preparation of morphine macrocycles from 198 
 
Open structure Alkyl linker Base/additive Solvent Yield 
[%] 
ClCl
 
KOH/KI or 
CsOH/KI THF 0 
Cl Cl
 
KOH/KI THF 0 
OH
O
O
N
CH3
O
OH
O
N
CH3
 
O O
I I
 
CsOH/KI THF 0 
Table  4.4 Attempted preparation of morphine macrocycles from 200 
 
Open structure Alkyl 
linker 
Base/additive Solvent Yield 
[%] 
ClCl
 
KOH/KI THF 0 
O
OH
O
N
CH3
O
N
OH
O
N
CH3
 
N
ClCl
 
KOH/KI THF 0 
Table  4.5 Attempted preparation of morphine macrocycles from 201 
 
Attempts to prepare morphine macrocycles (Table 4.2-4.5) were carried out in 
boiling THF in the presence of potassium or caesium hydroxide and potassium 
iodide, according to the usual protocol, without success. All the reaction conditions 
and working procedures were identical to those undertaken for the synthesis of 217- 
220, therefore we believe the reason for the lack of cyclization may be the rigidity of 
the morphine moiety.  
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The approach of introducing a propylene chain into 194 failed because of the 
competing elimination reaction which occurs, yielding product 222 in 19 % isolated 
yields. The reaction was carried out as in the previous cases, using potassium 
hydroxide and potassium iodide in boiling THF.  
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Fig.  4.17 Synthesis of 222 
 
Instead of the desired macrocyclic structure 223, the compound allylated on the 
secondary alcohol groups 222 was identified. This occurrence motivated us to 
attempt a ring closure reaction by olefin metathesis using Grubbs catalyst146, 
therefore 222 was prepared in larger quantities by a more practical method. 222 was 
preferably synthesised by treating 194 with allyl bromide or allyl iodide in the 
presence of potassium hydride in THF at -20 °C. Higher yields were observed with 
allyl iodide. However, in refluxing THF and potassium hydroxide alkylation with 
allyl bromide proved to proceed more smoothly. In the best case, 222 was isolated in 
37 % yield (Table 4.6). 
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Entry Alkylating agent Base solvent Temp 
[°C] 
Isolated yield [%] 
222 
1 Allyl bromide KH THF -20 to RT 16 
2 Allyl bromide KOH THF 66 24 
3 Allyl iodide KH THF -20 to RT 37 
4 Allyl iodide KOH THF 66 12 
Table  4.6 Reaction conditions for preparation of 222 
 
Attempt of ring closure by an olefin metathesis reaction on 222 employing 1st 147 and 
2nd generation Grubbs catalysts148. 
Ru
Cl
Cl Ph
P(Cy)3
NN
CH3
CH3
CH3
CH3
CH3
CH3
Ru
Cl
Cl
Ph
P(Cy)3
P(Cy)3
225 2nd generation224  1st generation
 
Fig.  4.18 1st and 2nd Generation of Grubbs catalysts 224  and 225 
 
Despite our efforts to perform this reaction under a variety of conditions, including 
refluxing in toluene and xylene with a stream of nitrogen to remove ethylene gas and 
shift the equilibrium, formation of the product was not observed in any case. 
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Fig.  4.19 Attempt of ring closure by metathesis on 222 
 
Synthesis of 226 using ring closure metathesis (RCM) was attempted using the 1st 
Generation Grubbs catalyst 224 in various solvents at molar concentrations of 5-
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10 mol%. First 1 mmol of 222 and 5 mol% of 224 was stirred under nitrogen in 
DCM at 40 °C for 2 days with no conversion of starting material. Next, 222 with 
10 mol % catalyst loading in 1,2-dichloroethane (b.p. 84 °C) and then toluene (b.p. 
110 °C) were investigated as solvents because they have higher boiling points that 
might promote the reaction. However, no success was achieved using Grubbs type I. 
It was then decided to perform trials using the 2nd generation Grubbs catalyst 225 
since it has been reported to be more useful in macrocyclization reactions149. 
Reactions in four different solvents were screened, dichloromethane, 1,2-
dichloroethane, toluene and para-xylene (b.p. 138 °C). In each case the reaction was 
refluxed under a stream of nitrogen to drive off ethylene and shift the equilibrium 
towards the product, but nevertheless in no case was macrocyclization achieved. In 
cases where the reaction temperature was below 100 °C starting material was 
recovered from the reaction mixture, whereas in synthesis performed at 105-110 °C 
only degradation of starting material was observed.  
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4.4 Spectroscopic discussion on morphine macrocycles  
4.4.1 NMR study of 194 and its macrocycles 217 and 218 
 
As expected from a chiral scaffold, the 1H NMR spectra of the macrocycles and their 
precursors containing the morphine moiety is more complex than for analogous 
model macrocycles. In the 1H NMR spectrum of 194 the protons of the morphine 
moiety gave resonances identical to those reported for morphine150. 194 is the 
phenoxy-linked morphine open structure, which has been used for the synthesis of 
novel morphine macrocycles 217, 218 and 219. The 1H NMR spectrum of the 
morphine macrocyclic precursor 194 and macrocycle 217 are shown in Fig. 4.21 and 
Fig. 4.22, respectively. Protons 18,18’ in 194 appear as a two doublets of double 
doublets at δ 4.22 and δ 4.10, with J values of 10.8, 5.2 and 1.2 Hz and these values 
could be calculated only for the first signal since the second one overlapped with the 
6,6’ protons of the morphine moiety. This multiplicity is due to the diastereotopic 
nature of these protons and is a result of geminal coupling between the two 18,18’ 
hydrogens and further coupling between 18,18’ and the adjacent hydrogens, 19,19’. 
The signal from the hydrogens 20, 20’ which also exhibit diastereotopicity, appear at 
δ 3.69 as two doublets of double doublets which overlap with one another, therefore 
exact calculation of the coupling constants was not possible.  
In the spectrum of 217 the appearance of protons in the ethereal chain has slightly 
changed, compared with 194. Specifically, the protons of 18,18’ in 217 appear as a 
triplet with a J value of 5.0 Hz, whereas protons 19,19’ which resonate as a triplet at 
δ 3.76 ppm with a J value of 4.8 Hz in 194, in 217 appear as a multiplet in the range 
δ 3.72-3.64. Protons 20,20’ at δ 3.56 are also diastereotopic and appear as two 
doublets of double doublets overlapping one another.  
The aromatic protons of the ortho-xylene unit (23,23’,24,24’) in 217 appear as 
double doublets at δ 7.43 and δ 7.24 with coupling constants of  5.6 and 3.6 Hz, 
respectively. Additional peaks arise from the xylene unit, in which the benzylic 
methylene groups appear as two individual doublets at δ 5.02 and δ 4.61 with 
coupling constants of 12.0 Hz. These protons (21,21’) are diastereotopic and 
therefore appear as two individual doublets, a consequence of their mutual coupling.  
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Fig.  4.20 Morphine macrocycle 217 and its precursor 194 
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Fig.  4.21 The 1H NMR spectrum of 194 
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Fig.  4.24 The 13C NMR spectrum of 217 
 
The 13C NMR spectra of 194 and 217 are depicted in Fig. 4.23 and Fig. 4.24. The 
resonance for the ethereal chain in 194 and 217 carbons also appear at very similar 
chemical shifts, however the order of appearance of ethereal carbons in 194 is 20, 
20’ (at δ 70.71), 19,19’ (at δ 69.93) and 18,18’ (at δ 69.14), whereas in 217 this 
arrangement has changed, with 18,18’ appearing at a higher chemical shift (δ 69.77) 
than 19,19’ at δ 69.54. The main difference in shifts between those two structures 
was observed for carbons 6, 6’ in the morphine moiety. In the spectrum of 194 6,6’ 
appears at δ 66.49 whereas in 217 it is shifted downfield to δ 73.07. Furthermore, the 
peaks related to the ortho-xylene ring differentiated these two spectra. The ortho- 
and meta-CH in the xylene ring (24,24’and 23,23’) in 217 appear at δ 128.53 and δ 
127.54 respectively, whereas the quaternary aromatic carbons 22,22’ resonate at δ 
136.79. The secondary benzylic methylene carbons 21,21’ appear at δ 68.29.  
In the 1H NMR spectrum of the morphine macrocycle, 218 (Fig. 4.26) the isolated 
aromatic hydrogen of meta-xylene (25) appears as a singlet at δ 7.34 integrating to 
one proton, whereas aromatic protons 23,23’ and 24 resonate as a muliplet 
integrating to 3 protons at δ 7.23-7.18. The protons of the benzylic methylene group 
appear as two individual doublets at δ 5.55 and δ 4.84, each with a coupling constant 
value of 11.4 Hz.  This coupling is due to the diastereotopic nature of these protons 
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and corresponds to a coupling between the two methylene protons. In 194 the 
protons 18,18’ appear as two doublets of double doublets, whereas in 218 their 
appearance is still more complex, and they resolve as a multiplet, absorbing in the 
range δ 4.15-4.07. Furthermore, protons 19,19’ which appear as a triplet at δ 3.76 in 
194, appear as a multiplet in 218 at a chemical shift from δ 3.65-3.55. Protons 20,20’ 
appear as a singlet at δ 3.42 integrating to 4 protons, in contrast to the corresponding 
protons in 194 which exhibit chemical non-equivalence.  
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Fig.  4.25 Morphine macrocycle 218 
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Fig.  4.26 The 1H NMR spectrum of 218 
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Fig.  4.27 The 13C NMR spectrum of 218 
 
In the 13C NMR spectrum (Fig. 4.27) of 218 signals appear in the aromatic region 
due to the quaternary carbons of the meta-xylene ring (22,22’), resonating as a peak 
of double intensity at δ 138.59. At higher field, peaks of single intensity assigned to 
aromatic CHs 24 and 25 appear at chemical shifts of δ 127.31 and δ 126.24, 
respectively. Finally the signals for the tertiary aromatic carbons 23,23’ resonate at δ 
126.50. Benzylic methylene carbons (21,22’) resonate at δ 70.44 and are shifted 
downfield compared with the signal of the corresponding carbons in 217 (δ 68.29). 
The carbons of 6,6’ in 194 appear at δ 66.49, whereas the corresponding carbons in 
218 are shifted downfield and can be seen at δ 73.41. In 218 remaining ethereal 
carbons appear at δ 70.50 for 20,20’, at δ 70.19 for  18,18’ and at δ 69.82 for 19,19’ 
as peaks of double intensity.  
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4.5 Conclusion 
 
The synthesis and structural characterization of a series of macrocyclic structures and 
their precursors with morphine moiety has been carried out.  
Synthesis of macrocyclic precursors with two morphine units have been developed 
and reaction conditions were optimised, therefore designed opens structures were 
prepared in moderate to high yields. Each of the phenol linked morphine open 
structures were synthesised for further employment in the synthesis of morphine 
macrocycles. Metal binding studies were carried out on each of the successfully 
synthesised and isolated phenol linked morphine open structures with a variety of 
metal ions. Ring closure reactions by introducing ortho and meta-xylenes and bis- 
(2,6-methyl)pyridine linkers was achieved by employing potassium and caesium 
hydroxides under high dilution conditions in boiling THF. The purpose of the base 
was to deprotonated the secondary alcohol group to generate an alkoxide while the 
metal template may serve to orient the reactive groups close to one another and lower 
the free energy of activation for the entropically disfavoured end-to-end cyclization.  
On the basis of the limited available evidence, it would appear that to facilitate 
cyclization of morphine macrocycles a small linker (e.g. ortho-xylene) is required to 
link the secondary alcohols in morphine macrocyclic precursor. This situation 
contrasts with reactions carried out on the more flexible 2-(2-hydroxyethoxy)phenol 
moiety which facilitates introduction of a variety of alkyl linkers that could not be 
incorporated into the bis-morphine macrocycle precursor. This experiment data can 
now be used to assist with future molecular modelling studies in the group, since 
computer modelling was not the remit of this PhD. 
Firstly the aims of the project with this group of compounds were achieved, 
especially as the synthesis of these novel structures had not been reported previously. 
Secondly when we consider the properties of these species and their potential 
applications as analgesic compounds, P-gp inhibitors and chiral ligands in 
asymmetric catalysis it opens numerous possibilities for future work. 
An advantage of preparing morphine macrocycles is that they may have applications 
as chiral ligands for asymmetric synthesis. Moreover, morphine’s three-dimensional 
rigid structure could then increase the likelihood of preferential binding of chiral 
guests. Furthermore, the rigid chiral structure may impart chirality onto the products 
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in any potential catalysed reactions, controlling stereoselectivity of the reaction, i.e. 
increase the enantiomeric excess of either the R or S enantiomer. 
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5 Crystallographic studies 
 
An understanding of the interactions in the crystals of a potential ion receptor can 
provide valuable information on the bonding mode and binding sites of “host” 
molecule in solution studies151. The crystallographic analysis of therapeutic 
compounds has also proven invaluable to chemists and biologists in understanding 
the key binding sites and modes of action of these therapeutic agents152. From the X-
ray crystallographic analysis of the macrocyclic structures 179 and 184 and their 
precursors 160, 161, 163-166 the cavity sizes of the cyclic species were estimated 
using Mercury 1.4.2 software. These data were based on solid state and it must be 
emphasised that the macrocycles and their precursors may undergo significant 
conformational changes when in solution or when binding to guest species. However 
the X-ray data regarding the cavity size of the macrocycles can be used to estimate 
which of the guest species might have a significant chance of binding to the 
macrocycle. In this project the guest species of interest are metal cations. The full 
data for each of the compounds is specified in the appendix A. By comparing trends 
in X-ray data with actual trends of metal cation binding this may lead to a more 
accurate predictive model for future work. 
 
5.1 Structural studies of macrocycle 179 
 
Crystals suitable for single crystal X-ray crystallographic determination of 179 were 
grown by slow evaporation from chloroform : hexane (4:1), yielding colourless block 
shaped crystals of m.p.=159-161 °C. Selected bond distances and angles of non-
hydrogen atoms are given in Table 5.1 and Table 5.2. Figure 5.2 shows perspective 
views of the crystal structure with the atomic numbering.    
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Fig.  5.1 X-ray structure of 179 
 
The presence of the four six member rings deformed the structure, severely 
restricting the flexibility commonly recognized for ethereal aliphatic crown ethers. 
The structure takes on the form of a flattened and slightly deformed ellipsoid.  
 
Bond distances 
C(7)–C(8) 1.468(10) 
C(11)–C(14) 1.480(10) 
C(14)–O(3) 1.404(8) 
O(2)–C(7) 1.421(9) 
O(3)–C(15) 1.359(9) 
C(6)–O(2) 1.360(8) 
O(5)–C(23) 1.365(8) 
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Bond angles 
C(6)–O(2)–C(7) 117.4(6) 
O(2)–C(7)–C(8) 106.7(6) 
O(3)–C(14)–C(11) 108.1(6) 
C(23)–O(5)–C(22) 113.8(6) 
O(6)–C(30)–C(28) 110.9(6) 
C(30)–O(6)–C(31) 113.9(5) 
Table  5.1 Selected bond distances [Å] angles [°] for 179 with estimated standard deviations 
 
O(2)–C(7)–C(8)–C(13) 84.7(9) 
C(12)–C(11)–C(14)–O(3) 2.3(10) 
O(5)–C(23)–C(24)–C(29) 157.0(7) 
C(29)–C(28)–C(30)–O(6) 166.7(6) 
Table  5.2 Selected torsion angles [°] for 179 
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Fig.  5.2 X-ray crystal structure of 2,3,6,9,12,13,19,21-tetrabenzo-1,4,11,14,17,23-
hexaoxacyclopentaeicosa-2,6,7,8,12,19,20-hexaene, 179 
 
 
 
Crystallographic studies 
 
118 
 
2-O6 O3-O5 O2-O4 O2-O5 O3-O1 O3-O6 C7-30 C14-23 
4.67 4.71 8.19 7.85 8.16 7.83 5.11 5.46 
Table  5.3 Dimensions of the cavity of compound 179 
 
Macrocycle 179 crystallizes in the monoclinic space group P21/n with four 
independent molecules per asymmetric unit. The bond length for C(7)–C(8) is 
1.468 Å and for C(11)–C(14) is 1.480 Å, whereas for O(2)–C(7) it is 1.421 Å and for 
C(14)–O(3) the bond length is slightly shorter at 1.404 Å. Bonds C(6)–O(2) and 
O(3)–C(15) are almost the same distances at 1.360 Å and 1.359 Å respectively. The 
angle for O(2)–C(7)–C(8) is 106.7° and is close to O(3)–C(14)–C(11) angle of 
108.1°. However, torsion angles for O(2)–C(7)–C(8)–C(13) and C(12)–C(11)–
C(14)–O(3) are  84.7° and 2.3° respectively. This gives an indication that the 
compound is not completely symmetrical in the solid state. However, torsion angle 
values associated with the meta-xylene unit are similar and equal 166.7° for C(29)–
C(28)–C(30)–O(6) and 157.0° for O(5)–C(23)–C(24)–C(29).  
 
5.2 Structural studies of macrocycle 184 
 
Macrocycle 184 containing two pyridine rings, with four aromatic rings in total is 
conformationally quite rigid. It is clearly depicted in Fig. 5.3 that the pyridine rings 
are almost perpendicular to each other, essentially shielding one side of the 
macrocycle, creating a potential binding pocket. Crystals suitable for single crystal 
X-ray crystallographic determination of 184 were grown from chloroform by slow 
solvent evaporation, yielding colourless block shaped crystals of m.p.=145-147 °C.  
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Fig.  5.3 X-ray structure of 184 visioned in Mercury 1.4.2  
 
Macrocycle 184 crystallizes in the monoclinic space group P21/n with two 
independent molecules per asymmetric unit. The bond length for O(1)–C(7) is 
1.376 Å which is slightly longer then the C(29)–O(6) which equals 1.360 Å, however 
both are shorter then C(14)–O(3) and O(4)–C(22) which are 1.410 Å and 1.406 Å 
respectively. A similar correlation which highlights the influence of the aromatic 
rings was observed for bonds C(5)–C(6), 1.473 Å and C(1)–C(30) 1.499 Å. These 
are slightly shorter than the corresponding bonds on the other pyridine ring C(15)–
C(16), 1.507 Å and C(20)–C(21), 1.508 Å. The angles for O(1)–C(6)–C(5) and 
O(6)–C(30)–C(1) display close values which are 110.5° and 108.2° respectively, and 
the angles for C(7)–O(1)–C(6) 118.0° and C(29)–O(6)–C(30) 119.6° are also similar. 
The angle of O(3)–C(15)–C(16) is 112.8 and is identical to O(4)–C(21)–C(20), while 
C(14)–O(3)–C(15) and C(22)–O(4)–C(21) differ slightly at 111.5° and 113.4°.     
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The torsion angles for C(5)–C(6)–O(1)–C(7) and C(29)–O(6)–C(30)–C(1) are 174.9° 
and 145.4° respectively, whereas C(6)–O(1)–C(7)–C(8) is 15.4° and C(28)–C(29)–
O(6)–C(30) is –42.6°. The torsional angles of  C(14)–O(3)–C(15)–C(16) and C(20)–
C(21)–O(4)–C(22) are –75.2° and 84.8°, whereas the values for O(3)–C(15)–C(16)–
C(17) and C(19)–C(20)–C(21)–O(4) are –32.8° and 22.4°, suggesting that 184 is not 
completely symmetrical in the solid state.  
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Fig.  5.4 View of the X-ray structure of 2,3,6,8,11,12,18,20-tetrabenzo-7,19-diaza-1,4,10,13,16,22-
hexaoxacyclo-tetraeicosa-2,6,7,11,18,19-hexaene, 184 
 
C3-C18 N1-C18 O1-O3 O6-O4 O1-O5 O1-O4 O6-O2 O6-O3 
4.029 Å 4.096 Å 4.834Å 4.793 Å 7.346 Å 7.859 Å 7.844 Å 8.498 Å 
Table  5.4 Dimensions of the cavity of compound 184 
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Table  5.5 Selected bond angles [°] for 184 with estimated standard deviations 
 
C(1)–C(30) 1.499(4) 
C(5)–C(6) 1.473(4) 
C(20)–C(21) 1.508(4) 
O(1)–C(7) 1.376(3) 
C(14)–O(3) 1.410(4) 
O(4)–C(22) 1.406(4) 
C(29)–O(6) 1.360(3) 
Table  5.6 Selected bond lengths [Å] for 184 with estimated standard deviations 
 
C(5)–C(6)–O(1)–C(7) 174.9(3) 
C(6)–O(1)–C(7)–C(8) 15.4(5) 
C(14)–O(3)–C(15)–C(16) –75.2(4) 
O(3)–C(15)–C(16)–C(17) –32.8(5) 
C(28)–C(29)–O(6)–C(30) –42.6(5) 
C(29)–O(6)–C(30)–C(1) 145.4(3) 
C(19)–C(20)–C(21)–O(4) 22.4(5) 
C(20)–C(21)–O(4)–C(22) 84.8(4) 
Table  5.7 Torsion angles [°] for 184 
O(1)–C(6)–C(5) 110.5(3) 
C(14)–O(3)–C(15) 111.5(3) 
O(3)–C(15)–C(16) 112.8(3) 
C(7)–O(1)–C(6) 118.0(2) 
O(4)–C(21)–C(20) 112.8(3) 
C(22)–O(4)–C(21) 113.4(3) 
C(29)–O(6)–C(30) 119.6(2) 
O(6)–C(30)–C(1) 108.2(2) 
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5.3 Structural studies of macrocyclic precursor 160 
 
Compound 160 crystallizes in the monoclinic space group C2 with four independent 
molecules per asymmetric unit. Bond lengths within the phenyl ring are normal with 
C-C distances of 1.365(6) Å to 1.407(5) Å, mean 1.386 Å. The ethereal C-O 
distances for O(2)–C(3) and C(8)–O(3) are 1.359(5) Å and 1.364(4) Å respectively. 
Refinement has shown that there are two types of disorder associated with 182. The 
atoms in the ethanol chain C2-C1-O1are disordered over two sites C2A-C1A-O1A/ 
C2B-C1B-O1B which differ in their orientation with respect to the aromatic ring 
moiety and with side occupancy factors subsequently fixed at 50% each. Therefore 
particular bond lengths for C(2A)–O(2) and C(2B)–O(2) are noticeably different at 
1.513 Å and 1.417 Å, whereas O(1A)–C(1A) is 1.466 Å and O(1B)–C(1B) 1.369 Å. 
The O-C-C bond angles range from 107.9° to 125.5° while distortions between C(3)–
O(2)–C(2B) at 132.3° and C(3)–O(2)–C(2A) at 108.7° can be also observed. 
Distances measured between O1-O1’= 9.861 Å, O3-O3’= 3.464 Å, O2-O2’=7.078 Å. 
 
C5
C4
C2A
C6
C1A
C3 O2
C7
O1A
C8
O3
C9
C9 C10
 
Fig.  5.5 View of the X-ray crystal structure of 1,3-bis[2-(2’-hydroxyethoxy) phenoxy]propane, 160, 
disorder neglected for clarity 
 
Crystallographic studies 
 
123 
Bond distances Bond angles 
O(1A)–C(1A) 1.466(15) C(3)–O(2)–C(2B) 132.3(8) 
C(2A)–O(2) 1.513(9) C(3)–O(2)–C(2A) 108.7(5) 
O(1B)–C(1B) 1.369(15) C(2B)–O(2)–C(2A) 33.5(6) 
C(2B)–O(2) 1.417(10) O(2)–C(3)–C(4) 125.5(4) 
C(3)–C(4) 1.393(6) O(2)–C(3)–C(8) 115.4(4) 
C(3)–C(8) 1.407(5) O(3)–C(8)–C(3) 116.2(3) 
C(4)–C(5) 1.383(6) C(7)–C(8)–C(3) 118.9(3) 
C(5)–C(6) 1.365(6) C(8)–O(3)–C(9) 116.7(2) 
C(6)–C(7) 1.391(5) O(3)–C(9)–C(10) 107.9(2) 
C(7)–C(8) 1.382(5) C(9)–C(10)–C(9) 113.3(5) 
Table  5.8 Selected bond lengths [Å] and angles [°] for 160 
 
5.4 Structural studies of macrocyclic precursor 161 
 
For macrocyclic precursor 161 the presence of a water molecule in the crystal has 
been detected. The water molecule is bound by hydrogen-bond interactions to the 
primary alcohol groups (Fig. 5.6). The flexible ether chain connecting the two diol 
units allows the structure to adopt twisted conformations, with distances between 
O1-O4 of 5.331 Å, O4-O5 of 7.897 Å and O1-O3 of 4.707 Å. 
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Fig.  5.6 X-ray crystal structure of 1,5-bis[2-(2’-hydroxyethoxy) phenoxy]-3-oxapentane, 161 
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161 crystallizes in the monoclinic space group C2 with two independent molecules 
per asymmetric unit. Bond lengths within the phenyl ring are normal with C-C 
distances of 1.374 Å to 1.406 Å, mean 1.390 Å. Ethereal bonds O(1)–C(1), C(2)–
O(2) and O(3)–C(9) show very similar bond lengths at around 1.434 Å, whereas 
shorter distances, about 1.372 Å have been detected for O(2)–C(3) and C(8)–O(3). 
Bond angles O(2)–C(2)–C(1) and C(3)–O(2)–C(2) are 108.6° and 116.1° 
respectively, whereas the angle O(3)–C(9)–C(10) was measured at 107.7° and O(4)–
C(10)–C(9) at 113.6°. Significant hydrogen bonding is taking place between H(1O4) 
and O(5) (separation of 1.87 Å) and also between H(2O5) and O(4) (separation of 
1.94 Å). 
 
O(1)–C(1) 1.430(3) 
C(2)–O(2) 1.437(3) 
O(2)–C(3) 1.375(3) 
C(3)–C(4) 1.383(4) 
C(3)–C(8) 1.406(4) 
C(4)–C(5) 1.395(5) 
C(5)–C(6) 1.374(5) 
C(6)–C(7) 1.395(4) 
C(7)–C(8) 1.384(4) 
C(8)–O(3) 1.372(3) 
O(3)–C(9) 1.436(3) 
C(10)–O(4) 1.423(3) 
Table  5.9 Selected bond lengths [Å] for 161 with estimated standard deviations 
 
O(2)–C(2)–C(1) 108.6(2) 
C(3)–O(2)–C(2) 116.1(2) 
O(3)–C(8)–C(3) 115.7(2) 
C(8)–O(3)–C(9) 116.7(2) 
O(3)–C(9)–C(10) 107.7(2) 
O(4)–C(10)–C(9) 113.6(2) 
Table  5.10 Selected bond angles [°] for 161 with estimated standard deviations 
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D–H...A d(D–H) d(H...A) d(D...A) <(DHA) 
O(4)–H(1O4)...O(5) 0.84 1.87 2.710(3) 176.1 
O(5)–H(2O5)...O(4) 0.843(19) 1.94(2) 2.782(3) 174(4) 
Table  5.11 Hydrogen bonds for 161 [Å and °] 
 
Fig.  5.7 X-ray crystal structure and unit cell of 1,5-bis[2-(2’-hydroxyethoxy) phenoxy]-3-oxapentane, 
161 depicting the hydrogen bond interactions 
 
5.5 Structural studies of macrocyclic precursor 163 
 
Compound 163 crystallizes in the monoclinic space group C2/c with four 
independent molecules per asymmetric unit. The bond lengths for the aromatic 
region are as expected with C-C distances of 1.355 Å to 1.396 Å, mean 1.375 Å also 
single bonds appear regular with C(1)–C(2) and C(9)–C(10) distances of 1.501 Å and 
1.503 Å respectively. The bond distances of C(8)–O(3) 1.371 Å and O(2)–C(3) 
1.374 Å between aromatic carbon and oxygen are shorter than the bond lengths of  
O(3)–C(9) (1.427 Å) and C(2)–O(2) (1.426 Å) formed between oxygen and the 
aliphatic carbon. The O-C-C and C-O-C bond angles range from 107.3° to 117.9°. 
The torsion angle between the ortho-substituted phenyl ring and alkyl alcohol 
functionality, C(1)–C(2)–O(2)–C(3) is 178.7°, whereas C(8)–O(3)–C(9)–C(10) is 
71.7°. Refinement has shown that there are two types of disorder associated with 
163. The alcohol oxygen atom is disordered over two sites O1A/O1B which differ in 
their orientation with respect to the alcohol chain moiety and with site occupancy 
factors subsequently fixed at 50 % (probability level) each. 
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Fig.  5.8 X-ray crystal structure of 1,4-bis[2-(2’-hydroxyethoxy) phenoxy]xylene, 163 
 
Bond distances  
C(1)–C(2) 1.501(5) Bond angles 
C(2)–O(2) 1.426(4) O(2)–C(2)–C(1) 107.3(3) 
O(2)–C(3) 1.374(3) C(3)–O(2)–C(2) 117.3(2) 
C(3)–C(8) 1.390(4) C(8)–O(3)–C(9) 117.9(2) 
C(4)–C(5) 1.396(4) O(3)–C(9)–C(10) 113.4(2) 
C(5)–C(6) 1.355(5)  
C(6)–C(7) 1.387(5) Torsion angles 
C(7)–C(8) 1.385(4) C(1)–C(2)–O(2)–C(3) 178.7(3) 
C(8)–O(3) 1.371(4) C(2)–O(2)–C(3)–C(4) –0.4(4) 
O(3)–C(9) 1.427(4) C(7)–C(8)–O(3)–C(9) 5.2(4) 
C(9)–C(10) 1.503(5) C(8)–O(3)–C(9)–C(10) 71.7(3) 
C(10)–C(12) 1.383(4) O(3)–C(9)–C(10)–(11) 41.9(4) 
C(10)–C(11) 1.390(4) O(2)–C(3)–C(8)–O(3) 1.9(4) 
C(11)–C(12) 1.374(5) O(3)–C(9)–C(10)–(12) –140.6(3) 
Table  5.12 Selected bond distances [Å] and angles [°] for 163 with estimated standard deviations 
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The crystal structure of 163 shows the spatial arrangement which the aromatic rings 
and alcohol chains adopt with respect to one another. The alcohol chains are 
orientated in opposite directions to one another so it can be concluded that formation 
of a macrocycle from this precursor would pose a considerable challenge without a 
templating agent. A templating agent would enable rearrangement of 163 to a 
conformation where ring closure by introduction of an alkyl linker would be 
preferred over oligomers formation. Table 5.13 shows distances between particular 
atoms measured for 163 in the solid state. 
 
2-O6 O3-O5 O2-O4 O2-O5 O3-O1 O3-O6 C7-30 C14-23 
4.67 4.71 8.19 7.85 8.16 7.83 5.11 5.46 
Table  5.13 Dimensions of the cavity of compound 163 
 
5.6 Structural studies of macrocyclic precursor 164 
 
Compound 164 crystallizes in the monoclinic space group P21/c with four 
independent molecules per asymmetric unit. Bond lengths within the phenyl ring are 
normal, with C-C distances of 1.374 Å to 1.411 Å, mean 1.392 Å. The bond 
distances of C(2)–O(2) (1.444 Å) and O(5)–C(23) (1.433 Å) are similar to those of 
O(3)–C(9) (1.439 Å) and C(16)–O(4) (1.437 Å) and are in agreement with typical 
bond lengths for aliphatic ethers (1.430 Å)153. Furthermore the C-O bond in the 
phenol ring has been reported to be considerably shorter (1.37 Å)154 and this includes 
bond lengths of C8-O3 (1.367 Å), C17-O4 (1.364 Å), C3-O2 (1.367 Å) and C22-O5 
(1.368 Å). The bond angles of O(3)–C(9)–C(10) and O(4)–C(16)–C(14) are 
practically identical and equal, 107.78° and 107.00° respectively, also C(15)–C(10)–
C(9)  and  C(15)–C(14)–C(16) exhibit very similar values of 120.36°. The torsion 
angles of C(8)–O(3)–C(9)–C(10) and C(14)–C(16)–O(4)–C(17) between the two 
aromatic rings are 175.12° and 176.38° respectively, while O(2)–C(3)–C(8)–O(3) 
and O(4)–C(17)–C(22)–O(5) are –1.47° and 1.49° which emphasises the regularity 
of the structure 164 in the solid state.  
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Fig.  5.9 X-ray crystal structure of 1,3-bis[2-(2’-hydroxyethoxy) phenoxy]xylene, 164 
 
Bond lengths 
C(2)–O(2) 1.4445(16) C(12)–C(13) 1.384(2) 
O(2)–C(3) 1.367(16) C(13)–C(14) 1.392(2) 
C(3)–C(4) 1.381(2) C(14)–C(15) 1.388(2) 
C(3)–C(8) 1.406(2) C(16)–O(4) 1.437(16) 
C(4)–C(5) 1.396(2) O(4)–C(17) 1.364(16) 
C(6)–C(7) 1.392(2) C(17)–C(22) 1.411(19) 
C(8)–O(3) 1.367(17) C(19)–C(20) 1.374(2) 
O(3)–C(9) 1.439(17) C(20)–C(21) 1.396(2) 
C(10)–C(11) 1.394(2) C(22)–O(5) 1.368(17) 
C(11)–C(12) 1.388(2) O(5)–C(23) 1.433(17) 
Bond angles Torsion angles 
O(3)–C(9)–C(10) 107.78(11) C(8)–O(3)–C(9)–C(10) 175.12(11) 
C(15)–C(10)–C(9) 120.08(13) C(14)–C(16)–O(4)–C(17) 176.38(11) 
C(15)–C(14)–C(16) 120.65(13) O(2)–C(3)–C(8)–O(3) –1.47(17) 
O(4)–C(16)–C(14) 107.00(11) O(4)–C(17)–C(22)–O(5) 1.49(17) 
Table  5.14 Selected bond distances [Å] bond angles [°] and torsion angles [°] for 164 with estimated 
standard deviations 
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The crystal structure of the single 164 unit shows the two OH groups to be in close 
proximity which is preferential for successful ring closure reactions. We believe that 
it is because of the meta-substituted xylene ring that macrocyclic precursor 164 
adopts this cyclic, hydrogen bonded conformation with a perfect arrangement for 
introduction of an alkyl linker to perform the ring closure step. The distances 
between particular atoms have been depicted in Table 5.15. 
 
O4-O2 O3-O5 O3-O4 O1-O6 O4-O1 O3-O6 
5.97 Å 6.12 Å 5.23 Å 4.87 Å 7.57 Å 5.71 Å 
O4-H6 O3-H6 O3-H1 H1-H6 O4-H1 H6-H15 
4.376 4.875 4.560 3.804 7.135 5.159 
Table  5.15 Dimensions of the cavity of compound 164 
 
The presence of intermolecular hydrogen bonds in 164 has been observed which 
links two neighbouring molecules on H106-O1 and H101-O2 and according to the 
literature can be classified as a medium hydrogen bond155. 
 
D–H...A d(D–H) d(H...A) d(D...A) <(DHA) 
O(6)–H(1O6)...O(1) 0.88(2) 1.89(2) 2.7628(16) 175.6(19) 
O(1)–H(1O1)...O(2) 0.867(19) 2.087(19) 2.8072(14) 140.0(16) 
Table  5.16 Hydrogen bonds for 164 [Å and °] 
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Fig.  5.10 The crystal structure of two molecules of 164 linked with intermolecular hydrogen bonds 
 
5.7 Structural studies of macrocyclic precursor 165 
 
Compound 165 crystallizes in the monoclinic space group C2/c with four 
independent molecules per asymmetric unit. Bond lengths within the phenyl rings are 
regular with C-C distances of 1.368 Å to 1.405 Å, mean 1.386 Å. The bond distances 
of O(2)–C(3) and C(8)–O(3) exhibit close values of 1.372 Å and 1.380 Å 
respectively, which are significantly shorter bond lengths than C(2)–O(2), at 1.426 
Å. The bond angles of O(3)–C(8)–C(3) and C(8)–O(3)–C(9) are quite similar, with 
values of 115.39° and 115.07° respectively. The torsion angle of the O(2)–C(3)–
C(8)–O(3) is 0.45°, in contrast to the values for 163 and 164 which are 1.9° and –
1.47° respectively. Furthermore the torsion angle of C(8)–O(3)–C(9)–C(10) in 165 is    
-179.70(12)°, whereas identically situated atoms in 163 and 164 created torsion 
angles of 71.7(3)° and 176.38(11)° respectively. Refinement has shown that there are 
two types of disorder associated with 165. The alcohol oxygen atom is disordered 
over the two sites O1A/O1B which differ in their orientation with respect to the 
alcohol chain moiety and with site occupancy factors subsequently fixed at 50 % 
(probability level) each. 
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Fig.  5.11 X-ray crystal structure of 1,2-bis[2-(2’-hydroxyethoxy) phenoxy]xylene 165, disorder 
neglected for clarity 
 
Bond distances Bond angles 
O(2)–C(3) 1.372(17)  
C(3)–C(4) 1.376(2) O(3)–C(8)–C(3) 115.39(12) 
C(3)–C(8) 1.404(2) C(8)–O(3)–C(9) 115.07(11) 
C(5)–C(6) 1.368(2) O(3)–C(9)–C(10) 109.02(11) 
C(6)–C(7) 1.392(2) C(10)–C(10)–C(9) 121.07(8) 
C(10)–C(11) 1.389(2)  
C(8)–O(3) 1.380(17) Torsion angles 
C(2)–O(2) 1.426(4) O(2)–C(3)–C(8)–O(3) 0.45(18) 
C(10)–C(10) 1.405(3) C(8)–O(3)–C(9)–C(10) –179.70(12) 
C(11)–C(12) 1.385(2) O(3)–C(9)–C(10)–C(11) 97.51(15) 
Table  5.17 Selected bond distances [Å] bond angles [°] and torsion angles [°] for 165 with estimated 
standard deviations 
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Crystallographic data for 165 provides constructive information about the 
arrangement of the aromatic rings and alcohol chains of 165 in the solid state. Steric 
interactions between the ortho-xylene units hinder the entire molecule adopting a 
pseudo-cyclic structure resembling the macrocyclic precursor 164. Furthermore, the 
measured distance between the two hydrogens of the alcohol groups (H1-H1) is 
11.157 Å and is too far apart for another meta-, para- or especially ortho-xylene unit 
to be introduced. This fact could perhaps shed some light on the unsuccessful results 
of ring closure reactions employing 165. Even trials to promote macrocyclization by 
introducing a para-xylene linker (7.45 Å) into the 165 failed, and also employment 
of a variety of templating agents (Li+, Na+, K+, Cs+) in that particular case did not 
promote the ring closure. In fact, only formation of oligomeric products was 
observed. 
 
O1-O1 O2-O2 O3-O3 C9-C9 H1-H1 O3-H1 
12.641 8.472 4.146 2.963 11.157 7.639 
Table  5.18 Dimensions of the cavity of compound 165 
 
By viewing the structure of 165 in Mercury 1.4.2, it is evident that the two 2-(2’-
hydroxyethoxy)phenoxy units are orientated antiperiplanar to the aromatic linker. 
The steric torsions introduced by the ortho-xylene ring joining the two diol units are 
the most likely reason for the unsuccessful macrocyclization reaction attempted in 
that particular case.   
 
Fig.  5.12 Drawing of the X-ray crystal structure of 165 depicting different 3D perspectives 
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5.8 Structural studies of macrocyclic precursor 166 
 
Compound 166 crystallizes in the monoclinic space group P21/c with four 
independent molecules per asymmetric unit. The phenyl C-C bond distances range 
from 1.364 Å to 1.406 Å (mean 1.385 Å) whereas in the pyridine moiety the range of 
C-C bond length is shorter (between 1.379 Å and 1.387 Å, mean 1.383 Å). Both C-N 
bond distances in the pyridine ring are around 1.342 Å in length, and are in 
agreement with reported data156. The O-C-C bond angles range from 108.69° to 
110.42°. The torsional angles of C(8)–O(3)–C(9)–C(10) and C(14)–C(15)–O(4)–
C(16) are -178.74° and -179.65° respectively, which are also close to the values for 
C(3)–C(8)–O(3)–C(9) and C(15)–O(4)–C(16)–C(21) (177.86° and 179.45°). All 
these features indicate that in the solid state the compound 166 adopts a planar form, 
apart from the disorder of the alcohol chains. Refinement has shown that there are 
two types of disorder associated with 166. One of the alcohol chains is disordered 
over two sites O1A/O1B which differ in their orientation with respect to the phenyl 
moiety and with site occupancy factors subsequently fixed at 50 % (probability level) 
each. 
 
Bond distances Bond angles 
C(3)–C(4) 1.381(2) C(8)–O(3)–C(9) 116.17(12) 
C(3)–C(8) 1.406(2) O(3)–C(9)–C(10) 108.69(13) 
C(17)–C(18) 1.388(3) O(4)–C(15)–C(14) 110.42(13) 
C(18)–C(19) 1.364(4) C(16)–O(4)–C(15) 115.19(13) 
C(10)–N 1.343(2) Torsion angles 
C(10)–C(11) 1.387(2) C(8)–O(3)–C(9)–C(10) –178.74(13) 
N–C(14) 1.341(2) O(3)–C(9)–C(10)–N 178.12(13) 
C(14)–C(15) 1.498(2) O(3)–C(9)–C(10)–C(11) –1.3(2) 
C(15)–O(4) 1.418(2) N–C(14)–C(15)–O(4) –178.61(13) 
O(3)–C(9) 1.416(2) C(13)–C(14)–C(15)–O(4) 1.3(2) 
O(4)–C(16) 1.373(2) C(14)–C(15)–O(4)–C(16) –179.65(13) 
C(8)–O(3) 1.372(2) C(15)–O(4)–C(16)–C(21) 179.45(17) 
Table  5.19 Selected bond distances [Å] bond angles [°] and torsion angles [°] for 166 with estimated 
standard deviations 
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Fig.  5.13 X-ray crystal structure of 1,6-bis[2-(2’-hydroxyethoxy) phenoxy]methylenepyridine, 166, 
disorder neglected for clarity 
 
O1-O6 O2-O6 O1-O5 O1-O3 O4-O6 H1-H6 O1-H12 O3-H1 
11.426 11.573 11.772 4.848 4.850 10.746 5.893 5.550 
Table  5.20 Dimensions of the cavity of compound 166 
 
In the Appendix A structure of macrocycle 176 and morphine macrocycle precursor 
200 have been attached.  
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5.9 Conclusion 
 
Crystal data and crystallographic descriptions of macrocyclic precursors 160, 161, 
163-166 provide information about spatial arrangement of particular atoms and 
chemical groups. This data highlights conformational differences between these 
structures. Apart from structure 165, the orientation of atoms in macrocyclic 
precursors 160, 161, 163, 164, 166 in the solid state ‘suggest’ potential for successful 
further ring closure steps. For example the crystal structure of 164 shows that it 
adopts a cyclic hydrogen bonded conformation with a perfect arrangement for 
introduction of an alkyl linker to perform the macrocyclization step. For that 
compound each of the ring closure step experiments were successful. This is in 
contrast to crystallographic data for 165. Steric interactions in the ortho-xylene unit 
hinder the entire molecule preventing it from adopting a pseudo-cyclic structure 
resembling the macrocyclic precursor 164. Therefore the two hydrogens of the 
alcohol groups in 165 are too far apart for another linker unit to be introduced. This 
fact could perhaps provide a reasonable explanation of the unsuccessful results of 
ring closure reactions employing 165, for which only formation of oligomeric 
products was observed. 
From the measurements of the cavity sizes and cation metal diameters it is possible 
to roughly estimate which metal “guest” would fit best into the macrocyclic cavity. 
Both 179 and 184 exhibit quite large cavity sizes (4.029 Å on 4.096 Å on 7.346 Å on 
8.498 Å) and therefore would be expected to bind preferentially to metal guests with 
diameters ranging from 2.66 to 3.34 Å (Table 6.2, Chapter 6 ) e.g. K+ (2.66 Å) Cs+ 
(3.34 Å), Rb+ (2.94 Å), Sr2+ (2.26 Å) or Ba2+ (2.68 Å). Macrocycle 184 in contrast to 
179 contains two pyridine rings which provide an alternative binding pocket. For 
macrocycle 184 binding affinity towards metal cations such as La3+ (2.30 Å) or Pb2+ 
(2.40 Å) would also be expected, in view of the presence of donor nitrogens in the 
two pyridine rings. Macrocycles 179 and 184 apart from having a relatively large 
polycyclic scaffold contain 4 aromatic rings each. This feature may reduce the 
potential flexibility of 179 and 184 which would surely influence the binding affinity 
towards metal cations.  
It is hard to make any estimation of binding preferences of macrocyclic precursors 
160-163 and 165, since the X-ray measurements reveal that they do not adopt a 
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pseudocyclic arrangement in the solid state. Therefore adequate measurement of the 
distances between donor atoms would not be possible. 
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Fig.  5.14 Pseudocyclic structure adopted by 164  and linear arrangement of 163 in the solid state 
 
From the estimation of the cavity size of the 164 (5.97 Å on 6.12 Å and 5.23 Å on 
5.71 Å) in the solid state, 164 would fit metal “guests” such as K+, Cs+, Ba2+ and 
Sr2+. Therefore this might be the answer of significant templating role of K+ and Cs+ 
in the macrocyclization step.  
Based on the X-ray crystallographic data representative measurements of the cavity 
sizes and distances between selected atoms in the macrocycles 179, 184 and their 
precursors 164 have been presented. These measurements are based purely on 
physical size of the cavity in the solid state and the potential guest cation and do not 
take into account the rigidity/flexibility of the “hosts”, the charge on the metal 
cations and the stability of the host-guest complex. This estimated data is likely to 
change in solution or on binding to the “guest” species.   
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6 Metal binding studies  
6.1 Introduction 
 
This chapter describes metal picrate extraction studies carried out on selected 
products synthesized in this project. A general view of the binding affinity of the 
macrocycles and their precursors, to a variety of metal cations, indicating which 
metal cation would bind to the corresponding macrocyclic compound, is the aim.  
The picrate method is commonly used to determine extracting efficiencies of 
macrocyclic ethers and their precursors by measuring the relative distribution of a 
coloured alkali metal salt (in this case picrate) between water and an immiscible 
organic solvent in the presence of the crown ether Fig. 6.1157. If the polyether host is 
a powerful complexing agent, most of the colour will remain in the organic phase, 
whereas a colourless organic phase after extraction, indicates a low binding affinity.  
 
Aqueous
Chloroform
K+ -O
N+
-O
O
N+ O-
O
N+ O-
O
N
O O
O O
O O
O
 
Fig.  6.1 Partitioning of crown ether and potassium picrate between water and chloroform solution 
 
The relationship between the diameter of an alkali cation and the crown ether has 
been noted in earlier literature of crown ethers and this is best referred by Pedersen 
as the “hole-size-rule”158. The diameters of the macrocyclic polyethers (A-E) are 
presented in Table 6.1, while cation diameters are shown in Table 6.2159. 
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 Macrocyclic Polyethers Diameters [Å] 
A All 14-crown-4 1.2-1.5 
B All 15-crown-5 1.7-2.2 
C All 18-crown-6 2.6-3.2 
D All 21-crown-7 3.4-4.3 
E All 24-crown-8 4.5-5.2 
Table  6.1 Diameter of cavity in Ångström Units 
 
Group I Group II Group III Group IV 
Li 1.36       
Na 1.94 Mg 1.44     
K 2.66 Ca 1.98     
Cu(I) 1.92 Zn 1.48     
Rb 2.94 Sr 2.26     
Ag 2.52 Cd 1.94     
Cs 3.34 Ba 2.68 La 2.30 Pb(II) 2.40 
NH4 2.86       
Table  6.2 Cations and their Diameters in Ångström Units  
 
6.2 Results and discussion 
 
Macrocyclic compounds and their precursors synthesised for this project were tested 
for cation selectivity using UV picrate extraction techniques. Each of the thirty 
compounds was tested against thirteen metal picrates and the results are presented in 
Tables 6.3-6.32. The metal picrate extraction experiments were performed by using 
host solutions of macrocycle or its precursor in chloroform and picrate solutions in 
deionised water according to the procedure described by Pedersen. The absorption of 
the extracted picrate was measured from the aqueous layer at 356 nm and compared 
against a blank solution (no host in chloroform) of the appropriate picrate. The 
average of three samples is reported with standard deviation < 0.01. It has to be 
mentioned that preparation of cadmium picrate was troublesome, despite several 
attempts to synthesize that particular salt only minimal amounts of it were obtained. 
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However the calibration curves constructed from the standard solutions were not 
complementary with the required standards therefore all the results obtained for 
extraction of the cadmium picrate had to be rejected.  
 
Binding Agent Cation % Extraction Cation % Extraction 
Li+ 12.7   
Na+ 4.1 Zn2+ 0.3 
K+ 1.4 Co2+ 2.3 
Cs+ 1.1 Cu2+ 0.3 
Ca2+ 0.7 Sr2+ 0.3 
Ba2+ 1.7 Pb2+ 1.4 
OO
OO
OHOH
 
160 
Mg2+ 1.4 La3+ 4.9 
Table  6.3 Extraction results with 160 
 
 
Binding Agent Cation % Extraction Cation % Extraction 
Li+ 24.1   
Na+ 7.9 Zn2+ 1.6 
K+ 5.9 Co2+ 1.0 
Cs+ 1.1 Cu2+ 2.5 
Ca2+ 2.5 Sr2+ 0.2 
Ba2+ 2.0 Pb2+ 1.1 
O
O
OH OH
O
O
O
161 
Mg2+ 1.9 La3+ 9.6 
Table  6.4 Extraction results with 161 
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Binding Agent Cation % Extraction Cation % Extraction 
Li+ 20.2   
Na+ 78.2 Zn2+ 1.6 
K+ 40.8 Co2+ 1.7 
Cs+ 7.5 Cu2+ 1.5 
Ca2+ 2.3 Sr2+ 0.5 
Ba2+ 3.4 Pb2+ 0.8 
OHOH
OO
OO
OO
 
162 
Mg2+ 0.9 La3+ 9.6 
Table  6.5 Extraction results with 162 
 
 
Binding Agent Cation % Extraction Cation % Extraction 
Li+ 0.0   
Na+ 3.5 Zn2+ 1.9 
K+ 8.0 Co2+ 0.1 
Cs+ 2.8 Cu2+ 1.9 
Ca2+ 0.1 Sr2+ 1.1 
Ba2+ 3.1 Pb2+ 1.1 
OH
O
OO
O
OH
163 
Mg2+ 2.1 La3+ 4.8 
Table  6.6 Extraction results with 163 
 
 
Binding Agent Cation % Extraction Cation % Extraction 
Li+ 6.2   
Na+ 59.1 Zn2+ 1.9 
K+ 13.3 Co2+ 0.1 
Cs+ 1.9 Cu2+ 2.5 
Ca2+ 2.4 Sr2+ 1.1 
Ba2+ 2.7 Pb2+ 1.5 
O
O
OH OH
O
O
 
164 
Mg2+ 0.8 La3+ 4.9 
Table  6.7 Extraction results with 164 
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Binding Agent Cation % Extraction Cation % Extraction 
Li+ 8.5   
Na+ 54.1 Zn2+ 0.4 
K+ 13.0 Co2+ 0.6 
Cs+ 2.5 Cu2+ 1.9 
Ca2+ 1.6 Sr2+ 1.2 
Ba2+ 2.3 Pb2+ 1.5 
O
O
OH OH
O
O
165 
Mg2+ 2.1 La3+ 4.5 
Table  6.8 Extraction results with 165 
 
 
Binding Agent Cation % Extraction Cation % Extraction 
Li+ 1.1   
Na+ 48.0 Zn2+ 0.7 
K+ 4.7 Co2+ 0.4 
Cs+ 2.4 Cu2+ 2.1 
Ca2+ 1.6 Sr2+ 1.1 
Ba2+ 0.8 Pb2+ 0.8 
N
O
O
OH OH
O
O
166 
Mg2+ 0.1 La3+ 10.3 
Table  6.9 Extraction results with 166 
 
 
Binding Agent Cation % Extraction Cation % Extraction 
Li+ 0.1   
Na+ 64.3 Zn2+ 0.0 
K+ 2.3 Co2+ 1.0 
Cs+ 0.7 Cu2+ 2.1 
Ca2+ 2.1 Sr2+ 1.3 
Ba2+ 1.2 Pb2+ 0.62 
N
O
O
O
O
O
O
OO
167
 
Mg2+ 0.8 La3+ 9.0 
Table  6.10 Extraction results with 167 
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Binding Agent Cation % Extraction Cation % Extraction 
Li+ 1.0   
Na+ 54.6 Zn2+ 0.6 
K+ 3.1 Co2+ 0.5 
Cs+ 0.3 Cu2+ 2.2 
Ca2+ 1.2 Sr2+ 1.2 
Ba2+ 2.0 Pb2+ 0.7 
N
O
OO
O
O
OO
O 168
 
Mg2+ 0.8 La3+ 10.1 
Table  6.11 Extraction results with 168 
 
 
Binding Agent Cation % Extraction Cation % Extraction 
Li+ 1.3   
Na+ 21.1 Zn2+ 0.9 
K+ 6.8 Co2+ 1.4 
Cs+ 0.4 Cu2+ 1.9 
Ca2+ 1.3 Sr2+ 1.0 
Ba2+ 2.1 Pb2+ 0.0 
O O
O O
O O
O
169
 
Mg2+ 0.8 La3+ 4.3 
Table  6.12 Extraction results with 169 
 
 
Binding Agent Cation % Extraction Cation % Extraction 
Li+ 1.7   
Na+ 5.8 Zn2+ 0.0 
K+ 1.3 Co2+ 0.2 
Cs+ 0.6 Cu2+ 2.1 
Ca2+ 1.0 Sr2+ 0.0 
Ba2+ 0.7 Pb2+ 0.5 
O
O
O
O
O O
O
170
 
Mg2+ 0.9 La3+ 2.3 
Table  6.13 Extraction results with 170 
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Binding Agent Cation % Extraction Cation % Extraction 
Li+ 0.2   
Na+ 4.6 Zn2+ 0.3 
K+ 0.1 Co2+ 0.1 
Cs+ 0.0 Cu2+ 1.9 
Ca2+ 0.3 Sr2+ 0.2 
Ba2+ 0.1 Pb2+ 0.2 
N
O O
O O
O O
O
171
 
Mg2+ 0.2 La3+ 5.5 
Table  6.14 Extraction results with 171 
 
 
Binding Agent Cation % Extraction Cation % Extraction 
Li+ 0.00   
Na+ 41.7 Zn2+ 0.00 
K+ 4.0 Co2+ 0.1 
Cs+ 0.34 Cu2+ 1.9 
Ca2+ 0.0 Sr2+ 1.2 
Ba2+ 1.0 Pb2+ 0.3 
O
O
O
OO
OO
O
173
 
Mg2+ 0.0 La3+ 4.7 
Table  6.15 Extraction results with 173 
 
 
Binding Agent Cation % Extraction Cation % Extraction 
Li+ 0.2   
Na+ 52.6 Zn2+ 1.4 
K+ 1.7 Co2+ 1.2 
Cs+ 1.2 Cu2+ 2.0 
Ca2+ 1.3 Sr2+ 1.1 
Ba2+ 0.7 Pb2+ 0.7 N
O
O
O
O
O
O
176
 Mg2+ 1.4 La3+ 7.2 
Table  6.16 Extraction results with 176 
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Binding Agent Cation % Extraction Cation % Extraction 
Li+ 1.2   
Na+ 72.0 Zn2+ 0.0 
K+ 4.8 Co2+ 0.29 
Cs+ 0.1 Cu2+ 1.9 
Ca2+ 0.0 Sr2+ 0.0 
Ba2+ 0.0 Pb2+ 0.5 
O O
O O
O O
177
 
Mg2+ 0.0 La3+ 4.3 
Table  6.17 Extraction results with 177 
 
 
Binding Agent Cation % Extraction Cation % Extraction 
Li+ 0.8   
Na+ 71.0 Zn2+ 0.88 
K+ 3.1 Co2+ 0.54 
Cs+ 16.1 Cu2+ 1.97 
Ca2+ 0.9 Sr2+ 0.53 
Ba2+ 0.7 Pb2+ 0.06 
O
O
O
O
O O
178
 Mg2+ 1.1 La3+ 2.62 
Table  6.18 Extraction results with 178 
 
 
Binding Agent Cation % Extraction Cation % Extraction 
Li+ 0.7   
Na+ 29.7 Zn2+ 0.9 
K+ 3.8 Co2+ 1.1 
Cs+ 1.2 Cu2+ 2.0 
Ca2+ 1.2 Sr2+ 1.0 
Ba2+ 2.1 Pb2+ 1.5 
O O
O
OO
O 179
 
Mg2+ 0.9 La3+ 9.7 
Table  6.19 Extraction results with 179 
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Binding Agent Cation % Extraction Cation % Extraction 
Li+ 1.9   
Na+ 57.4 Zn2+ 1.9 
K+ 13.8 Co2+ 1.7 
Cs+ 3.0 Cu2+ 1.6 
Ca2+ 1.5 Sr2+ 1.6 
Ba2+ 0.9 Pb2+ 1.00 
O
O
O
O
O
O
180
 
Mg2+ 1.2 La3+ 10.6 
Table  6.20 Extraction results with 180 
 
 
Binding Agent Cation % Extraction Cation % Extraction 
Li+ 0.2   
Na+ 32.5 Zn2+ 1.7 
K+ 5.8 Co2+ 1.1 
Cs+ 1.0 Cu2+ 1.2 
Ca2+ 0.3 Sr2+ 1.0 
Ba2+ 0.7 Pb2+ 0.7 
N
O
O
O
O
O
O
183
 Mg2+ 1.2 La3+ 6.7 
Table  6.21 Extraction results with 183 
 
 
Binding Agent Cation % Extraction Cation % Extraction 
Li+ 0.5   
Na+ 30.1 Zn2+ 0.9 
K+ 4.7 Co2+ 0.5 
Cs+ 0.0 Cu2+ 2.3 
Ca2+ 1.4 Sr2+ 1.0 
Ba2+ 0.9 Pb2+ 0.8 
N
N
O
O
O
O
O
O
184
 Mg2+ 0.1 La3+ 7.4 
Table  6.22 Extraction results with 184 
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Binding Agent Cation % Extraction Cation % Extraction 
Li+ 3.7   
Na+ 16.2 Zn2+ 0.4 
K+ 3.3 Co2+ 16.2 
Cs+ 1.1 Cu2+ 14.2 
Ca2+ 8.3 Sr2+ 11.1 
Ba2+ 10.4 Pb2+ 19.5 
OHO
O
OH
O
NCH3
197
 
Mg2+ 2.7 La3+ 11.2 
Table  6.23 Extraction results with 197 
 
 
Binding Agent Cation % Extraction Cation % Extraction 
Li+ 1.9   
Na+ 4.2 Zn2+ 12.2 
K+ 21.6 Co2+ 28.6 
Cs+ 24.0 Cu2+ 45.7 
Ca2+ 20.4 Sr2+ 20.3 
Ba2+ 16.4 Pb2+ 40.4 
OO
OO
OH
O
NCH3
OH
O
N CH3
 
194 
Mg2+ 4.5 La3+ 16.5 
Table  6.24 Extraction results with 194 
 
 
Binding Agent Cation % Extraction Cation % Extraction 
Li+ 0.00   
Na+ 0.2 Zn2+ 4.2 
K+ 2.5 Co2+ 8.1 
Cs+ 3.3 Cu2+ 8.9 
Ca2+ 8.7 Sr2+ 4.9 
Ba2+ 16.3 Pb2+ 24.7 
OO
OH
O
N CH3
OH
O
NCH3
 
198 
Mg2+ 8.0 La3+ 17.6 
Table  6.25 Extraction results with 198 
 
Metal binding studies 
 
147 
 
Binding Agent Cation % Extraction Cation % Extraction 
Li+ 0.00   
Na+ 0.6 Zn2+ 4.4 
K+ 0.2 Co2+ 12.7 
Cs+ 3.1 Cu2+ 20.5 
Ca2+ 3.5 Sr2+ 5.8 
Ba2+ 3.9 Pb2+ 28.9 
O
OH
O
N CH3
O
OH
O
NCH3
  199 
Mg2+ 2.0 La3+ 19.6 
Table  6.26 Extraction results with 199 
 
 
Binding Agent Cation % Extraction Cation % Extraction 
Li+ 1.2   
Na+ 41.9 Zn2+ 8.1 
K+ 3.8 Co2+ 17.0 
Cs+ 1.3 Cu2+ 28.8 
Ca2+ 16.0 Sr2+ 12.2 
Ba2+ 19.8 Pb2+ 45.9 
O
OH
O
N CH3
O
OH
O
NCH3
200 
Mg2+ 11.1 La3+ 20.1 
Table  6.27 Extraction results with 200 
 
 
Binding Agent Cation % Extraction Cation % Extraction 
Li+ 1.3   
Na+ 23.1 Zn2+ 16.7 
K+ 20.0 Co2+ 20.4 
Cs+ 4.5 Cu2+ 60.6 
Ca2+ 12.1 Sr2+ 12.0 
Ba2+ 11.6 Pb2+ 72.5 
O
OH
O
N CH3
N
O
OH
O
NCH3
  201 
Mg2+ 4.2 La3+ 23.9 
Table  6.28 Extraction results with 201 
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Binding Agent Cation % Extraction Cation % Extraction 
Li+ 3.1   
Na+ 11.9 Zn2+ 41.8 
K+ 17.5 Co2+ 54.6 
Cs+ 41.9 Cu2+ 72.6 
Ca2+ 19.8 Sr2+ 38.7 
Ba2+ 13.5 Pb2+ 78.0 
OO
OO
OO
O
NCH3
O
N CH3
  
217 
Mg2+ 21.3 La3+ 43.2 
Table  6.29 Extraction results with 217 
 
 
Binding Agent Cation % Extraction Cation % Extraction 
Li+ 0.8   
Na+ 0.2 Zn2+ 24.3 
K+ 0.0 Co2+ 16.1 
Cs+ 0.9 Cu2+ 34.0 
Ca2+ 12.9 Sr2+ 8.8 
Ba2+ 4.8 Pb2+ 53.2 
OO
OO
OO
O
NCH3
O
N CH3
  218 
Mg2+ 13.0 La3+ 17.1 
Table  6.30 Extraction results with 218 
 
 
Binding Agent Cation % Extraction Cation % Extraction 
Li+ 0.9   
Na+ 4.7 Zn2+ 4.2 
K+ 2.6 Co2+ 23.7 
Cs+ 1.6 Cu2+ 32.6 
Ca2+ 0.9 Sr2+ 20.3 
Ba2+ 4.3 Pb2+ 62.3 
OO
OO
OO
O
NCH3
O
N CH3
N
  219 
Mg2+ 0.8 La3+ 16.7 
Table  6.31 Extraction results with 219 
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Binding Agent Cation % Extraction Cation % Extraction 
Li+ 0.4   
Na+ 0.4 Zn2+ 23.5 
K+ 4.4 Co2+ 36.6 
Cs+ 8.7 Cu2+ 60.6 
Ca2+ 5.2 Sr2+ 27.4 
Ba2+ 7.2 Pb2+ 48.2 
OO
O
O
N CH3
O
NCH3
O
   
220 
Mg2+ 0.5 La3+ 39.8 
Table  6.32 Extraction results with 220 
 
Pedersen reported extraction values for crown ethers with various ring sizes and 
incorporating both cyclohexyl and benzene rings. The general conclusion according 
to the Table 6.33 is that crown ethers with benzene rings are more rigid and less 
flexible than their cyclohexyl analogues, therefore macrocycles with the same cavity 
size but with carbocyclic rings would extract the same metal picrate with different 
efficacies.  
The measured dimensions of the cavities of macrocycles 179 and 184 (Chapter 5) are 
quite large and these parameters correspond to the scaffold of 24-crown-8. Since 
macrocycles of the 24-crown-8 type exhibit moderate complexation of cations like 
K+ and Cs+ with diameters of 2.66 and 3.34 Å respectively, complexation of the 
potassium cation, despite its smaller diameter is slightly preferred over the caesium 
cation. A similar trend was observed for dicyclohexyl-21-crown-7 which extracted 
K+ and Cs+ from aqueous solution with good efficiency (Table 6.33), though 
preferential complexation of the potassium cation was spotted. According to the 
cavity size, similar binding properties would be expected from 179 and 184, however 
these macrocycles contain different number of donor oxygens which might influence 
their binding preferences.  
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Picrate Extracted [%] 
Crown Ether Li+ Na+ K+ Cs+ 
Dicyclohexyl-14-crown-4 1.1 0 0 0 
Cyclohexyl-15-crown-5 1.6 19.7 8.7 4.0 
Dibenzo-18-crown-6 0 1.6 25.2 5.8 
Dicyclohexyl-18-crown-6 3.3 25.6 77.8 44.2 
Dicyclohexyl-21-crown-7 3.1 22.6 51.3 49.7 
Dicyclohexyl-24-crown-8 2.9 8.9 20.1 18.1 
Table  6.33 Extraction results, two-phase liquid extraction: methylene chloride and water 
 
Macrocyclic compounds and their precursors described in this thesis contain at least 
two aromatic rings or rigid morphine units, therefore especially in the case of the 
cyclised structures we do not expect much flexibility and minimal conformational 
change is expected on binding to the metal cation making binding more entropically 
favourable. The acyclic polyethers 160, 161, 163 did not complex appreciably to any 
of the metal picrates. Among the thirty compounds tested twelve of them showed 
significant extraction values for sodium picrate. Pedersen’s crown ethers dibenzo-18-
crown-6 and dicyclohexyl-18-crown-6 exhibit higher affinity towards K+ over Na+. 
The same trend was observed for macrocycles with bigger cavities, dicyclohexyl-21-
crown-7 and dicyclohexyl-24-crown-8, whereas binding studies performed for this 
project showed the opposite trend. The highest extraction value for Na+ was observed 
for model macrocyclic precursor 162 (78.2 %). This result was quite surprising, 
considering the size of its cavity. Regrettably, of all the macrocyclic precursors 162 
was the only one that did not give good quality crystals for X-ray analysis.  
Metal binding studies 
 
151 
0
10
20
30
40
50
60
70
80
[%] Extraction
162 164 165 166
% Extraction values for Na+
 
OHOH
OO
OO
OO
O
O
OH OH
O
O
N
O
O
OH OH
O
OO
O
OH OH
O
O
162
164 165 166
 
Graph  6.1 % Extraction values for macrocyclic precursors 162, 164, 165, 166 
 
The extraction data showed significant binding of several macrocyclic structures and 
their precursors towards sodium picrate. Among the nineteen model macrocyclic 
systems the highest extraction values were observed for 177 (72.0 %), 178 (71.0 %), 
167 (64.3%), 180 (57.4 %) and 168 (54.6 %). The common feature linking all these 
compounds is the presence of four aromatic rings in their structures arranged in such 
a way as to form a rigid cavity surrounded by six donor oxygen atoms. According to 
the data in the table and from analysis of cavity sizes in the crystallographic 
(relevant) literature we would expect metal picrates with cation diameters larger than 
sodium to be bound more effectively. Also the most efficient extractions were 
observed in the case of model macrocycles containing 4 aromatic rings instead of 3 
in which the xylene linker is replaced by an ethereal chain. This may suggest that the 
presence of 4 aromatic rings in the macrocycle may facilitate binding process by 
arrangement of aromatic rings in a way which prevents from binding to the bigger 
cation. 
Macrocycles 169, 173,  167, 168, 176, 177 and their extraction values for Na+ and K+ 
are presented in Table 6.34. Macrocycle 169 exhibits relatively low extraction values 
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for Na+ 21.1 % and even lower for K+ 6.8 %, whereas macrocycle 173 the cavity 
selectivity towards Na+ over K+ increased and extraction values were 41.7 and 4.0 %, 
respectively. Macrocycles containing a pyridine ring 167, 168 and 176, gave high 
extraction values for Na+ (64.3 %, 54.6 % and 52.6 %, respectively) and proved to 
have significant binding affinity for La3+ (9.0 % and 10.1 %, 7.2 %) and to bind 
relatively weakly to K+. Macrocycle 177 showed an excellent 72 % extraction value 
for Na+ and about 5 % for K+. 
 
 169 173 167 168 176 177 
Na+ 21.1 41.7 64.3 54.6 52.6 72.0 
K+ 6.8 4.0 2.3 3.1 1.7 4.8 
La3+ 4.3 4.7 9.0 10.1 7.2 4.3 
Table  6.34 Extraction values of 167, 168, 169, 173, 176, 177 for Na+, K+ and La3+ 
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Graph  6.2 % Extraction values of 167, 168, 169, 173, 176, 177, 178, 180 for Na+ 
 
Apart from interactions between the cation and donor oxygen atoms, the 
complexation process may also be favoured by cation-pi interactions with pi-electrons 
from the aromatic rings. None of the tested ligands exhibited a high affinity for 
potassium and caesium whose hydroxides played a significant role in the ring closure 
step. The optimal metal for the preorganization of the acyclic precursor to facilitate 
ring closure does not necessary have optimal fit with the macrocyclic product. 
Careful selection of templates to assist synthesis versus binding metal studies is 
always an important compromise. 
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If a comparison is made between the extraction values of two macrocyclic 
precursors, one based on the 2-(2-hydroxyethoxy)phenol unit 162 and the second one 
incorporating two morphine units 194 interesting affinity can be observed. From the 
Graph 6.3 it is clear that 162 exhibits high extraction values for sodium 78.2 % and 
potassium 40.8 % and moderate values for caesium 7.5 % picrates, whereas 
noticeable signs of efficient binding towards transition metal cations (apart from 
lanthanum, 9.6 %) were not observed. However, increased extraction values with 194 
were observed towards copper (45.7 %), lead (40 %), cobalt (28.6 %) and strontium 
(20.3 %) picrates. 
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Graph  6.3 % Extraction values of 162 and 194 for series of various metal cations 
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Similar properties were observed for open structure 201 which preferentially 
extracted lead and copper, whereas 166 shows binding preference towards sodium 
picrate. Significant extraction values for the transition metal cations was not 
observed. 
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Graph  6.4 % Extraction values of 166 and 201 for series of various metal cations 
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217 was the only morphine macrocycle to show appreciable binding to the series of 
metal picrates. 41.9 % of the caesium picrate was extracted from the aqueous layer 
by 217 and this is the highest binding ability towards this metal picrate among all the 
compounds tested. Potassium, magnesium and calcium picrates were also extracted 
from the aqueous layer to the extent of 17.5 %, 21.3 % and 19.8 % respectively. 217 
proved to be an especially effective extracting agent towards lead (78.0 %) and 
copper (72.6 %) picrates, although quite significant values were also observed for 
cobalt (54.6 %), zinc (41.8 %), strontium (38.7 %) and lanthanum (43.2 %) picrates. 
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Graph  6.5 % Extraction values of 217 for series of various metal cations 
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Graph 6.6 emphasizes the high affinity of morphine macrocycles and their precursors 
towards lead and copper cations. Amongst all the ligands based on morphine, the 
highest extraction values were observed for lead and copper picrates, especially in 
the cases of 201 and 217. Further testing would be required in order to determine 
whether these macrocycles with their affinity for copper and lead might have 
applications as possible co-catalysts. 
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Graph  6.6 % Extraction values of morphine compounds for Pb2+ and Cu2+ 
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As can be seen from the graphs, the morphine macrocycles and their precursors 
showed higher affinity towards transition metals compared with aromatic polyether 
model systems. This is not just a result of modifying the host cavity, but rather may 
be due to the tertiary amino group of morphine, a soft ligating site which is known to 
increase the affinity of crown ethers for transition metals160,161. Therefore it was 
decided to perform a control experiment with morphine for copper and lead picrates.  
 
Cation % Extraction Cation % Extraction 
OH
OH
O
NCH3
187 
Pb2+ 10.7 Cu2+ 8.4 
Table  6.35 Extraction results for Pb2+ and Cu2+ with morphine 187 
 
Control experiments were performed in order to establish whether the significant 
binding values of morphine compounds toward Pb2+ and Cu2+ were due to the 
presence of morphine moiety in the tested compounds. Since tests showed that 
morphine itself exhibits a binding value of 10.7 % for Pb2+ and 8.4 % for Cu2+ it may 
be concluded that additional functional groups e.g. polyetheral chains, aromatic rings 
and also the effect of the cyclic structure play an important role in binding of 
transition metal cations.  
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6.3 Conclusion 
 
The macrocycles and their precursors synthesised in this project were tested for 
metal extraction ability against a variety of metal picrates. Some of these products 
did not exhibit significant extraction values for any of the metal picrates, although an 
ability to extract multiple metal picrates was more common. Furthermore, the 
preference exhibited by several crown ethers to bind with sodium suggests that the 
binding affinities of the novel crown ethers for cations are not based only on ionic 
size.  
It was interesting to note that morphine macrocycles and their precursors bind 
strongly to transition metals and that they are able to extract lead and copper picrates 
most effectively. For the calculations we have assumed the formation of 1:1 
complexes, but it is possible that the actual binding of metal picrates to crown ethers 
is a result of aggregation of metal ions and crown ethers, however, this aspect 
requires further investigation162. Steric effect from the opiate backbone may make 
1:2 or 2:3 complexes difficult to prepare. However, until X-ray structure of the opiate 
linker ligand and preferably the metal inclusion complex are solved, this is open to 
debate.  
The morphine macrocycles and their precursors could have applications as potential 
sensors or as co-catalysts with metals for asymmetric catalysis, for example in the 
catalytic Friedel-Crafts reaction163. This was an initial goal of the project, which was 
unaccomplished, therefore we are obliged to pass the idea to be investigated by 
following researchers.   
It has to be mentioned that these extraction studies do not take into account 
stoichiometry of the complexes, because the ratio of complexing agent:metal picrate 
is assumed to be 1:1 for the purpose of the calculations. However it is well known 
that the ratio can be more complex and formation of 1:2 or 2:3 complexes could also 
take place. 
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6.4 Experimental  
 
Thirty macrocyclic structures and their precursors were tested for their ability to 
extract a number of metal picrates.  
Picric acid (0.77g. 65% suspension in water) was suspended in 20 mL of water and 
warmed to 70 °C to make a saturated solution. The metal carbonate was added 
slowly to the hot solution with stirring until evolution of CO2 ceased. The solution 
was allowed to cool to 0 °C slowly and the yellow solid that precipitated was isolated 
by gravity filtration, washed with 5 mL of cold water and allowed to air-dry. All the 
following metal picrates were synthesised according to the same method: 
LiC6H2N3O7, NaC6H2N3O7, KC6H2N3O7, CsC6H2N3O7, Mg(C6H2N3O7)2, 
Ca(C6H2N3O7)2, Ba(C6H2N3O7)2, Zn(C6H2N3O7)2, Co(C6H2N3O7)2,  Cu(C6H2N3O7)2,  
Sr(C6H2N3O7)2, Pb(C6H2N3O7)2, and La(C6H2N3O7)3.       According to an agreement 
with the head of safety it was not permitted to completely dry the metal picrates and 
therefore accurate isolated yields products could not be recorded. 
 
1000 mL of 7x10-5 M solutions of each of the picrate salts were made up in deionised 
water. The solutions of extracting agents (500 mL each) were made up to a 
concentration of 1.75x10-5 M in chloroform. Each metal picrate was extracted with 
each of the 30 macrocyclic structures and their precursors.  
 
6 mL each of both the picrate solution and the macrocycle solution were transferred 
into a glass vial and shaken on an automatic shaker for 15 minutes and the same 
procedure was repeated 3 times. The UV absorption spectrum for each picrate salt 
was measured at 356 nm and then this was compared with the aqueous layer of each 
mixture after shaking.  
Blank extractions with chloroform were carried out for each of the picrate solutions. 
The recorded absorbance for each case was oscillating around the same value 
recorded for deionised water. Blank experiments showed that no picrate extraction 
occurred in the absence of crown ethers or their precursors.   
 
Picrate extraction studies were carried out and the % extraction values of various 
ions were calculated using the following equation: 
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Where (Mol picrate ) 0 is the number of moles of metal picrate in the aqueous layer 
originally, (Mol picrate ) E is the number of moles of the picrate salt in the aqueous 
layer after extraction and (Mol binding agent ) is the number of moles of binding agent in 
the organic layer. 
The calibration curves for each of the metal picrates were drawn according to data 
collected from standard solutions of metal picrates. The coefficient of determination 
(R2 value) for each calibration curve was > 99 % and these records were used to 
calculate the percentage extraction of metal picrates into the organic layer. 
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7 Biological activity of model macrocycles and their precursors 
7.1 Lung cell carcinoma assay 
 
For the purpose of this project, the bioactivity of macrocyclic compounds and their 
precursors was assessed by screening against non-small cell lung carcinoma cell 
lines. The in vitro model chosen for investigating the potential of synthesised 
compounds was DLKP and DLKP-A cell lines. The DLKP-A cell line is a daughter 
cell line of DLKP, a poorly differentiated squamous cell lung carcinoma. The main 
mechanism of multidrug resistance (MDR) for DLKP is via MRP1 and it is a poor 
expresser of P-glycoprotein (P-gp). DLKP-A’s line is a daughter cell line of DLKP 
and the main mechanism of MDR is via the P-gp membrane pump. DLKP-A mainly 
expresses P-gp, while expressing very low levels of multidrug resistance protein 1 
(MRP1). The compounds obtained in this project were designed with the idea of 
aiding the delivery of drug to the cell, thereby increasing the effectiveness of a dose. 
A range of macrocyclic compounds and their precursors were synthesized and their 
anti-proliferative effectiveness was studied, alone and in combination with a 
chemotherapeutic drugs, epirubicin 227 and taxotere 228. 
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Fig.  7.1 Structures of epirubicin 227 and taxotere 228 chemotherapeutics 
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7.2 MultiDrug Resistance Proteins 
 
MultiDrug Resistance (MDR) is a major factor in the failure of cancer chemotherapy. 
MDR is a phenomenon whereby tumour cells in vitro that have been exposed to one 
cytotoxic agent develop cross-resistance to a range of structurally and functionally 
unrelated compounds. This resistance is often due to an elevation in the expression of 
particular proteins, such as cell membrane transporters, which can result in an 
increased efflux of cytotoxic drugs from the cancer cells164.  
The two MDR proteins of interest in this report are P-gp and MRP1. Both of which 
are also members of the ATP-binding cassette (ABC) family. These proteins bind 
ATP and use the energy to drive the transport of various molecules across all cell 
membranes. 
P-gp is a transmembrane protein with a very broad specificity for the structures it 
pumps out of cells. One effective way to overcome P-gp-mediated drug resistance is 
either to block the drug pumping function of P-gp or to inhibit its expression. Many 
agents that modulate the function of P-gp have been identified, including calcium 
channel blockers, calmodulin antagonists, steroidal agents, protein kinase C 
inhibitors, immunosuppressive drugs, antibiotics, and surfactants165. MRP1 is located 
in the cytoplasm and is responsible for carrying cellular drugs to the cell membrane 
and expelling them from the cell. It is thought to play both a role in protecting cells 
from chemical toxicity and oxidative stress and to mediate inflammatory responses. 
Out of all the compounds synthesised, several were selected for biological 
investigation. Commercially purchased samples of 15-crown-5, benzo-15-crown-5, 
18-crown-6, benzo-18-crown-6, dibenzo-18-crown-6 and their linear precursors, tri-, 
tetra-, penta-, and hexaethylene glycols (Sigma Aldrich) were also screened. These 
compounds were primarily selected on the basis of solubility properties in aqueous 
solutions. Dimethylsulfoxide was used to solubilise the compounds in question, 
before solubility of the solution was tested in aqueous media. A minimum 
concentration of 0.5 mg/mL in the medium was required for a compound to undergo 
biological evaluation.  
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7.3 Biological results 
 
Compounds 160-166, 169, 170, 173 and 178 were examined for inhibition of the P-
gp efflux pump. These compounds were also studied for their anti-proliferative 
effectiveness against DLKP and DLKP-A cell lines, alone and in combination with 
the widely used chemotherapeutic drugs epirubicin and taxotere.  
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Fig.  7.2 Macrocycles and their precursors screened for the inhibition of the P-gp 
 
Of the 16 macrocyclic compounds and their precursors submitted for testing only 11 
had acceptable solubility properties. However, the majority of candidates with good 
water solubility did not inhibit P-gp, therefore full data with bar charts for those are 
separately included in the Appendix B. 
 
7.3.1 Biological activity of macrocyclic precursors 
 
The determination of IC50 values for the eight macrocyclic precursors was carried out 
on both the DLKP and DLKP-A cell lines. 165 (22 µM and 17.4 µM, respectively) 
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was found to have the greatest effect on cell proliferation whereas 160 (>50 µM and 
63.16±16 µM, respectively) was the least toxic.  
 
 
Graph  7.1 The IC50 values of the six testable compounds on both the DLKP and DLKPA cell lines. 
Experiments with no errors bars were only carried out once whereas those with error bars were carried 
out twice. 
 
 
 
 
 
 
 
 
 
 
 
Graph  7.2 Combination of 160 with epirubicin on the DLKP-A cell line 
 
The bar charts shown in Graphs 7.2 and 7.3 demonstrate the increase in activity 
when 160 and 165 are combined with the epirubicin. In the assay of cell line DLKP-
A, 160 inhibits cell growth by over 60 % at an epirubicin concentration of 0.3 µM 
IC50 values of testable compounds on the DLKP and DLKPA cell lines 
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and 160 at 56 µg/mL. 160 was also found to be nontoxic to DLKP-A cells up to a 
concentration of 20 ug/mL.  
Synergy was observed with 165 at a concentration of 2 µM and epirubicin at 0.5 µM. 
With a lower concentration of 165, 0.5µM, and a slightly higher concentration of 
epirubicin, 1.4 µM, synergy was also observed. The IC50 for this compound was 
found to be 17.4µM.  
 
 
Graph  7.3 Combination of 165 with epirubicin on the DLKP-A cell line. 
 
No effect was seen for the drug interaction study with epirubicin for 165 on the 
DLKP cell lines. The IC50 for 165 was found to be 22µM.  
 
 
Graph  7.4 The double combination of 165 with epirubicin on the DLKP cell line 
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Graph  7.5 Combination of 161 with epirubicin on the DLKP-A cell line 
 
A slightly antagonistic interaction was observed between 161 and epirubicin on the 
DLKP-A cell line (Graph 7.5). This can be seen at the two lower concentrations of 
161 with both concentrations of epirubicin. The IC50 for this compound was found to 
be 58.4±14 µM. Analogical, antagonistic interaction between 164 and epirubicin was 
observed at the higher concentration of epirubicin with both concentrations of 164 on 
the DLKP-A cell line (Graph 7.6). The IC50 for this compound was found to be 
35 µM.  
 
 
Graph  7.6 Combination of 164 with epirubicin on the DLKP-A cell line 
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Graph 7.7 shows that at the lowest 166 concentration, 0.5 µM, 166 acted 
antagonistically with 1.4 µM epirubicin, whereas no antagonism or synergy was 
noted at any other concentration. A separate IC50 curve was carried out and a 
concentration of 40.4±5 µM was required to kill 50% of the cells. 
 
 
Graph  7.7 Combination of 166 with epirubicin on the DLKP-A cell line 
 
Each of the macrocyclic precursors 160-166 was dissolved in ethanol but only six of 
them were found to be soluble in the cell culture medium, ATCC +5% FCS. The six 
compounds were tested for any anti-proliferation effects and also for a possible 
synergistic interaction with epirubicin in both the P-gp and MRP1 rich cell lines. It 
became clear that combinations of 160, 161, 162, 164, 165, 166 with epirubicin gave 
no synergistic interactions on the DLKP cell lines. This suggests that none of these 
five compounds have an effect on MRP1. 161 and 162 showed no effect in either 
assay, either by themselves or in combination with epirubicin on the DLKP-A cell 
line, whereas 160, 164 and 166 acted antagonistically with epirubicin on the DLKP-
A cell line. Compound 165 gave a synergistic interaction with epirubicin at all 
concentrations with 1.4 µM epirubicin on the DLKP-A cell line, providing a valuable 
lead for further testing. The calculated IC50 value for 165 with respect to both cell 
lines was found to be in the micromolar ranges for DLKP 19±3 and DLKP-A 34±4, 
respectively. Additionally when compared with other commonly used 
chemotherapeutic compounds, 165 is non-toxic to both the cell lines tested. 
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Graph  7.8 The effect of a combination of 165 with epirubicin on the DLKP cell line 
 
No synergy, additivity or antagonism is evident in Graph 7.8. This suggests that 165 
is neither a substrate nor an inhibitor of MRP1. Graph 7.8 is the result of two 
separate experiments and no synergy or antagonism is observed as a result of this 
combination. 
 
 
Graph  7.9 The effect of a combination of 165 and 5FU on the DLKP cell line 
 
When 165 was combined with 5FU on DLKP cell line (Graph 7.9), the combination 
showed neither synergism, antagonism nor additivity. This gives weight to the theory 
that the mechanism of action of compound 165 involves the inhibition of the P-gp 
pump. 
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Graph  7.10 Effect of a combination of 165 with epirubicin on the DLKP-A cell line 
 
The chart above, which is the result of two separate experiments, demonstrates that 
165 acts in neither a synergistic nor an antagonistic manner but rather has an additive 
effect when co-incubated with epirubicin on the DLKP-A cell line. 
 
Graph  7.11 Effect of a combination of 165 with taxotere on the DLKP-A cell line 
 
When 165 was combined with taxotere it appears to act synergistically at a 
concentration of 10 uM 165 and 10 µM taxotere. The observed increase in cell kill 
was roughly 50 % (Graph 7.11). Taxotere is pumped from the cell by P-gp and at a 
concentration of 25 µM 165 and 10 µM taxotere an even higher cell kill was 
observed. 165 was also tested with 5-flurouracil (5FU) which is not affected by P-gp 
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and as such no improvement in cell kill occurred when 165 was added as shown in 
Graph 7.12. The combination exhibits neither synergism, antagonism nor additivity.  
  
 
Graph  7.12 Effect of a 165 with 5FU on the DLKP-A cell line 
 
To date 165 has proven to be non-toxic on the two non-small cell lung carcinoma cell 
lines used, and toxic at 19 uM in the DLKP and 34 uM concentration in the DLKP-A 
cell lines. However after a second series of tests no synergy, additivity or antagonism 
was evident in combination with epirubicin and 5FU on the DLKP cell line. 
Therefore, 165 was ruled out as a compound that can overcome MRP1 resistance. In 
combination with epirubicin on the DLKP-A cell line, 165 appears to act in an 
additive manner but acts synergistically with taxotere. This indicates that 165 may 
have some form of inhibitory effect on P-gp.  
 
7.3.2 Biological activity of compounds with ester groups 
 
Compounds 229, 230, 231 (Fig. 7.3) were synthesised by another member of the 
group and tested as P-gp inhibitors. Both 229 and 230 exhibited a pronounced 
synergistic effect among the rest of tested compounds. 
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Fig.  7.3 Screened compounds containing ester groups 
 
In contrast with 165 in the DLKP-A assay, 229 at a concentration of 25 µM 
combined with 0.3 µM epirubicin inhibited cell survival by over 90%, whereas a 
combination of higher concentration of epirubicin (up to 1.4 µM) and 229 at 12 µM  
gave a similar cell survival rate.  
 
Graph  7.13 Effect of a combination of 229 with epirubicin on the DLKP-A cell line 
DLKP-A: Combination of 229 and epirubicin 
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Graph  7.14 Effect of a combination of 230 with epirubicin on the DLKP-A cell line 
 
The combination of 230 and epirubicin showed a significant increase in cell kill with 
increasing non-toxic concentrations of 230. 230 at concentrations of 12  µM with 
0.3 µM epirubicin cause a significant increase in cell kill, furthermore increased of 
the concentrations of  230 to 25 µM at the same level of epirubicin inhibits cell 
growth by over 90 %. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Graph  7.15 Combination of 230 with taxotere on DLKP-A cell line 
 
 
 
 
DLKP-A: Combination of 230 and epirubicin. 
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The combination of 230 with taxotere on DLKP-A cell line showed a significant 
increase in cell kill with increasing non-toxic concentrations of 230. 230 at the 
concentration of 12 µM with 2.0 µM of taxotere caused over 90 % cell kill. The 
assay performed for the combination of 231 with 5FU and taxotere gives weight to 
the theory that the mechanism of action of compound 231 involves the inhibition of 
the P-gp pump. 
 
Graph  7.16 Combination of 231 with epirubicin on the DLKP-A cell line 
 
Initial testing showed that 231 at concentrations of 40 µM with 0.3 µM epirubicin 
significantly increased cell kill in DLKP-A, whereas under the same conditions but 
with DLKP no significant increase occurred.  
 
 
 
 
 
 
 
 
 
 
Graph  7.17 Bar chart illustrating the double combination of 231 with taxotere on the DLKP-A cell 
line 
DLKP-A: Combination of 231 and epirubicin  
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The combination of 231 and taxotere on the DLKP-A cell line appears to act 
synergistically at a concentration of 40 µM 231 and 5.0 µM taxotere. The observed 
increase in cell kill was roughly 50 %.  
Next 2-(2-hydroxyethoxy)phenol 159 and 2,2-dimethylmalonic acid 232 the 
hydrolytic decomposition products of 229, 230 and 231 were screened in order to 
exclude the possibility that they were increasing cell kill in the assay. The results 
from this round of testing indicated that 2-(2-hydroxyethoxy)phenol 159 and 
dimethylmalonic acid 232 exhibit inhibition of P-gp. 
 
7.3.3 Summary of carcinoma assay for ester compounds  
 
The results presented above show that both 229 and 230 have a significant effect on 
cell survival in conjunction with epirubicin. This suggests that 229 and 230 are 
effective P-gp inhibitors, compared with 160-166. From the set of compounds 
containing ether groups it has been found that 165 containing the ortho-xylene 
moiety is the best P-gp inhibitor. Both 229 and 230 have suffered in consistent data 
between batches. The high activity observed with the first batch has not been 
reproduced. Work is ongoing in the group to determine the reason. Compound 165 
was found to give reproducible data in several batches. Presented data also indicate 
that the presence of ester groups may play a significant role in the inhibition of P-gp. 
The mechanism of P-gp inhibition has yet to be determined, however, these studies 
may aid future research into the design of P-gp inhibitor candidates.  
 
7.3.4 Biological activity of commercially available compounds 
 
Following analysis of the data from the compounds screened it was decided to 
subject a range of commercially available macrocycles and their linear precursors to 
biological investigation. Among them were triethylene 233, tetraethylene 234, 
pentaethylene 235 and hexaethyleneglycols 236 as well as benzo-15-crown-5 237, 
18-crown-6 4 and benzo-18-crown-6 238. Amongst these commercially available 
chemicals only benzo-18-crown-6 238 exhibited a synergistic effect with epirubicin 
on the DLKP-A cell line.  
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Fig.  7.4 Commercially available compounds screened in carcinoma assay 
 
 
 
 
 
 
 
 
 
 
 
 
Graph  7.18 Bar chart for the combination of 238 with epirubicin in the DLKP-A cell line 
 
The combination of epirubicin with benzo-18-crown-6 238 gave a slight synergistic 
interaction at the same concentration as the highest concentration (100 µM) of 238 
tested against DLKP-A cell line. 238 gave a slight synergy with epirubicin but only 
in the DLKP-A cell line. When the extent of the interaction is compared with that of 
230 with epirubicin in the same cell line, it is clear that 230 has a much greater 
effect. 238 only acts synergistically at 160 µM and above, whereas the required 
concentration of 230 lies between 12 µM and 25 µM. 
 
DLKP-A: Double combination of 238 and epirubicin.  
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7.3.5 Biological activity of macrocycles 
The macrocyclic compounds were then subjected to simple toxicity screening in 
control experiments to establish P-gp inhibition properties for these compounds. A 
combination assay with epirubicin and taxotere was carried out with macrocycle 
concentrations of 20.0, 10.0, 5.0 and 2.5 µM. Control experiments were compared 
with results for elacridar 125, a drug used in cancer treatment as a reverser of P-gp 
activity. The bioassays were carried out on the P-gp rich cell line DLKP-A with 
epirubicin 227 and taxotere 228 as anticancer drugs.  
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 Graph  7.19 Combination assay of 169 with epirubicin on the DLKP-A cell line 
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Graph  7.20 Combination assay of 170 with epirubicin on the DLKP-A cell line 
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Graph 7.19 and Graph 7.20 show bar charts demonstrating the increase of activity 
against the DLKP-A cell line when 169 and 170 are administered in combination 
with epirubicin. In the presence of potent P-gp inhibitor, elacridar an increase in cell 
growth was recorded after assay incubation. However when elacridar was combined 
with epirubicin a dramatic reverse in cell growth was observed. Inhibition of P-gp 
was also evident for the combination of either 169 or 170 with epirubicin at 
concentrations of 10 µM for 170 and 20 µM for 169. The combination of 170 with 
epirubicin exhibited an encouraging 40 % cell kill. Both compounds 169 and 170 in 
combination with taxotere showed positive result in the DLKP-A assay. The 
combination of elacridar at 0.25 µM with taxotere at 25 nM inhibits growth by over 
80 %. Likewise combinations 170 or 169 with taxotere also give significant cell kill, 
but only in the higher concentration ranges. In both cases cell survival was the lowest 
at the highest concentration of 20 µM.   
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Graph  7.21 Combination assay of 169 with taxotere on the DLKP-A cell line 
 
 
 
 
 
 
 
 
 
Biological screening 
 
179 
 
DLKPA  Double combination of 170 with taxotere
0
20
40
60
80
100
120
20 uM 10 uM 5 uM 2.5uM
Ce
ll 
su
rv
iv
al
 
(%
) Taxotere 25 nM
Elacridar: 0.25 uM
Elacridar combination
170
combination 170
 
Graph  7.22 Combination assay of 170 with taxotere on the DLKP-A cell line 
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 Graph  7.23 Combination assay of 173 with epirubicin on the DLKP-A cell line 
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Graph  7.24 Combination assay of 173 with taxotere on the DLKP-A cell line 
 
Macrocycle 173 was also subjected to biological evaluation against a DKLP-A cell 
line as a combination with either epirubicin or taxotere. The results are depicted in 
Graph 7.23 and graph 7.24 which also present cell survival data for elacridar 
combined with epirubicin and taxotere, respectively on the lung cancer cell line. In 
both cases addition of elacridar (0.25 µM) together with the chemotherapeutic agent 
inhibits cell growth dramatically. As seen from the graphs 173 seems to have a toxic 
effect on the cells itself. However, when combined with taxotere a still more 
pronounced increase in cell kill occurred. 
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Graph  7.25 Combination assay of 178 with epirubicin on the DLKP-A cell line 
 
Biological screening 
 
181 
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Graph  7.26 Combination assay of 178 with taxotere on the DLKP-A cell line 
 
Similar observations were made when the bioactivity of macrocycle 178 and its 
effect in combination with epirubicin (Graph 7.25) and taxotere (Graph 7.26) was 
investigated. In the DLKP-A assay 178 inhibits growth by over 30 % at the lowest 
concentration used. In both assays synergy was noted, however combination with 
taxotere at the usual range of concentrations led to cell survival of about 20 %.     
The usual control experiments were performed to determine whether the compounds 
screened exhibited any level of P-gp inhibition worthy of further investigation. These 
tests are not elaborate enough to determine bioactivity, but nevertheless resulted in 
important structure activity data regarding P-gp inhibition. 
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7.4 Conclusion 
 
The efforts made in this project towards identification of an anti P-gp 
pharmocophore do not yet constitute a complete structure activity relationship study. 
However, key information guiding future studies has been gained. It can be seen that 
the aromatic rings in the acyclic P-gp inhibitors are an important feature, although 
aromaticity alone does not indicate that similar compounds will act as P-gp 
inhibitors. Macrocyclic precursor 162 showed no effect on P-gp, either when 
screened in combination with epirubicin on DLKP or a DLKP-A cell line. 
Nevertheless, simple toxicity assay of 173 indicate a definite synergistic effect when 
173 was combined with epirubicin and taxotere. It seems that introduction of an 
additional aromatic ring into 162 could improve P-gp inhibition behaviour as in 
compound 173. A similar trend was observed for macrocyclic precursor 161 and its 
macrocycles 169 and 170. When a biological investigation into compound 161 with 
combination of epirubicin on DLKP and DLKP-A cell lines was carried out, neither 
a significant increase nor a decrease in the effect of the drug was seen. However, 
when 169 and 170 were assayed with DLKP-A in the absence of a cytotoxic 
anticancer agent, toxicity levels towards the cell line was found to be low (5-30%). 
In contrast when the macrocycles were administered to the cells with taxotere, 
synergistic effect and considerable cell kill level was observed. Amongst the four 
macrocycles screened, 173 (20 to 60% of cell kill) and 178 (40 to 50% cell kill) were 
most cytotoxic at the concentration range of 2.5 to 20 µM towards the DLKP-A cell 
line. This compares favourably with 170 (5-25%) and 169 (5-45%). These results 
emphasize the significance of retaining aromatic rings when designing the cyclic P-
gp inhibitors. This observation, drawn from compounds synthesized during this 
project, was supported by the bioassay results from commercially avaliable 15-
crown-5, 18-crown-6 and benzo-18-crown-6. The first two cyclic polyethers did not 
exhibit P-gp inhibiting properties whatsoever, while benzo-18-crown-6 shows signs 
of a slight synergistic interaction with epirubicin, at the highest concentration 
(100uM) in the DLKP-A cell line. However, this difference, particularly between 15-
crown-5 and benzo-18-crown-6 could merely be a result of the difference in the size 
of the rings.  
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The investigation carried out on the cancer cell lines indicated that the macrocyclic 
precursors containing ester groups 229 and 230 are more effective as P-gp inhibitors 
than macrocyclic precursors with aliphatic linker joining two 2-(2-
hydroxyethoxy)phenol units. Moreover, availability of phenolic hydroxyl groups in 
the structure may play an important role since 230 with free aromatic alcohol groups 
instead of primary alkyl alcohol acted more sufficiently towards P-gp than 229. 230 
at the concentration range of 12-24 µM proved to act synergistically with epirubicin 
(0.3 and 1.4 µM) causing cell kill over 80 %. Furthermore, 230 at the lower 
concentration range of 1.2-2.4 µM with taxotere (2.0-4.0 µM) increases cell kill over 
90 %. Macrocyclic precursor 165 showed neither synergy nor antagonism as a 
combination with epirubicin on DLKP and DLKP-A cell lines. However, 
combination with taxotere appears to act synergistically at a concentration of 10 µM 
of 165 and 10 µM of taxotere causing 30 % of cell kill.  
This investigation is just an opening for the work which needs to be done to prove 
claimed statements conclusively. It would be necessary for future research to 
synthesize and submit for a SAR study a number of other macrocycles of varying 
size and constituents. Few constructive conclusions can be made based on the 
structural properties of tested compounds. 
 
 
 
Fig.  7.5 Schematic view of screened compounds 
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In the Fig. 7.5 a simple view of screened compounds is presented. From the results of 
the cancer studies it can be concluded that: 
• Presence of aromatic rings, particularly ortho-substituted aromatic rings, 
increase P-gp inhibition 
• Macrocyclic precursors with ester linkers showed higher potency as a P-gp 
inhibitors compared to macrocyclic precursors with ethereal linkers  
• Macrocyclic precursors, both alkoxy-(C) and phenoxy-linked (B) with ester 
linkers showed higher potency as P-gp inhibitors than their macrocycles (A) 
• Macrocyclic precursors with ester linkers (B,C) exhibit high synergy with 
both epirubicin and taxotere 
• Presence of the aromatic ring in the macrocycle, increases P-gp inhibition 
activity (18-crown-6, benzo-18-crown-6) 
• Macrocycle with ester groups (A) exhibit higher synergy with epirubicin than 
taxotere 
• Macrocyclic precursors with ethereal linkers (E) showed higher P-gp 
inhibition when in combination with taxotere than epirubicin. 
• Macrocycles (D) with ethereal linkers exhibit higher P-gp inhibition when 
combined with taxotere than epirubicin. 
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8 Experimental 
 
 
All chemicals were purchased from Sigma-Aldrich, and used without further 
purification. Morphine hydrochloride trihydrate was purchased from Johnson 
Matthey Macfarlan Smith, Edinburgh, and was dried for one week under vacuum 
before use. Commercial grade reagents were used without further purification 
procedures. THF was distilled from sodium with benzophenone as indicator under 
nitrogen. Dichloromethane was distilled from CaH2 and triethylamine distilled and 
stored over potassium hydroxide pellets166. DMF, 1,4-dioxane and pyridine were 
purchased anhydrous from Sigma-Aldrich. 
Thin layer chromatography was performed on Fluka silica gel (60 F254) coated on 
aluminium plates. TLC plates were visualised by UV (254 nm) and/or developed 
using potassium permanganate. Davisil 60Å silica gel was used for column 
chromatography.  
Melting point determinations were carried out using a Stuart, SMP3 melting point 
apparatus. Infrared spectra were recorded on an Perkin Elmer FT-IR system, 
spectrum GX spectrometer. Optical rotations were measured on a Perkin Elmer 343 
Polarimeter in HPLC grade chloroform. High Resolution Mass Spectrometry was 
carried out on Liquid Chromatography Time of flight mass spectrometer from 
Micromass MS Technologies Centre by the Microanalytical Laboratory at University 
College Dublin. NMR spectra were obtained on a Bruker AC 400 NMR spectrometer 
operating at 400 MHz for 1H NMR and 100 MHz for 13C NMR. The 1H and 13C 
NMR shifts are expressed in ppm relative to tetramethylsilane and were internally 
referenced to the residual solvent signal. Coupling constants values (J) are in Hertz 
(Hz). Chemical-shift assignments for 1H and 13C spectra were assisted with COSY, 
DEPT and HMQC experiments. The splitting patterns for NMR spectra are 
designated as follows: s (singlet), d (doublet), t, (triplet), q, (quartet), p, (pentet), dd 
(doublet of doublets), ddd (doublet of doublet of doublets), dt (doublet of triplet) and 
m (multiplet). 
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8.1 Friedel-Crafts chemistry 
 
General procedure (127, 128, 129) 
Diethyl-L-tartrate (10 mmol) and the corresponding benzylamine (24 mmol) were 
added to the K2CO3 (1.0 mmol) in abs. methanol (15 mL). The mixture was heated at 
64 °C for 7 h and then allowed to cool to RT. The white solid was filtered and 
washed with copious of methanol. The crude product was then recrystallized from 
toluene.  
 
N,N’-dibenzyl-L-tartaric acid amide (127) 
The general procedure was used with the starting materials diethyl-L-tartrate 
(10 mmol, 2.06 g) and benzylamine (24 mmol, 2.57 g). Recrystallization from 
toluene gave the title product as white crystalline needles (2.98 g, 9.1 mmol, 91% 
yield). 
N
O
N
O
OH
OH
H
H
 
1H and 13C NMR data were in agreement with the literature121. 
1H NMR (400 MHz, DMSO) 8.29 (2H, t, J=6.0 Hz, NH) 7.31-7.20 (10H, m, Ar-H) 
5.72 (2H, d, J=6.0Hz, OH) 4.41-4.28 (6H, m, OCH, Ar-CH2) 
13C NMR (100 MHz, DMSO) 171.48, 139.45, 128.02, 127.10, 126.55, 72.52, 41.04. 
m.p.=200-201 oC 
 
N,N’-di-(4-metoxybenzyl)-L-tartaric acid amide (128) 
The general procedure was used with the starting materials diethyl-L-tartrate (0.52 g, 
2.5 mmol) and 4-methoxy-benzylamine (0.82 g, 6.0 mmol). Recrystallization from 
toluene gave the title product as white crystalline needles (0.81 g, 2.1 mmol, 84 % 
yield). 
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1H and 13C NMR data were in agreement with the literature121. 
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1H NMR (400 MHz, DMSO) 8.16 (2H, t, J =6.0 Hz, NH) 7.23 (4H, d, J=8.4 Hz, 
ArH) 6.85 (4H, d, J =8.4Hz, Ar-H) 5.71 (2H, d, J=7.2Hz, OH) 4.32 (2H, d, J=7.2Hz, 
OCH) 4.27 (4H, t, J=6.0 Hz, ArCH2) 3.72 (6H, s, CH3) 
13C NMR (100 MHz, DMSO) 171.96, 157.98, 131.02, 127.86, 112.76, 72.02, 55.01, 
40.96. 
m.p.=220-222 oC  
 
N,N’-di-(4-chlorobenzyl)-L-tartaric acid amide (129) 
The general procedure was used with the starting materials diethyl-L-tartrate (0.52 g, 
2.5 mmol) and 4-chloro-benzylamine (0.85 g, 6.0 mmol). Recrystallization from 
toluene gave the title product as white crystalline needles (0.64 g, 1.6 mmol, 65 % 
yield). 
N
O
N
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OH
OH
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Cl
 
1H and 13C NMR data were in agreement with the literature121. 
1H NMR (400 MHz, DMSO) 8.42 (2H, t, J=6.2Hz, NH) 7.35-7.20 (8H, m, ArH) 5.76 
(2H, s, OH) 4.40-4.15 (6H, m, OCH, ArCH2)  
13C NMR (100 MHz, DMSO) 171.94, 138.45, 130.52, 129.01, 127.49, 71.00, 41.02. 
m.p.=180-182 oC 
 
General procedure (130, 131) 
To a solution of diethyl-L-tartrate (131 mmol, 27.0 g ) in abs. methanol (40 mL) was 
added freshly distilled cyclic amine (420 mmol, 29.83 g). After 3 days at RT solvent 
and excess of amine were removed in vacuo. After period of time white crystals 
appeared. The crude product was recrystallised from benzene. The residue was dried 
in vacuo to give the corresponding tartramides. 
 
Diazacyclopentane-L-tartaric acid amide (130) 
The general procedure was used with the starting materials diethyl-L-tartrate 
(27.04 g, 131 mmol) and freshly distilled pyrrolidine (420 mmol, 29.83 g). 
Recrystallization from benzene gave the title product as white crystalline needles 
(24.45 g, 96 mmol, 74 % yield). 
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1H and 13C NMR data were in agreement with the literature122. 
1H NMR (400 MHz, DMSO) 5.19 (2H, d, J=7.2Hz, OH) 4.29 (2H, d, J=7.2Hz, CH) 
3.65-3.22 (8H, m, NCH2) 1.89-1.71 (8H, m, CH2) 
13C NMR (100 MHz, DMSO) 169.57, 70.53, 45.95, 44.29, 23.04, 21.82.  
m.p.=128-130 °C  
 
Diazacyclohexane-L-tartaric acid amide (131) 
The general procedure was used with the starting materials diethyl-L-tartrate 
(18.81 g, 93 mmol) and freshly distilled piperidine (31.48 g, 370 mmol). 
Recrystallization from toluene gave the title product as white crystalline needles 
(8.73 g, 31 mmol, 36 % yield). 
N
N
O
O
OH
OH
 
1H and 13C NMR data was in agreement with the literature122 
1H NMR (400 MHz, DMSO) 5.21 (2H, d, J=6.2 Hz, OH) 4.41 (2H, d, J=6.2Hz, CH) 
3.49-3.43 (8H, m, NCH2) 1.59-1.44 (12H, m, CH2) 
13C NMR (100 MHz, DMSO) 169.14, 70.12, 46.64, 45.86, 26.17, 25.56, 24.89. 
m.p.=179-181 oC  
 
Preparation of ethyl glyoxylate (105)  
Diethyl-L-tartrate 126 (1.03 g, 5.0 mmol) was dissolved in freshly distilled CH2Cl2 
(5 mL). Periodic acid (1.05 g, 5.0 mmol) was added in portions over 1 h and the 
reaction mixture was stirred at RT for an additional hour and then poured onto 
molecular sieves (4 Ǻ) for 15 minutes to remove any water. The solid was filtered off 
and the solvent was evaporated under reduced pressure (20 °C) to give the crude 
aldehyde as a colourless oil.  
Experimental 
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O
O
OC2H5
 
The presence of the aldehyde group was confirmed by 1H NMR, in which a singlet at 
9.36 ppm was observed. This material was not purified further, but instead used 
directly in the Friedel-Crafts reaction.  
 
Preparation of glyoxamides (132, 134) 
Tartramide (5.0 mmol) was dissolved in freshly distilled DCM (8 mL). Periodic acid 
(5.0 mmol) was added in portions over 1 h and the reaction mixture was stirred at RT 
for an additional hour and then poured onto molecular sieves (4 Ǻ) and allowed to 
stand for 15 minutes to remove any water. The solid was filtered off and the solvent 
was evaporated under reduced pressure (20 °C) to give crude glyoxamide as a white 
solid. 
O
O
N
CH3
CH3
O
O
N132 134
 
The presence of the aldehyde group was confirmed by 1H NMR, in which a singlet at 
9.38 ppm was observed. This material was not purified but used directly in the 
Friedel-Crafts reaction.  
 
Catalytic Friedel-Crafts reaction in organic solvent 
To a flame-dried flask fitted with stirring bar was added the Lewis acid catalyst MXn 
(0.05 mmol, 10 mol %) and then the flask and catalyst were dried under vacuum for 
4 h. Freshly distilled solvent (4 mL) and carbonyl compound (2-5 mmol) were added 
and stirred for 20 min. Subsequently the aromatic or heteroaromatic nucleophile 
(1 mmol) was added. After stirring for 1 to 2 days at RT the reaction mixture was 
filtered through a pad of silica with CH2Cl2, solvent was removed in vacuo and the 
product was purified by column chromatography.  
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2,2-di(1H-indol-3-yl)-N,N-dimethylacetamide (143)  
Catalytic Friedel-Crafts reaction 
The general procedure was used with the starting materials indole 142 (0.059 g, 
0.5 mmol) and N,N-dimethyl glyoxamide 132 (2.5 mmol as a crude mixture) in the 
presence of Cu(OTf)2 (0.045 g, 0.125 mmol, 25 mol %) in CH2Cl2. Product 143 was 
isolated as a dark orange solid after column chromatography on silica gel using ethyl 
acetate (0.014 g, 0.04 mmol, 17 % yield). 
Friedel-Crafts reaction in aqueous solution (143) 
A flask was charged with 1M NaCl
 
(4 mL) and then crude N,N-dimethyl 
glyoxyamide (0.28 g, 2.2 mmol) and indole (0.059 g, 0.50 mmol) were added. The 
reaction mixture was stirred for 3 h at RT then extracted with CH2Cl2 and dried over 
MgSO4. Solvent was evaporated and the reaction mixture was separated by flash 
chromatography on silica gel (EtOAc) to give product 143 (0.075 g, 0.21 mmol, 
86 % yield) as a dark orange solid. 
N
H
N
H
N
CH3
CH3O
12
1
23
5 6
7
8
9
4
1'
2'
3'
5'6'
7'8' 4'
10
11
 
1H NMR (400 MHz, CDCl3) 8.26 (2H, s, NH) 7.50 (2H, dd, J=7.6, 1.2Hz, (H3,3’)) 
7.13 (2H, d, J=7.6, 1.0Hz, (H6,6’)) 7.08 (2H, td, J=7.6, 1.0 Hz, (H4,4’)) 6.99 (2H, td, 
J=7.6, 1.2Hz, (H5,5’)) 6.13 (2H, d, J=2.0Hz, (H1,1’)) 5.61 (1H, s, (H9)) 3.01 (3H, s, 
(H11 or 12)) 2.96 (3H, s, (H11 or 12))  
13C NMR (100 MHz, CDCl3) 173.23 (C10), 136.41 (C2,2’), 126.67 (C7,7’), 123.87 
(C1,1’), 121.81 (C5,5’), 119.28 (C4,4’), 118.66 (C8,8’), 114.1 (C6,6’), 111.46 
(C3,3’), 46.34 (C9), 37.80 (C11 or 12), 37.29 (C11 or 12). 
IR (KBr) ν (cm-1) 3446, 2938, 1628, 1294, 1186. 
HRMS (EI, 70 eV) Calculated for 350.2227; Found 350.2234 
m.p.=167-169 °C 
Rf EtOAc=0.49 
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2,2-(di-indole-3-yl)-propionic acid ethyl ester (146) 
The general procedure was used with the starting materials indole 142 (0.117 g, 
1.0 mmol) and ethyl pyruvate 144 (0.58 g, 0.54 mL, 5.0 mmol) in the presence of 
Al(OTf)3 (0.024 g, 0.05 mmol, 5 mol %) in CH2Cl2. Product 146 was isolated by 
column chromatography on silica gel using dichloromethane/petroleum ether (4:1) as 
a white solid (0.149 g, 0.45 mmol, 91 % yield). 
O
N
H
N
H
O
1
23
5 6
7 8
9
4
1'
2'
3'
5'6'
7'8'
12
4'
10
11
13
 
1H NMR (400 MHz, CDCl3) 7.92 (2H, s, NH) 7.47 (2H, dd, J=8.0, 1.0Hz, (H3,3’)) 
7.29 (2H, dd, J=8.0, 0.8Hz, (H6,6’)) 7.09 (2H, td, J=8.0, 0.8Hz, (H4,4’)) 6.94 (2H, 
td, J=8.0, 1.0Hz, (H5,5’)) 6.89 (2H, d, J=2.8Hz, (H1,1’)) 4.11 (2H, q, J=7.0Hz, 
(H11)) 2.04 (3H, s, (H13)) 1.05 (3H, t, J=7.0 Hz, (H12)) 
13C NMR (100 MHz, CDCl3) 175.31 (C10), 136.80 (C2,2’), 126.14 (C7,7’), 122.86 
(C1,1’), 121.75 (C5,5’), 121.47 (C4,4’), 119.33 (C8,8’), 119.14 (C6,6’), 111.23 
(C3,3’), 61.08 (C11), 46.32 (C9), 25.89 (13), 14.23 (C12). 
IR (KBr) ν (cm-1) 3401, 2982, 1726, 1454, 1372, 1295, 1176. 
HRMS (EI, 70 eV) Calculated for 333.1598; Found 333.1611 
m.p.=160-162 °C 
Rf  Hex:EtOAc (4:1)=0.54 
 
2,2-(di-1-methyl-indole-3-yl)-propionic acid ethyl ester (148) 
The general procedure was used with the starting materials N-methylindole 145 
(0.131 g, 0.12 mL, 1.0 mmol) and ethyl pyruvate 144 (0.29 g, 0.27 mL, 2.5 mmol) in 
the presence of Zn(OTf)2 (0.05 mmol, 5 mol %) in CH2Cl2. Product 148 was isolated 
by column chromatography on silica gel using dichloromethane/petroleum ether 
(1:1) as a white solid (0.158 g, 0.44 mmol, 89 % yield). 
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O
N
CH3
N
CH3
O
1
23
5 6
7
8
9
4
1'
2'
3'
5'6'
7'8'
12
4'
10
11
13
14 14'
 
1H NMR (400 MHz, CDCl3) 7.48 (2H, dd, J=8.0, 1.2Hz, (H3,3’)) 7.23 (2H, dd, 
J=8.0, 1.0Hz, (H6,6’)) 7.14 (2H, td, J=8.0, 1.0Hz, (H4,4’)) 6.96 (2H, td, J=8.0, 
1.2Hz, (H5,5’)) 6.76 (2H, s, (H1,1’)) 4.08 (2H, q, J=7.2Hz, (H11)) 3.67 (6H, s, 
(H14,14’)) 2.40 (3H, s, (H13)) 1.05 (3H, t, J=7.2Hz, (H12)) 
13C NMR (100 MHz, CDCl3) 175.45 (C10), 137.52 (C2,2’), 127.56 (C7,7’), 126.48 
(C1,1’), 121.61 (5,5’), 121.34 (C4,4’), 118.57 (C8,8’), 117.65 (C6,6’), 109.21 (3,3’), 
61.07 (C11), 46.34 (C9), 32.78 (C14,14’), 26.29 (C13), 14.23 (C12). 
IR (KBr) ν (cm-1) 2986, 1728, 1618, 1305, 1226, 1161. 
HRMS (EI, 70 eV) Calculated for 361.1911; Found 361.1921 
m.p.=201-203 oC 
Rf EtOAc=0.48 
 
2,2-(di-5-bromo-1H-indole-3-yl)-propionic acid ethyl ester (149) 
The general procedure was used with the starting materials 5-bromoindole (0.194 g, 
1.0 mmol) and ethyl pyruvate 144 (0.58 g, 0.54 mL, 5.0 mmol) in the presence of 
Al(OTf)3 (0.023 g, 0.05 mmol, 5 mol %) in CH2Cl2. Product 149 was isolated by 
column chromatography on silica gel using dichloromethane/petroleum ether (5:1) as 
a white solid (0.213 g, 0.45 mmol, 91 % yield). 
O
N
H
N
H
O
Br Br
12
3
5 6
7 8
9
4
1'
2' 3'
5'6'
7'8'
12
10
11
13
4'
 
1H NMR (400 MHz, CDCl3) 8.04 (2H, s, NH) 7.55 (2H, s, (H6,6’)) 7.17 (2H, d, 
J=7.6Hz, (H3,3’)) 7.05 (2H, d, J=7.6Hz, (H4,4’)) 6.91 (2H, s, (H1,1’)) 4.12 (2H, q, 
J=7.2Hz, (H11)) 1.99 (3H, s, (H13)) 1.10 (3H, t, J=7.2Hz, (H12)) 
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13C NMR (100 MHz, CDCl3) 174.67 (C10), 135.46 (C2,2’), 127.57 (C7,7’), 124.86 
(C1,1’)), 124.03 (C6,6’), 123.82 (C4,4’), 119.47 (C8,8’), 118.56 (C5,5’), 112.73 
(C3,3’), 61.48 (C11), 46.08 (C9), 25.76 (C13), 14.1 (C12). 
IR (KBr) ν (cm-1) 3401, 2984, 2081, 1732, 1620, 1543, 1462, 1304, 1227. 
HRMS (EI, 70 eV) Calculated for 474.9651; Found 474.9667 
m.p.=82-84 oC 
Rf  DCM/PET (5:1) =0.40 
 
2-(4-Dimethylaminophenyl)-2-hydroxyacetic acid ethyl ester (137)  
The general procedure was used with the starting materials N,N-dimethylaniline 104 
(0.097 g, 0.101 mL, 0.8 mmol) and ethyl glyoxylate 105 (1.76 mmol in a crude 
mixture) in the presence of Cu(OTf)2 (0.029g, 0.08 mmol 10 mol %) in THF. 
Product 137 was isolated by column chromatography on silica gel using petroleum 
ether/diethyl ether (3:1) as a white powder (0.098 g, 0.44 mmol, 56 % yield) 
O
OEt
OH
H
NMe2
 
1H and 13C NMR data were in agreement with the literature93. 
1H NMR (400 MHz, CDCl3) 7.66 (2H, d, J=9.2Hz, Ar-H) 6.76 (2H, d, J=9.2Hz, Ar-
H) 5.05 (1H, d, J=5.8Hz, CH) 4.31 (1H, dq, J=10.8, 7.2Hz, CH2CH3) 4.22 (1H, dq, 
J=10.8, 7.2Hz, CH2CH3) 3.42 (1H, d, J=5.8Hz, OH) 3.00 (6H, s, NCH3) 1.29 (3H, t, 
J=7.2Hz, CH2CH3) 
13C NMR (100 MHz, CDCl3) 172.37, 150.86, 127.56, 126.25, 112.79, 73.02, 62.19, 
40.43, 14.91 
 
2-(2,4-Dimethoxyphenyl) -2-hydroxyacetic acid ethyl ester (138) 
The general procedure was used with the starting materials 1,3-dimethoxybenzene 
(0.138 g, 0.132 mL, 1.0 mmol) and ethyl glyoxylate 105 (1.52 mmol in a crude 
mixture) in the presence of Cu(OTf)2 (0.036g, 0.1 mmol 10 mol %) in THF. Product 
138 was isolated by column chromatography on silica gel using petroleum 
ether/diethyl ether (5:1) as a colorless oil (0.134 g, 0.56 mmol, 56 % yield) 
Experimental 
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1H and 13C NMR data were in agreement with the literature93. 
1H NMR (400 MHz, CDCl3) 7.32 (1H, d, J=8.6Hz, Ar-H) 6.43 (1H, dd, J=8.6, 
2.4Hz, Ar-H) 6.38 (1H, d, 2.4Hz, Ar-H) 5.07 (1H, d, J=6.0Hz, CH).4.33 (1H, d, 
J=6.0Hz, OH) 4.31 (1H, dq, J=10.4, 7.2Hz, CH2CH3) 4.24 (1H, dq, J=10.4, 7.2Hz, 
CH2CH3) 3.71 (3H, s, OCH3) 3.67 (3H, s, OCH3) 1.29 (3H, t, J=7.2 Hz, CH2CH3) 
13C NMR (100 MHz, CDCl3) 171.10, 161.18, 158.94, 128.13, 114.98, 112.09, 
105.06, 72.04, 62.14, 55.53, 55.40, 14.84. 
 
2-(4-Dimethylaminophenyl)-3,3,3-trifluoro-2-hydroxypropionic acid ethyl ester 
(140) 
The general procedure was used with the starting materials N,N-dimethylaniline 
(0.06 g, 0.06 mL, 0.5 mmol) and ethyl 3,3,3-trifluoropyruvate 139 (0.16 g, 0.13 mL, 
0.96 mmol) in the presence of Cu(OTf)2 (0.009 g, 0.025 mmol, 5 mol %) in THF. 
Product 140 was purified by column chromatography on silica gel using petroleum 
ether/diethyl ether (4:1) mixture as a pale yellow oil (0.129 g, 0.48 mmol, 98 % ) 
O
OEt
OH
F3C
NMe2
 
1H and 13C NMR data were in agreement with the literature94. 
1H NMR (400 MHz, CDCl3) 7.65 (2H, d, J=9.2Hz, Ar-H) 6.75 (2H, d, J=9.2Hz, Ar-
H) 4.46 (1H, dq, J=10.8,7.2Hz, CH2CH3) 4.40 (1H, dq, J=10.8, 7.2Hz, CH2CH3) 4.28 
(1H, s, OH) 3.00 (6H, s, NCH3) 1.41 (3H, t, J=7.2Hz, CH2CH3) 
13C NMR (100 MHz, CDCl3) 169.38, 150.79, 127.61, 127.50 (q, JC-F =283.8 Hz), 
112.56, 111.93, 77.06 (q, JC-F =30.0 Hz), 64.09, 40.41, 13.95 
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2-(2,4-dimethoxyphenyl)-3,3,3-trifluoro-2-hydroxypropionic acid ethyl ester 
(141) 
The general procedure was used with the starting materials 1,3-dimethoxybenzene 
(0.069 g, 0.070 mL, 0.5 mmol) and ethyl 3,3,3-trifluoropyruvate 139 (0.16 g, 0.13 
mL, 0.96 mmol) in the presence of Cu(OTf)2 (0.009 g, 0.025 mmol, 5 mol %) in 
THF. Product 141 was purified by column chromatography on silica gel using 
petroleum ether/diethyl ether (5:1) mixture as a colorless oil (0.113 g, 0.37 mmol, 
73 %). 
O
OEt
OH
F3C OMe
OMe  
1H and 13C NMR data were in agreement with the literature94. 
1H NMR (400 MHz, CDCl3) 7.34 (1H, d, J=9.0Hz, Ar-H) 6.47 (1H, dd, J=9.0, 
2.2Hz, Ar-H) 6.43 (1H, d, 2.2Hz, Ar-H) 4.47 (1H, s, OH) 4.24 (1H, dq, J=10.8, 
7.2Hz, CH2CH3) 4.18 (1H, dq, J= 10.8, 7.2 Hz, CH2CH3) 3.73 (3H, s, OCH3) 3.68 
(3H, s, OCH3) 1.21 (3H, t, J=7.2Hz, CH2CH3) 
13C NMR (100 MHz, CDCl3) 169.71, 161.63, 158.44, 129.01, 122.60 (q, JC-F= 
285.8Hz), 115.63, 112.36, 109.41, 77.86 (q, JC-F= 29.8Hz), 63.39, 55.59, 55.44, 
13.81. 
 
3,3,3-trifluoro-2-hydroxy-2-(1’-methyl-indole-3’-yl)-propionic acid ethyl ester 
(150)  
The general procedure was used with the starting materials N-methylindole (0.066 g, 
0.5 mmol) and ethyl 3,3,3-trifluoropyruvate (0.43 g, 0.33 mL, 2.5 mmol) in the 
presence of Cu(OTf)2 (0.018 g, 0.05 mmol, 10 mol %) in CH2Cl2. Product 150 was 
purified by column chromatography on silica gel using petroleum ether/diethyl ether 
(4:1) mixture as a white powder (0.143 g, 0.47 mmol, 94 %). 
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1H and 13C NMR data were in agreement with the literature94. 
1H NMR (400 MHz, CDCl3) 7.94 (1H, d, J=8.2Hz, Ar-H) 7.37 (1H, s, Ar-H) 7.31-
7.25 (2H, m, Ar-H) 7.18 (1H, ddd, J=8.2, 6.6, 1.2Hz, Ar-H) 4.44 (1H, dq, J=10.6, 
7.4Hz, CH2CH3) 4.41 (1H, s, OH) 4.38 (1H, dq, J=10.6, 7.4Hz, CH2CH3) 3.74 (3H, 
s, NCH3) 1.31 (3H, t, J=7.4 Hz, CH2CH3) 
13C NMR (100 MHz, CDCl3) 169.61, 136.87, 129.01, 125.86, 123.12 (q, JC-F= 
284.2Hz), 121.97, 121.13, 120.04, 109.76, 106.95, 77.02 (q, JC-F= 28.9Hz), 65.01, 
33.25, 14.40. 
 
3,3,3-trifluoro-2-hydroxy-2-(indole-3’-yl)-propionic acid ethyl ester (151) 
The general procedure was used with the starting materials indole (0.059 g, 0.048 ml, 
0.5 mmol) and ethyl 3,3,3-trifluoropyruvate (0.43 g, 0.33 mL, 2.5 mmol) in the 
presence of Cu(OTf)2 (0.018 g, 0.05 mmol, 10 mol %) in CH2Cl2. Product 151 was 
purified by column chromatography on silica gel using petroleum ether/diethyl ether 
(5:1) mixture as a white powder (0.133 g, 0.46 mmol, 91 %). 
 
N
H
OH CF3
OCH2CH3
O
 
1H and 13C NMR data were in agreement with the literature94. 
1H NMR (400 MHz, CDCl3) 8.03 (1H, s, NH)7.92 (1H, d, J=8.2Hz, Ar-H) 7.36 (1H, 
d, J=2.6Hz, Ar-H) 7.32 (1H, dd, J=8.2, 1.4Hz, Ar-H) 7.21-7.14 (2H, m, Ar-H) 4.46 
(1H, dq, J=10.8, 7.4Hz, CH2CH3) 4.44 (1H, s, OH) 4.37 (1H, dq, J=10.8, 7.4Hz, 
CH2CH3) 3.74 (3H, s, NCH3) 1.31 (3H, t, J=7.4 Hz, CH2CH3) 
13C NMR (100 MHz, CDCl3) 169.64, 136.82, 125.31, 124.66, 123.61 (q, JC-F= 
284.8Hz), 122.19, 121.26, 120.37, 111.64, 109.03, 77.07 (q, JC-F= 29.3Hz), 64.72, 
14.35. 
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Friedel-Crafts reaction in water 
General procedure 
To a flask was added sat. NaHCO3 or 1M NaCl, subsequently glyoxamide (as a 
crude) and N-methylpyrrole were added. Reaction mixture was stirred for 20 h at RT. 
After that time reaction mixture was extracted with CH2Cl2 (6 x 10 mL), dried by 
MgSO4, solvent was removed by rotary evaporation and the mixture was submitted 
to flash chromatography.  
2-Hydroxy-N,N-dimethyl-2-(1’-methylpyrrol-2’-yl)acetamide (153) 
The general procedure was used with starting materials of N-methylpyrrole (0.057 g, 
0.7 mmol) and N,N-dimethyl glyoxamide (0.16 g, 1.4 mmol as a crude) in saturated 
NaHCO3 (3 mL). Product 153 was isolated by column chromatography on silica gel 
using EtOAc, as a pale yellow solid (0.12 g, 0.65 mmol, 94 % yield). 
NN
Me OH
O
CH3
CH3
1
23
5
6
7
8
4
8'
 
1H NMR (400 MHz, CDCl3) 6.54 (1H, dd, J=3.0, 3.0Hz, (H3)) 5.95 (1H, dd, J=3.0, 
1.6, (H4)) 5.87 (1H, dd, J=3.0, 1.6Hz, (H2)) 5.22 (1H, d, J=6.0Hz, (H6)) 4.27 (1H, d, 
J=6.0Hz, OH) 3.62 (3H, s, (H5)) 3.01 (3H, s, (H8 or 8’)) 2.75 (3H, s, (H8 or 8’))  
13C NMR (100 MHz, CDCl3) 171.62 (C7), 129.27 (C1), 123.86 (C4), 108.45 (C3), 
106.88 (C2), 64.28 (C6), 36.56 (C8 or 8’), 36.27 (C8 or 8’), 34.12 (C5). 
IR (KBr) ν (cm-1) 3462, 2984, 2052, 1681, 1636, 1486, 1369, 1301. 
HRMS (EI, 70 eV) Calculated for 183.1128; Found 183.1130 
Rf EtOAc=0.48 
m.p.=64-66 °C 
 
2-hydroxy-2-(1’-methylpyrrol-2’-yl)-1-(pyrrolidin-1-yl) ethanone (154) 
The general procedure was used with starting materials of N-methylpyrrole (0.081 g, 
1.0 mmol) and 2-oxo-2-(pyrrolidin-1-yl)acetaldehyde 134 (0.51 g, 4.0 mmol as a 
crude) in saturated NaHCO3 (3 mL). Product 154 was isolated by column 
chromatography on silica gel using EtOAc, as a pale yellow solid (0.192 g, 
0.92 mmol, 92 % yield). 
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Me OH
O
1
23
5
6
7
8
9
4
1011
 
1H NMR (400 MHz, CDCl3) 6.53 (1H, dd, J=2.8, 2.8Hz, (H3)) 5.99 (1H, dd, J=2.8, 
1.4Hz, (H4)) 5.96 (2H, td, J=2.8, 1.4Hz, (H2)) 5.08 (1H, s, (H6)) 4.28 (1H, s, OH) 
3.59 (3H, s, (H5)) 3.59-3.21 (4H, m, (H8,11)) 1.83-1.77 (4H, m, (H9,10)) 
13C NMR (100 MHz, CDCl3) 169.78 (C7), 128.96 (C1), 123.86 (C4), 109.05 (C3), 
106.76 (C2), 65.45 (C6), 46.50 (C8 or 11), 45.84 (C8 or 11), 34.12 (C5), 25.90 (C9 
or 10), 23.86 (C9 or 10). 
IR (KBr) ν (cm-1) 3464, 2986, 2056, 1678, 1634, 1487, 1372, 1301. 
HRMS (EI, 70 eV) Calculated for 209.1285; Found 209.1283 
Rf EtOAc=0.45 
m.p.=66-68 °C 
 
Product 136 was isolated as a white solid after catalytic Friedel-Crafts reactions 
carried with 2-oxo-2-(pyrrolidin-1-yl)acetaldehyde 134. Proposed structure below, 
see page 54 for possible alternative structure. 
N N
O
O
H
OH H OH
O
1
2
3
5
6
7
8
4
1'
2'
3'
5'
6'
7' 8'
4'
 
NMR in CDCl3 
1H NMR (400 MHz, CDCl3) 5.51 (2H, d, J= 9.4 Hz, (H7,7’)) 5.21 (2H, d, J= 9.4 Hz, 
(H8,8’)) 3.71-3.44 (8H, m, (H1,4,1’,4’)) 1.98-1.94 (8H, m, (H2,3,2’,3’)) 
13C NMR (100 MHz, CDCl3) 166.87 (C5,5’), 86.88 (C6,6’), 46.32 (C1,1’ or 4,4’), 
45.70 (C1,1’ or 4,4’), 25.83 (C2,2’ or 3,3’), 23.91 (C2,2’ or 3,3’). 
NMR in D2O 
1H NMR (400 MHz, D2O) 5.37 (2H, s, (H7,7’)) 3.47 (4H, t, J= 6.8 Hz, (H1,1’ or 
4,4’)) 3.30 (4H, t, J= 6.8 Hz, (H1,1’ or 4,4’)) 1.87-1.724 (8H, m, (H2,3,2’,3’)) 
13C NMR (100 MHz, D2O) 168.56 (C5,5’), 85.04 (C6,6’), 46.4 (C1,1’ or 4,4’), 46.3 
(C1,1’ or 4,4’), 25.3 (C2,2’ or 3,3’), 23.4 (C2,2’ or 3,3’). 
IR (KBr) ν (cm-1) 3484, 2981, 1676, 1158, 1125. 
HRMS (EI, 70 eV) Calculated for 273.1445; Found 273.1458 
m.p.=109-111 °C 
Experimental 
 
199 
2,2-Bis(4-(dimethylamino)phenyl)-1-phenylethanone (156) 
To a flame-dried flask catalyst Zn(OTf)2 (0.036g, 0.05 mmol, 20 mol%) was added 
and dried under vacuum for 4 h. Then BMIMBF4 (5 mL) and phenylglyoxal 
monohydrate 155 (0.30 g, 2.0 mmol) were added under N2 and stirred for 20 min. 
N,N-Dimethylaniline 104 (0.061 g, 0.063 mL, 0.50 mmol) was added in one portion 
and the reaction mixture stirred at 40 °C for 14 h. after that time the reaction mixture 
was filtered through a pad of silica with CH2Cl2, solvent was removed in vacuo and 
the product was purified by flash chromatography on silica gel using Et2O/petroleum 
ether (1:1). Product 156 was isolated as a pale green solid (0.23 mmol, 0.083 g, 93 % 
yield). 
Experiment was repeated using the same ratio of starting materials in BDMIMBF4 
(5 mL) at 60 °C to give product 156 in 91 % isolated yield (0.081 g, 0.22 mmol). 
 
NMe2
O
Me2N
1
2
3
4
5
6
8
9
10
7
10'
9'
12
1111'
10
10'
11'
11
12
13,14
13,14
 
1H NMR (400 MHz, CDCl3) 7.92 (2H, dd, J=7.2,1.6Hz, (H2,6)) 7.41-7.26 (3H, m, 
(H3,4,5)) 7.04 (4H, d, J=7.8Hz, (H10,10’)) 6.60 (4H, d, J=7.8Hz, (H11,11’)) 5.77 
(1H, s, (H8)) 2.81 (12H, s, (H13,14)) 
13C NMR (100 MHz, CDCl3) 199.41 (C7), 149.52 (12,12’), 137.30 (C1), 132.56 
(C4), 129.72 (C9,9’), 129.03 (C10,10’), 128.45 (C2,6), 127.78 (C3,5), 112.87 
(C11,11’), 57.65 (C8), 40.67 (C13,14). 
Rf  Et2O/PET 1:1=0.5 
m.p.=87-89 °C 
Experimental 
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8.2 Model macrocycles and their precursord 
 
General procedure (160-166) 
A mixture of 2-(2-hydroxyethoxy)phenol 159 (10.0 mmol), alkyl dihalide (5.0 mmol) 
and sodium carbonate (15.0 mmol) in dry DMF (5.0 mL) was stirred for 7 h at 
120 oC. After that time the reaction mixture was allowed to cool to room temperature 
and distilled water was added. Solid precipitated and was filtered under vacuum and 
washed with copious amounts of water. Crude product was recrystallized from 
chloroform/hexane or when necessary separated by flash chromatography. 
 
1,3-Bis[2-(2-hydroxyethoxy)phenoxy]propane (160) 
The general procedure was used with the starting materials 2-(2-hydroxy-
ethoxy)phenol (10.0 mmol), and 1,3-dichloropropane (0.56 g, 5.0 mmol). Product 
160 was isolated by column chromatography on silica gel using CH2Cl2:EtOAc (1:1) 
as a white solid (0.94 g, 2.7 mmol, 54 % yield). 
OO
OO
OHOH
1
2
34
5
6
7
8
9
10
9'
1'
2'
3'
4'
5'
6'
7'
8'
 
1H NMR (400 MHz, CDCl3) 6.92-6.81 (8H, m, (H3-6,3’-6’)) 4.23 (4H, t, J= 5.6Hz, 
(H9,9’)) 3.99 (4H, t, J= 4.4Hz, (H7,7’)) 3.83 (4H, t, J=4.4 Hz, (H8,8’)) 2.14 (2H, p, 
J= 5.6 Hz, (H10)) 
13C NMR (100 MHz, CDCl3) 149.49 (C2,2’), 148.21 (C1,1’), 122.38 (C5,5’), 121.56 
(C4,4’), 115.98 (C6,6’), 114.13 (C3,3’), 70.98 (C7,7’), 66.72 (C9,9’), 61.23 (C8,8’), 
29.04 (C10). 
IR (KBr) ν (cm-1) 3334, 2932, 2875, 1593, 1507, 1455, 1385, 1255, 1126, 1052. 
HRMS (EI, 70 eV) Calculated for C19H24O6H+ 349.1646; Found 349.1659;  
m.p.= 82-84 oC     
Rf EtOAc/DCM (1:1)= 0.34 
 
 
Experimental 
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1,5-Bis[2-(2-hydroxyethoxy)phenoxy]-3-oxapentane (161) 
The general procedure was used with the starting materials 2-(2-hydroxy-
ethoxy)phenol (10.0 mmol), and 2,2’-chloroethylether (1.13 g, 0.63 mL, 5.0 mmol). 
Recrystallization from chloroform:hexane (3:1) gave the title product as white 
powder (1.63 g, 4.3 mmol, 86% yield) and (1.29 g, 3.4 mmol, 68% yield) when 2,2’-
bromoethylether was used as a starting material. 
O
O
OH OH
O
O
O
1
2
3
4
5
6
7
8
9
10
9'
1'
2'
3'
4'
5'
6'
7'
8'
10'
 
 
1H NMR (400 MHz, CDCl3) 6.93-6.78 (8H, m, (H3-6,3’-6’)) 4.13 (4H, t, J= 4.4Hz, 
(H9,9’)) 4.01 (4H, t, J= 4.2Hz, (H7,7’)) 3.91 (4H, t, J= 4.4Hz, (H10,10’)) 3.84 (4H, t, 
J= 4.2Hz, (H8,8’))  
13C NMR (100 MHz, CDCl3) 148.91 (C2,2’), 148.45 (C1,1’), 122.11 (C5,5’), 121.48 
(C4,4’), 114.43 (C6,6’), 114.09 (C3,3’), 71.19 (C7,7’), 69.89 (C10,10’), 68.91 (9,9’), 
60.98 (C8,8’). 
IR (KBr) ν (cm-1) 3552, 3376, 3213, 2939, 1667, 1595, 1507, 1455, 1325, 1255, 
1242, 1124, 1053. 
HRMS (EI, 70 eV) Calculated for C20H26O7H+ 379.1751; Found 379.1750;  
m.p.= 92-94°C    
Rf EtOAc = 0.22 
 
1,8-Bis[2-(2-hydroxyethoxy)phenoxy]- 3,6-dioxaoctane (162) 
The general procedure was used with the starting materials 2-(2-hydroxy-
ethoxy)phenol (10.0 mmol), and 1,2-bis(2-chloroethoxy)ethane (0.93 g, 0.50 mL, 
5.0 mmol). Recrystallization from chloroform:hexane (4:1) gave the title product as 
white powder (1.71 g, 4.05 mmol, 81 % yield) and (1.14 g, 2.7 mmol, 54 % yield) 
when 1,2-bis(2-iodoethoxy)ethane was used as a starting material. 
Experimental 
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OHOH
OO
OO
OO
1
2
3
4
5
6
7
8
9
10
11
9'
1'
2'
3'
4'
5'
6'
7'
8'
10'
11'
  
 
1H NMR (400 MHz, CDCl3) 6.89-6.77 (8H, m, (H3-6,3’-6’)) 4.09 (4H, t, J=4.6Hz, 
(H9,9’)) 3.99 (4H, t, J=4.4Hz, (H7,7’)) 3.81-3.78 (8H, m, overlap, (H8,8’,10,10’)) 
3.71 (4H, s, (H11,11’))  
13C NMR (100 MHz, CDCl3) 148.79 (C2,2’), 148.61 (C1,1’), 121.78 (5,5’), 121.45 
(C4,4’), 114.27 (C6,6’), 113.91 (C3,3’), 71.56 (C7,7’), 70.71 (C11,11’), 69.78 
(C10,10’), 68.81 (C9,9’), 61.02 (C8,8’). 
IR (KBr) ν (cm-1) 3370, 2933, 1594, 1514, 1452, 1332, 1259, 1224, 1126, 1089, 
1045. 
HRMS (EI, 70 eV) Calculated for C22H30O8H+ 423.2013; Found 423.2026; 
m.p.=69-71°C 
Rf EtOAc=0.12 
 
1,4-Bis[2-(2-hydroxyethoxy)phenoxy]-p-xylene (163) 
The general procedure was used with the starting materials 2-(2-hydroxy-
ethoxy)phenol (10.0 mmol), and α,α’-dibromo-p-xylene (1.32 g, 5.0 mmol). 
Recrystallization from chloroform:hexane (5:1) gave the title product as white 
powder (1.58 g, 3.9 mmol, 77 % yield) and (1.80 g, 4.4 mmol, 88 % yield) when  
α,α’-dichloro-p-xylene was used as a starting material. 
OH
O
OO
O
OH
1
2
34
5
6
7
8
9 10
11
12'
9'
1'
2'
3'
4'
5'
6'
7'
8'
10'
11'
12
 
 
1H NMR (400 MHz, CDCl3) 7.36 (4H, s, (H11,11’,12,12’)) 6.88-6.55 (8H, m, (H3-
6,3’-6’)) 5.01 (4H, s, (H9,9’)) 4.00 (4H, t, J= 4.6Hz, (H7,7’)) 3.76 (4H, t, J= 4.6Hz, 
(H8,8’)) 
Experimental 
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13C NMR (100 MHz, CDCl3) 149.08 (C2,2’), 148.79 (C1,1’), 136.76 (C10,10’), 
127.88 (C11,11’,12,12’), 122.12 (C5,5’), 121.89 (C4,4’), 115.56 (C6,6’), 114.67 
(C3,3’), 71.45 (C9,9’), 71.21 (C7,7’), 61.18 (C8,8’).  
IR (KBr) ν (cm-1) 3536, 3488, 2938, 2871, 1593, 1506, 1454, 1329, 1252, 1211, 
1199, 1125, 1014. 
HRMS (EI, 70 eV) Calculated for C24H26O6H+ 411.1802; Found 411.1800;  
m.p. = 104-106 °C 
Rf (EtOAc/DCM 1:1) = 0.31 
 
1,3-Bis[2-(2-hydroxyethoxy)phenoxy]-m-xylene (164) 
The general procedure was used with the starting materials 2-(2-hydroxy-
ethoxy)phenol (10.0 mmol), and α,α’-dibromo-m-xylene (1.32 g, 5.0 mmol). 
Recrystallization from chloroform:hexane (5:1) gave the title product as white 
powder (1.46 g, 3.6 mmol, 71 % yield) and (1.87 g, 4.6 mmol, 91 % yield) when 
α,α’-dichloro-m-xylene was used as a starting material. 
O
O
OH OH
O
O
1
2
3
4
5
6
7
8
9
10
11
13
9'
1'
2'
3'
4'
5'
6'
7'
8'
10'
11'
12
 
 
1H NMR (400 MHz, CDCl3) 7.56 (1H, s, (H13)) 7.31-7.22 (3H, m, (H11,11’,12)) 
6.89-6.80 (8H, m, (H3-6,3’-6’)) 5.02 (4H, s, (H9,9’)) 3.99 (4H, t, J= 4.6Hz, (H7,7’)) 
3.76 (4H, t, J= 4.6Hz, (H8,8’))  
13C NMR (100 MHz, CDCl3) 148.99 (C2,2’), 148.82 (C1,1’), 137.61 (C10,10’), 
128.82 (C12), 127.17 (C11,11’), 126.78 (C13), 121.94 (C5,5’), 121.92 (C4,4’), 
115.18 (C6,6’), 115.08 (C3,3’), 71.62 (C9,9’), 71.43 (C7,7’), 61.18 (C8,8’) 
IR (KBr) ν (cm-1) 3499, 3360, 2924, 1590, 1507, 1452, 1329, 1249, 1211, 1124, 
1081, 1050, 1008. 
HRMS (EI, 70 eV) Calculated for C24H26O6H+ 411.1802; Found 411.1797;  
m.p.=84-86°C 
Rf (EtOAc)=0.57 
 
Experimental 
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1,2-Bis[2-(2-hydroxyethoxy)phenoxy]-o-xylene (165) 
The general procedure was used with the starting materials 2-(2-hydroxy-
ethoxy)phenol (10.0 mmol), and α,α’-dibromo-o-xylene (1.32 g, 5.0 mmol). 
Recrystallization from chloroform:hexane (5:1) gave the title product as white 
powder (1.56 g, 3.8 mmol, 76 % yield) and (1.60 g, 3.9 mmol 78 % yield) when α,α’-
dichloro-o-xylene was used as a starting material. 
O
O
OH
O
O
OH
1
2
3
4
5
6
7
8
9
10
11
12'
9'
1'
2'
3'
4'
5'
6'
7'
8'
10'
11'
12
 
 
1H NMR (400 MHz, CDCl3) 7.37 (2H, dd, J=5.6, 3.6Hz, (H12,12’)) 7.25-7.21 (2H, 
dd, J=5.6, 3.6Hz, (H11,11’)) 6.88-6.77 (8H, m, (H3-6,3’-6’)) 5.26 (4H, s, (H9,9’)) 
3.96 (4H, t, J= 4.2Hz, (H7,7’)) 3.75 (4H, t, J= 4.2Hz, (H8,8’))  
13C NMR (100 MHz, CDCl3) 148.27 (C2,2’), 146.96 (C1,1’), 134.32 (C10,10’), 
128.27 (C12,12’), 127.33 (C11,11’), 121.27 (C5,5’), 120.34 (C4,4’), 114.89 (C6,6’), 
112.83 (C3,3’), 69.70 (C9,9’), 69.22 (C7,7’), 60.09 (C8,8’). 
IR (KBr) ν (cm-1) 3267, 2901, 1590, 1505, 1395, 1323, 1256, 1126, 1040, 1000. 
HRMS (EI, 70 eV) Calculated for C24H26O6H+ 411.1802;  Found 411.1805;  
m.p.=66-68 °C 
Rf (EtOAc)=0.52 
 
1,6-Bis[2-(2-hydroxyethoxy)phenoxy]lutidine (166) 
The general procedure was used with the starting materials 2-(2-hydroxy-
ethoxy)phenol (10.0 mmol), and 2,6-bis(chloromethyl)pyridine (0.88 g, 5.0 mmol). 
Recrystallization from chloroform gave the title product as white powder (1.89 g, 
4.6 mmol, 92 % yield). 
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N
O
O
OH OH
O
O
1
2
3
4
5
6
7
8
9
10
11
9'
1'
2'
3'
4'
5'
6'
7'
8'
10'
11'
12
 
 
1H NMR (400 MHz, CDCl3) 7.69 (1H, t, J=7.6Hz, (H12)) 7.41 (2H, d, J=7.6Hz, 
(H11,11’)) 6.92-6.81 (8H, m, (H3-6,3’-6’)) 5.18 (4H, s, (H9,9’)) 4.06 (4H, t, 
J=4.4Hz, (H7,7’)) 3.85 (4H, t, J=4.4Hz, (H8,8’)) 
13C NMR (100 MHz, CDCl3) 156.68 (C10,10’), 149.18 (C2,2’), 148.45 (C1,1’), 
138.07 (C12), 122.63 (C11,11’), 121.89 (C5,5’), 121.24 (C4,4’), 116.22 (C6,6’), 
115.03 (C3,3’), 72.10 (C9,9’), 71.38 (C7,7’), 61.04 (C8,8’). 
IR (KBr) ν (cm-1) 3341, 2927, 1592, 1506, 1452, 1379, 1328, 1259, 1222, 1126, 
1085, 1049. 
HRMS (EI, 70 eV) Calculated for C23H25NO6H+ 412.1755; Found 412.1743;  
m.p.=101-103 °C 
Rf (EtOAc)=0.36 
 
Experimental 
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Macrocyclizations 
 
General procedure 1 (169-184) 
Open structure (1.0 mmol) was dissolved in dry 1,4-dioxane (80 mL) then potassium 
hydroxide (0.78 g, 14.0 mmol) was added and mixture was warmed up to 60 °C and 
stirred for 30 min.  Alkyl dichloride (1.0 mmol) and potassium iodide (0.2 mmol) 
were added in one portion and reaction mixture was refluxed for 36 hours. After that 
time organic solvent was removed by rotary evaporation and distilled water (70 mL) 
was added to the residue. Then reaction mixture was transferred to a separation 
funnel and extracted with chloroform (6 x 30 mL). The organic layer was dried over 
MgSO4 and filtered then solvent was evaporated to give the crude. Purification of the 
product was carried out by column chromatography on silica gel.  
 
General procedure 2 (167, 168) 
Open structure (1.0 mmol) was dissolved in dry dichloromethane (150 mL) then 
potassium carbonate (1.93 g, 14.0 mmol) was added under atmosphere of nitrogen 
and then acyl dichloride (1.0 mmol) was added in one portion and reaction mixture 
was refluxed over night. After that time reaction mixture was quenched with distilled 
water (70 mL) and all was transferred to a separation funnel and the organic and 
aqueous layers were separated. The organic layer was dried over MgSO4, filtered 
then organic solvent was evaporated to give the crude. Purification of the product 
was carried out by column chromatography on silica gel.  
Experimental 
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2,3,6,8,11,12,18,20-tetrabenzo-19-aza-1,4,10,13,16,22-hexaoxacyclotetraeicosa-
2,6,7,11,18,19-hexaene-17,21-dione (167) 
The general procedure 2 was used with the starting materials 164 (0.41 g, 1.0 mmol) 
and 2,6-pyridine dicarbonyl dichloride (0.21 g, 1.0 mmol). Product 167 was isolated 
by column chromatography on silica gel using EtOAc as a white solid (0.19 g, 
0.31 mmol, 31 % yield). 
N
O
O
O
O
O
O
O O
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
17
16
1'
2'
3' 4'
5'
6'
7'
8'
9'
10'
11'
14'
15'
16'
 
1H NMR (400 MHz, CDCl3) 7.92 (2H, d, J=7.6Hz, (H16,16’)) 7.66 (1H, t, J=7.6Hz, 
(H17)) 7.44 (1H, s, (H13)) 7.12-7.10 (3H, m, overlap, (H11,11’,12)) 6.94-6.84 (8H, 
m, (H3-6,3’-6’)) 4.92 (4H, s, (H9,9’)) 4.69 (4H, t, J=4.4Hz, (H8,8’)) 4.37 (4H, t, J= 
4.4Hz, (H7,7’)) 
13C NMR (100 MHz, CDCl3) 163.17 (C14,14’), 148.45 (C2,2’), 148.42 (C15,15’), 
146.89 (C1,1’), 136.71 (C17), 136.43 (C10,10’), 128.08 (C16,16’), 127.07 (C12), 
126.67 (C13), 125.40 (C11,11’), 121.48 (C4,4’), 121.39 (C5,5’), 116.32 (C6,6’), 
115.07 (C3,3’), 71.21 (C9,9’), 66.70 (C7,7’), 63.39 (C8,8’). 
IR (KBr) ν (cm-1) 2942, 1743, 1588, 1506, 1450, 1378, 1291, 1256, 1125, 1081. 
HRMS (EI, 70 eV) Calculated for C31H27NO8H+ 542.1809; Found 542.1791; 
m.p.= 164-166 °C 
Rf EtOAc= 0.66 
 
2,3,6,9,12,13,19,21-tetrabenzo-20-aza-1,4,11,14,17,23-hexaoxacyclopentaeicosa-
2,6,7,8,12,19,20-hexaene-18,22-dione (168) 
The general procedure 2 was used with the starting materials 163 (0.41 g, 1.0 mmol) 
and 2,6-pyridine dicarbonyl dichloride (0.21 g, 1.0 mmol). Product 168 was isolated 
by column chromatography on silica gel using EtOAc as a white solid (0.14 g, 
0.26 mmol, 26 % yield). 
Experimental 
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N
O O
O O
O O
OO
1
2
34
5
6
7
8
9
10
11
12
13
14
15
16
1'
2'
3'
4'
5'
6'
7'
8'
9'
10'
11'
14'
15'
12'
13'
 
1H NMR (400 MHz, DMSO) 8.18 (2H, d, J=7.6Hz, (H15,15’)) 7.71 (1H, t, J=7.6Hz, 
(H16)) 7.16-6.92 (12H, m, overlap, (H3-6,3’-6’,11,11’,12,12’)) 4.99 (4H, s, (H9,9’)) 
4.79 (4H, t, J= 4.4Hz, (H8,8’)) 4.47 (4H, t, J= 4.4Hz, (H7,7’)) 
13C NMR (100MHz, DMSO) 163.78 (C13,13’), 148.31 (C14,14’), 147.90 (C2,2’), 
147.83 (C1,1’), 139.21 (C16), 136.40 (C10,10’), 128.19 (C15,15’), 126.89 
(C11,11’,12,12’), 121.60 (C4,4’), 121.34 (C5,5’), 115.20 (C6,6’), 113.89 (C3,3’), 
69.70 (C9,9’), 66.17 (C7,7’), 63.58 (C8,8’). 
IR (KBr) ν (cm-1) 2932, 1759, 1591, 1503, 1460, 1388, 1293, 1254, 1126, 1019. 
HRMS (EI, 70 eV) Calculated for C31H27NO8H+ 542.1809; Found 542.1810;  
m.p.=185-187 °C 
Rf EtOAc=0.64 
 
2,3,11,12,18,20-tribenzo-1,4,7,10,13,16,22-heptaoxacyclotetraeicosa-2,11,18,19-
tetraene (169) 
The general procedure 1 was used with the starting materials 161 (0.38 g, 1.0 mmol) 
and α,α’-dichloro-m-xylene (0.17 g, 1.0 mmol). Product 169 was isolated by column 
chromatography on silica gel using EtOAc/CHCl3 (1:1) as a white solid (0.19 g, 
0.40 mmol, 40 % yield). 
O O
O O
O O
O
1
2
34
5
6
9
10
11 12
13
14
15
1'
2'
3' 4'
5'
6'
7'
8'
9'
10'
11'
13'
12'
7
8
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1H NMR (400 MHz, CDCl3) 7.35 (1H, s, (H15)) 7.22-7.18 (3H, m, overlap, 
(H13,13’,14)) 6.86-6.78 (8H, m, (H3-6,3’-6’)) 4.61 (4H, s, (H11,11’)) 4.11 (4H, t, 
J=4.6Hz, (H9,9’)) 4.08 (4H, t, J=4.8Hz, (H7,7’)) 3.82 (4H, t, J=4.6Hz, (H10,10’)) 
3.80 (4H, t, J=4.8Hz, (H8,8’)  
13C NMR (100 MHz, CDCl3) 149.40 (C2,2’), 149.02 (C1,1’), 138.45 (C12,12’), 
128.41 (C14), 127.4 (C15), 127.11 (C13,13’), 121.89 (C4,4’), 121.60 (C5,5’), 115.87 
(C6,6’), 114.42 (C3,3’), 73.46 (C11,11’), 70.29 (C8,8’), 69.72 (C9,9’), 69.30 (C7,7’) 
68.78 (C10,10’) 
IR (KBr) ν (cm-1) 2930, 1594, 1505, 1449, 1357, 1256, 1123, 1041. 
HRMS (EI, 70 eV) Calculated for C28H32O7H+ 481.2221; Found 481.2215;  
m.p.=90-92 °C 
Rf EtOAc/CHCl3=0.81 
 
2,3,11,12,18,19-tribenzo-1,4,7,10,13,16,21-heptaoxacyclotrieicosa-2,11,18-triene 
(170)  
The general procedure 1 was used with the starting materials 161 (0.38 g, 1.0 mmol) 
and α,α’-dichloro-o-xylene (0.17 g, 1.0 mmol). Product 170 was isolated by column 
chromatography on silica gel using CHCl3 as a white solid (0.25 g, 0.50 mmol, 50 % 
yield). 
OO
O
O
O
O O
1
2
3
4
5
6
9
10
11
12
13
14
1'
2'
3'
4'
5'
6'
7'
8'
9'
10'
11'
13'
12'
7
8
14'
  
1H NMR (400 MHz, CDCl3) 7.33 (2H, dd, J=5.6, 3.2Hz, (H14,14’)) 7.22 (2H, dd, 
J=5.6, 3.2Hz, (H13,13’)) 6.88-6.79 (8H, m, (H3-5,3’-6’)) 4.71 (4H, s, (H11,11’)) 
4.13-4.08 (4H, m, overlap, (H7,7’,9,9’)) 3.95 (4H, t, J=4.4Hz, (H10,10’)) 3.77 (4H, t, 
J=4.6Hz, (H8,8’))  
13C NMR (100 MHz, CDCl3) 149.40 (C2,2’), 148.68 (C1,1’), 136.71 (C12,12’), 
129.02 (C14,14’), 127.78 (C13,13’), 121.81 (C5,5’), 121.32 (C4,4’), 115.30 (C6,6’), 
113.59 (3,3’), 71.29 (C11,11’), 70.21 (C8,8’), 69.58 (C9,9’), 68.90 (C7,7’), 68.69 
(C10,10’) 
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IR (KBr) ν (cm-1) 2931, 1593, 1509, 1452, 1260, 1130, 1030. 
HRMS (EI, 70 eV) Calculated for C28H32O7H+ 481.2221; Found 481.2240;  
Na adduct Calculated for C28H32O7Na+ 503.2040; Found 503.2052; 
m.p.=109-111 °C  
Rf CHCl3=0.30   
 
2,3,11,12,18,20-tribenzo-19-aza-1,4,7,10,13,16,22-heptaoxacyclotetra-eicosa-
2,11,18,19-tetraene (171) 
The general procedure 1 was used with the starting materials 161 (0.38 g, 1.0 mmol) 
and 2,6-bis(chloromethyl)pyridine (0.17 g, 1.0 mmol). Product 171 was isolated by 
column chromatography on silica gel using EtOAc/CHCl3 (3:1) as a white solid 
(0.21 g, 0.45 mmol, 45 % yield). 
N
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O O
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2
3
6
12
1'
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7
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1H NMR (400 MHz, CDCl3) 7.67 (1H, t, J= 7.6Hz, (H14)) 7.35 (2H, d, J= 7.6Hz, 
(H13,13’)) 6.85-6.81 (8H, m, (H3-6,3’-6’)) 4.82 (4H, s, (H11,11’)) 4.14 (4H, t, J= 
4.4Hz, (H9,9’)) 4.03 (4H, t, J= 4.8Hz, (H7,7’)) 3.93 (4H, t, J= 4.4Hz, (H10,10’)) 3.83 
(4H, t, J= 4.8Hz, (H8,8’)) 
13C NMR (100 MHz, CDCl3) 158.08 (C12,12’), 149.17 (C2,2’), 149.04 (C1,1’), 
137.41 (C14), 121.60 (C4,4’), 121.37 (C5,5’), 119.89 (C13,13’), 114.87 (C6,6’), 
113.80 (C3,3’), 74.58 (C11,11’), 70.29 (C8,8’), 69.63 (C9,9’), 69.42 (C10,10’), 
69.31 (C7,7’). 
IR (KBr) ν (cm-1) 2933, 1599, 1509, 1460, 1258, 1131, 1058. 
HRMS (EI, 70 eV) Calculated for C27H31NO7H+ 482.2173; Found 482.2169  
m.p.=150-152 °C 
Rf EtOAc/CHCl3(3:1)=0.25 
 
 
Experimental 
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2,3,14,15,21,23-tribenzo-1,4,7,10,13,16,19,25-octaoxacyclo-heptaeicosa-2,14,21, 
22-tetraene (172) 
The general procedure 1 was used with the starting materials 162 (0.42 g, 1.0 mmol) 
and α,α’-dichloro-m-xylene (0.17 g, 1.0 mmol). Product 172 was isolated by column 
chromatography on silica gel using CHCl3/EtOAc (3:1) as a white solid (0.23 g, 
0.43 mmol, 43 % yield). 
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1H NMR (400 MHz, CDCl3) 7.28 (1H, s, (H16)) 7.24-7.22 (3H, m, (H14,14’,15)) 
6.82-6.78 (8H, m, (H3-6,3’-6’)) 4.60 (4H, s, (H12,12’)) 4.11 (4H, t, J=4.4Hz, 
(H9,9’)) 4.05 (4H, t, J=4.8Hz, (H7,7’)) 3.79 (4H, t, J=4.4Hz, (H10,10’)) 3.71 (4H, t, 
J=4.8Hz, (H8,8’)) 3.53 (4H, s, (H11,11’)) 
13C NMR (100 MHz, CDCl3) 149.08 (C2,2’), 148.99 (C1,1’), 138.46 (C13,13’), 
128.56 (C15), 127.32 (C16), 127.22 (C14,14’), 121.64 (C5,5’), 121.51 (C4,4’), 
114.50 (C3,3’,6,6’)*, 73.45 (C12,12’), 70.89 (C11,11’), 69.80 (C8,8’), 69.43 (C9,9’), 
69.22 (C7,7’), 68.80 (C10,10’)  * double intensity peak 
IR (KBr) ν (cm-1) 2928, 2872, 1594, 1511, 1447, 1348, 1259, 1126, 1047.  
Na adduct Calculated for C30H36O8Na+ 547.2308; Found 547.2320; 
m.p.=109-111 °C  
Rf CHCl3/EtOAc (3:1)=0.51 
 
2,3,14,15,21,24-tribenzo-1,4,7,10, 13,16,19,26-octaoxacyclooctaeicosa-2,14,21,22, 
23-tetraene (173) 
The general procedure 1 was used with the starting materials 162 (0.42 g, 1.0 mmol) 
and α,α’-dichloro-p-xylene (0.17 g, 1.0 mmol). Product 173 was isolated by column 
chromatography on silica gel using EtOAc/CHCl3 (1:1) as a white solid (0.19 g, 
0.38 mmol, 38 % yield). 
Experimental 
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1H NMR (400 MHz, CDCl3) 7.33 (4H, s, (H14,14’,15,15’)) 6.88-6.77 (8H, m, (H3-6, 
3’-6’)) 4.62 (4H, s, (H12,12’)) 4.12 (4H, t, J=4.4Hz, (H9,9’)) 4.07 (4H, t, J=4.8Hz, 
(H7,7’)) 3.79 (4H, t, J=4.4Hz, (H10,10’)) 3.74 (4H, t, J=4.8Hz, (H8,8’)) 3.56 (4H, s, 
(H11,11’)) 
13C NMR (100 MHz, CDCl3) 148.98 (C1,1’,2,2’), 137.71 (C13,13’), 127.93 
(C14,14’,15,15’), 121.49 (C4,4’), 121.46 (C5,5’), 114.31 (C6,6’), 114.07 (C3,3’), 
73.15 (C12,12’), 70.88 (C11,11’), 69.79 (C8,8’), 69.18 (C9,9’), 69.06 (C7,7’), 68.41 
(C10,10’) 
IR (KBr) ν (cm-1) 2928, 1595, 1507, 1454, 1334, 1259, 1125, 1048. 
HRMS (EI, 70 eV) Calculated for C30H36O8H+ 525.2483; Found 525.2486;  
m.p.= 104-106 °C 
Rf  EtOAc/CHCl3= 0.63        
 
2,3,14,15,21,22-tribenzo-1,4,7,10,13,16,19,25-octaoxacyclohexaeicosa-2,14,21-
triene (174) 
The general procedure 1 was used with the starting materials 162 (0.42 g, 1.0 mmol) 
and α,α’-dichloro-o-xylene (0.17 g, 1.0 mmol). Product 174 was isolated by column 
chromatography on silica gel using CHCl3/EtOAc (3:1) as a white solid (0.28 g, 
0.51 mmol, 51 % yield). 
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1H NMR (400 MHz, CDCl3) 7.35 (2H, dd, J=5.6, 3.2Hz, (H15,15’)) 7.20 (2H, dd, 
J=5.6, 3.2Hz, (H14,14’)) 6.81-6.76 (8H, m, (H3-6,3’-6’)) 4.69 (4H, s, (H12,12’)) 
4.08-4.03 (8H, m, overlap, (H7,7’,9,9’)) 3.78-3.75 (8H, m, overlap, (H8,8’,10,10’)) 
3.62 (4H, s, (H11,11’)) 
13C NMR (100 MHz, CDCl3) 147.94 (C2,2’), 147.91 (C1,1’), 135.58 (C13,13’), 
127.89 (C15,15’), 126.70 (C14,14’), 120.38 (C4,4’), 120.31 (C5,5’), 113.16 (C6,6’), 
113.07 (C3,3’), 70.02 (C12,12’), 69.90 (C11,11’), 68.66 (C8,8’), 68.09 (C9,9'), 67.92 
(C7,7’), 67.80 (C10,10’) 
IR (KBr) ν (cm-1) 2922, 1594, 1511, 1454, 1261, 1127, 1055.  
Na adduct Calculated for C30H36O8Na+ 547.2308; Found 547.2315; 
m.p.=91-93 °C  
Rf CHCl3/EtOAc (3:1)= 0.5 
 
2,3,14,15,21,23-tribenzo-22-aza-1,4,7,10,13,16,19,25-octaoxacycloheptaeicosa-
2,14,21,22-tetraene (175)  
The general procedure 1 was used with the starting materials 162 (0.42 g, 1.0 mmol) 
and 2,6-bis(chloromethyl)pyridine (0.17 g, 1.0 mmol). Product 175 was isolated by 
column chromatography on silica gel using EtOAc/CHCl3 (3:1) as a white solid 
(0.20 g, 0.38 mmol, 38 % yield). 
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1H NMR (400 MHz, CDCl3) 7.89 (1H, t, J=7.2Hz, (H15)) 7.54 (2H, d, J=7.2Hz, 
(H14,14’)) 6.88-6.80 (8H, m, (H3-6,3’-6’)) 4.78 (4H, s, (H12,12’)) 4.15 (4H, t, J= 
4.2Hz, (H9,9’)) 4.07 (4H, t, J=4.8Hz, (H7,7’)) 3.90 (4H, t, J=4.2Hz, (H10,10’)) 3.76 
(4H, t, J=4.8Hz, (H8,8’)) 3.56 (4H, s, (H11,11’)) 
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13C NMR (100 MHz, CDCl3) 157.68 (C13,13’), 148.78 (C1,1’,2,2’) *, 137.21 (C15), 
121.40 (C4,4’,5,5’)*, 120.23 (C14,14’), 113.83 (C6,6’), 113.45 (C3,3’), 73.61 
(C12,12’), 70.80 (C8,8’), 69.92 (C10,10’), 69.34 (C7,7’), 68.71 (C9,9’). * double 
intensity peak 
IR (KBr) ν (cm-1) 2932, 2866, 1594, 1508, 1452, 1258, 1125, 1055;  
HRMS (EI, 70 eV) Calculated for C29H35NO8H+ 526.2435; Found 526.2432;  
m.p.=144-146 °C  
Rf EtOAc/CHCl3 (3:1)=0.19 
 
2,3,6,8,11,12,18,20-tetrabenzo-19-aza-1,4,10,13,16,22-hexaoxacyclotetraeicosa-
2,6,7,11,18,19-hexaene (176) 
The general procedure 1 was used with the starting materials 164 (0.41 g, 1.0 mmol) 
and 2,6-bis(chloromethyl)pyridine (0.17 g, 1.0 mmol). Product 176 was isolated by 
column chromatography on silica gel using EtOAc/CHCl3 (3:1) as a white solid 
(0.22 g, 0.43 mmol, 43 % yield). 
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1H NMR (400 MHz, CDCl3) 7.67 (1H, t, J=7.6Hz, (H17)) 7.54-7.46 (6H, m, overlap, 
(H11,11’,12,13,16,16’)) 7.02-6.83 (8H, m, (H3-6,3’-6’) 4.96 (4H, s, (H9,9’)) 4.63 
(4H, s, (H14,14’)) 4.12 (4H, t, J=4.6Hz, (H7,7’)) 3.81 (4H, t, J=4.6Hz, (H8,8’))  
13C NMR (100 MHz, CDCl3) 158.38 (C15,15’), 148.78 (C2,2’), 148.69 (C1,1’), 
137.60 (C17), 137.14 (C10,10’), 130.03 (C12), 129.45 (C13), 121.22 (C5,5’), 120.89 
(C4,4’), 119.45 (C16,16’) 112.91 (C6,6’), 111.90 (C3,3'), 74.32 (C9,9’), 70.98 
(14,14’), 70.43 (C8,8’), 69.83 (C7,7’).  
IR (KBr) ν (cm-1) 2937, 1597, 1508, 1459, 1377, 1258, 1127, 1059, 1008. 
HRMS (EI, 70 eV) Calculated for C31H33NO6H+ 514.2224; Found 514.2224  
m.p.=178-180 °C  
Rf EtOAc/CHCl3(3:1)=0.39        
Experimental 
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2,3,6,8,11,12,18,21-tetrabenzo-1,4,10,13,16,23-hexaoxacyclopentaeicosa-
2,6,7,11,18,19,20-hexaene (177) 
The general procedure 1 was used with the starting materials 164 (0.41 g, 1.0 mmol) 
and α,α’-dichloro-p-xylene (0.17 g, 1.0 mmol). Product 177 was isolated by column 
chromatography on silica gel using CHCl3 as a white solid (0.22 g, 0.44 mmol, 44 % 
yield). 
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1H NMR (400 MHz, CDCl3) 7.37 (4H, s, (H16,16’,17,17’)) 7.25-7.11 (4H, m, 
overlap, (H11,11’,12,13)) 6.86-6.82 (8H, m, (H3-6,3’-6’)) 4.99 (4H, s, (H9,9’)) 4.60 
(4H, s, (H14,14’)) 4.14 (4H, t, J=4.2Hz, (H7,7’)) 3.83 (4H, t, J=4.2Hz, (H8,8’)) 
13C NMR (100 MHz, CDCl3) 149.37 (C2,2’), 148.71 (C1,1’), 138.45 (C15,15’), 
136.78 (C10,10’), 128.71 (C12), 127.69 (C16,16’,17,17’)*, 126.88 (C13), 126.82 
(C11,11’), 121.81 (C4,4’), 121.28 (C5,5’), 115.02 (C6,6’), 113.69 (C3,3’), 73.70 
(C9,9’), 71.01 (C14,14’), 69.38 (C7,7’), 68.89 (C8,8’). *double intensity peak 
IR (KBr) ν (cm-1) 2922, 1592, 1505, 1455, 1374, 1254, 1122, 1008. 
HRMS (EI, 70 eV) Calculated for C32H32O6H+ 513.2272; Found 513.2285;  
m.p.=155-157 °C 
Rf CHCl3 =0.21      
 
2,3,6,8,11,12,18,19-tetrabenzo-1,4,10,13,16,21-hexaoxacyclo-trieicosa-
2,6,7,11,18-pentaene (178) 
The general procedure 1 was used with the starting materials 164 (0.41 g, 1.0 mmol) 
and α,α’-dichloro-o-xylene (0.17 g, 1.0 mmol). Product 178 was isolated by column 
chromatography on silica gel using CHCl3 as a white solid (0.16 g, 0.29 mmol, 29 % 
yield). 
Experimental 
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1H NMR (400 MHz, CDCl3) 7.67 (1H, s, (H13)) 7.27-7.23 (3H, m, (H12,11,11’)) 
7.21 (2H, dd, J=5.6, 3.2Hz, (H17,17’)) 7.15 (2H, dd, J=5.6, 3.2Hz, (H16,16’)) 6.93-
6.77 (8H, m, (H3-6,3’-6’)) 5.02 (4H, s, (H9,9’)) 4.65 (4H, s, (H14,14’)) 4.08 (4H, t, 
J=4.4Hz, (H7,7’)) 3.72 (4H, t, J=4.4Hz, (H8,8’))  
13C NMR (100 MHz, CDCl3) 149.78 (C2,2’), 149.01 (C1,1’), 138.04 (C10,10’), 
136.78 (C15,15’), 129.21 (C17,17’), 128.29 (C13), 127.67 (C16,16’), 127.21 (C12), 
127.09 (C11,11’), 122.20 (C4,4’), 121.37 (C5,5’), 116.61 (C6,6’), 114.33 (C3,3’), 
72.19 (C9,9’), 71.42 (C14,14’), 69.01 (C7,7’), 68.72 (C8,8’) 
IR (KBr) ν (cm-1) 2930, 1592, 1506, 1452, 1378, 1255, 1124, 1097, 1021. 
HRMS (EI, 70eV) Na+ adduct Calculated for C32H32O6Na+ 535.2091; Found 
535.2092; 
m.p.=84-86 °C 
Rf CHCl3=0.34    
 
2,3,6,9,12,13,19,21-tetrabenzo-1,4,11,14,17,23-hexaoxacyclopentaeicosa-
2,6,7,8,12,19,20-hexaene (179) 
The general procedure 1 was used with the starting materials 163 (0.41 g, 1.0 mmol) 
and α,α’-dichloro-m-xylene (0.17 g, 1.0 mmol). Product 179 was isolated by column 
chromatography on silica gel using CHCl3 as a white solid (0.22 g, 0.43 mmol, 43 % 
yield). 
Experimental 
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1H NMR (400 MHz, CDCl3) 7.37 (4H, s, (H11,11’,12,12’)) 7.24-7.12 (4H, m, 
overlap, (H15,15’,16,17)) 6.93-6.84 (8H, m, (H3-6,3’-6’)) 4.99 (4H, s, (H9,9’)) 4.61 
(4H, s, (H13,13’)) 4.15 (4H, t, J=4.4Hz, (H7,7’)) 3.84 (4H, t, J=4.4Hz, (H8,8’)) 
13C NMR (100 MHz, CDCl3) 149.38 (C2,2’), 148.72 (C1,1’), 138.47 (C10,10’), 
136.78 (C14,14’), 128.60 (C16), 127.59 (C11,11’,12,12’)*, 126.90 (C17), 126.82 
(C15,15’), 121.80 (C4,4’), 121.29 (5,5’), 115.03 (C6,6’), 113.70 (C3,3’), 73.71 
(C9,9’), 71.02 (C13,13’), 69.42 (C7,7’), 68.89 (C8,8’). *double intensity peak 
IR (KBr) ν (cm-1) 2924, 1591, 1505, 1455, 1374, 1254, 1121, 1121, 1008. 
HRMS (EI, 70 eV) Calculated for C32H32O6H+ 513.2272; Found 513.2291;  
m.p.=159-161 °C 
Rf CHCl3 =0.26     
 
2,3,6,9,12,13,19,22-tetrabenzo-1,4,11,14,17,24-hexaoxacyclohexaeicosa-
2,6,7,8,12,19,20,21-hexaene (180) 
The general procedure 1 was used with the starting materials 163 (0.41 g, 1.0 mmol) 
and α,α’-dichloro-p-xylene (0.17 g, 1.0 mmol). Product 180 was isolated by column 
chromatography on silica gel using CHCl3 as a white solid (0.19 g, 0.38 mmol, 38 % 
yield). 
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1H NMR (400 MHz, CDCl3) 7.41 (4H, s, (H11,11’,12,12’)) 7.15 (4H, s, (H15,15’, 
16,16’)) 6.97-6.82 (8H, m, (H3-6,3’-6’)) 5.03 (4H, s, (H9,9’)) 4.59 (4H, s, (H13,13’)) 
4.15 (4H, t, J= 4.2 Hz, (H7,7’)) 3.79 (4H, t, J= 4.2 Hz, (H8,8’))  
13C NMR (100 MHz, CDCl3) 149.29 (C2,2’), 148.56 (C1,1’), 137.50 (C10,10’), 
136.78 (C14,14’), 127.70 (C11,11’,12,12’)*, 127.62 (15,15’,16,16’)*, 121.70 (C4,4’), 
121.08 (C5,5’), 114.79 (C6,6’), 113.12 (C3,3’), 73.00 (C9,9’), 71.02 (C13,13’), 
68.83 (C7,7’), 68.08 (C8,8’). *double intensity peak 
IR (KBr) ν (cm-1) 1591, 1506, 1451, 1257, 1216, 1124, 1097, 1049, 1015. 
HRMS (EI, 70 eV) Calculated for C32H32O6H+ 513.2272; Found 513.2265;  
Rf CHCl3=0.32  
m.p.=135-137 °C 
 
2,3,6,9,12,13,19,20-tetrabenzo-1,4,11,14,17,22-hexaoxacyclo-tetraeicosa-
2,6,7,8,12,19-hexaene (181)  
The general procedure 1 was used with the starting materials 163 (0.41 g, 1.0 mmol) 
and α,α’-dichloro-o-xylene (0.17 g, 1.0 mmol). Product 181 was isolated by column 
chromatography on silica gel using CH2Cl2 as a white solid (0.26 g, 0.48 mmol, 48 % 
yield). 
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1H NMR (400 MHz, CDCl3) 7.41 (4H, s, (H11,11’,12,12’)) 7.36 (2H, dd, J=5.6, 
3.2Hz, (H16,16’)) 7.21 (2H, dd, J=5.6, 3.2Hz, (H15,15’)) 6.96-6.82 (8H, m, (H3-
6,3’-6’)) 5.00 (4H, s, (H9,9’)) 4.67 (4H, s, (H13,13’)) 4.12 (4H, t, J=4.4Hz, (H7,7’)) 
3.77 (4H, t, J=4.4Hz, (H8,8’))  
13C NMR (100 MHz, CDCl3) 149.49 (C2,2’), 149.05 (C1,1’), 136.85 (C10,10’), 
136.44 (C14,14’), 128.95 (C16,16’), 127.79 (C15,15’), 127.43 (C11,11’,12,12’), 
121.83 (C4,4’), 121.59 (C5,5’), 115.19 (C6,6’), 114.52 (C3,3’), 71.21 (C9,9’), 70.99 
(C13,13’), 69.32 (C7,7’), 69.05 (C8,8’) 
Experimental 
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IR (KBr) ν (cm-1) 2933, 1591, 1509, 1452, 1259, 1125, 1028.  
HRMS (EI, 70 eV) Na+ adduct Calculated for C32H32O6Na+ 535.2091; Found 
535.2079; 
m.p.=175-177 °C   
Rf DCM =0.44 
 
2,3,6,9,12,13-tribenzo-1,4,11,14,17,20,23,26-octaoxacyclooctaeicosa-2,6,7,8,12-
tetraene (182)  
The general procedure 1 was used with the starting materials 163 (0.41 g, 1.0 mmol) 
and 1,2-bis-(2-chloroethoxy)ethane (0.19 g, 0.10 mL, 1.0 mmol). Product 182 was 
isolated by column chromatography on silica gel using EtOAc/Et2O (1:1) as a white 
solid (0.027 g, 0.05 mmol, 5 % yield). 
O O
O
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3
4
5
6
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13
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1'
2' 3'
4'
5'
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7'
8'
9'
10'
11'
14'
15'
13'
12'
7
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1H NMR (400 MHz, CDCl3) 7.42 (4H, s, (H11,11’,12,12’)) 6.92-6.81 (8H, m, (H3-6, 
3’-6’)) 5.05 (4H, s, (H9,9’)) 4.12 (4H, t, J=4.4Hz, (H7,7’)) 3.84 (4H, t, J=4.4Hz, 
(H8,8’)) 3.69 (4H, t, J=4.6Hz, (H13,13’)) 3.54 (4H, t, J=4.6Hz, (H14,14’)) 3.52 (4H, 
s, (H15,15’)) 
13C NMR (100 MHz, CDCl3) 149.38 (C2,2’), 148.61 (C1,1’), 136.99 (C10,10’), 
127.71 (C11,11’,12,12’)*, 121.87 (C4,4’), 121.32 (C5,5’), 115.48 (C6,6’), 113.82 
(C3, 3’), 71.21 (C9,9’) 71.06 (C15,15’), 70.79 (C13,13’), 70.72 (C14,14’), 69.74 
(C8,8’), 69.09 (C7,7’). *double intensity peak 
IR (KBr) ν (cm-1) 2931, 1593, 1506, 1452, 1336, 1255, 1125, 1046. 
HRMS (EI, 70 eV) Calculated for C30H36O8H+ 525.2483; Found 525.2477;  
Na adduct Calculated for C30H36O8Na+ 547.2302; Found 547.2284;  
m.p.=84-86 °C 
Rf EtOAc/Et2O 1:1=0.28 
 
Experimental 
 
220 
2,3,6,811,12,18,20-tetrabenzo-7-aza-1,4,10,13,16,22-hexaoxacyclo-tetraeicosa-
2,6,7,11,18,19-hexaene (183) 
The general procedure 1 was used with the starting materials 166 (0.41 g, 1.0 mmol) 
and α,α’-dichloro-m-xylene (0.17 g, 1.0 mmol). Product 183 was isolated by column 
chromatography on silica gel using EtOAc as a white solid (0.19 g, 0.38 mmol, 38 % 
yield). 
N
O
O
O
O
O
O
1
2
34
5
6
9
10
11
12
13
14
15
1'
2'
3' 4'
5'
6'
7'
8'
9'
10'
11'
13'
7
8
14'
16
15'
17
 
1H NMR (400 MHz, CDCl3) 7.65 (1H, t, J=7.6Hz, (H12)) 7.58 (1H, s, H17)), 7.53-
7.44 (5H, m, overlap, (H11,11’,15,15’,16,)) 7.02-6.83 (8H, m, (H3-6,3’-6’)) 4.94 
(4H, s, (H9,9’)) 4.62 (4H, s, (H13,13’)) 4.11 (4H, t, J=4.4Hz, (H7,7’)) 3.81 (4H, t, 
J=4.4Hz, (H8,8’)) 
13C NMR (100 MHz, CDCl3) 157.57 (C10,10’), 148.78 (C2,2’), 148.71 (C1,1’), 
137.06 (C14,14’), 129.98 (C15,15’), 129.65 (C11,11’), 129.51 (C12), 127.18 (C16), 
121.30 (C4,4’), 121.00 (C5,5’), 119.52 (C17), 113.11 (C6,6’), 112.13 (C3,3’), 73.58 
(C9,9’), 71.12 (C13,13’), 68.45 (C7,7’), 67.89 (C8,8’) 
IR (KBr) ν (cm-1) 2937, 1596, 1509, 1459, 1377, 1258, 1127, 1056. 
HRMS (EI, 70 eV) Calculated for C31H31NO6H+ 514.2224; Found 514.2222;  
m.p.=166-168 °C 
Rf EtOAc =0.28   
 
2,3,6,8,11,12,18,20-tetrabenzo-7,19-diaza-1,4,10,13,16,22-hexaoxacyclo-
tetraeicosa-2,6,7,11,18,19-hexaene (184) 
The general procedure 1 was used with the starting materials 166 (0.41 g, 1.0 mmol) 
and 2,6-bis(chloromethyl)pyridine (0.17 g, 1.0 mmol). Product 184 was isolated by 
column chromatography on silica gel using EtOAc as a white solid (0.25 g, 
0.49 mmol, 49 % yield). 
Experimental 
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N
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1
2
34
5
6
9
10
11
12
13
14
15
1'
2'
3' 4'
5'
6'
7'
8'
9'
10'
11'
13'
7
8
14'
16
15'
 
1H NMR (400 MHz, CDCl3) 7.48 (2H, d, J=7.8Hz, (H11,11’)) 7.34 (3H, m, overlap, 
(H12,15,15’)) 7.02-6.87 (8H, m, (H3-6,3’-6’)) 6.78 (1H, t, J=7.8Hz, (H16)) 5.07 
(4H, s, (H9,9’)) 4.61 (4H, s, (H13,13’)) 4.17 (4H, t, J=4.4Hz, (H7,7’)) 3.87 (4H, t, 
J= 4.4Hz, (H8,8’)) 
13C NMR (100 MHz, CDCl3) 157.61 (C10,10’), 156.47 (C14,14’), 149.32 (C2,2’), 
148.90 (C1,1’), 137.51 (C12), 137.20 (C16), 122.03 (C11,11’), 121.58 (C4,4’), 
121.42 (C5,5’), 119.40 (C15,15’), 114.89 (C6,6’), 113.52 (C3,3’), 73.70 (C9,9’), 
72.51 (C13,13’), 69.37 (C7,7’), 68.66 (C8,8’) 
IR (KBr) ν (cm-1) 2920, 1594, 1507, 1456, 1362, 1259, 1125, 1053; 
HRMS (EI, 70 eV) Calculated for C30H30N2O6H+ 514.2230; Found 514.2245;  
m.p.=145-147 °C      
Rf EtOAc=0.18      
 
Experimental 
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8.3 Morphine macrocycles and their precursors 
 
General procedure 194, 198, 199, 200  
Morphine hydrochloride (0.43 g, 1.5 mmol) was suspended in absolute methanol 
(3 mL) and while stirring sodium methoxide (0.22 g, 4.0 mmol) as a suspension in 
absolute methanol (3 mL) was added dropwise over 1h. α,α’-Dibromoxylene (0.20 g, 
0.75 mmol) was added and mixture was refluxed for 48 h. After that time solvent 
was removed by rotary evaporation and distilled water (40 mL) was added into the 
crude. Mixture was extracted with dichloromethane (5 x 20 mL) organic layer was 
dried over sodium sulphate, concentrated in vacuo and purified by column 
chromatography on silica gel and CH2Cl2/MeOH/NH4OH mixture (10:1:0.01) as a 
mobile phase. Rf values are calculated with this solvent mixture. 
 
 
General procedure 197, 201, 202 
Morphine hydrochloride (0.43 g, 1.5 mmol) was suspended in dry tetrahydrofuran 
(3 mL) and while stirring potassium tert-butoxide (0.17 g, 1.5 mmol) as a suspension 
in tetrahydrofuran (3 mL) was added dropwise over 1h. α,α’-Dibromoxylene 
(0.75 mmol) was added into the mixture and was refluxed for 18 h. After that time 
solvent was removed by rotary evaporation and distilled water (40 mL) was added 
into the crude. Mixture was extracted with dichloromethane (5 x 20 mL) organic 
layer was dried over sodium sulphate, concentrated in vacuo and purified by column 
chromatography on silica gel and CH2Cl2/MeOH/NH4OH mixture (10:1:0.01) as a 
mobile phase.  
Experimental 
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1,8-Bis(3-morphinyl)-3,6-dioxaoctane (194) 
The general procedure was used with the starting materials morphine hydrochloride 
(0.43 g, 1.5 mmol), and 1,2-bis(iodoethoxyethane) (0.277 g, 0.137 mL, 0.75 mmol). 
Product 194 was isolated by column chromatography as white foam (0.349 g, 
0.51 mmol, 68 % yield). 
OO
OO
OH
O
NCH3
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O
N CH3
1
2
3
4
5
6
7
8
9
10
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12
13
14
1516
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19'
20 20'
18'
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1'
2'
3'
4'
5'
6'
7'
8'
9'
10'
11'
12'
13'
14'
15' 16'
17'
 
1H NMR (400 MHz, CDCl3) 6.62 (2H, d, J=8.4Hz, (H2,2’)) 6.47 (2H, d, J=8.4Hz, 
(H1,1’)) 5.62 (2H, ddd, J=10.0, 2.8, 1.2Hz, (H7,7’)) 5.20 (2H, dt, J=10.0, 2.6Hz, 
(H8,8’)) 4.81 (2H, dd, J=6.4, 1.2Hz, (H5,5’)) 4.22-4.18 (2H, m, (H18,18’) 4.11-4.02 
(4H, m, overlap, (H6,6’,18,18’)) 3.76 (4H, t, J=4.8Hz, (H19,19’) 3.69-3.61 (4H, m, 
(H20,20’)) 3.49 (2H, s, OH) 3.35 (2H, dd, J=6.2, 3.2Hz, (H9,9’)) 2.99 (2H, d, 
J=18.8Hz, (H10,10’)) 2.68 (2H, dd, J=3.2, 2.6Hz, (H14,14’)) 2.61 (2H, dd, J=12.4, 
4.2Hz, (H16,16’)) 2.41 (6H, s, (H17,17’)) 2.39 (2H, td, J=12.4, 3.6Hz, (H16,16’)) 
2.31 (2H, dd, J=18.8, 6.2Hz, (H10,10’)) 2.10 (2H, td, J=12.4, 5.2Hz, (H15,15’)) 1.83 
(2H, dd, J=12.4, 4.2Hz, (H15,15’)) 
13C NMR (100 MHz, CDCl3) 146.98 (C3,3’), 141.05 (C4,4’), 133.49 (C7,7’), 131.36 
(C12,12’), 128.21 (C11,11’), 127.79 (C8,8’), 119.51 (C1,1’), 115.55 (C2,2’), 91.39 
(C5,5’), 70.71 (C20,20’), 69.93 (C19,19’), 69.14 (C18,18’), 66.49 (C6,6’), 58.82 
(C9,9’), 46.42 (C16,16’), 43.10 (C17,17’), 42.86 (C13,13’), 40.74 (C14,14’), 35.76 
(C15,15’), 20.47 (C10,10’). 
IR (KBr disc): ν (cm-1) 3389, 2925, 2779, 1504, 1451, 1259, 1120. 
HRMS (EI, 70 eV) Calculated for C40H49N2O8 685.3489; Found 685.3489; 
m.p.= 54-56 °C 
Rf CH2Cl2/MeOH/NH4OH mixture (10:1:0.01) = 0.11  
[α]D = -75° c = (0.2, CHCl3, 589 nm, 20 °C) 
Experimental 
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1,4-Bis(3-morphinyl)-p-xylene (198) 
The general procedure was used with the starting materials morphine hydrochloride 
(0.43 g, 1.5 mmol), and α,α’-dibromo-p-xylene (0.198 g, 0.75 mmol). Product 198 
was isolated by column chromatography as a white solid (0.303 g, 0.45 mmol, 60 % 
yield). 
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N CH3
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1H NMR (400 MHz, CDCl3) 7.34 (4H, s, (H20,20’,21,21’)) 6.64 (2H, d, J=8.4Hz, 
(H2,2’)) 6.47 (2H, d, J=8.4Hz, (H1,1’)) 5.62 (2H, ddd J=9.8, 2.8, 1.2Hz, (H7,7’)) 
5.23 (2H, dt, J=9.8, 2.6Hz, (H8,8’)) 5.10 (2H, d, J=12.0Hz, (H18,18’)) 5.02 (2H, d, 
J=12.0Hz, (H18,18’)) 4.82 (2H, dd, J=6.4, 1.2Hz, (H5,5’)) 4.11 (2H, dd, J=6.4, 
2.8Hz, (H6,6’)) 3.31 (2H, dd, J=6.0, 3.2Hz, (H9,9’)) 2.99 (2H, d, J=18.8Hz, 
(H10,10’)) 2.66 (2H, dd, J=3.2, 2.6Hz, (H14,14’)) 2.57 (2H, dd, J=12.2, 4.0Hz, 
(H16,16’)) 2.38 (6H, s, (H17,17’)) 2.33 (2H, td, J=12.2, 3.2Hz, (H16,16’)) 2.27 (2H, 
dd, J=18.8, 6.4Hz, (H10,10’)) 2.05 (2H, td, J=12.2, 4.8Hz, (H15,15’)) 1.83 (2H, dd, 
J=12.2, 4.0Hz, (H15,15’)) 
13C NMR (100 MHz, CDCl3) 146.90 (C3,3’), 141.05 (C4,4’), 137.04 (C19,19’), 
133.36 (C7,7’), 131.40 (C12,12’), 128.30 (C11,11’), 127.86 (C8,8’), 127.72 
(C20,20’, 21,21’), 119.67 (C1,1’), 115.71 (C2,2’), 91.34 (C5,5’), 71.47 (C18,18’), 
66.44 (C6,6’), 58.83 (C9,9’), 46.43 (C16,16’), 43.10 (C17,17’), 42.90 (C13,13’), 
40.74 (C14,14’), 35.76 (C15,15’), 20.50 (C10,10’) 
IR (KBr disc): ν (cm-1) 3383, 2927, 1497, 1446, 1259, 1119. 
HRMS (EI, 70 eV) Calculated for C42H44N2O6H+ 673.3272; Found 673.3267; 
m.p.=118-120 °C 
Rf CH2Cl2/MeOH/NH4OH mixture (10:1:0.01) =0.34  
[α]D = -140° (c = 0.2, CHCl3, 589 nm, 20 °C) 
 
 
 
 
 
Experimental 
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1,3-Bis(3-morphinyl)-m-xylene (199) 
The general procedure was used with the starting materials morphine hydrochloride 
(0.43 g, 1.5 mmol), and α,α’-dibromo-m-xylene (0.198 g, 0.75 mmol). Product 199 
was isolated by column chromatography as a white solid (0.363 g, 0.54 mmol, 72 % 
yield). 
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1H NMR (400 MHz, CDCl3) 7.42 (1H, s, (H22)) 7.31-7.27 (3H, m, (H20,20’,21)) 
6.64 (2H, d, J=8.2Hz, (H2,2’)) 6.46 (2H, d, J=8.2Hz, (H1,1’)) 5.61 (2H, ddd, J=10.0, 
2.8, 1.2Hz, (H7,7’)) 5.22 (2H, dt, J=10.0, 2.4Hz, (H8,8’)) 5.10 (2H, d, J=12.0Hz, 
(H18,18’)) 5.01 (2H, d, J=12.0Hz, (H18,18’)) 4.81 (2H, dd, J=6.4, 0.8Hz, (H5,5’)) 
4.10 (2H, dd, J=6.4, 2.8Hz, (H6,6’)) 3.29 (2H, dd, J=6.2, 3.0Hz, (H9,9’)) 2.98 (2H, 
d, J=18.8Hz, (H10,10’)) 2.63 (2H, dd, J=3.0, 2.4Hz, (H14,14’)) 2.54 (2H, dd, 
J=12.2, 4.0Hz, (H16,16’)) 2.36 (6H, s, (H17,17’)) 2.34 (2H, td, J=12.2, 3.6Hz, 
(H16,16’)) 2.25 (2H, dd, J=18.8, 6.2Hz, (H10,10’)) 2.01 (2H, td, J=12.2, 5.2Hz, 
(H15,15’)) 1.80 (2H, dd, J=12.2, 4.0Hz, (H15,15’)) 
13C NMR (100 MHz, CDCl3) 146.99 (C3,3’), 141.08 (C4,4’), 137.66 (C19,19’), 
133.36 (C7,7’), 131.38 (C12,12’), 128.70 (C21), 128.25 (C8,8’), 127.83 (C11,11’), 
127.10 (C20,20’), 126.60 (C22), 119.63 (C1,1’), 115.81 (C2,2’), 91.39 (C5,5’), 71.65 
(C18,18’), 66.50 (C6,6’), 58.84 (C9,9’), 46.44 (C16,16’), 43.06 (C17,17’), 42.91 
(C13,13’), 40.69 (C14,14’), 35.69 (C15,15’), 20.54 (C10,10’). 
IR (KBr disc): ν (cm-1) 3391, 2926, 1498, 1445, 1251, 1120. 
HRMS (EI, 70 eV) Calculated for C42H44N2O6H+ 673.3272; Found 673.3294; 
m.p.=110-112 °C 
Rf CH2Cl2/MeOH/NH4OH mixture (10:1:0.01) =0.31 
[α]D = -164° (c = 0.2, CHCl3, 589 nm, 20 °C) 
 
 
 
Experimental 
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1,2-Bis(3-morphinyl)-o-xylene (200) 
The general procedure was used with the starting materials morphine hydrochloride 
(0.43 g, 1.5 mmol), and α,α’-dibromo-o-xylene (0.198 g, 0.75 mmol). Product 200 
was isolated by column chromatography as a white solid (0.242 g, 0.36 mmol, 48 % 
yield). 
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1H NMR (400 MHz, CDCl3) 7.44 (2H, dd, J=5.6, 3.6Hz, (H21,21’)) 7.27 (2H, dd, 
J=5.6, 3.6Hz, (H20,20’)) 6.61 (2H, d, J=8.2Hz, (H2,2’)) 6.46 (2H, d, J=8.2Hz, 
(H1,1’)) 5.63 (2H, ddd, J=9.8, 2.8, 1.0Hz, (H7,7’)) 5.27-5.06 (6H, m, overlap, 
(H8,8’,18,18’)) 4.79 (2H, dd, J=6.4, 1.0Hz, (H5,5’)) 4.12 (2H, dd, J=6.4, 2.8Hz, 
(H6,6’)) 3.27 (2H, dd, J=6.0, 3.0Hz, (H9,9’)) 2.97 (2H, d, J=18.6Hz, (H10,10’)) 2.61 
(2H, dd, J=3.0, 2.4Hz, (H14,14’)) 2.54 (2H, dd, J=12.2, 4.0Hz, (H16,16’)) 2.36 (6H, 
s, (H17,17’)) 2.33 (2H, td, J=12.2, 3.6Hz, (H16,16’)) 2.23 (2H, dd, J=18.6, 6.2Hz, 
(H10,10’)) 1.99 (2H, td, J=12.4, 5.2Hz, (H15,15’)) 1.78 (2H, dd, J=12.4, 4.0Hz, 
(H15,15’)) 
13C NMR (100 MHz, CDCl3) 147.45 (C3,3’), 141.23 (C4,4’), 136.68 (C19,19’), 
133.58 (C7,7’), 131.32 (C12,12’), 128.72 (C21,21’), 128.21 (C11,11’), 127.64 
(C8,8’), 127.34 (C20,20’), 119.32 (C1,1’), 115.57 (C2,2’), 91.13 (C5,5’), 71.32 
(C18,18’), 66.84 (C6,6’), 58.61 (C9,9’), 46.34 (C16,16’), 43.04 (C17,17’), 42.92 
(C13,13’), 40.63 (C14,14’), 35.82 (C15,15’), 20.53 (C10,10’). 
IR (KBr disc): ν (cm-1) 3343, 2924, 1502, 1449, 1276, 1121. 
HRMS (EI, 70 eV) Calculated for C42H44N2O6H+ 673.3272; Found 673.3269; 
m.p.=125-127 °C 
Rf CH2Cl2/MeOH/NH4OH mixture (10:1:0.01) =0.37  
[α]D = -121° (c = 0.2, CHCl3, 589 nm, 20 °C) 
 
 
 
Experimental 
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2-[(3-morphinyl)ethoxy]ethanol (197) 
The general procedure was used with the starting materials morphine hydrochloride 
(0.33 g, 1.0 mmol), and 2-bromoethyl ether (0.116 g, 0.062 mL, 0.5 mmol). Product 
197 was isolated by column chromatography as yellow oil (0.052 g, 0.14 mmol, 
28 % yield). 
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1H NMR (400 MHz, CDCl3) 6.61 (1H, d, J=8.4Hz, (H2)) 6.46 (1H, d, J=8.4Hz, 
(H1)) 5.63 (1H, ddd, J=9.8, 2.6, 1.0Hz, (H7)) 5.23 (1H, dt, J=9.8, 2.6Hz, (H8)) 4.82 
(1H, dd, J=6.4, 1.0Hz, (H5)) 4.24-4.19 (1H, m, (H18)) 4.18-4.07 (2H, m, overlap, 
(H6,18)) 3.76-3.71 (4H, m, overlap, (H19,20)) 3.58 (2H, t, J=5.6Hz, (H21)) 3.31 
(1H, dd, J=6.2, 3.2Hz, (H9)) 2.98 (1H, d, J=18.6Hz, (H10)) 2.62 (1H, dd, J=3.2, 
2.6Hz, (H14)) 2.56 (1H, dd, J=12.2, 3.8Hz, (H16)) 2.39 (3H, s, (H17)) 2.37 (1H, td, 
J=12.2, 3.2Hz, (H16)) 2.27 (1H, dd, J=18.6, 6.2Hz, (H10)) 2.04 (1H, td, J=12.4, 
5.2Hz, (H15)) 1.81 (1H, dd, J=12.2, 3.8Hz, (H15)) 
13C NMR (100 MHz, CDCl3) 146.89 (C3), 140.95 (C4), 133.47 (C7), 131.36 (C12), 
128.19 (C11), 127.82 (C8), 119.63 (C1), 115.58 (C2), 91.38 (C5), 71.43 (C20), 69.99 
(C19), 69.11 (C18), 66.41 (C6), 58.83 (C9), 46.41 (C16), 43.02 (C21), 43.02 (C17), 
42.80 (C13), 40.58 (C14), 35.63 (C15), 20.50 (C10).  
IR (KBr disc): ν (cm-1) 3334, 2925, 2782, 1502, 1449, 1257, 1121. 
HRMS (EI, 70 eV) Calculated for C21H27NO5H+ 374.1962; Found 374.1978; 
Rf CH2Cl2/MeOH/NH4OH mixture (10:1:0.01) =0.27  
[α]D = -84° c = (0.2, CHCl3, 589 nm, 20 °C) 
 
 
 
 
 
 
 
 
Experimental 
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2,6-Bis-(3-morphinylmethylene)lutidine (201) 
The general procedure was used with the starting materials morphine hydrochloride 
(0.43 g, 1.5 mmol), and 2,6-bis(chloromethyl)pyridine (0.132 g, 0.75 mmol). Product 
201 was isolated by column chromatography as a white solid (0.216 g, 0.32 mmol, 
42 % yield). 
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1H NMR (400 MHz, CDCl3) 7.66 (1H, t, J=7.6Hz, (H21)) 7.40 (2H, d, J=7.6Hz, 
(H20,20’)) 6.61 (2H, d, J=8.4Hz, (H2,2’)) 6.42 (2H, d, J=8.4Hz, (H1,1’)) 5.58 (2H, 
ddd, J=9.8, 2.8, 0.8Hz, (H7,7’)) 5.38 (2H, d, J=13.6Hz, (H18,18’)) 5.19 (2H, dt, 
J=9.8, 2.4Hz, (H8,8’)) 5.14 (2H, d, J=13.6Hz, (H18,18’)) 4.82 (2H, dd, J=6.4, 
0.8Hz, (H5,5’)) 4.12 (2H, dd, J=6.4, 2.8Hz, (H6,6’)) 3.28 (2H, dd, J=6.0, 3.2Hz, 
(H9,9’)) 2.96 (2H, d, J=18.4Hz, (H10,10’)) 2.61 (2H, dd, J=3.2, 2.4Hz, (H14,14’)) 
2.54 (2H, dd, J=12.4, 4.2Hz, (H16,16’)) 2.36 (3H, s, (H17,17’)) 2.33 (2H, td, 
J=12.4, 3.6Hz (H16,16’)) 2.22 (2H, dd, J=18.4, 6.0Hz, (H10,10’)) 2.03 (2H, td, 
J=12.4, 5.2Hz, (H15,15’)) 1.81 (2H, dd, J=12.4, 4.2Hz, (H15,15’)) 
13C NMR (100 MHz, CDCl3) 156.01 (C19,19’), 145.78 (C3,3’), 139.32 (C4,4’), 
136.69 (C21), 132.34 (C7,7’), 130.63 (C12,12’), 127.29 (C11,11’), 127.07 (C8,8’), 
119.87 (C20,20’), 118.59 (C1,1’), 115.56 (C2,2’), 90.61 (C5,5’), 71.04 (C18,18’), 
65.54 (C6,6’), 57.82 (C9,9’), 45.37 (C16,16’), 42.05 (C17,17’), 41.77 (C13,13’), 
39.67 (C14,14’), 34.66 (C15,15’), 19.50 (C10,10’).  
IR (KBr disc): ν (cm-1) 3341, 2927, 1503, 1452, 1259, 1126. 
HRMS (EI, 70 eV) Calculated for C41H43N3O6H+ 674.3225; Found 674.3245;  
m.p.=129-131 °C 
Rf CH2Cl2/MeOH/NH4OH mixture (10:1:0.01) =0.26  
[α]D = -167° c = (0.2, CHCl3, 589 nm, 20 °C) 
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1,2-Bis(3-morphinyl)-o-(1’,2’-15-crown-5)xylene (202) 
The general procedure was used with the starting materials morphine hydrochloride 
(0.33 g, 1.0 mmol), and α,α’-dibromo-1,2-(15-crown-5)xylene (0.226 g, 0.5 mmol). 
Product 202 was isolated by column chromatography as white foam (0.164 g, 
0.19 mmol, 37 % yield). 
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1H NMR (400 MHz, CDCl3) 6.85 (2H, s, (H20,20’)), 6.68 (2H, d, J=8.2Hz, (H2,2’)) 
6.46 (2H, d, J=8.2Hz, (H1,1’)) 5.62 (2H, ddd, J=9.6, 2.0, 1.0Hz, (H7,7’)) 5.21 (2H, 
dt, J=9.6, 2.8Hz, (H8,8’)) 5.17 (2H, d, J=11.6Hz, (H18,18’)) 5.11 (2H, d, J=11.6Hz, 
(H18,18’)) 4.78 (2H, dd, J=6.4, 1.2Hz, (H5,5’)) 4.07-3.99 (6H, m, overlap, 
(H6,6’,22,22’)) 3.82 (4H, t, J=4.4Hz, (H23,23’)) 3.69-3.61 (8H, m, (H24,24’,25,25’) 
3.34 (2H, dd, J=6.0, 3.2Hz, (H9,9’)) 2.99 (2H, d, J=18.8Hz, (H10,10’)) 2.68 (2H, dd, 
J=3.2, 2.8Hz, (H14,14’)) 2.59 (2H, dd, J=12.0, 4.2Hz, (H16,16’)) 2.41 (6H, s, 
(H17,17’)) 2.36 (2H, td, J=12.0, 3.2Hz, (H16,16’)) 2.30 (2H, dd, J=18.8, 6.0Hz, 
(H10,10’)) 2.07 (2H, td, J=12.0, 5.2Hz, (H15,15’)) 1.80 (2H, dd, J=12.0, 4.2Hz, 
(H15,15’)) 
13C NMR (100 MHz, CDCl3) 148.56 (C3,3’), 147.88 (C21,21’), 140.64 (C4,4’), 
133.55 (C12,12’), 131.34 (C7,7’), 128.71 (C19,19’), 128.32 (C11,11’), 127.94 
(C8,8’), 119.60 (C1,1’), 117.26 (C20,20’), 115.73 (C2,2’), 91.46 (C5,5’), 70.96 
(C18,18’), 70.40 (C25,25’), 70.14 (C24,24’), 69.47 (C22,22’), 69.04 (C23,23’), 
66.63 (C6,6’), 58.97 (C9,9’), 46.48 (C16,16’), 42.94 (C17,17’), 42.82 (C13,13’), 
40.46 (C14,14’), 35.39 (C15,15’), 20.73 (C10,10’). 
IR (KBr disc): ν (cm-1) 3437, 2928, 2778, 1496, 1445, 1256, 1123. 
HRMS (EI, 70 eV) Calculated for C50H58N2O11H+ 863.4113; Found 863.4117; 
m.p.= 112-114°C     Rf CH2Cl2/MeOH/NH4OH mixture (10:1:0.01) =0.34  
[α]D = -118° c = (0.10, CHCl3, 589 nm, 20°C) 
Experimental 
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Morphine 3,6-dinicotinate (213) 
Compound was prepared according to the method reported in the literature. 
Recrystallization from water furnished 213 as a white crystalline product (0.59 g, 
1.2 mmol, 71 % isolated yields). 
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1H and 13C NMR data were in agreement with the literature145. 
 
215 
A mixture of nicotinic acid (0.16 g, 1.3 mmol) and thionyl chloride (0.77 g, 0.50 mL, 
6.5 mmol) was refluxed for 2 hours. Excess of thionyl chloride was removed by 
rotary evaporation. Dry chloroform (1.5 mL) and dry pyridine (0.3 mL) were added 
to the residue and was refluxed for 2 h. After that time mixture was cooled down to 
10 °C and 194 (0.301 g, 0.44 mmol) was added in small portions over a 30 min 
period of time then all was stirred at room temperature for 2 days. Chloroform was 
removed in vacuo and product was separated by column chromatography using 
CH2Cl2/MeOH (3:1) as a mobile phase to give 215 as white solid (0.089 g, 
0.10 mmol, 22 % yield). 
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1H NMR (400 MHz, CDCl3) 9.16 (2H, d, J=1.8Hz, (H23,23’)) 8.70 (2H, dd, J=4.8, 
1.8 Hz, (H24,24’)) 8.27 (2H, dt, J=7.8, 1.8Hz, (H26,26’)) 7.34 (2H, dd, J=7.8, 4.8Hz, 
(H25,25’)) 6.63 (2H, d, J=8.0Hz, (H2,2’)) 6.48 (2H, d, J=8.0Hz, (H1,1’)) 5.70 (2H, 
ddd, J=10.0, 2.0, 0.8Hz, (H7,7’)) 5.47 (2H, dt, J=10.0, 2.8Hz, (H8,8’)) 5.40 (2H, ddd, 
J=6.8, 2.8, 2.0Hz, (H6,6’)) 5.13 (2H, dd, J=6.8, 0.8Hz, (H5,5’)) 3.98 (4H, t, 
J=5.2Hz, (H18,18’)) 3.42 (4H, t, J=5.2Hz, (H19,19’)) 3.40 (4H, s, (H20,20’)) 3.36 
(2H, dd, J=5.2, 3.2Hz, (H9,9’)) 3.00 (2H, d, J=18.8Hz, (H10,10’)) 2.82 (2H, dd, 
J=3.2, 2.8Hz, (H14,14’)) 2.59 (2H, dd, J=12.2, 4.0Hz, (H16,16’)) 2.41 (6H, s, 
(H17,17’)) 2.37 (2H, td, J=12.2, 3.6Hz, (H16,16’)) 2.31 (2H, dd, J=18.8, 5.2Hz, 
(H10,10’)) 2.07 (2H, td, J=12.2, 4.8Hz, (H15,15’)) 1.83 (2H, dd, J=12.2, 4.0Hz, 
(H15,15’)) 
13C NMR (100 MHz, CDCl3) 163.66 (C21,21’), 152.54 (C24,24’), 150.13 (C23,23’), 
145.77 (C3,3’), 140.16 (C4,4’), 136.28 (C26,26’), 129.67 (C12,12’), 128.79 (C8,8’), 
127.05 (C7,7’), 126.16 (C22,22’), 124.86 (C11,11’), 122.29 (C25,25’), 118.50 
(C1,1’), 115.60 (C2,2’), 86.48 (C5,5’), 69.49 (C20,20’), 68.70 (C19,19’), 68.21 
(C18,18’), 67.76 (C6,6’), 58.17 (C9,9’), 45.74 (C16,16’), 41.95 (C17,17’), 41.36 
(C13,13’), 39.40 (C14,14’), 34.14 (C15,15’), 19.42 (C10,10’). 
IR (KBr disc): ν (cm-1) 2968, 2780, 2496, 1728, 1452, 1286, 1133. 
HRMS (EI, 70 eV) Calculated for C52H54N4O10H+ 895.3913; Found 895.3900;  
m.p.= 89-91 °C 
Rf CH2Cl2/MeOH (3:1) =0.53  
[α]D = -88° c = (0.10, CHCl3, 589 nm, 20 °C) 
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216 
Morphine macrocyclic precursor 199 (0.471 g, 0.70 mmol) and acetic anhydride 
(5 mL) were stirred at 60 °C overnight. Reaction mixture was quenched with distilled 
water (40 mL) and extracted with CH2Cl2 (5 x 20 mL). Organic layer was dried with 
Na2SO4, filtered, solvent was removed by rotary evaporation. Purification was 
performed by column chromatography on silica gel using CH2Cl2/MeOH (3:1). 
Product was isolated as brown oil (0.098 g, 0.13 mmol, 19 % yield). 
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1H NMR (400 MHz, CDCl3) 7.34 (1H, s, (H22)) 7.32-7.27 (3H, m, (H20,20’,21)) 
6.60 (2H, d, J=8.4Hz, (H2,2’)) 6.43 (2H, d, J=8.4Hz, (H1,1’)) 5.58 (2H, ddd, J=9.8, 
2.8, 1.0Hz, (H7,7’)) 5.38 (2H, dt, J=9.8, 2.6Hz, (H8,8’)) 5.14-5.10 (2H, m, (H6,6’)) 
5.10-5.02 (6H, m, overlap, (H5,5’,18,18’)) 3.30 (2H, dd, J=6.0, 3.4Hz, (H9,9’)) 2.98 
(2H, d, J=18.4Hz, (H10,10’)) 2.69 (2H, dd, J=3.4, 2.6Hz, (H14,14’)) 2.54 (2H, dd, 
J=12.4, 3.8Hz, (H16,16’)) 2.37 (6H, s, (H17,17’)) 2.34 (2H, td, J=12.4, 3.6Hz, 
(H16,16’)) 2.25 (2H, dd, J=18.4, 6.0Hz, (H10,10’)) 2.03 (6H, s, (H24,24’)) 2.01 (2H, 
td, J=12.4, 5.2Hz, (H15,15’)) 1.82 (2H, dd, J=12.4, 3.8Hz, (H15,15’)) 
13C NMR (100 MHz, CDCl3) 169.97 (C23,23’), 146.73 (C3,3’), 140.36 (C4,4’), 
137.09 (C19,19’), 130.36 (C12,12’), 128.99 (C8,8’), 127.93 (C21), 127.81 (C7,7’), 
127.12 (C11,11’), 126.50 (C20,20’), 126.18 (C22), 118.67 (C1,1’), 116.16 (C2,2’), 
87.34 (C5,5’), 71.16 (C18,18’), 67.59 (C6,6’), 58.45 (C9,9’), 46.07 (C16,16’), 42.44 
(C17,17’), 41.96 (C13,13’), 40.02 (C14,14’), 34.73 (C15,15’), 20.24 (C24,24’), 
19.79 (C10,10’). 
IR (KBr disc): ν (cm-1) 3391, 2926, 1726, 1501, 1448, 1254, 1121. 
HRMS (EI, 70 eV) Calculated for C46H48N2O8H+ 757.3483; Found 757.3489;  
m.p.= 101-103 °C         Rf CH2Cl2/MeOH (3:1)  =0.41  
[α]D = -152° c = (0.2, CHCl3, 589 nm, 20°C) 
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222 
Dry tetrahydrofuran (10 mL) was cooled to -20 °C and excess of potassium hydride 
as a 36% suspension in mineral oil (3.30 g) was added under nitrogen. 194 (0.48 g, 
0.70 mmol) was added into the mixture and stirred for 10 min. Allyl bromide 
(0.247 g, 0.178 mL, 2.1 mmol) was added in one portion and reaction was stirred at -
20 °C for 4 h then overnight at RT. Absolute ethanol (80 mL) was added into the 
mixture to neutralize the excess of potassium hydride and solvents were removed by 
rotary evaporation. Distilled water (40 mL) was added to the residue and extracted 
with dichloromethane (5 x 20 mL) organic layer was dried with sodium sulphate. 
Product was purified by column chromatography on silica gel with 
CH2Cl2/MeOH/NH4OH (10:1:0.01) as eluent to give a brown oil (0.084 g, 0.11 
mmol, 16 % yield) 
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1H NMR (400 MHz, CDCl3) 6.61 (2H, d, J=8.4Hz, (H2,2’)) 6.41 (2H, d, J=8.4Hz, 
(H1,1’)) 5.95 (2H, ddt, J=16.0, 10.8, 5.6Hz, (H22,22’)) 5.65 (2H, ddd, J=10.0, 2.8, 
1.2Hz, (H7,7’)) 5.28-5.22 (4H, m, overlap, (H8,8’,23,23’)) 5.14 (2H, dd, J=10.0, 
1.4Hz, (H23,23’)) 4.86 (2H, dd, J=6.4, 1.2Hz, (H5,5’)) 4.22-4.05 (8H, m, overlap, 
(H18,18’,21,21’) 3.89 (2H, ddd, J=6.4, 2.8, 2.4Hz (H6,6’)) 3.73 (4H, t, J=5.0Hz, 
(H19,19’) 3.62 (4H, s, (H20,20’)) 3.30 (2H, dd, J=6.2, 3.2Hz, (H9,9’)) 2.97 (2H, d, 
J=18.8Hz, (H10,10’)) 2.58 (2H, dd, J=3.2, 2.6Hz, (H14,14’)) 2.54 (2H, dd, J=12.2, 
4.0Hz, (H16,16’)) 2.38 (6H, s, (H17,17’)) 2.37-2.31 (2H, td, J=12.2, 3.6Hz, 
(H16,16’)) 2.26 (2H, dd, J=18.8, 6.2Hz, (H10,10’)) 2.00 (2H, td, J=12.2, 4.8Hz, 
(H15,15’)) 1.83 (2H, dd, J=12.2, 4.0Hz, (H15,15’)) 
13C NMR (100 MHz, CDCl3) 146.78 (C3,3’), 139.89 (C4,4’), 133.82 (C12,12’), 
130.09 (C7,7’), 129.93 (C11,11’), 127.56 (C8,8’), 126.42 (C22,22’), 117.94 (C1,1’), 
116.11 (C2,2’), 115.81 (C23,23’), 88.53 (C5,5’), 72.29 (C6,6’), 69.65 (C20,20’), 
68.92 (C21,21’), 68.88 (C19,19’), 68.41 (C18,18’), 57.95 (C9,9’), 45.52 (C16,16’), 
Experimental 
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42.12 (C17,17’), 42.04 (C13,13’), 39.96 (C14,14’), 34.81 (C15,15’), 19.52 
(C10,10’).  
IR (KBr disc): ν (cm-1) 2928, 2778, 1501, 1450, 1256, 1120. 
HRMS (EI, 70 eV) Calculated for C46H56N2O8H+ 765.4109; Found 765.4092;  
m.p.= 43-45 °C 
Rf CH2Cl2/MeOH/NH4OH (10:1:0.01)=0.46 
[α]D = -77° c = (0.1, CHCl3, 589 nm, 20 °C) 
 
 
Morphine macrocycles 
 
General procedure 
Morphine macrocyclic precursor (1.0 mmol) was dissolved in dry tetrahydrofuran 
(80 mL) then cesium hydoxide (12.0 mmol) was added in one portion. Mixture was 
warmed up to 50 °C and strirred for additional 40 min. α,α’-Dichloroxylene 
(1.0 mmol) and KI (0.2 mmol) were added and mixture was refluxed overnight. 
Solvent was removed by rotary evaporation and distilled water was added (30 mL) to 
the crude and solid crashed out. Solid was then filtered by vacuum filtration, dried 
under high vacuum for 4 h and mixture was separated by column chromatography on 
silica gel and CH2Cl2/MeOH/NH4OH mixture (10:1:0.01) as a mobile phase.  
 
Experimental 
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Morphine macrocycle (217) 
The general procedure was used with the starting materials 194 (0.343 g, 
0.50 mmol), and α,α’-dichloro-o-xylene (0.087 g, 0.50 mmol). Product 217 was 
isolated by column chromatography as a white solid (0.094 g, 0.13 mmol, 26% 
yield). 
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1H NMR (400 MHz, CDCl3) 7.43 (2H, dd, J=5.6, 3.6Hz, (H24,24’)) 7.24 (2H, dd, 
J=5.6, 3.6Hz, (H23,23’)) 6.58 (2H, d, J=8.0Hz, (H2,2’)) 6.41 (2H, d, J=8.0Hz, 
(H1,1’)) 5.73-5.66 (2H, m, (H7,7’)) 5.25 (2H, dt, J=9.8, 2.4Hz, (H8,8’)) 5.02 (2H, d, 
J=12.0Hz, (H21,21’)) 4.88 (2H, dd, J=6.0, 1.2Hz, (H5,5’)) 4.61 (2H, d, J=12.0Hz, 
(H21,21’)) 4.12 (4H, t, J=5.0Hz, (H18,18’)) 3.91 (2H, ddd, J=6.0, 2.8, 2.4Hz, 
(H6,6’)) 3.72-3.64 (4H, m, (H19,19’)) 3.56 (4H, s, (H20,20’)) 3.26 (2H, dd, J=6.0, 
3.2Hz, (H9,9’)) 2.96 (2H, d, J=18.8Hz, (H10,10’)) 2.58 (2H, dd, J=3.2, 2.4Hz, 
(H14,14’)) 2.50 (2H, dd, J=12.0, 4.0Hz, (H16,16’)) 2.34 (6H, s, H17,17’)) 2.30 (2H, 
td, J=12.2, 3.2Hz, (H16,16’)) 2.24 (2H, dd, J=18.8, 6.0Hz, (H10,10’)) 1.92 (2H, td, 
J=12.2, 5.2Hz, (H15,15’)) 1.83 (2H, dd, J=12.2, 4.0Hz, (H15,15’)) 
13C NMR (100 MHz, CDCl3) 147.79 (C3,3’), 141.05 (C4,4’), 136.77 (C22,22’), 
131.26 (C7,7’), 131.13 (C12,12’), 129.06 (C11,11’), 128.50 (C24,24’), 127.83 
(C8,8’), 127.45 (C23,23’), 118.93 (C1,1’), 116.31 (C2,2’), 89.24 (C5,5’), 73.02 
(C6,6’), 70.58 (C20,20’), 69.62 (C18,18’) 69.56 (C19,19’) 68.29 (C21,21’), 58.98 
(C9,9’), 46.57 (C16,16’), 43.05 (C17,17’), 43.01 (C13,13’), 40.86 (C14,14’), 35.72 
(C15,15’), 20.48 (C10,10’). 
IR (KBr disc): ν (cm-1) 2923, 2782, 1509, 1459, 1258, 1127. 
HRMS (EI, 70 eV) Calculated for C48H54N2O8H+ 787.3953; Found 787.3934;  
m.p.=127-129°C 
Rf CH2Cl2/MeOH/NH4OH (10:1:0.01) = 0.29  
[α]D = -124° c = (0.10, CHCl3, 589 nm, 20 °C) 
Experimental 
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Morphine macrocycle (218) 
The general procedure was used with the starting materials 194 (0.685 g, 
1.00 mmol), and α,α’-dichloro-m-xylene (0.175 g, 1.00 mmol). Product 218 was 
isolated by column chromatography as a white solid (0.141 g, 0.18 mmol, 18 % 
yield). 
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1H NMR (400 MHz, CDCl3) 7.40 (1H, s, (H25)) 7.30-7.22 (3H, m, (H23,23’,24)) 
6.61 (2H, d, J=8.0Hz, (H2,2’)) 6.43 (2H, d, J=8.0Hz, (H1,1’)) 5.74-5.68 (2H, m, 
(H7,7’)) 5.28 (2H, dt, J=10.0, 2.6Hz, (H8,8’)) 4.99 (2H, dd, J=6.2, 0.8Hz, (H5,5’)) 
4.84 (2H, d, J=11.6Hz, (H21,21’)) 4.55 (2H, d, J=11.6Hz, (H21,21’)) 4.15-4.07 (4H, 
m, (H18,18’) 4.01 (2H, dd, J= 5.6, 2.8Hz, (H6,6’)) 3.65-3.55 (4H, m, (H19,19’)) 
3.42 (4H, s, (H20,20’)) 3.35 (2H, dd, J=5.8, 3.2Hz, (H9,9’)) 2.98 (2H, d, J=18.8Hz, 
(H10,10’)) 2.72 (2H, dd, J=3.2, 2.6Hz, (H14,14’)) 2.60 (2H, dd, J=12.0, 3.6Hz, 
(H16,16’)) 2.41 (6H, s, (H17,17’)) 2.38 (2H, td, J=12.0, 3.6Hz (H16,16’)) 2.31 (2H, 
dd, J=18.8, 6.0Hz, (H10,10’)) 2.06 (2H, td, J=12.4, 5.0Hz, (H15,15’)) 1.86 (2H, dd, 
J=12.4, 3.6Hz, (H15,15’)) 
13C NMR (100 MHz, CDCl3) 147.86 (C3,3’), 141.16 (C4,4’), 138.67 (C22,22’), 
131.33 (C12,12’), 131.15 (C7,7’), 128.30 (C11,11’), 128.08 (C8,8’), 127.31 (C24), 
126.50 (C23,23’), 126.24 (C25), 119.17 (C1,1’), 117.57 (C2,2’), 89.02 (C5,5’), 73.41 
(C6,6’), 70.50 (C20,20’), 70.44 (C21,21’), 70.19 (C18,18’), 69.82 (C19,19’) 59.20 
(C9,9’), 46.69 (C16,16’), 42.95 (C17,17’), 42.75 (C13,13’), 40.56 (C14,14’), 35.50 
(C15,15’), 20.61 (C10,10’). 
IR (KBr disc): ν (cm-1) 2927, 2778, 1497, 1445, 1254, 1124. 
HRMS (EI, 70 eV) Calculated for C48H54N2O8H+ 787.3953; Found 787.3955;  
m.p.=123-125°C               Rf CH2Cl2/MeOH/NH4OH (10:1:0.01) = 0.23  
[α]D = -133° c = (0.10, CHCl3, 589 nm, 20 °C) 
Experimental 
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Morphine macrocycle 219 
The general procedure was used with the starting materials 194 (0.343 g, 
0.50 mmol), and 2,6-bis(chloromethyl)pyridine (0.088 g, 0.50 mmol). Product 219 
was isolated by column chromatography as a white solid (0.085 g, 0.11 mmol, 21% 
yield). 
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1H NMR (400 MHz, CDCl3) 7.78 (1H, t, J=7.6Hz, (H24)) 7.56 (2H, d, J=7.6Hz, 
(H23,23’)) 6.60 (2H, d, J=8.0Hz, (H2,2’)) 6.44 (2H, d, J=8.0Hz, (H1,1’)) 5.79-5.71 
(2H, m, (H7,7’)) 5.31 (2H, dt, J=10.0, 2.6Hz, (H8,8’)) 5.02 (2H, dd, J=6.4, 1.0Hz, 
(H5,5’)) 4.85 (2H, d, J=12.0Hz, (H21,21’)) 4.67 (2H, d, J=12.0Hz, (H21,21’)) 4.12-
4.04 (6H, m, overlap (H6,6’,18,18’)) 3.60-3.56 (4H, m, (H19,19’)) 3.38 (4H, s, 
(H20,20’)) 3.35 (2H, dd, J=6.0, 3.2Hz, (H9,9’)) 2.99 (2H, d, J=18.4Hz, (H10,10’)) 
2.73 (2H, dd, J=3.2, 2.6Hz, (H14,14’)) 2.60 (2H, dd, J=12.0, 4.0Hz, (H16,16’)) 2.41 
(6H, s, (H17,17’)) 2.39 (2H, td, J=12.0, 3.6Hz (H16,16’)) 2.31 (2H, dd, J=18.6, 
6.0Hz, (H10,10’)) 2.07 (2H, td, J=12.0, 5.0Hz, (H15,15’)) 1.83 (2H, dd, J=12.0, 
4.0Hz, (H15,15’)) 
13C NMR (100 MHz, CDCl3) 157.52 (C22,22’), 147.67 (C3,3’), 141.23 (C4,4’), 
137.51 (C24), 131.18 (C12,12’), 130.87 (C7,7’), 128.30 (C8,8’), 127.36 (C11,11’), 
120.69 (C23,23’), 119.18 (C1,1’), 117.07 (C2,2’), 89.14 (C5,5’), 73.89 (C6,6’), 
71.63 (C21,21’), 70.50 (C20,20’), 70.03 (C19,19’), 69.84 (C18,18’), 59.20 (C9,9’), 
46.70 (C16,16’), 43.00 (C17,17’), 42.73 (C13,13’), 40.56 (C14,14’), 35.51 
(C15,15’), 20.58 (C10,10’). 
IR (KBr disc): ν (cm-1) 2926, 2778, 1497, 1447, 1255, 1124. 
HRMS (EI, 70 eV) Calculated for C47H53N3O8H+ 775.3747; Found 775.3724;  
m.p.=138-140 °C        Rf CH2Cl2/MeOH/NH4OH (10:1:0.01) = 0.18  
[α]D = -138° c = (0.10, CHCl3, 589nm, 20 °C) 
Experimental 
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Morphine macrocycle 220 
The general procedure was used with the starting materials 198 (0.673 g, 
1.00 mmol), and α,α’-dichloro-m-xylene (0.175 g, 1.00 mmol). Product 220 was 
isolated by column chromatography as a white solid (0.133 g, 0.17 mmol, 17% 
yield). 
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1H NMR (400 MHz, CDCl3) 7.51 (2H, dd, J=5.6, 3.6Hz, (H25, 25’)) 7.29 (2H, dd, 
J=5.6, 3.6Hz, (H24,24’)) 7.27 (4H, s, (H20,20’,21,21’)) 6.68 (2H, d, J=8.0Hz, 
(H2,2’)) 6.39 (2H, d, J=8.0Hz, (H1,1’)) 5.71-5.65 (2H, m, 1.0Hz, (H7,7’)) 5.15 (2H, 
dt, J=10.0, 2.6Hz, (H8,8’)) 5.07-4.98 (6H, m, overlap, (H18,18’,22,22’)) 4.91 (2H, 
dd, J=6.4, 1.0Hz, (H5,5’)) 4.65 (2H, d, J=12.0Hz, (H22,22’)) 3.85 (2H, dd, J=6.4, 
2.6Hz, (H6,6’)) 3.27 (2H, dd, J=6.0, 3.2Hz, (H9,9’)) 2.94 (2H, d, J=18.8Hz, 
(H10,10’)) 2.58-2.52 (2H, m, (H14,14’)) 2.54 (2H, dd, J=12.2, 3.6Hz, (H16,16’)) 
2.36 (6H, s, (H17,17’)) 2.32 (2H, td, J=12.2, 3.8Hz, (H16,16’)) 2.24 (2H, dd, J=18.8, 
6.0Hz, (H10,10’)) 1.99 (2H, td, J=12.2, 4.8Hz, (H15,15’)) 1.84 (2H, dd, J=12.2, 
3.8Hz, (H15,15’)) 
13C NMR (100 MHz, CDCl3) 149.20 (C3,3’), 140.62 (C4,4’), 136.79 (C19,19’), 
136.47 (C23,23’), 131.12 (C7,7’), 130.98 (C12,12’), 129.00 (C25,25’), 128.23 
(C8,8’), 127.95 (C24,24’), 127.63 (C11,11’), 127.45 (C20,20’,21,21’), 118.85 
(C1,1’), 116.56 (C2,2’), 90.08 (C5,5’), 73.89 (C6,6’), 71.77 (C18,18’), 68.45 
(C22,22’), 59.03 (C9,9’), 46.52 (C16,16’), 43.36 (C17,17’), 42.97 (C13,13’), 40.80 
(C14,14’), 35.54 (C15,15’), 20.68 (C10,10’). 
IR (KBr disc): ν (cm-1) 2931, 2782, 1501, 1448, 1254, 1126. 
HRMS (EI, 70 eV) Calculated for C50H50N2O6H+ 787.3958; Found 787.3934;  
m.p.= 218-220 °C 
Rf CH2Cl2/MeOH/NH4OH (10:1:0.01) =0.36  
[α]D = -147° c = (0.10, CHCl3, 589 nm, 20 °C)  
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9 Appendix  
9.1 Appendix A 
 
1,3-Bis[2-(2-hydroxyethoxy)phenoxy]propane (160) 
 
C5
C4
C2A
C6
C1A
C3 O2
C7
O1A
C8
O3
C9
C9 C10
 
Fig. A 1 X-ray crystal structure of 1,3-Bis[2-(2-hydroxyethoxy)phenoxy]propane 160 
 
 Table A 1  Crystal data and structure refinement for 160 
Identification code  gat11 
Empirical formula  C19 H24.50 O6.25 
Molecular formula C19 H24 O6 x 0.25 (H2 O) a) 
Formula weight  352.89 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C2 (#5) 
Unit cell dimensions a = 22.897(3) Å  α= 90°. 
 b = 4.9486(6) Å  β= 116.539(2)°. 
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 c = 17.2590(19) Å γ = 90°. 
Volume 1749.5(3) Å3 
Z 4 
Density (calculated) 1.340 Mg/m3 
Absorption coefficient 0.100 mm–1 
F(000) 754 
Crystal size 0.80 x 0.10 x 0.10 mm3 
Theta range for data collection 1.83 to 25.99°. 
Index ranges –28<=h<=28, –6<=k<=6, –21<=l<=21 
Reflections collected 7435 
Independent reflections 1923 [R(int) = 0.0221] 
Completeness to theta = 25.99° 99.7 %  
Absorption correction Semi–empirical from equivalents 
Max. and min. transmission 0.9901 and 0.8489 
Refinement method Full–matrix least–squares on F2 
Data / restraints / parameters 1923 / 76 / 292 b) 
Goodness–of–fit on F2 1.059 
Final R indices [I>2sigma(I)] R1 = 0.0644, wR2 = 0.1637 
R indices (all data) R1 = 0.0683, wR2 = 0.1676 
Largest diff. peak and hole 0.476 and –0.251 e.Å–3 
a)
 The hydrogen atoms of the water molecule could not be detected. 
b)
 DELU restraints were applied to all thermal displacement parameters. Equivalent distances in the 
disorder parts were restrained to be similar using SADI. 
 
Table A 2 Bond lengths [Å] and angles [°] for 160 
O(1A)–C(1A)  1.466(15) 
O(1A)–H(1A)  0.8400 
C(1A)–C(2A)  1.485(10) 
C(1A)–H(1A1)  0.9900 
C(1A)–H(1A2)  0.9900 
C(2A)–O(2)  1.513(9) 
C(2A)–H(2A1)  0.9900 
C(2A)–H(2A2)  0.9900 
O(1B)–C(1B)  1.369(15) 
O(1B)–H(1B)  0.8400 
C(1B)–C(2B)  1.565(15) 
C(1B)–H(1B1)  0.9900 
C(1B)–H(1B2)  0.9900 
C(2B)–O(2)  1.417(10) 
C(2B)–H(2B1)  0.9900 
C(2B)–H(2B2)  0.9900 
O(2)–C(3)  1.359(5) 
C(3)–C(4)  1.393(6) 
C(3)–C(8)  1.407(5) 
C(4)–C(5)  1.383(6) 
C(4)–H(4)  0.9500 
C(5)–C(6)  1.365(6) 
C(5)–H(5)  0.9500 
C(6)–C(7)  1.391(5) 
C(6)–H(6)  0.9500 
C(7)–C(8)  1.382(5) 
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C(7)–H(7)  0.9500 
C(8)–O(3)  1.364(4) 
O(3)–C(9)  1.430(4) 
C(9)–C(10)  1.514(5) 
C(9)–H(9A)  0.9900 
C(9)–H(9B)  0.9900 
C(10)–C(9)#1  1.514(5) 
C(10)–H(10)  0.9900 
C(10)–H(10)#1  0.9900 
O(4A)–C(11A)  1.362(18) 
O(4A)–H(4A)  0.8400 
C(11A)–C(12A)  1.495(16) 
C(11A)–H(11A)  0.9900 
C(11A)–H(11B)  0.9900 
C(12A)–O(5)  1.479(16) 
C(12A)–H(12A)  0.9900 
C(12A)–H(12B)  0.9900 
O(4B)–C(11B)  1.34(2) 
O(4B)–H(4B)  0.8400 
C(11B)–C(12B)  1.493(18) 
C(11B)–H(11C)  0.9900 
C(11B)–H(11D)  0.9900 
C(12B)–O(5)  1.460(13) 
C(12B)–H(12C)  0.9900 
C(12B)–H(12D)  0.9900 
O(5)–C(13)  1.351(5) 
C(13)–C(14)  1.384(6) 
C(13)–C(18)  1.412(7) 
C(14)–C(15)  1.344(7) 
C(14)–H(14)  0.9500 
C(15)–C(16)  1.349(9) 
C(15)–H(15)  0.9500 
C(16)–C(17)  1.429(8) 
C(16)–H(16)  0.9500 
C(17)–C(18)  1.370(6) 
C(17)–H(17)  0.9500 
C(18)–O(6)  1.366(5) 
O(6)–C(19)  1.434(5) 
C(19)–C(20)  1.513(6) 
C(19)–H(19A)  0.9900 
C(19)–H(19B)  0.9900 
C(20)–C(19)#2  1.513(6) 
C(20)–H(20)  0.9900 
C(20)–H(20)#2  0.9900 
  
C(1A)–O(1A)–H(1A) 109.5 
O(1A)–C(1A)–C(2A) 109.0(9) 
O(1A)–C(1A)–H(1A1) 109.9 
C(2A)–C(1A)–H(1A1) 109.9 
O(1A)–C(1A)–H(1A2) 109.9 
C(2A)–C(1A)–H(1A2) 109.9 
H(1A1)–C(1A)–H(1A2) 108.3 
C(1A)–C(2A)–O(2) 106.5(6) 
C(1A)–C(2A)–H(2A1) 110.4 
O(2)–C(2A)–H(2A1) 110.4 
C(1A)–C(2A)–H(2A2) 110.4 
O(2)–C(2A)–H(2A2) 110.4 
H(2A1)–C(2A)–H(2A2) 108.6 
C(1B)–O(1B)–H(1B) 109.5 
O(1B)–C(1B)–C(2B) 107.3(9) 
O(1B)–C(1B)–H(1B1) 110.3 
C(2B)–C(1B)–H(1B1) 110.3 
O(1B)–C(1B)–H(1B2) 110.3 
C(2B)–C(1B)–H(1B2) 110.3 
H(1B1)–C(1B)–H(1B2) 108.5 
O(2)–C(2B)–C(1B) 104.4(9) 
O(2)–C(2B)–H(2B1) 110.9 
C(1B)–C(2B)–H(2B1) 110.9 
O(2)–C(2B)–H(2B2) 110.9 
C(1B)–C(2B)–H(2B2) 110.9 
H(2B1)–C(2B)–H(2B2) 108.9 
C(3)–O(2)–C(2B) 132.3(8) 
C(3)–O(2)–C(2A) 108.7(5) 
C(2B)–O(2)–C(2A) 33.5(6) 
O(2)–C(3)–C(4) 125.5(4) 
O(2)–C(3)–C(8) 115.4(4) 
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C(4)–C(3)–C(8) 119.1(3) 
C(5)–C(4)–C(3) 121.2(4) 
C(5)–C(4)–H(4) 119.4 
C(3)–C(4)–H(4) 119.4 
C(6)–C(5)–C(4) 119.4(4) 
C(6)–C(5)–H(5) 120.3 
C(4)–C(5)–H(5) 120.3 
C(5)–C(6)–C(7) 120.7(4) 
C(5)–C(6)–H(6) 119.7 
C(7)–C(6)–H(6) 119.7 
C(8)–C(7)–C(6) 120.7(3) 
C(8)–C(7)–H(7) 119.6 
C(6)–C(7)–H(7) 119.6 
O(3)–C(8)–C(7) 124.9(3) 
O(3)–C(8)–C(3) 116.2(3) 
C(7)–C(8)–C(3) 118.9(3) 
C(8)–O(3)–C(9) 116.7(2) 
O(3)–C(9)–C(10) 107.9(2) 
O(3)–C(9)–H(9A) 110.1 
C(10)–C(9)–H(9A) 110.1 
O(3)–C(9)–H(9B) 110.1 
C(10)–C(9)–H(9B) 110.1 
H(9A)–C(9)–H(9B) 108.4 
C(9)–C(10)–C(9)#1 113.3(5) 
C(9)–C(10)–H(10) 108.9 
C(9)#1–C(10)–H(10) 108.9 
H(10)–C(10)–H(10)#1 107.7 
C(11A)–O(4A)–H(4A) 109.5 
O(4A)–C(11A)–C(12A) 108.2(15) 
O(4A)–C(11A)–H(11A) 110.1 
C(12A)–C(11A)–H(11A) 110.1 
O(4A)–C(11A)–H(11B) 110.1 
C(12A)–C(11A)–H(11B) 110.1 
H(11A)–C(11A)–H(11B) 108.4 
O(5)–C(12A)–C(11A) 117.5(15) 
O(5)–C(12A)–H(12A) 107.9 
C(11A)–C(12A)–H(12A) 107.9 
O(5)–C(12A)–H(12B) 107.9 
C(11A)–C(12A)–H(12B) 107.9 
H(12A)–C(12A)–H(12B) 107.2 
C(11B)–O(4B)–H(4B) 109.5 
O(4B)–C(11B)–C(12B) 110.2(18) 
O(4B)–C(11B)–H(11C) 109.6 
C(12B)–C(11B)–H(11C) 109.6 
O(4B)–C(11B)–H(11D) 109.6 
C(12B)–C(11B)–H(11D) 109.6 
H(11C)–C(11B)–H(11D) 108.1 
O(5)–C(12B)–C(11B) 104.3(12) 
O(5)–C(12B)–H(12C) 110.9 
C(11B)–C(12B)–H(12C) 110.9 
O(5)–C(12B)–H(12D) 110.9 
C(11B)–C(12B)–H(12D) 110.9 
H(12C)–C(12B)–H(12D) 108.9 
C(13)–O(5)–C(12B) 119.5(7) 
C(13)–O(5)–C(12A) 113.2(7) 
C(12B)–O(5)–C(12A) 16.0(15) 
O(5)–C(13)–C(14) 124.1(5) 
O(5)–C(13)–C(18) 115.4(4) 
C(14)–C(13)–C(18) 120.6(4) 
C(15)–C(14)–C(13) 120.5(5) 
C(15)–C(14)–H(14) 119.8 
C(13)–C(14)–H(14) 119.8 
C(14)–C(15)–C(16) 120.7(5) 
C(14)–C(15)–H(15) 119.6 
C(16)–C(15)–H(15) 119.6 
C(15)–C(16)–C(17) 120.8(4) 
C(15)–C(16)–H(16) 119.6 
C(17)–C(16)–H(16) 119.6 
C(18)–C(17)–C(16) 119.1(5) 
C(18)–C(17)–H(17) 120.5 
C(16)–C(17)–H(17) 120.5 
O(6)–C(18)–C(17) 126.0(5) 
O(6)–C(18)–C(13) 115.6(4) 
C(17)–C(18)–C(13) 118.4(4) 
C(18)–O(6)–C(19) 117.2(3) 
O(6)–C(19)–C(20) 107.6(3) 
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O(6)–C(19)–H(19A) 110.2 
C(20)–C(19)–H(19A) 110.2 
O(6)–C(19)–H(19B) 110.2 
C(20)–C(19)–H(19B) 110.2 
H(19A)–C(19)–H(19B) 108.5 
C(19)–C(20)–C(19)#2 115.6(6) 
C(19)–C(20)–H(20) 108.4 
C(19)#2–C(20)–H(20) 108.4 
H(20)–C(20)–H(20)#2 107.4 
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1,5-Bis[2-(2-hydroxyethoxy)phenoxy]-3-oxapentane 161 
 
C6
C7
C9
C10
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O4
C8
O3
H1O4
H1O4
C4
C3
O2
O5
O5
C2
O1C1
C1
 
Fig. A 2 X-ray crystal structure of 1,5-Bis[2-(2-hydroxyethoxy)phenoxy]-3-oxapentane 161 
 
Table A 3 Crystal data and structure refinement for 161 
Identification code  gat05 
Empirical formula  C20 H30 O9 
Molecular formula C20 H26 O7 x 2 (H2 O) 
Formula weight  414.44 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C2 (#5) 
Unit cell dimensions a = 22.433(8) Å  α= 90°. 
 b = 4.7894(18) Å  β= 108.808(7)°. 
 c = 9.937(4) Å  γ = 90°. 
Volume 1010.7(6) Å3 
Z 2 
Density (calculated) 1.362 Mg/m3 
Absorption coefficient 0.107 mm–1 
F(000) 444 
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Crystal size 0.80 x 0.15 x 0.02 mm3 
Theta range for data collection 1.92 to 26.97°. 
Index ranges –28<=h<=28, –6<=k<=6, –12<=l<=12 
Reflections collected 4116 
Independent reflections 1223 [R(int) = 0.0560] 
Completeness to theta = 26.97° 99.5 %  
Absorption correction Semi–empirical from equivalents 
Max. and min. transmission 0.9979 and 0.8558 
Refinement method Full–matrix least–squares on F2 
Data / restraints / parameters 1223 / 3 / 139 a) 
Goodness–of–fit on F2 1.083 
Final R indices [I>2sigma(I)] R1 = 0.0457, wR2 = 0.1022 
R indices (all data) R1 = 0.0560, wR2 = 0.1054 
Largest diff. peak and hole 0.261 and –0.185 e.Å–3 
The O–H bond distances in the water molecule are restrained to be 0.84 Å. 
 
Table A 4 Bond lengths [Å] and angles [°] for 161 
O(1)–C(1)  1.430(3) 
O(1)–C(1)#1  1.430(3) 
C(1)–C(2)  1.498(4) 
C(1)–H(1A)  0.9900 
C(1)–H(1B)  0.9900 
C(2)–O(2)  1.437(3) 
C(2)–H(2A)  0.9900 
C(2)–H(2B)  0.9900 
O(2)–C(3)  1.375(3) 
C(3)–C(4)  1.383(4) 
C(3)–C(8)  1.406(4) 
C(4)–C(5)  1.395(5) 
C(4)–H(4)  0.9500 
C(5)–C(6)  1.374(5) 
C(5)–H(5)  0.9500 
C(6)–C(7)  1.395(4) 
C(6)–H(6)  0.9500 
C(7)–C(8)  1.384(4) 
C(7)–H(7)  0.9500 
C(8)–O(3)  1.372(3) 
O(3)–C(9)  1.436(3) 
C(9)–C(10)  1.503(4) 
C(9)–H(9A)  0.9900 
C(9)–H(9B)  0.9900 
C(10)–O(4)  1.423(3) 
C(10)–H(10A)  0.9900 
C(10)–H(10B)  0.9900 
O(4)–H(1O4)  0.8400 
O(5)–H(1O5)  0.835(19) 
O(5)–H(2O5)  0.843(19) 
  
C(1)–O(1)–C(1)#1 110.1(3) 
O(1)–C(1)–C(2) 110.1(2) 
O(1)–C(1)–H(1A) 109.6 
C(2)–C(1)–H(1A) 109.6 
O(1)–C(1)–H(1B) 109.6 
C(2)–C(1)–H(1B) 109.6 
H(1A)–C(1)–H(1B) 108.2 
O(2)–C(2)–C(1) 108.6(2) 
O(2)–C(2)–H(2A) 110.0 
C(1)–C(2)–H(2A) 110.0 
O(2)–C(2)–H(2B) 110.0 
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C(1)–C(2)–H(2B) 110.0 
H(2A)–C(2)–H(2B) 108.4 
C(3)–O(2)–C(2) 116.1(2) 
O(2)–C(3)–C(4) 124.8(3) 
O(2)–C(3)–C(8) 115.9(2) 
C(4)–C(3)–C(8) 119.3(2) 
C(3)–C(4)–C(5) 120.6(3) 
C(3)–C(4)–H(4) 119.7 
C(5)–C(4)–H(4) 119.7 
C(6)–C(5)–C(4) 119.9(3) 
C(6)–C(5)–H(5) 120.0 
C(4)–C(5)–H(5) 120.0 
C(5)–C(6)–C(7) 120.2(3) 
C(5)–C(6)–H(6) 119.9 
C(7)–C(6)–H(6) 119.9 
C(8)–C(7)–C(6) 120.1(3) 
C(8)–C(7)–H(7) 120.0 
C(6)–C(7)–H(7) 120.0 
O(3)–C(8)–C(7) 124.4(2) 
O(3)–C(8)–C(3) 115.7(2) 
C(7)–C(8)–C(3) 119.9(2) 
C(8)–O(3)–C(9) 116.7(2) 
O(3)–C(9)–C(10) 107.7(2) 
O(3)–C(9)–H(9A) 110.2 
C(10)–C(9)–H(9A) 110.2 
O(3)–C(9)–H(9B) 110.2 
C(10)–C(9)–H(9B) 110.2 
H(9A)–C(9)–H(9B) 108.5 
O(4)–C(10)–C(9) 113.6(2) 
O(4)–C(10)–H(10A) 108.8 
C(9)–C(10)–H(10A) 108.8 
O(4)–C(10)–H(10B) 108.8 
C(9)–C(10)–H(10B) 108.8 
H(10A)–C(10)–H(10B) 107.7 
C(10)–O(4)–H(1O4) 109.5 
H(1O5)–O(5)–H(2O5) 97(4) 
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1,4-Bis[2-(2-hydroxyethoxy)phenoxy]-p-xylene 163 
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Fig. A 3 X-ray crystal structure of 1,4-Bis[2-(2-hydroxyethoxy)phenoxy]-p-xylene 163 
   
Table A 5  Crystal data and structure refinement for 163 
Identification code  gat12 
Empirical formula  C24 H26 O6 
Formula weight  410.45 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C2/c (#15) 
Unit cell dimensions a = 24.449(5) Å  α= 90°. 
 b = 4.9250(11) Å  β= 91.677(5)°. 
 c = 16.381(4) Å  γ = 90°. 
Volume 1971.6(8) Å3 
Z 4 
Density (calculated) 1.383 Mg/m3 
Absorption coefficient 0.099 mm–1 
F(000) 872 
Crystal size 0.50 x 0.15 x 0.10 mm3 
Theta range for data collection 1.67 to 23.00°. 
Index ranges –26<=h<=26, –5<=k<=5, –18<=l<=18 
Reflections collected 5918 
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Independent reflections 1371 [R(int) = 0.0570] 
Completeness to theta = 23.00° 99.6 %  
Absorption correction Semi–empirical from equivalents 
Max. and min. transmission 0.9902 and 0.6363 
Refinement method Full–matrix least–squares on F2 
Data / restraints / parameters 1371 / 36 / 148 a) 
Goodness–of–fit on F2 1.156 
Final R indices [I>2sigma(I)] R1 = 0.0616, wR2 = 0.1445 
R indices (all data) R1 = 0.0680, wR2 = 0.1483 
Largest diff. peak and hole 0.180 and –0.189 e.Å–3 
DELU restraints were applied to all thermal displacement parameters. 
 
Table A 6 Bond lengths [Å] and angles [°] for 163 
O(1A)–C(1)  1.532(5) 
O(1A)–H(1OA)  0.8400 
C(1)–C(2)  1.501(5) 
C(1)–H(1A)  0.9900 
C(1)–H(1B)  0.9900 
C(1)–H(1C)  0.9900 
C(1)–H(1D)  0.9900 
O(1B)–C(1)  1.352(6) 
O(1B)–H(1OB)  0.8400 
C(2)–O(2)  1.426(4) 
C(2)–H(2A)  0.9900 
C(2)–H(2B)  0.9900 
O(2)–C(3)  1.374(3) 
C(3)–C(4)  1.373(5) 
C(3)–C(8)  1.390(4) 
C(4)–C(5)  1.396(4) 
C(4)–H(4)  0.9500 
C(5)–C(6)  1.355(5) 
C(5)–H(5)  0.9500 
C(6)–C(7)  1.387(5) 
C(6)–H(6)  0.9500 
C(7)–C(8)  1.385(4) 
C(7)–H(7)  0.9500 
C(8)–O(3)  1.371(4) 
O(3)–C(9)  1.427(4) 
C(9)–C(10)  1.503(5) 
C(9)–H(9A)  0.9900 
C(9)–H(9B)  0.9900 
C(10)–C(12)#1  1.383(4) 
C(10)–C(11)  1.390(4) 
C(11)–C(12)  1.374(5) 
C(11)–H(11)  0.9500 
C(12)–C(10)#1  1.383(4) 
C(12)–H(12)  0.9500 
  
H(1OA)–O(1A)–C(1) 109.5 
H(1OB)–O(1B)–C(1) 109.5 
C(2)–C(1)–O(1A) 114.8(3) 
C(2)–C(1)–H(1A) 108.6 
O(1A)–C(1)–H(1A) 108.6 
C(2)–C(1)–H(1B) 108.6 
O(1A)–C(1)–H(1B) 108.6 
H(1A)–C(1)–H(1B) 107.5 
C(2)–C(1)–O(1B) 104.9(3) 
C(2)–C(1)–H(1C) 110.8 
O(1A)–C(1)–H(1C) 110.8 
C(2)–C(1)–H(1D) 110.8 
O(1A)–C(1)–H(1D) 110.8 
H(1C)–C(1)–H(1D) 108.7 
O(2)–C(2)–C(1) 107.3(3) 
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O(2)–C(2)–H(2A) 110.3 
C(1)–C(2)–H(2A) 110.3 
O(2)–C(2)–H(2B) 110.3 
C(1)–C(2)–H(2B) 110.3 
H(2A)–C(2)–H(2B) 108.5 
C(3)–O(2)–C(2) 117.3(2) 
C(4)–C(3)–O(2) 124.4(3) 
C(4)–C(3)–C(8) 120.1(3) 
O(2)–C(3)–C(8) 115.5(3) 
C(3)–C(4)–C(5) 119.8(3) 
C(3)–C(4)–H(4) 120.1 
C(5)–C(4)–H(4) 120.1 
C(6)–C(5)–C(4) 120.2(3) 
C(6)–C(5)–H(5) 119.9 
C(4)–C(5)–H(5) 119.9 
C(5)–C(6)–C(7) 120.6(3) 
C(5)–C(6)–H(6) 119.7 
C(7)–C(6)–H(6) 119.7 
C(8)–C(7)–C(6) 119.7(3) 
C(8)–C(7)–H(7) 120.1 
C(6)–C(7)–H(7) 120.1 
O(3)–C(8)–C(7) 124.9(3) 
O(3)–C(8)–C(3) 115.5(2) 
C(7)–C(8)–C(3) 119.6(3) 
C(8)–O(3)–C(9) 117.9(2) 
O(3)–C(9)–C(10) 113.4(2) 
O(3)–C(9)–H(9A) 108.9 
C(10)–C(9)–H(9A) 108.9 
O(3)–C(9)–H(9B) 108.9 
C(10)–C(9)–H(9B) 108.9 
H(9A)–C(9)–H(9B) 107.7 
C(12)#1–C(10)–C(11) 117.8(3) 
C(12)#1–C(10)–C(9) 121.3(3) 
C(11)–C(10)–C(9) 120.9(3) 
C(12)–C(11)–C(10) 120.6(3) 
C(12)–C(11)–H(11) 119.7 
C(10)–C(11)–H(11) 119.7 
C(11)–C(12)–C(10)#1 121.5(3) 
C(11)–C(12)–H(12) 119.2 
C(10)#1–C(12)–H(12) 119.2 
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1,3-Bis[2-(2-hydroxyethoxy)phenoxy]-m-xylene 164  
 
C12
O1
C11 C13
C24C1 O6
C10
C23
C14
O5
C2
C9
C15
O4
O3
C16
O2
C22
C17
C8
C3
C21
C18
C7
C4
C20
C19
C6
C5
 
 
Fig. A 4 X-ray crystal structure of 1,3-Bis[2-(2-hydroxyethoxy)phenoxy]-m-xylene 164  
 
Table A 7 Crystal data and structure refinement for 164 
Identification code  gat04 
Empirical formula  C24 H26 O6 
Formula weight  410.45 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21/c (#14) 
Unit cell dimensions a = 13.4964(16) Å α= 90°. 
 b = 7.0234(8) Å  β= 104.665(2)°. 
 c = 22.476(3) Å  γ = 90°. 
Volume 2061.2(4) Å3 
Z 4 
Density (calculated) 1.323 Mg/m3 
Absorption coefficient 0.095 mm–1 
F(000) 872 
Crystal size 0.60 x 0.40 x 0.05 mm3 
Theta range for data collection 1.87 to 26.00°. 
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Index ranges –16<=h<=16, –8<=k<=8, –27<=l<=27 
Reflections collected 17123 
Independent reflections 4056 [R(int) = 0.0359] 
Completeness to theta = 26.00° 100.0 %  
Absorption correction Semi–empirical from equivalents 
Max. and min. transmission 0.9953 and 0.8160 
Refinement method Full–matrix least–squares on F2 
Data / restraints / parameters 4056 / 0 / 375 
Goodness–of–fit on F2 1.018 
Final R indices [I>2sigma(I)] R1 = 0.0372, wR2 = 0.0815 
R indices (all data) R1 = 0.0490, wR2 = 0.0873 
Largest diff. peak and hole 0.246 and –0.167 e.Å–3 
 
Table A 8 Bond lengths [Å] and angles [°] for 164 
O(1)–C(1)  1.4225(17) 
O(1)–H(1O1)  0.867(19) 
C(1)–C(2)  1.505(2) 
C(1)–H(1A)  0.984(14) 
C(1)–H(1B)  1.006(15) 
C(2)–O(2)  1.4445(16) 
C(2)–H(2A)  0.977(15) 
C(2)–H(2B)  0.982(16) 
O(2)–C(3)  1.3679(16) 
C(3)–C(4)  1.381(2) 
C(3)–C(8)  1.406(2) 
C(4)–C(5)  1.396(2) 
C(4)–H(4)  0.941(16) 
C(5)–C(6)  1.378(2) 
C(5)–H(5)  0.938(16) 
C(6)–C(7)  1.392(2) 
C(6)–H(6)  0.963(15) 
C(7)–C(8)  1.384(2) 
C(7)–H(7)  0.973(16) 
C(8)–O(3)  1.3679(17) 
O(3)–C(9)  1.4392(17) 
C(9)–C(10)  1.500(2) 
C(9)–H(9A)  0.989(15) 
C(9)–H(9B)  0.995(17) 
C(10)–C(15)  1.3919(19) 
C(10)–C(11)  1.394(2) 
C(11)–C(12)  1.388(2) 
C(11)–H(11)  0.960(15) 
C(12)–C(13)  1.384(2) 
C(12)–H(12)  0.963(17) 
C(13)–C(14)  1.392(2) 
C(13)–H(13)  0.996(16) 
C(14)–C(15)  1.388(2) 
C(14)–C(16)  1.498(2) 
C(15)–H(15)  0.961(15) 
C(16)–O(4)  1.4370(16) 
C(16)–H(16A)  0.979(15) 
C(16)–H(16B)  0.980(16) 
O(4)–C(17)  1.3644(16) 
C(17)–C(18)  1.383(2) 
C(17)–C(22)  1.4113(19) 
C(18)–C(19)  1.393(2) 
C(18)–H(18)  0.942(15) 
C(19)–C(20)  1.374(2) 
C(19)–H(19)  0.968(16) 
C(20)–C(21)  1.396(2) 
C(20)–H(20)  0.963(16) 
C(21)–C(22)  1.384(2) 
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C(21)–H(21)  0.963(16) 
C(22)–O(5)  1.3687(17) 
O(5)–C(23)  1.4338(17) 
C(23)–C(24)  1.500(2) 
C(23)–H(23A)  0.984(15) 
C(23)–H(23B)  0.992(17) 
C(24)–O(6)  1.4155(18) 
C(24)–H(24A)  0.991(15) 
C(24)–H(24B)  0.999(15) 
O(6)–H(1O6)  0.88(2) 
  
C(1)–O(1)–H(1O1) 109.5(12) 
O(1)–C(1)–C(2) 112.52(12) 
O(1)–C(1)–H(1A) 107.2(8) 
C(2)–C(1)–H(1A) 111.3(8) 
O(1)–C(1)–H(1B) 110.4(9) 
C(2)–C(1)–H(1B) 108.7(9) 
H(1A)–C(1)–H(1B) 106.6(11) 
O(2)–C(2)–C(1) 112.21(12) 
O(2)–C(2)–H(2A) 103.8(9) 
C(1)–C(2)–H(2A) 109.7(9) 
O(2)–C(2)–H(2B) 111.4(8) 
C(1)–C(2)–H(2B) 110.2(9) 
H(2A)–C(2)–H(2B) 109.2(12) 
C(3)–O(2)–C(2) 118.16(11) 
O(2)–C(3)–C(4) 125.23(13) 
O(2)–C(3)–C(8) 114.89(12) 
C(4)–C(3)–C(8) 119.86(13) 
C(3)–C(4)–C(5) 120.18(14) 
C(3)–C(4)–H(4) 119.7(9) 
C(5)–C(4)–H(4) 120.2(9) 
C(6)–C(5)–C(4) 119.92(14) 
C(6)–C(5)–H(5) 118.9(10) 
C(4)–C(5)–H(5) 121.2(9) 
C(5)–C(6)–C(7) 120.25(14) 
C(5)–C(6)–H(6) 120.3(9) 
C(7)–C(6)–H(6) 119.4(9) 
C(8)–C(7)–C(6) 120.21(14) 
C(8)–C(7)–H(7) 120.1(9) 
C(6)–C(7)–H(7) 119.6(9) 
O(3)–C(8)–C(7) 125.39(13) 
O(3)–C(8)–C(3) 115.10(12) 
C(7)–C(8)–C(3) 119.51(13) 
C(8)–O(3)–C(9) 116.42(10) 
O(3)–C(9)–C(10) 107.78(11) 
O(3)–C(9)–H(9A) 109.6(9) 
C(10)–C(9)–H(9A) 110.5(8) 
O(3)–C(9)–H(9B) 109.1(9) 
C(10)–C(9)–H(9B) 110.2(9) 
H(9A)–C(9)–H(9B) 109.5(12) 
C(15)–C(10)–C(11) 119.08(13) 
C(15)–C(10)–C(9) 120.08(13) 
C(11)–C(10)–C(9) 120.84(13) 
C(12)–C(11)–C(10) 120.64(14) 
C(12)–C(11)–H(11) 120.1(9) 
C(10)–C(11)–H(11) 119.2(9) 
C(13)–C(12)–C(11) 119.56(14) 
C(13)–C(12)–H(12) 121.1(10) 
C(11)–C(12)–H(12) 119.4(10) 
C(12)–C(13)–C(14) 120.64(14) 
C(12)–C(13)–H(13) 121.3(9) 
C(14)–C(13)–H(13) 118.1(9) 
C(15)–C(14)–C(13) 119.36(13) 
C(15)–C(14)–C(16) 120.65(13) 
C(13)–C(14)–C(16) 119.94(13) 
C(14)–C(15)–C(10) 120.68(13) 
C(14)–C(15)–H(15) 120.9(9) 
C(10)–C(15)–H(15) 118.4(9) 
O(4)–C(16)–C(14) 107.00(11) 
O(4)–C(16)–H(16A) 107.9(9) 
C(14)–C(16)–H(16A) 112.2(9) 
O(4)–C(16)–H(16B) 110.8(9) 
C(14)–C(16)–H(16B) 110.4(9) 
H(16A)–C(16)–
H(16B) 
108.5(12) 
C(17)–O(4)–C(16) 116.43(10) 
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O(4)–C(17)–C(18) 125.15(13) 
O(4)–C(17)–C(22) 115.46(12) 
C(18)–C(17)–C(22) 119.38(13) 
C(17)–C(18)–C(19) 120.46(14) 
C(17)–C(18)–H(18) 120.2(9) 
C(19)–C(18)–H(18) 119.3(9) 
C(20)–C(19)–C(18) 120.31(14) 
C(20)–C(19)–H(19) 121.1(9) 
C(18)–C(19)–H(19) 118.6(9) 
C(19)–C(20)–C(21) 119.86(14) 
C(19)–C(20)–H(20) 119.7(9) 
C(21)–C(20)–H(20) 120.4(9) 
C(22)–C(21)–C(20) 120.42(14) 
C(22)–C(21)–H(21) 119.4(9) 
C(20)–C(21)–H(21) 120.2(9) 
O(5)–C(22)–C(21) 124.60(13) 
O(5)–C(22)–C(17) 115.84(12) 
C(21)–C(22)–C(17) 119.55(13) 
C(22)–O(5)–C(23) 116.25(11) 
O(5)–C(23)–C(24) 108.46(12) 
O(5)–C(23)–H(23A) 109.7(9) 
C(24)–C(23)–H(23A) 110.3(9) 
O(5)–C(23)–H(23B) 108.8(9) 
C(24)–C(23)–H(23B) 110.8(9) 
H(23A)–C(23)–
H(23B) 
108.7(12) 
O(6)–C(24)–C(23) 113.56(13) 
O(6)–C(24)–H(24A) 111.4(8) 
C(23)–C(24)–H(24A) 109.7(8) 
O(6)–C(24)–H(24B) 107.6(8) 
C(23)–C(24)–H(24B) 107.6(9) 
H(24A)–C(24)–
H(24B) 
106.8(12) 
C(24)–O(6)–H(1O6) 108.0(13) 
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1,2-Bis[2-(2-hydroxyethoxy)phenoxy]-o-xylene 165 
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Fig. A 5 X-ray crystal structure of 1,2-Bis[2-(2-hydroxyethoxy)phenoxy]-o-xylene 165 
  
Table A 9 Crystal data and structure refinement for 165 
Identification code  gat06 
Empirical formula  C24 H26 O6 
Formula weight  410.45 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C2/c (#15) 
Unit cell dimensions a = 26.492(4) Å  α= 90°. 
 b = 9.8112(15) Å β= 106.831(3)°. 
 c = 8.4897(13) Å γ = 90°. 
Volume 2112.1(6) Å3 
Z 4 
Appendix 
 
263 
Density (calculated) 1.291 Mg/m3 
Absorption coefficient 0.092 mm–1 
F(000) 872 
Crystal size 0.60 x 0.40 x 0.01 mm3 
Theta range for data collection 1.61 to 24.73°. 
Index ranges –31<=h<=31, –11<=k<=11, –9<=l<=9 
Reflections collected 7805 
Independent reflections 1794 [R(int) = 0.0263] 
Completeness to theta = 24.73° 99.9 %  
Absorption correction Semi–empirical from equivalents 
Max. and min. transmission 0.9991 and 0.8816 
Refinement method Full–matrix least–squares on F2 
Data / restraints / parameters 1794 / 0 / 148 
Goodness–of–fit on F2 1.024 
Final R indices [I>2sigma(I)] R1 = 0.0369, wR2 = 0.0851 
R indices (all data) R1 = 0.0452, wR2 = 0.0894 
Largest diff. peak and hole 0.257 and –0.163 e.Å–3 
 
Table A 10 Bond lengths [Å] and angles [°] for 165 
O(1A)–C(1)  1.505(3) 
O(1A)–H(1A)  0.8400 
C(1)–C(2)  1.485(2) 
C(1)–H(1A1)  0.9900 
C(1)–H(1A2)  0.9900 
C(1)–H(1B1)  0.9900 
C(1)–H(1B2)  0.9900 
O(1B)–C(1)  1.491(3) 
O(1B)–H(1B)  0.8400 
C(2)–O(2)  1.4289(17) 
C(2)–H(2A)  0.9900 
C(2)–H(2B)  0.9900 
O(2)–C(3)  1.3725(17) 
C(3)–C(4)  1.376(2) 
C(3)–C(8)  1.404(2) 
C(4)–C(5)  1.394(2) 
C(4)–H(4)  0.9500 
C(5)–C(6)  1.368(2) 
C(5)–H(5)  0.9500 
C(6)–C(7)  1.392(2) 
C(6)–H(6)  0.9500 
C(7)–C(8)  1.382(2) 
C(7)–H(7)  0.9500 
C(8)–O(3)  1.3809(17) 
O(3)–C(9)  1.4457(17) 
C(9)–C(10)  1.503(2) 
C(9)–H(9A)  0.9900 
C(9)–H(9B)  0.9900 
C(10)–C(11)  1.389(2) 
C(10)–C(10)#1  1.405(3) 
C(11)–C(12)  1.385(2) 
C(11)–H(11)  0.9500 
C(12)–C(12)#1  1.386(3) 
C(12)–H(12)  0.9500 
  
C(2)–C(1)–O(1A) 103.84(14) 
C(2)–C(1)–H(1A1) 111.0 
O(1A)–C(1)–H(1A1) 111.0 
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C(2)–C(1)–H(1A2) 111.0 
O(1A)–C(1)–H(1A2) 111.0 
H(1A1)–C(1)–H(1A2) 109.0 
C(2)–C(1)–O(1B) 102.9(2) 
C(2)–C(1)–H(1B1) 111.3 
O(1B)–C(1)–H(1B1) 111.3 
C(2)–C(1)–H(1B2) 111.3 
O(1B)–C(1)–H(1B2) 111.3 
H(1B1)–C(1)–H(1B2) 109.1 
O(2)–C(2)–C(1) 108.83(12) 
O(2)–C(2)–H(2A) 109.9 
C(1)–C(2)–H(2A) 109.9 
O(2)–C(2)–H(2B) 109.9 
C(1)–C(2)–H(2B) 109.9 
H(2A)–C(2)–H(2B) 108.3 
C(3)–O(2)–C(2) 116.89(11) 
O(2)–C(3)–C(4) 124.76(13) 
O(2)–C(3)–C(8) 116.02(12) 
C(4)–C(3)–C(8) 119.22(13) 
C(3)–C(4)–C(5) 120.35(14) 
C(3)–C(4)–H(4) 119.8 
C(5)–C(4)–H(4) 119.8 
C(6)–C(5)–C(4) 120.45(14) 
C(6)–C(5)–H(5) 119.8 
C(4)–C(5)–H(5) 119.8 
C(5)–C(6)–C(7) 119.83(14) 
C(5)–C(6)–H(6) 120.1 
C(7)–C(6)–H(6) 120.1 
C(8)–C(7)–C(6) 120.17(14) 
C(8)–C(7)–H(7) 119.9 
C(6)–C(7)–H(7) 119.9 
O(3)–C(8)–C(7) 124.61(13) 
O(3)–C(8)–C(3) 115.39(12) 
C(7)–C(8)–C(3) 119.98(13) 
C(8)–O(3)–C(9) 115.07(11) 
O(3)–C(9)–C(10) 109.02(11) 
O(3)–C(9)–H(9A) 109.9 
C(10)–C(9)–H(9A) 109.9 
O(3)–C(9)–H(9B) 109.9 
C(10)–C(9)–H(9B) 109.9 
H(9A)–C(9)–H(9B) 108.3 
C(11)–C(10)–C(10)#1 119.11(8) 
C(11)–C(10)–C(9) 119.78(13) 
C(10)#1–C(10)–C(9) 121.07(8) 
C(12)–C(11)–C(10) 121.23(14) 
C(12)–C(11)–H(11) 119.4 
C(10)–C(11)–H(11) 119.4 
C(11)–C(12)–C(12)#1 119.67(9) 
C(11)–C(12)–H(12) 120.2 
C(12)#1–C(12)–H(12) 120.2 
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1,6-Bis[2-(2-hydroxyethoxy)phenoxy]lutidine 166 
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Fig. A 6 X-ray crystal structure of  1,6-Bis[2-(2-hydroxyethoxy)phenoxy]lutidine 166 
 
Table A 11  Crystal data and structure refinement for 166 
Identification code  gat14 
Empirical formula  C23 H25 N O6 
Formula weight  411.44 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21/c (#14) 
Unit cell dimensions a = 25.257(2) Å  α= 90°. 
 b = 4.8053(5) Å  β= 108.907(2)°. 
 c = 17.7782(17) Å γ = 90°. 
Volume 2041.3(3) Å3 
Z 4 
Density (calculated) 1.339 Mg/m3 
Absorption coefficient 0.097 mm–1 
F(000) 872 
Crystal size 0.80 x 0.10 x 0.03 mm3 
Theta range for data collection 0.85 to 24.00°. 
Index ranges –28<=h<=28, –5<=k<=5, –20<=l<=20 
Reflections collected 13847 
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Independent reflections 3210 [R(int) = 0.0237] 
Completeness to theta = 24.00° 100.0 %  
Absorption correction Semi–empirical from equivalents 
Max. and min. transmission 0.9971 and 0.7643 
Refinement method Full–matrix least–squares on F2 
Data / restraints / parameters 3210 / 0 / 311 
Goodness–of–fit on F2 1.035 
Final R indices [I>2sigma(I)] R1 = 0.0432, wR2 = 0.1076 
R indices (all data) R1 = 0.0500, wR2 = 0.1132 
Largest diff. peak and hole 0.455 and –0.211 e.Å–3 
 
Table A 12 Bond lengths [Å] and angles [°] for 166 
O(1)–C(1)  1.418(2) 
O(1)–H(1O1)  0.8400 
C(1)–C(2)  1.501(3) 
C(1)–H(1A)  0.9900 
C(1)–H(1B)  0.9900 
C(2)–O(2)  1.432(2) 
C(2)–H(2A)  0.9900 
C(2)–H(2B)  0.9900 
O(2)–C(3)  1.368(2) 
C(3)–C(4)  1.381(2) 
C(3)–C(8)  1.406(2) 
C(4)–C(5)  1.390(3) 
C(4)–H(4)  0.9500 
C(5)–C(6)  1.375(3) 
C(5)–H(5)  0.9500 
C(6)–C(7)  1.390(3) 
C(6)–H(6)  0.9500 
C(7)–C(8)  1.382(2) 
C(7)–H(7)  0.9500 
C(8)–O(3)  1.372(2) 
O(3)–C(9)  1.416(2) 
C(9)–C(10)  1.500(2) 
C(9)–H(9A)  0.9900 
C(9)–H(9B)  0.9900 
C(10)–N  1.343(2) 
C(10)–C(11)  1.387(2) 
N–C(14)  1.341(2) 
C(11)–C(12)  1.379(3) 
C(11)–H(11)  0.9500 
C(12)–C(13)  1.383(3) 
C(12)–H(12)  0.9500 
C(13)–C(14)  1.385(2) 
C(13)–H(13)  0.9500 
C(14)–C(15)  1.498(2) 
C(15)–O(4)  1.418(2) 
C(15)–H(15A)  0.9900 
C(15)–H(15B)  0.9900 
O(4)–C(16)  1.373(2) 
C(16)–C(17)  1.373(3) 
C(16)–C(21)  1.392(3) 
C(17)–C(18)  1.388(3) 
C(17)–H(17)  0.9500 
C(18)–C(19)  1.364(4) 
C(18)–H(18)  0.9500 
C(19)–C(20)  1.378(4) 
C(19)–H(19)  0.9500 
C(20)–C(21)  1.377(3) 
C(20)–H(20)  0.9500 
C(21)–O(5B)  1.379(4) 
C(21)–O(5A)  1.462(5) 
O(5A)–C(22A)  1.471(12) 
C(22A)–C(23A)  1.580(10) 
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C(22A)–H(22A)  0.9900 
C(22A)–H(22B)  0.9900 
C(23A)–O(6A)  1.406(5) 
C(23A)–H(23A)  0.9900 
C(23A)–H(23B)  0.9900 
O(6A)–H(6A)  0.8400 
O(5B)–C(22B)  1.371(8) 
C(22B)–C(23B)  1.390(15) 
C(22B)–H(22C)  0.9900 
C(22B)–H(22D)  0.9900 
C(23B)–O(6B)  1.490(10) 
C(23B)–H(23C)  0.9900 
C(23B)–H(23D)  0.9900 
O(6B)–H(6B)  0.8400 
  
C(1)–O(1)–H(1O1) 109.5 
O(1)–C(1)–C(2) 109.79(15) 
O(1)–C(1)–H(1A) 109.7 
C(2)–C(1)–H(1A) 109.7 
O(1)–C(1)–H(1B) 109.7 
C(2)–C(1)–H(1B) 109.7 
H(1A)–C(1)–H(1B) 108.2 
O(2)–C(2)–C(1) 107.58(15) 
O(2)–C(2)–H(2A) 110.2 
C(1)–C(2)–H(2A) 110.2 
O(2)–C(2)–H(2B) 110.2 
C(1)–C(2)–H(2B) 110.2 
H(2A)–C(2)–H(2B) 108.5 
C(3)–O(2)–C(2) 117.18(13) 
O(2)–C(3)–C(4) 125.32(15) 
O(2)–C(3)–C(8) 115.30(14) 
C(4)–C(3)–C(8) 119.38(15) 
C(3)–C(4)–C(5) 120.29(17) 
C(3)–C(4)–H(4) 119.9 
C(5)–C(4)–H(4) 119.9 
C(6)–C(5)–C(4) 120.25(17) 
C(6)–C(5)–H(5) 119.9 
C(4)–C(5)–H(5) 119.9 
C(5)–C(6)–C(7) 120.14(16) 
C(5)–C(6)–H(6) 119.9 
C(7)–C(6)–H(6) 119.9 
C(8)–C(7)–C(6) 120.01(16) 
C(8)–C(7)–H(7) 120.0 
C(6)–C(7)–H(7) 120.0 
O(3)–C(8)–C(7) 125.08(15) 
O(3)–C(8)–C(3) 115.00(14) 
C(7)–C(8)–C(3) 119.92(15) 
C(8)–O(3)–C(9) 116.17(12) 
O(3)–C(9)–C(10) 108.69(13) 
O(3)–C(9)–H(9A) 110.0 
C(10)–C(9)–H(9A) 110.0 
O(3)–C(9)–H(9B) 110.0 
C(10)–C(9)–H(9B) 110.0 
H(9A)–C(9)–H(9B) 108.3 
N–C(10)–C(11) 122.27(16) 
N–C(10)–C(9) 114.22(14) 
C(11)–C(10)–C(9) 123.51(15) 
C(14)–N–C(10) 118.56(14) 
C(12)–C(11)–C(10) 118.50(16) 
C(12)–C(11)–H(11) 120.7 
C(10)–C(11)–H(11) 120.7 
C(11)–C(12)–C(13) 119.83(16) 
C(11)–C(12)–H(12) 120.1 
C(13)–C(12)–H(12) 120.1 
C(12)–C(13)–C(14) 118.23(16) 
C(12)–C(13)–H(13) 120.9 
C(14)–C(13)–H(13) 120.9 
N–C(14)–C(13) 122.59(16) 
N–C(14)–C(15) 113.14(14) 
C(13)–C(14)–C(15) 124.26(15) 
O(4)–C(15)–C(14) 110.42(13) 
O(4)–C(15)–H(15A) 109.6 
C(14)–C(15)–H(15A) 109.6 
O(4)–C(15)–H(15B) 109.6 
C(14)–C(15)–H(15B) 109.6 
H(15A)–C(15)–H(15B) 108.1 
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C(16)–O(4)–C(15) 115.19(13) 
O(4)–C(16)–C(17) 124.84(17) 
O(4)–C(16)–C(21) 115.91(16) 
C(17)–C(16)–C(21) 119.25(18) 
C(16)–C(17)–C(18) 120.2(2) 
C(16)–C(17)–H(17) 119.9 
C(18)–C(17)–H(17) 119.9 
C(19)–C(18)–C(17) 120.7(2) 
C(19)–C(18)–H(18) 119.7 
C(17)–C(18)–H(18) 119.7 
C(18)–C(19)–C(20) 119.3(2) 
C(18)–C(19)–H(19) 120.3 
C(20)–C(19)–H(19) 120.3 
C(21)–C(20)–C(19) 120.8(2) 
C(21)–C(20)–H(20) 119.6 
C(19)–C(20)–H(20) 119.6 
C(20)–C(21)–O(5B) 117.1(2) 
C(20)–C(21)–C(16) 119.8(2) 
O(5B)–C(21)–C(16) 117.0(2) 
C(20)–C(21)–O(5A) 124.6(3) 
O(5B)–C(21)–O(5A) 38.63(19) 
C(16)–C(21)–O(5A) 113.8(2) 
C(21)–O(5A)–C(22A) 118.1(4) 
O(5A)–C(22A)–C(23A) 102.3(6) 
O(5A)–C(22A)–H(22A) 111.3 
C(23A)–C(22A)–H(22A) 111.3 
O(5A)–C(22A)–H(22B) 111.3 
C(23A)–C(22A)–H(22B) 111.3 
H(22A)–C(22A)–H(22B) 109.2 
O(6A)–C(23A)–C(22A) 115.6(5) 
O(6A)–C(23A)–H(23A) 108.4 
C(22A)–C(23A)–H(23A) 108.4 
O(6A)–C(23A)–H(23B) 108.4 
C(22A)–C(23A)–H(23B) 108.4 
H(23A)–C(23A)–H(23B) 107.4 
C(22B)–O(5B)–C(21) 105.2(4) 
O(5B)–C(22B)–C(23B) 111.1(6) 
O(5B)–C(22B)–H(22C) 109.4 
C(23B)–C(22B)–H(22C) 109.4 
O(5B)–C(22B)–H(22D) 109.4 
C(23B)–C(22B)–H(22D) 109.4 
H(22C)–C(22B)–H(22D) 108.0 
C(22B)–C(23B)–O(6B) 112.7(6) 
C(22B)–C(23B)–H(23C) 109.0 
O(6B)–C(23B)–H(23C) 109.0 
C(22B)–C(23B)–H(23D) 109.0 
O(6B)–C(23B)–H(23D) 109.0 
H(23C)–C(23B)–H(23D) 107.8 
C(23B)–O(6B)–H(6B) 109.5 
 
Appendix 
 
269 
 
2,3,6,9,12,13,19,21-tetrabenzo-1,4,11,14,17,23-hexaoxacyclopentaeicosa-
2,6,7,8,12,19,20-hexaene 179 
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Fig. A 7  X-ray crystal structure of 2,3,6,9,12,13,19,21-tetrabenzo-1,4,11,14,17,23-
hexaoxacyclopentaeicosa-2,6,7,8,12,19,20-hexaene 179 
 
  Table A 13 Crystal data and structure refinement for 179 
Identification code  gat15 
Empirical formula  C32 H32 O6 
Formula weight  512.58 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21/n (#14) 
Unit cell dimensions a = 4.606(3) Å  α= 90°. 
 b = 17.852(10) Å β= 93.071(11)°. 
 c = 30.159(16) Å γ = 90°. 
Volume 2476(2) Å3 
Z 4 
Density (calculated) 1.375 Mg/m3 
Absorption coefficient 0.094 mm–1 
F(000) 1088 
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Crystal size 0.50 x 0.05 x 0.05 mm3 
Theta range for data collection 1.33 to 19.00°. 
Index ranges –4<=h<=4, –16<=k<=16, –27<=l<=27 
Reflections collected 6108 
Independent reflections 1979 [R(int) = 0.0606] 
Completeness to theta = 19.00° 99.1 %  
Absorption correction Semi–empirical from equivalents 
Max. and min. transmission 0.9953 and 0.7304 
Refinement method Full–matrix least–squares on F2 
Data / restraints / parameters 1979 / 348 / 343 a) 
Goodness–of–fit on F2 1.127 
Final R indices [I>2sigma(I)] R1 = 0.0811, wR2 = 0.1776 
R indices (all data) R1 = 0.1044, wR2 = 0.1868 
Largest diff. peak and hole 0.322 and –0.248 e.Å–3 
DELU and SIMU restraints were applied to all thermal displacement parameters. 
 
Table A 14 Bond lengths [Å] and angles [°] for 179 
O(1)–C(1)  1.335(8) 
O(1)–C(32)  1.414(8) 
C(1)–C(6)  1.372(10) 
C(1)–C(2)  1.373(10) 
C(2)–C(3)  1.354(11) 
C(2)–H(2)  0.9500 
C(3)–C(4)  1.340(12) 
C(3)–H(3)  0.9500 
C(4)–C(5)  1.387(11) 
C(4)–H(4)  0.9500 
C(5)–C(6)  1.362(10) 
C(5)–H(5)  0.9500 
C(6)–O(2)  1.360(8) 
O(2)–C(7)  1.421(9) 
C(7)–C(8)  1.468(10) 
C(7)–H(7A)  0.9900 
C(7)–H(7B)  0.9900 
C(8)–C(9)  1.335(10) 
C(8)–C(13)  1.364(11) 
C(9)–C(10)  1.367(11) 
C(9)–H(9)  0.9500 
C(10)–C(11)  1.347(10) 
C(10)–H(10)  0.9500 
C(11)–C(12)  1.370(10) 
C(11)–C(14)  1.480(10) 
C(12)–C(13)  1.369(11) 
C(12)–H(12)  0.9500 
C(13)–H(13)  0.9500 
C(14)–O(3)  1.404(8) 
C(14)–H(14A)  0.9900 
C(14)–H(14B)  0.9900 
O(3)–C(15)  1.359(9) 
C(15)–C(16)  1.351(10) 
C(15)–C(20)  1.386(10) 
C(16)–C(17)  1.362(11) 
C(16)–H(16)  0.9500 
C(17)–C(18)  1.352(11) 
C(17)–H(17)  0.9500 
C(18)–C(19)  1.364(10) 
C(18)–H(18)  0.9500 
C(19)–C(20)  1.378(9) 
C(19)–H(19)  0.9500 
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C(20)–O(4)  1.342(8) 
O(4)–C(21)  1.421(8) 
C(21)–C(22)  1.479(9) 
C(21)–H(21A)  0.9900 
C(21)–H(21B)  0.9900 
C(22)–O(5)  1.402(8) 
C(22)–H(22A)  0.9900 
C(22)–H(22B)  0.9900 
O(5)–C(23)  1.365(8) 
C(23)–C(24)  1.493(10) 
C(23)–H(23A)  0.9900 
C(23)–H(23B)  0.9900 
C(24)–C(25)  1.356(10) 
C(24)–C(29)  1.368(10) 
C(25)–C(26)  1.382(10) 
C(25)–H(25)  0.9500 
C(26)–C(27)  1.362(9) 
C(26)–H(26)  0.9500 
C(27)–C(28)  1.372(9) 
C(27)–H(27)  0.9500 
C(28)–C(29)  1.381(9) 
C(28)–C(30)  1.475(9) 
C(29)–H(29)  0.9500 
C(30)–O(6)  1.407(7) 
C(30)–H(30A)  0.9900 
C(30)–H(30B)  0.9900 
O(6)–C(31)  1.415(8) 
C(31)–C(32)  1.467(10) 
C(31)–H(31A)  0.9900 
C(31)–H(31B)  0.9900 
C(32)–H(32A)  0.9900 
C(32)–H(32B)  0.9900 
  
C(1)–O(1)–C(32) 117.7(6) 
O(1)–C(1)–C(6) 115.7(7) 
O(1)–C(1)–C(2) 125.7(8) 
C(6)–C(1)–C(2) 118.6(8) 
C(3)–C(2)–C(1) 120.4(9) 
C(3)–C(2)–H(2) 119.8 
C(1)–C(2)–H(2) 119.8 
C(4)–C(3)–C(2) 122.1(9) 
C(4)–C(3)–H(3) 119.0 
C(2)–C(3)–H(3) 119.0 
C(3)–C(4)–C(5) 118.0(9) 
C(3)–C(4)–H(4) 121.0 
C(5)–C(4)–H(4) 121.0 
C(6)–C(5)–C(4) 120.9(9) 
C(6)–C(5)–H(5) 119.6 
C(4)–C(5)–H(5) 119.6 
O(2)–C(6)–C(5) 125.4(8) 
O(2)–C(6)–C(1) 114.5(7) 
C(5)–C(6)–C(1) 120.1(8) 
C(6)–O(2)–C(7) 117.4(6) 
O(2)–C(7)–C(8) 106.7(6) 
O(2)–C(7)–H(7A) 110.4 
C(8)–C(7)–H(7A) 110.4 
O(2)–C(7)–H(7B) 110.4 
C(8)–C(7)–H(7B) 110.4 
H(7A)–C(7)–H(7B) 108.6 
C(9)–C(8)–C(13) 117.4(8) 
C(9)–C(8)–C(7) 121.1(8) 
C(13)–C(8)–C(7) 121.5(8) 
C(8)–C(9)–C(10) 120.6(8) 
C(8)–C(9)–H(9) 119.7 
C(10)–C(9)–H(9) 119.7 
C(11)–C(10)–C(9) 123.3(8) 
C(11)–C(10)–H(10) 118.4 
C(9)–C(10)–H(10) 118.4 
C(10)–C(11)–C(12) 116.3(7) 
C(10)–C(11)–C(14) 121.4(7) 
C(12)–C(11)–C(14) 122.3(7) 
C(13)–C(12)–C(11) 120.3(8) 
C(13)–C(12)–H(12) 119.9 
C(11)–C(12)–H(12) 119.9 
C(8)–C(13)–C(12) 122.1(8) 
C(8)–C(13)–H(13) 119.0 
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C(12)–C(13)–H(13) 119.0 
O(3)–C(14)–C(11) 108.1(6) 
O(3)–C(14)–H(14A) 110.1 
C(11)–C(14)–H(14A) 110.1 
O(3)–C(14)–H(14B) 110.1 
C(11)–C(14)–H(14B) 110.1 
H(14A)–C(14)–H(14B) 108.4 
C(15)–O(3)–C(14) 117.9(6) 
C(16)–C(15)–O(3) 126.0(7) 
C(16)–C(15)–C(20) 120.9(8) 
O(3)–C(15)–C(20) 113.1(6) 
C(15)–C(16)–C(17) 119.1(8) 
C(15)–C(16)–H(16) 120.4 
C(17)–C(16)–H(16) 120.4 
C(18)–C(17)–C(16) 121.3(8) 
C(18)–C(17)–H(17) 119.4 
C(16)–C(17)–H(17) 119.4 
C(17)–C(18)–C(19) 120.1(8) 
C(17)–C(18)–H(18) 119.9 
C(19)–C(18)–H(18) 119.9 
C(18)–C(19)–C(20) 119.7(8) 
C(18)–C(19)–H(19) 120.2 
C(20)–C(19)–H(19) 120.2 
O(4)–C(20)–C(19) 125.9(7) 
O(4)–C(20)–C(15) 115.3(6) 
C(19)–C(20)–C(15) 118.8(7) 
C(20)–O(4)–C(21) 118.3(5) 
O(4)–C(21)–C(22) 108.0(5) 
O(4)–C(21)–H(21A) 110.1 
C(22)–C(21)–H(21A) 110.1 
O(4)–C(21)–H(21B) 110.1 
C(22)–C(21)–H(21B) 110.1 
H(21A)–C(21)–H(21B) 108.4 
O(5)–C(22)–C(21) 113.1(6) 
O(5)–C(22)–H(22A) 109.0 
C(21)–C(22)–H(22A) 109.0 
O(5)–C(22)–H(22B) 109.0 
C(21)–C(22)–H(22B) 109.0 
H(22A)–C(22)–H(22B) 107.8 
C(23)–O(5)–C(22) 113.8(6) 
O(5)–C(23)–C(24) 110.4(7) 
O(5)–C(23)–H(23A) 109.6 
C(24)–C(23)–H(23A) 109.6 
O(5)–C(23)–H(23B) 109.6 
C(24)–C(23)–H(23B) 109.6 
H(23A)–C(23)–H(23B) 108.1 
C(25)–C(24)–C(29) 118.7(7) 
C(25)–C(24)–C(23) 124.0(7) 
C(29)–C(24)–C(23) 117.2(8) 
C(24)–C(25)–C(26) 120.5(7) 
C(24)–C(25)–H(25) 119.7 
C(26)–C(25)–H(25) 119.7 
C(27)–C(26)–C(25) 120.8(7) 
C(27)–C(26)–H(26) 119.6 
C(25)–C(26)–H(26) 119.6 
C(26)–C(27)–C(28) 118.9(7) 
C(26)–C(27)–H(27) 120.5 
C(28)–C(27)–H(27) 120.5 
C(27)–C(28)–C(29) 119.8(7) 
C(27)–C(28)–C(30) 122.1(6) 
C(29)–C(28)–C(30) 118.1(7) 
C(24)–C(29)–C(28) 121.2(7) 
C(24)–C(29)–H(29) 119.4 
C(28)–C(29)–H(29) 119.4 
O(6)–C(30)–C(28) 110.9(6) 
O(6)–C(30)–H(30A) 109.5 
C(28)–C(30)–H(30A) 109.5 
O(6)–C(30)–H(30B) 109.5 
C(28)–C(30)–H(30B) 109.5 
H(30A)–C(30)–H(30B) 108.1 
C(30)–O(6)–C(31) 113.9(5) 
O(6)–C(31)–C(32) 112.9(6) 
O(6)–C(31)–H(31A) 109.0 
C(32)–C(31)–H(31A) 109.0 
O(6)–C(31)–H(31B) 109.0 
C(32)–C(31)–H(31B) 109.0 
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H(31A)–C(31)–H(31B) 107.8 
O(1)–C(32)–C(31) 107.7(6) 
O(1)–C(32)–H(32A) 110.2 
C(31)–C(32)–H(32A) 110.2 
O(1)–C(32)–H(32B) 110.2 
C(31)–C(32)–H(32B) 110.2 
H(32A)–C(32)–H(32B) 108.5 
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2,3,6,8,11,12,18,20-tetrabenzo-7,19-diaza-1,4,10,13,16,22-hexaoxacyclo-
tetraeicosa-2,6,7,11,18,19-hexaene 184 
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Fig. A 8 X-ray crystal structure of  2,3,6,8,11,12,18,20-tetrabenzo-7,19-diaza-1,4,10,13,16,22-
hexaoxacyclo-tetraeicosa-2,6,7,11,18,19-hexaene 184 
 
Table A 15 Crystal data and structure refinement for 184 
Identification code  gat21 
Empirical formula  C30 H30 N2 O6 
Formula weight  514.56 
Temperature  293(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21 (#4) 
Unit cell dimensions a = 15.080(2) Å  α= 90°. 
 b = 5.4720(8) Å  β= 113.695(3)°. 
 c = 17.191(2) Å  γ = 90°. 
Volume 1299.0(3) Å3 
Z 2 
Density (calculated) 1.316 Mg/m3 
Absorption coefficient 0.092 mm–1 
F(000) 544 
Crystal size 0.50 x 0.30 x 0.20 mm3 
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Theta range for data collection 1.29 to 24.11°. 
Index ranges –17<=h<=17, –6<=k<=6, –19<=l<=19 
Reflections collected 9612 
Independent reflections 2314 [R(int) = 0.0233] 
Completeness to theta = 24.11° 99.9 %  
Absorption correction Semi–empirical from equivalents 
Max. and min. transmission 0.9818 and 0.8775 
Refinement method Full–matrix least–squares on F2 
Data / restraints / parameters 2314 / 97 / 343 a) 
Goodness–of–fit on F2 1.037 
Final R indices [I>2sigma(I)] R1 = 0.0385, wR2 = 0.0973 
R indices (all data) R1 = 0.0423, wR2 = 0.1006 
Largest diff. peak and hole 0.336 and –0.209 e.Å–3 
DELU (rigid bond) restraints were applied to all themal displacement parameters. 
 
Table A 16 Bond lengths [Å] and angles [°] for 184 
N(1)–C(1)  1.329(3) 
N(1)–C(5)  1.347(4) 
C(1)–C(2)  1.379(4) 
C(1)–C(30)  1.499(4) 
C(2)–C(3)  1.362(5) 
C(2)–H(2)  0.9300 
C(3)–C(4)  1.370(5) 
C(3)–H(3)  0.9300 
C(4)–C(5)  1.356(5) 
C(4)–H(4)  0.9300 
C(5)–C(6)  1.473(4) 
C(6)–O(1)  1.405(4) 
C(6)–H(6A)  0.9700 
C(6)–H(6B)  0.9700 
O(1)–C(7)  1.376(3) 
C(7)–C(8)  1.379(4) 
C(7)–C(12)  1.393(4) 
C(8)–C(9)  1.388(5) 
C(8)–H(8)  0.9300 
C(9)–C(10)  1.361(6) 
C(9)–H(9)  0.9300 
C(10)–C(11)  1.382(4) 
C(10)–H(10)  0.9300 
C(11)–C(12)  1.378(4) 
C(11)–H(11)  0.9300 
C(12)–O(2)  1.367(3) 
O(2)–C(13)  1.425(4) 
C(13)–C(14)  1.482(4) 
C(13)–H(13A)  0.9700 
C(13)–H(13B)  0.9700 
C(14)–O(3)  1.410(4) 
C(14)–H(14A)  0.9700 
C(14)–H(14B)  0.9700 
O(3)–C(15)  1.422(3) 
C(15)–C(16)  1.507(4) 
C(15)–H(15A)  0.9700 
C(15)–H(15B)  0.9700 
C(16)–N(2)  1.336(4) 
C(16)–C(17)  1.381(5) 
N(2)–C(20)  1.337(4) 
C(17)–C(18)  1.362(5) 
C(17)–H(17)  0.9300 
C(18)–C(19)  1.372(5) 
C(18)–H(18)  0.9300 
Appendix 
 
276 
C(19)–C(20)  1.379(4) 
C(19)–H(19)  0.9300 
C(20)–C(21)  1.508(4) 
C(21)–O(4)  1.419(4) 
C(21)–H(21A)  0.9700 
C(21)–H(21B)  0.9700 
O(4)–C(22)  1.406(4) 
C(22)–C(23)  1.485(4) 
C(22)–H(22A)  0.9700 
C(22)–H(22B)  0.9700 
C(23)–O(5)  1.426(4) 
C(23)–H(23A)  0.9700 
C(23)–H(23B)  0.9700 
O(5)–C(24)  1.357(4) 
C(24)–C(25)  1.384(4) 
C(24)–C(29)  1.388(4) 
C(25)–C(26)  1.374(6) 
C(25)–H(25)  0.9300 
C(26)–C(27)  1.348(7) 
C(26)–H(26)  0.9300 
C(27)–C(28)  1.387(6) 
C(27)–H(27)  0.9300 
C(28)–C(29)  1.370(5) 
C(28)–H(28)  0.9300 
C(29)–O(6)  1.360(3) 
O(6)–C(30)  1.417(4) 
C(30)–H(30A)  0.9700 
C(30)–H(30B)  0.9700 
  
C(1)–N(1)–C(5) 117.4(3) 
N(1)–C(1)–C(2) 122.4(3) 
N(1)–C(1)–C(30) 116.7(3) 
C(2)–C(1)–C(30) 120.8(3) 
C(3)–C(2)–C(1) 119.0(3) 
C(3)–C(2)–H(2) 120.5 
C(1)–C(2)–H(2) 120.5 
C(2)–C(3)–C(4) 119.2(3) 
C(2)–C(3)–H(3) 120.4 
C(4)–C(3)–H(3) 120.4 
C(5)–C(4)–C(3) 118.9(3) 
C(5)–C(4)–H(4) 120.6 
C(3)–C(4)–H(4) 120.6 
N(1)–C(5)–C(4) 123.0(3) 
N(1)–C(5)–C(6) 118.4(4) 
C(4)–C(5)–C(6) 118.5(4) 
O(1)–C(6)–C(5) 110.5(3) 
O(1)–C(6)–H(6A) 109.5 
C(5)–C(6)–H(6A) 109.5 
O(1)–C(6)–H(6B) 109.5 
C(5)–C(6)–H(6B) 109.5 
H(6A)–C(6)–H(6B) 108.1 
C(7)–O(1)–C(6) 118.0(2) 
O(1)–C(7)–C(8) 124.3(3) 
O(1)–C(7)–C(12) 116.4(2) 
C(8)–C(7)–C(12) 119.3(3) 
C(7)–C(8)–C(9) 120.2(4) 
C(7)–C(8)–H(8) 119.9 
C(9)–C(8)–H(8) 119.9 
C(10)–C(9)–C(8) 120.3(3) 
C(10)–C(9)–H(9) 119.8 
C(8)–C(9)–H(9) 119.8 
C(9)–C(10)–C(11) 120.1(3) 
C(9)–C(10)–H(10) 120.0 
C(11)–C(10)–H(10) 120.0 
C(12)–C(11)–C(10) 120.2(3) 
C(12)–C(11)–H(11) 119.9 
C(10)–C(11)–H(11) 119.9 
O(2)–C(12)–C(11) 124.7(3) 
O(2)–C(12)–C(7) 115.4(2) 
C(11)–C(12)–C(7) 119.9(3) 
C(12)–O(2)–C(13) 117.8(2) 
O(2)–C(13)–C(14) 108.1(2) 
O(2)–C(13)–H(13A) 110.1 
C(14)–C(13)–H(13A) 110.1 
O(2)–C(13)–H(13B) 110.1 
C(14)–C(13)–H(13B) 110.1 
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H(13A)–C(13)–H(13B) 108.4 
O(3)–C(14)–C(13) 110.2(3) 
O(3)–C(14)–H(14A) 109.6 
C(13)–C(14)–H(14A) 109.6 
O(3)–C(14)–H(14B) 109.6 
C(13)–C(14)–H(14B) 109.6 
H(14A)–C(14)–H(14B) 108.1 
C(14)–O(3)–C(15) 111.5(3) 
O(3)–C(15)–C(16) 112.8(3) 
O(3)–C(15)–H(15A) 109.0 
C(16)–C(15)–H(15A) 109.0 
O(3)–C(15)–H(15B) 109.0 
C(16)–C(15)–H(15B) 109.0 
H(15A)–C(15)–H(15B) 107.8 
N(2)–C(16)–C(17) 122.8(3) 
N(2)–C(16)–C(15) 115.0(3) 
C(17)–C(16)–C(15) 122.2(3) 
C(16)–N(2)–C(20) 117.8(3) 
C(18)–C(17)–C(16) 118.6(3) 
C(18)–C(17)–H(17) 120.7 
C(16)–C(17)–H(17) 120.7 
C(17)–C(18)–C(19) 119.7(3) 
C(17)–C(18)–H(18) 120.2 
C(19)–C(18)–H(18) 120.2 
C(18)–C(19)–C(20) 118.6(3) 
C(18)–C(19)–H(19) 120.7 
C(20)–C(19)–H(19) 120.7 
N(2)–C(20)–C(19) 122.5(3) 
N(2)–C(20)–C(21) 114.5(3) 
C(19)–C(20)–C(21) 122.9(3) 
O(4)–C(21)–C(20) 112.8(3) 
O(4)–C(21)–H(21A) 109.0 
C(20)–C(21)–H(21A) 109.0 
O(4)–C(21)–H(21B) 109.0 
C(20)–C(21)–H(21B) 109.0 
H(21A)–C(21)–H(21B) 107.8 
C(22)–O(4)–C(21) 113.4(3) 
O(4)–C(22)–C(23) 109.3(3) 
O(4)–C(22)–H(22A) 109.8 
C(23)–C(22)–H(22A) 109.8 
O(4)–C(22)–H(22B) 109.8 
C(23)–C(22)–H(22B) 109.8 
H(22A)–C(22)–H(22B) 108.3 
O(5)–C(23)–C(22) 107.2(3) 
O(5)–C(23)–H(23A) 110.3 
C(22)–C(23)–H(23A) 110.3 
O(5)–C(23)–H(23B) 110.3 
C(22)–C(23)–H(23B) 110.3 
H(23A)–C(23)–H(23B) 108.5 
C(24)–O(5)–C(23) 118.9(2) 
O(5)–C(24)–C(25) 125.3(3) 
O(5)–C(24)–C(29) 115.3(2) 
C(25)–C(24)–C(29) 119.3(3) 
C(26)–C(25)–C(24) 120.1(4) 
C(26)–C(25)–H(25) 120.0 
C(24)–C(25)–H(25) 120.0 
C(27)–C(26)–C(25) 120.9(3) 
C(27)–C(26)–H(26) 119.6 
C(25)–C(26)–H(26) 119.6 
C(26)–C(27)–C(28) 119.6(4) 
C(26)–C(27)–H(27) 120.2 
C(28)–C(27)–H(27) 120.2 
C(29)–C(28)–C(27) 120.8(4) 
C(29)–C(28)–H(28) 119.6 
C(27)–C(28)–H(28) 119.6 
O(6)–C(29)–C(28) 124.4(3) 
O(6)–C(29)–C(24) 116.1(3) 
C(28)–C(29)–C(24) 119.3(3) 
C(29)–O(6)–C(30) 119.6(2) 
O(6)–C(30)–C(1) 108.2(2) 
O(6)–C(30)–H(30A) 110.1 
C(1)–C(30)–H(30A) 110.1 
O(6)–C(30)–H(30B) 110.1 
C(1)–C(30)–H(30B) 110.1 
H(30A)–C(30)–H(30B) 108.4 
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2,3,6,8,11,12,18,20-tetrabenzo-19-aza-1,4,10,13,16,22-hexaoxacyclotetraeicosa-
2,6,7,11,18,19-hexaene 176 
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Fig. A 9 X-ray crystal structure of  2,3,6,8,11,12,18,20-tetrabenzo-19-aza-1,4,10,13,16,22-
hexaoxacyclotetraeicosa-2,6,7,11,18,19-hexaene 176 
 
Table A 17 Crystal data and structure refinement for 176 
Identification code  gat23 
Empirical formula  C31 H31 N O6 
Formula weight  513.57 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21 (#4) 
Unit cell dimensions a = 14.6295(9) Å α= 90°. 
 b = 5.2396(3) Å  β= 107.767(1)°. 
 c = 17.8162(11) Å γ = 90°. 
Volume 1300.53(14) Å3 
Z 2 
Density (calculated) 1.311 Mg/m3 
Absorption coefficient 0.091 mm–1 
F(000) 544 
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Crystal size 0.5 x 0.2 x 0.2 mm3 
Theta range for data collection 1.46 to 30.52°. 
Index ranges –20<=h<=20, –7<=k<=7, –25<=l<=23 
Reflections collected 15434 
Independent reflections 4361 [R(int) = 0.0242] 
Completeness to theta = 30.52° 99.3 %  
Absorption correction Semi–empirical from equivalents 
Max. and min. transmission 0.9821 and 0.8246 
Refinement method Full–matrix least–squares on F2 
Data / restraints / parameters 4361 / 1 / 343 
Goodness–of–fit on F2 1.031 
Final R indices [I>2sigma(I)] R1 = 0.0420, wR2 = 0.1029 
R indices (all data) R1 = 0.0452, wR2 = 0.1052 
Largest diff. peak and hole 0.361 and –0.216 e.Å–3 
 
Table A 18  Bond lengths [Å] and angles [°] for 176 
N–C(5)  1.341(2) 
N–C(1)  1.3412(19) 
C(1)–C(2)  1.392(2) 
C(1)–C(31)  1.508(2) 
C(2)–C(3)  1.386(2) 
C(2)–H(2)  0.9500 
C(3)–C(4)  1.385(2) 
C(3)–H(3)  0.9500 
C(4)–C(5)  1.389(2) 
C(4)–H(4)  0.9500 
C(5)–C(6)  1.511(2) 
C(6)–O(1)  1.4206(18) 
C(6)–H(6A)  0.9900 
C(6)–H(6B)  0.9900 
O(1)–C(7)  1.423(2) 
C(7)–C(8)  1.503(2) 
C(7)–H(7A)  0.9900 
C(7)–H(7B)  0.9900 
C(8)–O(2)  1.4331(19) 
C(8)–H(8A)  0.9900 
C(8)–H(8B)  0.9900 
O(2)–C(9)  1.3647(18) 
C(9)–C(10)  1.388(2) 
C(9)–C(14)  1.412(2) 
C(10)–C(11)  1.403(2) 
C(10)–H(10)  0.9500 
C(11)–C(12)  1.375(3) 
C(11)–H(11)  0.9500 
C(12)–C(13)  1.401(2) 
C(12)–H(12)  0.9500 
C(13)–C(14)  1.389(2) 
C(13)–H(13)  0.9500 
C(14)–O(3)  1.3689(18) 
O(3)–C(15)  1.4390(19) 
C(15)–C(16)  1.501(2) 
C(15)–H(15A)  0.9900 
C(15)–H(15B)  0.9900 
C(16)–C(21)  1.388(3) 
C(16)–C(17)  1.396(2) 
C(17)–C(18)  1.393(2) 
C(17)–H(17)  0.9500 
C(18)–C(19)  1.392(3) 
C(18)–C(22)  1.499(2) 
C(19)–C(20)  1.378(3) 
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C(19)–H(19)  0.9500 
C(20)–C(21)  1.390(2) 
C(20)–H(20)  0.9500 
C(21)–H(21)  0.9500 
C(22)–O(4)  1.4310(19) 
C(22)–H(22A)  0.9900 
C(22)–H(22B)  0.9900 
O(4)–C(23)  1.3719(18) 
C(23)–C(24)  1.390(2) 
C(23)–C(28)  1.406(2) 
C(24)–C(25)  1.396(2) 
C(24)–H(24)  0.9500 
C(25)–C(26)  1.371(3) 
C(25)–H(25)  0.9500 
C(26)–C(27)  1.401(2) 
C(26)–H(26)  0.9500 
C(27)–C(28)  1.387(2) 
C(27)–H(27)  0.9500 
C(28)–O(5)  1.3678(17) 
O(5)–C(29)  1.4315(19) 
C(29)–C(30)  1.503(2) 
C(29)–H(29A)  0.9900 
C(29)–H(29B)  0.9900 
C(30)–O(6)  1.421(2) 
C(30)–H(30A)  0.9900 
C(30)–H(30B)  0.9900 
O(6)–C(31)  1.4248(18) 
C(31)–H(31A)  0.9900 
C(31)–H(31B)  0.9900 
  
C(5)–N–C(1) 118.05(13) 
N–C(1)–C(2) 122.73(14) 
N–C(1)–C(31) 114.71(13) 
C(2)–C(1)–C(31) 122.55(14) 
C(3)–C(2)–C(1) 118.35(14) 
C(3)–C(2)–H(2) 120.8 
C(1)–C(2)–H(2) 120.8 
C(4)–C(3)–C(2) 119.60(15) 
C(4)–C(3)–H(3) 120.2 
C(2)–C(3)–H(3) 120.2 
C(3)–C(4)–C(5) 118.11(15) 
C(3)–C(4)–H(4) 120.9 
C(5)–C(4)–H(4) 120.9 
N–C(5)–C(4) 123.15(14) 
N–C(5)–C(6) 115.32(14) 
C(4)–C(5)–C(6) 121.52(14) 
O(1)–C(6)–C(5) 112.37(12) 
O(1)–C(6)–H(6A) 109.1 
C(5)–C(6)–H(6A) 109.1 
O(1)–C(6)–H(6B) 109.1 
C(5)–C(6)–H(6B) 109.1 
H(6A)–C(6)–H(6B) 107.9 
C(6)–O(1)–C(7) 111.77(13) 
O(1)–C(7)–C(8) 108.83(14) 
O(1)–C(7)–H(7A) 109.9 
C(8)–C(7)–H(7A) 109.9 
O(1)–C(7)–H(7B) 109.9 
C(8)–C(7)–H(7B) 109.9 
H(7A)–C(7)–H(7B) 108.3 
O(2)–C(8)–C(7) 107.40(13) 
O(2)–C(8)–H(8A) 110.2 
C(7)–C(8)–H(8A) 110.2 
O(2)–C(8)–H(8B) 110.2 
C(7)–C(8)–H(8B) 110.2 
H(8A)–C(8)–H(8B) 108.5 
C(9)–O(2)–C(8) 116.03(12) 
O(2)–C(9)–C(10) 124.56(15) 
O(2)–C(9)–C(14) 115.54(13) 
C(10)–C(9)–C(14) 119.91(14) 
C(9)–C(10)–C(11) 120.21(16) 
C(9)–C(10)–H(10) 119.9 
C(11)–C(10)–H(10) 119.9 
C(12)–C(11)–C(10) 119.89(15) 
C(12)–C(11)–H(11) 120.1 
C(10)–C(11)–H(11) 120.1 
C(11)–C(12)–C(13) 120.36(15) 
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C(11)–C(12)–H(12) 119.8 
C(13)–C(12)–H(12) 119.8 
C(14)–C(13)–C(12) 120.36(16) 
C(14)–C(13)–H(13) 119.8 
C(12)–C(13)–H(13) 119.8 
O(3)–C(14)–C(13) 124.90(15) 
O(3)–C(14)–C(9) 115.90(13) 
C(13)–C(14)–C(9) 119.19(14) 
C(14)–O(3)–C(15) 116.27(12) 
O(3)–C(15)–C(16) 108.33(12) 
O(3)–C(15)–H(15A) 110.0 
C(16)–C(15)–H(15A) 110.0 
O(3)–C(15)–H(15B) 110.0 
C(16)–C(15)–H(15B) 110.0 
H(15A)–C(15)–H(15B) 108.4 
C(21)–C(16)–C(17) 119.40(15) 
C(21)–C(16)–C(15) 119.92(15) 
C(17)–C(16)–C(15) 120.68(16) 
C(18)–C(17)–C(16) 120.79(16) 
C(18)–C(17)–H(17) 119.6 
C(16)–C(17)–H(17) 119.6 
C(19)–C(18)–C(17) 119.03(16) 
C(19)–C(18)–C(22) 119.25(16) 
C(17)–C(18)–C(22) 121.69(18) 
C(20)–C(19)–C(18) 120.26(16) 
C(20)–C(19)–H(19) 119.9 
C(18)–C(19)–H(19) 119.9 
C(19)–C(20)–C(21) 120.78(18) 
C(19)–C(20)–H(20) 119.6 
C(21)–C(20)–H(20) 119.6 
C(16)–C(21)–C(20) 119.73(16) 
C(16)–C(21)–H(21) 120.1 
C(20)–C(21)–H(21) 120.1 
O(4)–C(22)–C(18) 108.86(13) 
O(4)–C(22)–H(22A) 109.9 
C(18)–C(22)–H(22A) 109.9 
O(4)–C(22)–H(22B) 109.9 
C(18)–C(22)–H(22B) 109.9 
H(22A)–C(22)–H(22B) 108.3 
C(23)–O(4)–C(22) 115.90(12) 
O(4)–C(23)–C(24) 124.50(14) 
O(4)–C(23)–C(28) 116.34(13) 
C(24)–C(23)–C(28) 119.14(14) 
C(23)–C(24)–C(25) 120.54(16) 
C(23)–C(24)–H(24) 119.7 
C(25)–C(24)–H(24) 119.7 
C(26)–C(25)–C(24) 120.40(15) 
C(26)–C(25)–H(25) 119.8 
C(24)–C(25)–H(25) 119.8 
C(25)–C(26)–C(27) 119.70(15) 
C(25)–C(26)–H(26) 120.1 
C(27)–C(26)–H(26) 120.1 
C(28)–C(27)–C(26) 120.47(16) 
C(28)–C(27)–H(27) 119.8 
C(26)–C(27)–H(27) 119.8 
O(5)–C(28)–C(27) 124.64(14) 
O(5)–C(28)–C(23) 115.61(13) 
C(27)–C(28)–C(23) 119.74(14) 
C(28)–O(5)–C(29) 116.41(12) 
O(5)–C(29)–C(30) 107.29(13) 
O(5)–C(29)–H(29A) 110.3 
C(30)–C(29)–H(29A) 110.3 
O(5)–C(29)–H(29B) 110.3 
C(30)–C(29)–H(29B) 110.3 
H(29A)–C(29)–H(29B) 108.5 
O(6)–C(30)–C(29) 109.29(14) 
O(6)–C(30)–H(30A) 109.8 
C(29)–C(30)–H(30A) 109.8 
O(6)–C(30)–H(30B) 109.8 
C(29)–C(30)–H(30B) 109.8 
H(30A)–C(30)–H(30B) 108.3 
C(30)–O(6)–C(31) 110.96(13) 
O(6)–C(31)–C(1) 112.93(12) 
O(6)–C(31)–H(31A) 109.0 
C(1)–C(31)–H(31A) 109.0 
O(6)–C(31)–H(31B) 109.0 
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1,2-Bis(3-morphinyl)-o-xylene 200 
C37
C38 C3
C11
C36
N2
C2
C17
C7
C12
C16C35
C4
C39
C8
C34
O5
C33
N1
C13
C1
O1C18
C15
C40
C30
C14
C5
C31
O6
O3
C20
C32
C29
C6
C19
C9
O2
C42
C41 C26
C21
O4
C10
C28
C27
C24
C25
C22
C23
 
 
Fig. A 10 X-ray crystal structure of 1,2-Bis(3-morphinyl)-o-xylene 200 
 
Table A 19 Crystal data and structure refinement for 200 
Identification code  gat22 
Empirical formula  C42 H48 N2 O8 
Molecular formula C42 H44 N2 O6 x 2 (H2 O)  
Formula weight  708.82 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P212121 (#19) 
Unit cell dimensions a = 10.6944(15) Å α= 90°. 
 b = 16.220(2) Å  β= 90°. 
 c = 19.964(3) Å  γ = 90°. 
Volume 3463.0(9) Å3 
Z 4 
Appendix 
 
283 
Density (calculated) 1.360 Mg/m3 
Absorption coefficient 0.094 mm–1 
F(000) 1512 
Crystal size 0.50 x 0.40 x 0.03 mm3 
Theta range for data collection 1.62 to 19.91°. 
Index ranges –9<=h<=10, –13<=k<=15, –19<=l<=14 
Reflections collected 11758 
Independent reflections 1835 [R(int) = 0.0708] 
Completeness to theta = 19.91° 99.7 %  
Absorption correction Semi–empirical from equivalents 
Max. and min. transmission 0.9972 and 0.3887 
Refinement method Full–matrix least–squares on F2 
Data / restraints / parameters 1835 / 156 / 469 a) 
Goodness–of–fit on F2 1.045 
Final R indices [I>2sigma(I)] R1 = 0.0434, wR2 = 0.1113 
R indices (all data) R1 = 0.0541, wR2 = 0.1205 
Largest diff. peak and hole 0.249 and –0.186 e.Å–3 
a)
 DELU (rigid bond) restraints were applied to all thermal displacement parameters. 
 
Table A 20 Bond lengths [Å] and angles [°] for 200 
O(1)–C(1)  1.426(8) 
O(1)–H(1O1)  0.8400 
C(1)–C(2)  1.477(10) 
C(1)–C(6)  1.516(10) 
C(1)–H(1A)  1.0000 
C(2)–C(3)  1.306(8) 
C(2)–H(2)  0.9500 
C(3)–C(4)  1.485(9) 
C(3)–H(3)  0.9500 
C(4)–C(5)  1.531(9) 
C(4)–C(7)  1.531(8) 
C(4)–H(4)  1.0000 
C(5)–C(13)  1.500(8) 
C(5)–C(10)  1.524(9) 
C(5)–C(6)  1.558(9) 
C(6)–O(2)  1.472(8) 
C(6)–H(6A)  1.0000 
O(2)–C(14)  1.377(7) 
C(7)–N(1)  1.486(8) 
C(7)–C(11)  1.551(8) 
C(7)–H(7)  1.0000 
N(1)–C(9)  1.452(9) 
N(1)–C(8)  1.463(9) 
C(8)–H(8A)  0.9800 
C(8)–H(8B)  0.9800 
C(8)–H(8C)  0.9800 
C(9)–C(10)  1.503(10) 
C(9)–H(9A)  0.9900 
C(9)–H(9B)  0.9900 
C(10)–H(10A)  0.9900 
C(10)–H(10B)  0.9900 
C(11)–C(12)  1.499(8) 
C(11)–H(11A)  0.9900 
C(11)–H(11B)  0.9900 
C(12)–C(13)  1.362(8) 
C(12)–C(17)  1.381(8) 
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C(13)–C(14)  1.386(8) 
C(14)–C(15)  1.366(8) 
C(15)–C(16)  1.387(8) 
C(15)–O(3)  1.397(7) 
O(3)–C(18)  1.435(7) 
C(16)–C(17)  1.400(8) 
C(16)–H(16)  0.9500 
C(17)–H(17)  0.9500 
C(18)–C(19)  1.504(8) 
C(18)–H(18A)  0.9900 
C(18)–H(18B)  0.9900 
C(19)–C(24)  1.376(8) 
C(19)–C(20)  1.388(9) 
C(20)–C(21)  1.375(10) 
C(20)–H(20)  0.9500 
C(21)–C(22)  1.361(11) 
C(21)–H(21)  0.9500 
C(22)–C(23)  1.377(9) 
C(22)–H(22)  0.9500 
C(23)–C(24)  1.392(8) 
C(23)–H(23)  0.9500 
C(24)–C(25)  1.486(8) 
C(25)–O(4)  1.434(7) 
C(25)–H(25A)  0.9900 
C(25)–H(25B)  0.9900 
O(4)–C(26)  1.372(7) 
C(26)–C(27)  1.381(8) 
C(26)–C(31)  1.383(8) 
C(27)–C(28)  1.384(8) 
C(27)–H(27)  0.9500 
C(28)–C(29)  1.388(8) 
C(28)–H(28)  0.9500 
C(29)–C(30)  1.373(8) 
C(29)–C(32)  1.495(8) 
C(30)–C(31)  1.375(7) 
C(30)–C(35)  1.484(8) 
C(31)–O(5)  1.365(7) 
O(5)–C(39)  1.465(7) 
C(32)–C(33)  1.548(9) 
C(32)–H(32A)  0.9900 
C(32)–H(32B)  0.9900 
C(33)–N(2)  1.472(9) 
C(33)–C(34)  1.532(8) 
C(33)–H(33)  1.0000 
C(34)–C(42)  1.492(9) 
C(34)–C(35)  1.532(9) 
C(34)–H(34)  1.0000 
C(35)–C(38)  1.526(9) 
C(35)–C(39)  1.571(8) 
N(2)–C(37)  1.463(8) 
N(2)–C(36)  1.471(8) 
C(36)–H(36A)  0.9800 
C(36)–H(36B)  0.9800 
C(36)–H(36C)  0.9800 
C(37)–C(38)  1.531(8) 
C(37)–H(37A)  0.9900 
C(37)–H(37B)  0.9900 
C(38)–H(38A)  0.9900 
C(38)–H(38B)  0.9900 
C(39)–C(40)  1.493(9) 
C(39)–H(39)  1.0000 
C(40)–O(6)  1.413(8) 
C(40)–C(41)  1.476(10) 
C(40)–H(40)  1.0000 
O(6)–H(1O6)  0.8400 
C(41)–C(42)  1.314(9) 
C(41)–H(41)  0.9500 
C(42)–H(42)  0.9500 
O(7)–H(1O7)  0.8206 
O(7)–H(2O7)  0.8406 
O(8)–H(1O8)  0.8610 
O(8)–H(2O8)  0.8561 
  
C(1)–O(1)–H(1O1) 109.5 
O(1)–C(1)–C(2) 109.6(6) 
O(1)–C(1)–C(6) 110.3(6) 
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C(2)–C(1)–C(6) 114.2(5) 
O(1)–C(1)–H(1A) 107.5 
C(2)–C(1)–H(1A) 107.5 
C(6)–C(1)–H(1A) 107.5 
C(3)–C(2)–C(1) 121.2(7) 
C(3)–C(2)–H(2) 119.4 
C(1)–C(2)–H(2) 119.4 
C(2)–C(3)–C(4) 121.2(6) 
C(2)–C(3)–H(3) 119.4 
C(4)–C(3)–H(3) 119.4 
C(3)–C(4)–C(5) 109.5(5) 
C(3)–C(4)–C(7) 114.1(5) 
C(5)–C(4)–C(7) 107.7(5) 
C(3)–C(4)–H(4) 108.5 
C(5)–C(4)–H(4) 108.5 
C(7)–C(4)–H(4) 108.5 
C(13)–C(5)–C(10) 112.2(6) 
C(13)–C(5)–C(4) 106.5(5) 
C(10)–C(5)–C(4) 108.4(5) 
C(13)–C(5)–C(6) 100.4(5) 
C(10)–C(5)–C(6) 113.3(6) 
C(4)–C(5)–C(6) 115.7(6) 
O(2)–C(6)–C(1) 110.5(6) 
O(2)–C(6)–C(5) 106.0(5) 
C(1)–C(6)–C(5) 113.3(5) 
O(2)–C(6)–H(6A) 109.0 
C(1)–C(6)–H(6A) 109.0 
C(5)–C(6)–H(6A) 109.0 
C(14)–O(2)–C(6) 107.3(4) 
N(1)–C(7)–C(4) 105.7(5) 
N(1)–C(7)–C(11) 115.7(5) 
C(4)–C(7)–C(11) 112.4(5) 
N(1)–C(7)–H(7) 107.6 
C(4)–C(7)–H(7) 107.6 
C(11)–C(7)–H(7) 107.6 
C(9)–N(1)–C(8) 111.0(6) 
C(9)–N(1)–C(7) 112.5(5) 
C(8)–N(1)–C(7) 111.2(6) 
N(1)–C(8)–H(8A) 109.5 
N(1)–C(8)–H(8B) 109.5 
H(8A)–C(8)–H(8B) 109.5 
N(1)–C(8)–H(8C) 109.5 
H(8A)–C(8)–H(8C) 109.5 
H(8B)–C(8)–H(8C) 109.5 
N(1)–C(9)–C(10) 110.8(6) 
N(1)–C(9)–H(9A) 109.5 
C(10)–C(9)–H(9A) 109.5 
N(1)–C(9)–H(9B) 109.5 
C(10)–C(9)–H(9B) 109.5 
H(9A)–C(9)–H(9B) 108.1 
C(9)–C(10)–C(5) 111.8(6) 
C(9)–C(10)–H(10A) 109.3 
C(5)–C(10)–H(10A) 109.3 
C(9)–C(10)–H(10B) 109.3 
C(5)–C(10)–H(10B) 109.3 
H(10A)–C(10)–H(10B) 107.9 
C(12)–C(11)–C(7) 115.0(5) 
C(12)–C(11)–H(11A) 108.5 
C(7)–C(11)–H(11A) 108.5 
C(12)–C(11)–H(11B) 108.5 
C(7)–C(11)–H(11B) 108.5 
H(11A)–C(11)–H(11B) 107.5 
C(13)–C(12)–C(17) 115.9(5) 
C(13)–C(12)–C(11) 118.4(5) 
C(17)–C(12)–C(11) 125.1(6) 
C(12)–C(13)–C(14) 122.7(6) 
C(12)–C(13)–C(5) 127.0(5) 
C(14)–C(13)–C(5) 109.8(6) 
C(15)–C(14)–O(2) 126.5(5) 
C(15)–C(14)–C(13) 121.2(6) 
O(2)–C(14)–C(13) 112.2(5) 
C(14)–C(15)–C(16) 117.0(6) 
C(14)–C(15)–O(3) 117.6(5) 
C(16)–C(15)–O(3) 125.4(5) 
C(15)–O(3)–C(18) 116.3(5) 
C(15)–C(16)–C(17) 120.6(6) 
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C(15)–C(16)–H(16) 119.7 
C(17)–C(16)–H(16) 119.7 
C(12)–C(17)–C(16) 121.9(6) 
C(12)–C(17)–H(17) 119.1 
C(16)–C(17)–H(17) 119.1 
O(3)–C(18)–C(19) 109.2(5) 
O(3)–C(18)–H(18A) 109.8 
C(19)–C(18)–H(18A) 109.8 
O(3)–C(18)–H(18B) 109.8 
C(19)–C(18)–H(18B) 109.8 
H(18A)–C(18)–H(18B) 108.3 
C(24)–C(19)–C(20) 119.5(6) 
C(24)–C(19)–C(18) 120.7(5) 
C(20)–C(19)–C(18) 119.5(6) 
C(21)–C(20)–C(19) 119.9(7) 
C(21)–C(20)–H(20) 120.1 
C(19)–C(20)–H(20) 120.1 
C(22)–C(21)–C(20) 120.6(7) 
C(22)–C(21)–H(21) 119.7 
C(20)–C(21)–H(21) 119.7 
C(21)–C(22)–C(23) 120.4(7) 
C(21)–C(22)–H(22) 119.8 
C(23)–C(22)–H(22) 119.8 
C(22)–C(23)–C(24) 119.4(6) 
C(22)–C(23)–H(23) 120.3 
C(24)–C(23)–H(23) 120.3 
C(19)–C(24)–C(23) 120.1(6) 
C(19)–C(24)–C(25) 120.5(5) 
C(23)–C(24)–C(25) 119.4(5) 
O(4)–C(25)–C(24) 105.3(5) 
O(4)–C(25)–H(25A) 110.7 
C(24)–C(25)–H(25A) 110.7 
O(4)–C(25)–H(25B) 110.7 
C(24)–C(25)–H(25B) 110.7 
H(25A)–C(25)–H(25B) 108.8 
C(26)–O(4)–C(25) 116.8(5) 
O(4)–C(26)–C(27) 126.5(5) 
O(4)–C(26)–C(31) 115.7(5) 
C(27)–C(26)–C(31) 117.7(5) 
C(26)–C(27)–C(28) 120.8(6) 
C(26)–C(27)–H(27) 119.6 
C(28)–C(27)–H(27) 119.6 
C(27)–C(28)–C(29) 121.0(6) 
C(27)–C(28)–H(28) 119.5 
C(29)–C(28)–H(28) 119.5 
C(30)–C(29)–C(28) 117.4(5) 
C(30)–C(29)–C(32) 117.6(5) 
C(28)–C(29)–C(32) 124.1(5) 
C(29)–C(30)–C(31) 121.4(5) 
C(29)–C(30)–C(35) 127.1(5) 
C(31)–C(30)–C(35) 110.4(5) 
O(5)–C(31)–C(30) 112.5(5) 
O(5)–C(31)–C(26) 126.3(5) 
C(30)–C(31)–C(26) 121.0(5) 
C(31)–O(5)–C(39) 107.6(4) 
C(29)–C(32)–C(33) 115.0(5) 
C(29)–C(32)–H(32A) 108.5 
C(33)–C(32)–H(32A) 108.5 
C(29)–C(32)–H(32B) 108.5 
C(33)–C(32)–H(32B) 108.5 
H(32A)–C(32)–H(32B) 107.5 
N(2)–C(33)–C(34) 108.4(5) 
N(2)–C(33)–C(32) 115.5(6) 
C(34)–C(33)–C(32) 112.4(5) 
N(2)–C(33)–H(33) 106.7 
C(34)–C(33)–H(33) 106.7 
C(32)–C(33)–H(33) 106.7 
C(42)–C(34)–C(35) 109.2(5) 
C(42)–C(34)–C(33) 115.9(5) 
C(35)–C(34)–C(33) 105.8(5) 
C(42)–C(34)–H(34) 108.6 
C(35)–C(34)–H(34) 108.6 
C(33)–C(34)–H(34) 108.6 
C(30)–C(35)–C(38) 114.4(5) 
C(30)–C(35)–C(34) 106.3(5) 
C(38)–C(35)–C(34) 108.8(5) 
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C(30)–C(35)–C(39) 100.5(5) 
C(38)–C(35)–C(39) 111.5(5) 
C(34)–C(35)–C(39) 115.2(5) 
C(37)–N(2)–C(36) 110.6(5) 
C(37)–N(2)–C(33) 112.3(4) 
C(36)–N(2)–C(33) 113.2(5) 
N(2)–C(36)–H(36A) 109.5 
N(2)–C(36)–H(36B) 109.5 
H(36A)–C(36)–H(36B) 109.5 
N(2)–C(36)–H(36C) 109.5 
H(36A)–C(36)–H(36C) 109.5 
H(36B)–C(36)–H(36C) 109.5 
N(2)–C(37)–C(38) 109.8(5) 
N(2)–C(37)–H(37A) 109.7 
C(38)–C(37)–H(37A) 109.7 
N(2)–C(37)–H(37B) 109.7 
C(38)–C(37)–H(37B) 109.7 
H(37A)–C(37)–H(37B) 108.2 
C(35)–C(38)–C(37) 111.5(5) 
C(35)–C(38)–H(38A) 109.3 
C(37)–C(38)–H(38A) 109.3 
C(35)–C(38)–H(38B) 109.3 
C(37)–C(38)–H(38B) 109.3 
H(38A)–C(38)–H(38B) 108.0 
O(5)–C(39)–C(40) 110.5(5) 
O(5)–C(39)–C(35) 105.6(4) 
C(40)–C(39)–C(35) 112.6(5) 
O(5)–C(39)–H(39) 109.4 
C(40)–C(39)–H(39) 109.4 
C(35)–C(39)–H(39) 109.4 
O(6)–C(40)–C(41) 109.7(6) 
O(6)–C(40)–C(39) 112.5(5) 
C(41)–C(40)–C(39) 113.9(5) 
O(6)–C(40)–H(40) 106.8 
C(41)–C(40)–H(40) 106.8 
C(39)–C(40)–H(40) 106.8 
C(40)–O(6)–H(1O6) 109.5 
C(42)–C(41)–C(40) 121.0(7) 
C(42)–C(41)–H(41) 119.5 
C(40)–C(41)–H(41) 119.5 
C(41)–C(42)–C(34) 119.4(7) 
C(41)–C(42)–H(42) 120.3 
C(34)–C(42)–H(42) 120.3 
H(1O7)–O(7)–H(2O7) 108.5 
H(1O8)–O(8)–H(2O8) 105.3 
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9.2 Appendix B 
 
Cells and cell culture 
IC50, definition: 
The concentration of a drug or novel compound which causes a 50% cell kill (IC50 
for that drug) can be determined from a plot of the % survival (relative to the control 
cells) versus drug concentration using Calcusyn software.  
 
Drug combinations terminology: 
Antagonism is when the 2 or more drugs in combination act against each other 
therefore decreasing the effect on the cells. (1 + 1 = -1) 
Additivity is when the total toxicity of 2 or more drugs in combination is equal to the 
sum of the cell kill each drug has on the cells. (1 + 1 = 2) 
Synergy is when the total cell kill is greater than additivity. (1 + 1 = 3) 
 
All cell culture work was carried out in a class II laminar airflow cabinet (Holten 
LaminAir). All experiments involving cytotoxic compounds were conducted in a 
cytogard laminar airflow cabinet (Hoolten LaminAir Maxisafe). Before and after use 
the laminar airflow cabinet was cleaned with 70% industrial methylated spirits 
(IMS). Any items brought into the cabinet were also swabbed with IMS. Only one 
cell line was used in the laminar airflow cabinet at a time and upon completion of 
work with any given cell line he laminar airflow cabinet was allowed to clear for at 
least 15 minutes before use. This was to eliminate any possibilities of cross-
contamination between cell lines. The cabinets were cleaned fortnightly with 
industrial disinfectants (Virkon or TEGO). These disinfectants were alternated 
fortnightly. All cells were incubated at 37oC with an atmosphere of 5% CO2. The 
DLKP and DLKP-A cell lines do not have CO2 requirement. Cell were fed with fresh 
media or subcultured every 2-3 days in order to maintain active cell growth.  
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Double combinations of 233, 234, 235, 236 and 4 with epirubicin in the DLKP cell 
line 
 
 
 
 
 
 
 
 
Graph B 1 Bar chart of the double combination of 233 with epirubicin in the DLKP cell line. This 
combination did not result in synergistic reaction. 
 
 
 
 
 
 
 
 
Graph B 2 Bar chart of the double combination of 234 with epirubicin in the DLKP cell line. This 
combination did not result in synergistic reaction. 
 
 
 
 
 
 
 
 
Graph B 3 Bar chart of the double combination of 235 with epirubicin in the DLKP cell line. This 
combination did not result in a synergistic interaction. 
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Graph B 4 Bar chart of the double combination of 236 with epirubicin in the DLKP cell line. This 
combination did not result in a synergistic interaction. 
 
 
Double combinations of 233, 234, 235, 236 and 4with epirubicin in the DLKP-A cell 
line. 
 
 
 
 
 
 
 
Graph B 5 Bar chart of the double combination of 233 with epirubicin on the DLKP-A cell line. The 
combination of this compound with epirubicin did not show any synergistic interactions in the DLKP-
A cell line.  
 
 
 
 
 
 
 
Graph B 6 Bar chart of the double combination of 234 with epirubicin in the DLKP-A cell line. This 
combination did not result in a synergistic reaction in the DLKP-A cell line. 
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Graph B 7 Bar chart of the double combination of 235 with epirubicin in the DLKP-A cell line. This 
combination did not result in a synergistic reaction in the DLKP-A cell line. 
 
 
 
 
 
 
 
 
Graph B 8 Bar chart of the double combination of 236 with epirubicin in the DLKP-A cell line. This 
combination did not result in a synergistic interaction in the DLKP-A cell line. 
 
 
 
 
 
 
 
Graph B 9 Bar chart of the double combination of 237 with epirubicin in the DLKP-A cell line. This 
combination did not result in a synergistic interaction in the DLK-A cell line. 
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